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Abstract
Background
Diabetes mellitus is a chronic condition primarily characterised by elevated levels of plasma
glucose due to a lack of insulin. Diabetes is a risk factor for a number of acute and chronic
complications and is associated with significant morbidity and mortality, the risks and impact of
which may be modifiable through high-quality primary care. This thesis examines the relationship
between the quality of primary care and emergency admissions, readmissions and mortality. 
Methodology
Associations between primary care quality and clinical outcomes for people with diabetes were
assessed at the practice and patient level. Practice-level analyses, utilising Quality and Outcomes
Framework (QOF) and Hospital Episodes Statistics (HES) data, modelled the impact of practice
achievement of thematically-grouped QOF indicators on standardised emergency admission rates,
controlling for characteristics of the practice, the socioeconomic environment and the patient
population. Patient-level analyses utilised a Clinical Practice Research Datalink (CPRD-HES) dataset
linking primary care activity with hospitalisations. Modelling examined associations between QOF
target-based indicators and National Diabetes Audit (NDA) care processes and rates of emergency
admissions, readmissions and the odds of death.
Results
In practice-level analyses, QOF indicators pertaining to processes of care and availability of
appointments were most consistently associated with reduced emergency admission rates. For
patient-level analyses, a number of NDA processes were consistently associated with reduced
emergency admission and readmission rates and reduced odds of death across follow-up periods
ranging from one to five years. Associations with QOF targets were less consistent. Across all
practice- and patient-level analyses, deprivation was strongly associated with changes in admission
rates and odds of death.
Conclusions
High-quality primary care has the potential to meaningfully improve outcomes for people with
diabetes; the eﬀects of socio-economic deprivation remain sizeable even after adjustment for
primary care quality.
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Introduction
In the coming years, the National Health Service (NHS) stands to face
considerably increased demand for its services, largely due to an increasingly co-
morbid and ageing population.1, 2 Over 300 million patient consultations,
representing 70–90% of all patient contacts in the English NHS, take place in
primary care.3 Primary care consultation rates have been increasing year-on-year,
with an average number of consultations per patient rising from 3.9 per year in 1995
to 5.4 per year in 2008 (Figure 1).3
Figure 1. Crude consultation rates and estimated number of primary care consultations in England
(reproduced from Hippisley-Cox & Vinogradova, 2009).
Many chronic conditions, such as diabetes, are often termed ‘ambulatory care
sensitive conditions’ (ACSCs).4, 5 ACSCs are considered conditions for which high
quality primary care – the key components of which include person-centeredness,
provision of comprehensive care and continuity of care6 – can reduce the need for
hospitalisation or for which early intervention can prevent disease complications or
progression.4, 7 ACSCs are generally grouped into three categories – vaccine-
preventable, acute and chronic conditions (Table 1).8 
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Vaccine-Preventable Acute Chronic
Influenza and pneumonia Dehydration and Gastroenteritis Asthma
Other vaccine-preventable 
conditions
Pyelonephritis Congestive heart failure
Perforated/bleeding ulcer Diabetes complications
Cellulitis Chronic obstructive pulmonary 
disease
Pelvic inflammatory disease Angina
Ear, nose and throat infections Iron-deficiency Anaemia
Dental conditions Hypertension
Convulsions and epilepsy Nutritional Deficiencies
Gangrene
Table 1. The 19 Conditions Considered as ACSCs in The NHS.
Emergency admissions for ACSCs are gaining popularity as an indicator of the
quality of primary care on the assumption that the provision of timely, appropriate,
comprehensive and eﬀective care in the community for these conditions should
reduce the risk of unexpected and potentially preventable complications.7, 9 Clinical
care is only one aspect of providing high-quality primary care; access to provided
services is key, as evidenced by an inverse relationship between accessibility of
primary care and the risk of hospitalisation due to ACSCs.10-12
The use and interpretation of emergency admission rates for ACSCs as an
indicator of primary care quality, whilst both logical and intuitive, does imply that
primary care is considered a closed system. It is likely that primary care is not able
exert complete control over many of the myriad factors, be they cultural, financial or
sociopolitical, influencing the interactions between patients and the healthcare
system. Many of these factors are arguably outside of the sphere of influence of
medicine, yet can exert a profound eﬀect on an individual’s health and their health
outcomes.7 Such factors, to a certain degree, may explain the considerable
variation in emergency admission rates for ACSCs observed between general
practices in England.13, 14
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In the period covering 1st April 2009 to March 31st 2010, 15.9% of all
emergency hospital admissions (816,433 of 5,135,974) in England were attributable
to ACSCs; of these, 30% occurred in patients aged 75 years or older, in whom
emergency admissions for chronic conditions were more common.14 The associated
costs of these admissions is considerable; of the £20.5b spent on inpatient
admissions in England in 2009/10, emergency admissions accounted for £12.2b of
which the estimated cost of emergency admissions for ACSCs was £1.42b.14-16 The
cost of these emergency admissions for ACSCs was also associated with patient
age, with individuals aged 75 years or older accounting for 40% of expenditure
(£563m of £1.42b).14
In light of the marked variation between general practices in emergency
admission rates for ACSCs observed in England14, there is considerable potential to
reduce the burden of opportunity costs associated with unscheduled care for
ACSCs. A recent King’s Fund report14 estimated that the number of emergency
admissions for ACSCs could be reduced by between 8% (63,214 admissions) to
18% (150,373 admissions), equating to savings of £96m and £238m respectively, if
poorer performing Local Authorities reduced their emergency admission rates to
those of the best performing Local Authorities.
The restructuring of NHS England in 2013 saw the responsibilities for the
planning and commissioning of services for local populations move from Primary
Care Trusts (PCTs) to Clinical Commissioning Groups (CCGs). CCGs are clinically-
led consortia of general practices that provide primary care services for a defined
area and are responsible for the purchasing of urgent and emergency care, elective
hospital care, community health services, maternity and newborn services and
mental health services for the population that they serve.17
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The new structure of NHS England, and the resultant shift in commissioning
duties, poses a clear opportunity for primary care to remodel the way in which care
is delivered so as to maximise outcomes, cost-eﬃciency and patient access in a
way that closely reflects the evolving needs of local populations. In light of the
projected demand for the care of older, more co-morbid individuals, significant
headway towards these aims may be made through a renewed focus on diseases
that are particularly suited to management in primary care, albeit subject to the
impact of external sociopolitical factors discussed above in addition to the need for
adequate resourcing of primary care.18, 19
Diabetes Mellitus
Diabetes mellitus is a chronic condition that is primarily characterised by
elevated levels of plasma glucose due to an absolute or relative lack of the
pancreatic hormone insulin.20 Diabetes is associated with a number of acute and
chronic complications and is associated with significant morbidity and mortality.21-25
In health, insulin is one of the principle hormones that regulates glucose
homeostasis and, in broad terms, acts to promote storage of energy. Insulin is
secreted by the β-cells of the pancreas in response to elevated plasma glucose
concentrations; the primary functions of insulin are to promote glucose uptake by
cells, promote glucose storage in the liver through its conversion to glycogen,
promote lipid formation and storage in adipocytes, inhibition of lipolysis and
proteolysis within cells and inhibition of gluconeogenesis (Figure 2).
The other key hormone in glucose homeostasis is glucagon, secreted by the α-
cells of the pancreas in response to low plasma glucose concentrations. Glucagon
acts to liberate energy from stores via promotion of the conversion of glycogen to
glucose in the liver, promotion of lipolysis and proteolysis in cells and promotion of
gluconeogenesis. Lipolysis yields free fatty acids (FFAs), which are metabolised to
ketones by the liver for use as an alternative energy source for the heart and brain;
proteolysis produces lactate, pyruvate and amino acids, all of which are substrates
for gluconeogenesis (Figure 2).
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In diabetes, insulin insuﬃciency (be it relative or absolute) ultimately leads to
deranged glucose homeostasis. A lack of circulating insulin means that there is no
stimulus to promote the storage of glucose and the inhibition of gluconeogenesis,
glycolysis, lipolysis and proteolysis, leading to the production of glucose and, in the
absolute absence of insulin, FFAs and ketone bodies despite physiologically
adequate concentrations of plasma glucose.
Figure 2. Overview of Glucose Homeostasis.
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Types and Epidemiology of Diabetes Mellitus
Diabetes mellitus is an increasingly common chronic disease in England,
characterised by chronically elevated levels of blood glucose. In 2009, the
estimated prevalence of diabetes mellitus – both diagnosed and undiagnosed – was
approximately 3.1m (7.4% of the population) and has been projected to rise to 4.6m
(9.5%) by 2030.26 The crude prevalence of diabetes mellitus diﬀers by age, sex and
ethnicity, with the highest prevalences observed in men, South Asian and Black
ethnic groups and with increasing age (Figure 3).26-29
Figure 3. Estimated Crude Prevalence of Diabetes Mellitus by Gender, Ethnicity and Age.26
In addition to the demographic diﬀerences observed in the prevalence of
diabetes mellitus, there are considerable geographic diﬀerences in diabetes
prevalence across Strategic Health Authorities in England, with estimated
prevalence ranging from 6.6% in South Central England to 8.1% in the West
Midlands.26, 29 Deprivation is also strongly associated with diabetes prevalence28, 30,
with the most aﬄuent areas exhibiting between 33% to 57% fewer cases of
diabetes in comparison to the poorest areas.28, 30
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The two most common forms of diabetes encountered in clinical practice are
type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Other,
markedly less common, types of diabetes, such as gestational diabetes mellitus
and malnutrition-related diabetes mellitus also exist but are outside of the scope of
this thesis.
Diabetes of either type is associated with considerable morbidity and mortality.
Individuals diagnosed with diabetes were nearly 35% more likely to die than their
peers in the general population during 2013; excess mortality in T1DM and T2DM
was 131% and 32% respectively during this period, with approximately 22,000
deaths due to diabetes during this period.21 Although diabetes confers an excess
risk of mortality across all age groups, the relative risks are greatest for females, at
younger ages and in T1DM – females with T1DM aged 15-34 years are 6.6 times
more likely to die than non-diabetic females in this age group.21
Regardless of diabetes type, the core therapeutic goal in the management of
diabetes is control of blood glucose concentrations. Persistently elevated blood
glucose levels are associated with poorer outcomes in diabetes31-33 and adequacy
of glucose control can be routinely and easily assessed through measurement of
the relative concentration of glycated haemoglobin (HbA1c).
Glucose in the blood stream attaches to haemoglobin molecules in
concentration-dependent manner; persistently high concentrations of blood glucose
causes more glucose molecules to bind to haemoglobin, thereby leading to the
increased formation of glycated haemoglobin. Binding of glucose to haemoglobin is
permanent, meaning that glycated haemoglobin can only be cleared from the blood
stream upon destruction of red blood cells, the normal lifespan of which is
approximately 120 days. The ratio of glycated haemoglobin (HbA1c) to normal,
unglycated haemoglobin therefore provides an estimate of the adequacy of blood
glucose control over the previous 1-3 months. HbA1c is commonly reported
according to International Federation of Clinical Chemistry (IFCC) or Diabetes
Control and Complications Trial (DCCT) guidelines, which express the relative
amount of HbA1c to unglycated haemoglobin as mmol/mol or % respectively.
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Whilst control of blood glucose concentrations is a core therapeutic goal in
diabetes, patients on intensive hypoglycaemic therapy (be it subcutaneous insulin
or oral hypoglycaemic agents) are at risk of hypoglycaemia as a result of their
treatment. Hypoglycaemia is a serious complication of diabetes treatment, with an
estimated annual cost of emergency calls of £13.6m in England34 and is associated
with decreased quality of life35, increased hospital length of stay36 and both all-
cause36, 37 and cardiovascular mortality.38
Type 1 Diabetes Mellitus
T1DM, also known as juvenile-onset diabetes mellitus or insulin-dependent
diabetes mellitus (IDDM), is a subtype of diabetes mellitus, most commonly
resulting from an absolute lack of insulin secondary to autoimmune destruction of
the β-cells in the pancreas; a minority of cases of T1DM are due to idiopathic
destruction or failure of β-cells.39 It has been hypothesised that such destruction
may be triggered by environmental exposures.40
An absolute lack of insulin leads to a profound disruption of glucose
homeostasis, resulting in hyperglycaemia, a lack of inhibition of gluconeogenesis, a
lack of stimulus to store glucose within the liver and peripheral cells and an increase
in proteolysis and lipolysis, leading to an increase in FFAs and ketone bodies that,
in turn, can lead to metabolic acidosis (Figure 2).
T1DM predominantly occurs in younger individuals, with a peak age of onset of
10 - 19 years of age; however, T1DM can occur at any age and up to 10% of adults
initially diagnosed with T2DM are subsequently found to have autoantibodies
associated with T1DM.27, 39 Of people with diabetes aged 19 years old or younger,
96% have T1DM; however, only 9% of all people with diabetes (adults and children)
have T1DM.27 Unlike many other autoimmune conditions, which tend to
disproportionately aﬀect females, there is an over-representation of males in
incident and prevalent T1DM in England and wales, with males comprising
approximately 60% and 57% of cases respectively.
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Despite the fact that over 85% of incident T1DM cases have no family history of
the condition, there is evidence of a genetic predisposition to T1DM, with first-
degree relatives of patients with T1DM exhibiting a 15-fold increase in risk of
developing the disease.41
Diagnosis of Type 1 Diabetes Mellitus
The WHO diagnostic criteria for T1DM42, published in 2006 and currently
recommended by NICE43, 44, are largely based upon the symptoms and signs that
result from the grossly impaired glucose homeostasis which is pathognomic of
T1DM in the presence of hyperglycaemia (defined as a random blood glucose of ≥
11.1 mmol/L), namely:
• Polyuria
• Polydipsia
• Marked weight loss
The presence of ketonuria in the context of hyperglycaemia is also strongly
suggestive of T1DM as opposed to other types of diabetes mellitus. Measurement
of HbA1c has largely supplanted blood glucose measurements in the diagnosis of
diabetes, with an HbA1c ≥ 6.5% / 47.5 mmol/mol considered compatible with a
diagnosis of diabetes.45, 46 Some individuals may present with diabetic ketoacidosis
(DKA), an acute complication of T1DM that is discussed in greater detail below.
Treatment of Type 1 Diabetes Mellitus
As there is an absence of endogenous insulin secretion in T1DM, the primary
goal of treatment is to provide exogenous insulin in the form of regular
subcutaneous iǌections. Insulin is available in a number of forms (rapid-, short-,
intermediate- and long-acting) and the exact regimen prescribed to achieve
glycaemic control will depend on an individual patient’s needs and lifestyle.43
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In addition to the prescription of insulin, patient education on how diabetes
interacts with their diet, intercurrent infections and exercise are essential
cornerstones of the holistic package of care necessary for eﬀective management of
T1DM.43 Additionally, proactive surveillance and, where appropriate, initiation of
treatment for the chronic complications of diabetes will maximise outcomes in
patients with T1DM.
Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA) is characterised by ketonaemia (ketosis),
hyperglycaemia and acidosis. DKA is a life-threatening emergency, necessitating
urgent medical care. DKA is commonly precipitated by infection, but can also result
from other acute systemic diseases such as myocardial infarction, pancreatitis,
poor compliance with or inadequate insulin regimens or may be the presenting
condition in individuals not previously know to have T1DM.47-49
The crude prevalence of DKA in people with T1DM was 3.57% in England and
Wales during 2012/1321; mortality rates for DKA have fallen over the past 2 decades
from 7.96% to 0.67%, but remains high in non-hospitalised patients and the elderly
and is the leading cause of death in young people with T1DM.48, 50
In T1DM, the characteristics of DKA are a direct result of a lack of insulin,
leading to lack of suppression of gluconeogenesis, lack of suppression of lipolysis
and proteolysis, enhancement of glycogenolysis – the net result of these
disturbances is severe hyperglycaemia and the release of large quantities of ketone
bodies which, in turn, leads to acidosis.
In addition to the metabolic disturbances discussed above, DKA also leads to
profound fluid depletion as a result of osmotic diuresis secondary to severe
hyperglycaemia and ketosis, fluid loss due to vomiting and, in severe episodes of
DKA, inability to take in fluid due to reduced consciousness and coma. This loss of
fluid and, to a certain degree, the lack of action of insulin, can lead to disturbances
in electrolyte balance and, in particular, hyper- or hypokalaemia.49, 50
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Overt DKA tends to develop rapidly, usually over a period less than a day;
however, antecedent polyuria and polydipsia may be present over the previous few
days prior to onset of DKA. Vomiting and abdominal pain are common presenting
symptoms of DKA; levels of consciousness can vary from full alertness to lethargy
to loss of consciousness.
On examination, patients presenting with DKA are often tachycardic and
hypotensive as a result of fluid depletion; severe acidosis is associated with the
presence of deep, laboured breathing (referred to as Kussmaul respiration), a
physiological response that is attempting to correct metabolic acidosis.
The aims of DKA treatment are to restore fluid balance, reduce acidosis through
clearance of ketone bodies, restore normoglycaemia and to correct electrolyte
imbalances. Treatment of DKA usually consists of administration of intravenous
fluids, to which electrolytes are added in order to correct any detected electrolyte
imbalances, and an insulin infusion. In addition to restoring normoglycaemia, an
infusion of insulin acts to suppress ketogenesis and aids the correction of
electrolyte disturbances.
As DKA infers a disturbance of the normal management of a patient’s diabetes,
it is essential that diabetes specialist teams are involved in the care of all patients
presenting with DKA. Involvement of such teams ensures that precipitating factors
are assessed, appropriate acute management is undertaken, follow-up is arranged
and structured education provided.50
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Type 2 Diabetes Mellitus
T2DM, also referred to as adult-onset diabetes mellitus or non-insulin-
dependent diabetes mellitus (NIDDM), is a sub-type of diabetes mellitus chiefly
associated with hyperglycaemia in the context of insulin resistance (or relative
insulin insuﬃciency); this contrasts with T1DM, where an absolute deficiency of
insulin results in hyperglycaemia. Accordingly, excess production of ketone bodies
is considerably less common in T2DM in comparison to T1DM as despite the fact
that there is, in relative terms, insuﬃcient insulin to ensure adequate glucose
homeostasis, circulating levels of insulin are suﬃcient to suppress gluconeogenesis
and widespread proteolysis and lipolysis (Figure 2).
The primary pathophysiological mechanism leading to hyperglycaemia in T2DM
is resistance of peripheral tissues to insulin, a phenomenon observed in obesity. At
the onset of insulin resistance, pancreatic β-cells may be able to increase insulin
production to a level that maintains glucose homeostasis; however, as insulin
resistance increases – for example, in conditions of increasing adiposity – β-cells
may no longer be able to produce suﬃcient quantities of insulin to correct for insulin
resistance and maintenance of normoglycaemia.51
T2DM is the most common form of diabetes mellitus, comprising over 90% of all
cases of diabetes in England and Wales.27 T2DM most commonly occurs in middle-
aged to older adults, most commonly between 60-69 years of age in England and
Wales27, although T2DM is being increasingly diagnosed in younger, obese
individuals and tends to aﬀect individuals of black and asian ethnicity at a younger
age compared to caucasians.52 T2DM arises through a complex interplay of
environmental and genetic factors, as borne out by local, national and international
diﬀerences in incidence and evidence of familial clustering.51-53
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Increases in the incidence of T2DM have driven the considerable expansion of
numbers of people with diabetes both in England and worldwide. Although
population ageing accounts for some of the observed increase in T2DM prevalence,
obesity is responsible for the vast majority of new diagnoses of T2DM; 80-85% of
the risk of developing T2DM is attributable to obesity.54 In addition to the underlying
trends of increased caloric intake and reductions in physical activity, increased
amounts of dietary fat – specifically saturated fats – are particularly linked to the
development of obesity and insulin resistance.51
In the vast majority of cases, development of T2DM is preceded by onset of one
or more components of the metabolic syndrome, characterised by abdominal
obesity, glucose intolerance, dyslipidaemia and hypertension.55 The notion of a ‘pre-
diabetic’ state allows for derivation of risk scores for T2DM, which would potentially
allow for individuals who have undiagnosed T2DM to be identified and oﬀered
treatment at an earlier stage of the disease.56, 57 The prevalence of ‘pre-diabetes’ is
estimated to have risen considerably over the past decade, with a prevalence of
over 50% in obese adults aged 40 years or older.58
A number of studies have demonstrated that instigation of lifestyle measures,
particularly exercise and weight loss, can reduce the risk of progression from pre-
diabetes to T2DM by up to 60%; however, whether the eﬃcacy of such
interventions would translate to tangible, cost-eﬀective public health benefits when
implemented outside of the context of a clinical study has been called into
question.59-69
It should be noted that whilst these risk scores have demonstrated eﬃcacy in
the context of cohort studies, real-world eﬀectiveness would depend upon
adequate resourcing of primary care to allow for regular, systematic surveillance of
individuals deemed to be at potentially increased risk.
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Diagnosis of Type 2 Diabetes Mellitus
Patients with T2DM may present with classical symptoms of diabetes, namely
polydipsia and polyuria, or may be identified as high risk individuals as a result of
their lifestyle, family history or weight. T2DM is primarily diagnosed through
demonstration of glucose intolerance or through measurement of HbA1c as per the
2011 recommendations of the World Health Organisation (WHO).45
HbA1c ≥ 6.5% (47.5 mmol/mol) is considered diagnostic of diabetes; however,
HbA1c values less than 6.5% (47.5 mmol/mol) cannot exclude T2DM diagnosed
using glucose tolerance tests. As with T1DM, some individuals with previously
undiagnosed T2DM may present with acute metabolic complications of diabetes or
acute complications related to micro- or macrovascular disease such as myocardial
infarctions or stroke. Hyperosmolar hyperglycaemic state (HHS) is the most
common acute metabolic disturbance observed in T2DM, although a small
proportion of patients may present with DKA under conditions of catabolic stress
associated with other acute illnesses.48
Treatment of Type 2 Diabetes Mellitus70, 71
Unlike those with T1DM, individuals diagnosed with T2DM continue to secrete
insulin, albeit at physiologically insuﬃcient levels. As T2DM is tightly linked to insulin
resistance, a major determinant of which is obesity, initial management of T2DM
may consist of dietary and lifestyle advice to achieve normoglycaemia and reduce
the risk of chronic complications of diabetes; weight loss is of particular
importance.
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In individuals who cannot achieve adequate glucose control – generally defined
as an HbA1c ≥ 6.5% (48 mmol/mol) after 3 - 6 months of intervention – through diet
and lifestyle modifications, commencement of oral hypoglycaemic agents may need
to be considered. In the NHS, metformin is the most commonly used first-line agent
in T2DM; however, dual or triple oral hypoglycaemic therapy (through addition of
medications such as sulfonylurea, DPP-4 inhibitors or pioglitazone) may need to be
considered if adequate glycaemic control cannot be achieved. If oral therapy fails,
individuals with T2DM may need to be commenced on subcutaneous insulin in
order to control blood glucose.
Regardless of the necessary treatment regimen required for glycaemic control
for an individual with T2DM, regular clinical review, patient education, assessment
of risk of chronic complications of diabetes and provision of appropriate primary,
secondary and tertiary prevention is essential to maximise clinical outcomes.
Hyperosmolar Hyperglycaemic State
HHS is a profound metabolic disturbance associated with T2DM, characterised
by severe hyperglycaemia, severe dehydration and hyperosmolality. Unlike DKA,
which tends to present within hours of onset, HHS follows a more indolent and
gradual course over a period of several days; as a result, the metabolic
disturbances and dehydration associated with HHS can be considerably more
severe than DKA.72 The mortality of HHS is much higher than that of DKA, and is
estimated to have a case fatality rate approaching 5-10%.48
The primary goals of management of HHS are to aggressively rehydrate the
patient through administration of intravenous fluids, normalisation of osmolality and
reversal of any electrolyte disturbances; insulin infusion is not usually initially
indicated unless significant ketonaemia is present and may increase the risk of
cardiovascular collapse.72 The severe dehydration and hyperosmolality associated
with HHS also increase the risk of additional complications such as arterial or
venous thrombosis, cerebral oedema or central pontine myelinolysis; as such, all
patients admitted with HHS require intensive monitoring and may require transfer to
high dependency or intensive care for stabilisation.
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In HHS, restoration of euvolaemia and electrolyte balance must be done
gradually as rapid correction of these abnormalities may be harmful to the patient,
increasing the risk of cerebral oedema.48 Insulin is often started following initial fluid
resuscitation and, in the case of previously undiagnosed individuals with T2DM or
those previously managed on oral agents, may be switched to oral agents after a
period of demonstrable stability over weeks and months.72 Other supportive
measures, such as anticoagulation and nutritional support are also recommended.72
Referral to a specialist diabetes team as soon as is practicable after admission is
essential to ensure a through review of precipitating factors, delivery of patient
education and establishment of adequate follow-up.
Chronic Complications of Diabetes
The physiological aberrations associated with the dysfunction of glucose
homeostasis in diabetes lead to a number of signs, symptoms and acute and
chronic complications.
The acute complications most commonly associated with specific types of
diabetes mellitus have been discussed in previous sections (see pages 10 and 15);
there are, however, a number of complications and symptoms that directly or
indirectly result from chronic hypoglycaemia that are common to all types of
diabetes (Table 2).
Microvascular Macrovascular Other
Nephropathy Coronary heart disease Cataracts
Neuropathy Peripheral arterial disease Infection and Immunity
Retinopathy Myonecrosis
Cerebrovascular disease and 
stroke
Table 2. Chronic, Non-Acute, Complications of Diabetes .
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The chronic complications of diabetes can be broadly classified into the groups
described in Table 2. The hyperglycaemia, increased FFA release and insulin
insuﬃciency observed in diabetes promotes vascular damage and formation of
atherosclerotic plaques via impaired function of vascular endothelial cells,
vasoconstriction, inflammation, thickening of vascular smooth muscle and
increased thrombosis.22 The net result of atherosclerotic plaque formation is
narrowing of arterial blood vessels throughout the body, impairing the delivery of
blood and oxygen; rupture of these plaques leads to acute interruption of distal
blood flow and subsequent tissue infarction.
Vascular damage occurs in both large and small blood vessels (termed macro-
and microvascular damage respectively) and, ultimately, the tissues and organs that
they supply.
The risk of vascular iǌury, and the significant morbidity and mortality associated
with it, in diabetes mellitus can be greatly reduced by adequate control of serum
glucose concentration in addition to common interventions and treatments that aim
to reduce the cardiovascular risk profile of patients through control of factors such
as blood pressure and cholesterol.33, 73-76
Microvascular Complications of Diabetes
Diabetic Retinopathy
Diabetic retinopathy is a common complication of diabetes and a leading cause
of preventable blindness in England, accounting for 7% of individuals registered as
blind in England.77 Diabetic retinopathy results from vascular iǌury to the blood
vessels supplying the retina, leading to retinal hypoxia, and progresses from
background retinopathy to proliferative retinopathy.
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Background retinopathy is considered an early stage of diabetic retinopathy,
where damage to retinal blood vessels have become clinically detectable. Features
of background retinopathy include localised haemorrhage within the middle layer of
the retina, deposition of lipids within the retina (‘hard exudates’), microaneurysm
formation due to weakening of blood vessel walls and vascular leakage within the
retina, which can lead to retinal oedema and visual disturbance.
Proliferative retinopathy generally occurs once retinal hypoxia has become
established due to vascular damage, with overtly ischaemic areas of the retina
visible on fundoscopy as diﬀuse white patches (‘cotton wool spots’). Retinal
hypoxia drives the formation of new blood vessels on the surface of the retina and
within the vitreous humour within the eye in an attempt to restore adequate
perfusion. These new, fragile blood vessels are liable to rupture, resulting in vitreous
haemorrhage and visual loss; blindness can also occur as a result of the
fibrovascular growth associated with proliferative retinopathy, leading to tractional
retinal detachment.
The incidence and risk of progression of diabetic retinopathy can be reduced
through control of serum glucose, blood pressure and cholesterol levels73, 78, but
despite advances in the management of diabetes and cardiovascular risk factors
over the past few decades, most patients with T1DM develop retinopathy within 20
years of diagnosis and may develop in individuals with T2DM 7 years prior to being
diagnosed with diabetes.79, 80
Aside from the benefits of secondary and tertiary prevention as discussed
above, ablation of new, potentially sight-threatening retinal blood vessels through
use of laser photocoagulation is a mainstay of treatment for established diabetic
retinopathy.78
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Early detection of diabetic retinopathy is key to reduce the risk of sight loss in
people who have been diagnosed with diabetes; to this end, the NHS operates a
diabetic eye screening programme that is delivered through locally commissioned
programmes. The current recommendations for retinal screening are that all adults
with diabetes should be screened upon diagnosis and every year thereafter.81 In
2011/12, the screening programme covered (i.e. oﬀered screening to) 73.9% of the
adult diabetic population, with 80.9% of these individuals taking up the oﬀer of
screening oﬀered to them.82 Levels of coverage of the programme were, however,
highly variable across the country, ranging from 52% to 95%.82
Diabetic Nephropathy
Diabetic nephropathy results from damage to the microvasculature of glomeruli,
consequently inhibiting the ability of the kidney to filter blood, leading to chronic
kidney disease (CKD) and, potentially, end-stage renal failure (ESRF) requiring renal
replacement therapy (RRT).
Diabetes is the leading cause of CKD in the developed world83, 84, with diabetes
being associated with an odds ratio (OR) of developing CKD of 2.60.84 Furthermore,
the presence of severe CKD (stages 4 - 5) and ESRF denote relative risks of death
due to cardiovascular complications of approximately 2 - 4 and 100 respectively
over a 10-year period. In the context of diabetes, a disorder that confers additional
risk of cardiovascular events due to the eﬀects of chronic hyperglycaemia on blood
vessels, CKD and its sequelae pose a significant risk to people with diabetes.
In health, the kidneys act to filter the blood through filtration and selective
reabsorption of ions, amino acids and glucose that is primarily mediated by the
renin-angiotensin-aldosterone system, the hormone feedback loop that controls
blood pressure and fluid balance within the body. In diabetes, microvascular
damage aﬀects filtration within the kidneys, allowing larger molecules such as
proteins, which would usually be retained in the blood, to pass through glomeruli
and be excreted in urine. Additionally, damage to the microvasculature of the kidney
leads to tubulointerstitial fibrosis, impairing selective reabsorption of nutrients and
increasing the pressure within the glomerulus, leading to further vascular damage.85
- 19 -
In time, the microvascular damage to the kidney progresses to ESRF, where renal
function has been completely compromised, leading to further complications such
as hypertension, fluid overload, heart failure and ionic disturbances such as
hyperkalaemia. The onset of ESRF necessitates RRT, generally peritoneal or
haemodialysis, to normalise body fluid balance and ionic imbalances.
As with diabetic retinopathy, the progress of diabetic nephropathy can be
slowed through early diagnosis and treatment. As alluded to above, one of the early
stages of diabetic nephropathy is the appearance of protein in urine. This can be
easily tested for, and is referred to as either micro- or macroalbuminuria according
to the amount of albumin relative to the amount of creatinine, a normal waste
product of muscle metabolism; the urinary albumin:creatinine ratio (ACR).
Current guidelines specify that people with diabetes should receive annual
checks for albuminuria and renal function, quantified as an estimated glomerular
filtration rate that is calculated based on age, ethnicity, sex and serum creatinine
concentration, should be checked annually in people with diabetes.70 An annual
check should allow for early diagnosis, treatment and monitoring of diabetic
nephropathy.
Treatment for diabetic nephropathy is primarily aimed at reducing the pressure
of blood passing through the glomeruli, thereby reducing the amount of stress that
they are put under. Two classes of drugs – angiotensin converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) – act via the renin-angiotensin-
aldosterone system, preferentially dilating the vessel that leaves each glomerulus
and thereby reducing the blood pressure within it. Consequently, as the renin-
angiotensin-aldosterone system is being inhibited, systemic blood pressure should
also drop, placing reduced stress on systemic blood vessels and the heart. In order
to further minimise glomerular damage in those with diabetic nephropathy, it is
further recommended that people with diabetes who have an abnormal ACR should
maintain a blood pressure of 130/80 mmHg or less.71 However, some individuals
may experience worsening of their renal function despite optimal therapy in primary
care and should be considered for early referral to specialist renal services for
additional input and, if required, consideration of RRT.71
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Diabetic Neuropathy
Diabetic neuropathy results from damage to the microvasculature supplying the
peripheral nerves of the body, known as vasa nervorum. 
Diabetic neuropathy is a common complication of diabetes, estimated to aﬀect
60 - 70% of people with diabetes86, but may be asymptomatic in up to 50% and
potentially remain undiagnosed unless regular and thorough assessment for
diabetic neuropathy is performed.87 The risk factors for diabetic neuropathy are
similar to any other micro- or macrovascular complication of diabetes, namely
hypertension, poor glucose control, hypercholesterolaemia, duration or diabetes in
addition to body mass index (BMI).88
All types of nerves – sensory, motor and autonomic – can be aﬀected, leading to
a relatively broad range of signs and symptoms. The lower limbs are most
commonly aﬀected, but diabetic neuropathy can be defined as a clinical or
subclinical neuropathy aﬀecting one or more nerves in the context of diabetes and
in the absence of any other cause of peripheral neuropathy.89
Diabetic neuropathy can present with variety of symptoms according to the
pattern of nerve damage that a given patient has sustained as a result of
microvascular iǌury.
Peripheral sensorimotor neuropathy is arguably the most common manifestation
of symptomatic diabetic neuropathy87; sensory nerve fibres are generally aﬀected
more then motor nerve fibres. The longest nerves in the body are typically aﬀected
first, meaning that symptoms commonly begin in the toes and gradually ascend the
legs and can involve the fingers and hands, leading to the classical ‘glove and
stocking’ distribution of sensory impairment. The severity of sensory symptoms can
vary, ranging from numbness and ‘pins and needles’ to pain that is burning or
lancing in nature. Proprioception (perception of joint or limb position) can also be
aﬀected, potentially leading to disturbances of gait, weakness and deformity.
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The symptoms of peripheral sensorimotor neuropathy can also present acutely,
albeit predominantly with severe burning pain aﬀecting the feet and lower limbs
rather than motor deficits, as acute peripheral neuritis. Acute peripheral neuritis is
generally associated with newly diagnosed diabetes or in individuals with poor
glycaemic control, but can paradoxically occur following establishment of improved
glycaemic controls. Unlike peripheral sensorimotor neuropathy, acute peripheral
neuritis can resolve completely, with symptoms responsive to improvements in
glycaemic control.
Individuals with diabetes are also prone to iǌury to single nerves, known as
mononeuropathies. A wide variety of nerves can be aﬀected, with symptoms usually
related to external compression or nerve entrapment – in diabetes, the relative
under-perfusion of nerve fibres likely renders them more susceptible to dysfunction
as a result of external force.87 Presentations of mononeuropathies include carpal
tunnel syndrome or wasting of the muscles of the hand (median nerve), foot drop
(peroneal nerve), ophthalmoplegia (cranial nerves III, IV or VI), Bell’s palsy (cranial
nerve VII) and wasting of the quadriceps muscle (femoral nerve). Patients may
experience concurrent mononeuropathies in disparate, anatomically unrelated
nerves – this simply reflects the same pathological process occurring in two or more
nerves at the same time, and is referred to as mononeuritis multiplex.
Damage to the nerve fibres that form part of the autonomic nervous system
leads to autonomic neuropathy. A number of signs and symptoms can result from
disruption of the autonomic nervous system in diabetes:
• Vascular dysfunction
– Lack of innervation to the smooth muscle of peripheral vasculature leads to
vasodilation and ateriovenous shunting; veins, particularly in the feet, become
engorged, resulting in peripheral oedema resistant to diuretic therapy87
– A loss of reflexive constriction of blood vessels on standing, resulting in
postural hypotension
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• Cardiac autonomic neuropathy
– A lack of autonomic nervous signalling to the heart can lead to a range of signs
and symptoms that include tachy- or bradycardia, intolerance of exercise,
impairment of baroreceptor sensitivity and resultant cardiovascular lability,
increased incidence of asymptomatic myocardial ischaemia and infarction and
congestive heart failure
• Genitourinary and gastrointestinal
– The autonomic nervous system plays a key role in the normal functioning of
the bladder, the gastrointestinal tract and in male sexual function. Autonomic
neuropathy can lead to urinary hesitancy or incontinence, dysphagia, nausea,
vomiting, diarrhoea erectile dysfunction and retrograde ejaculation
• Lack of sweating
– Denervation of sweat glands can lead to anhidrosis, particularly aﬀecting the
feet, which can lead to dry, fissured skin that is prone to infection
In addition to dysfunction of peripheral sensorimotor and autonomic nerve
fibres, people with diabetes may also experience diabetic amyotrophy, where the
spinal nerve roots that innervate the upper part of the lower limb – L2, L3 and L4 –
become inflamed. Such patients tend to have a history of T2DM and be in their
fifties or sixties and present with severe unilateral thigh pain associated with
paraesthesia that progresses to muscle weakness and wasting.87 Diabetic
amyotrophy generally resolves over the period of 6 - 12 months.
The treatment of many forms of established diabetic neuropathy are largely
supportive, with a particular focus on relieving patients from neuropathic pain (e.g.
anti-inflammatories, amitriptyline, topical capsaicin cream). However, attaining and
maintaining adequate glucose control is key to delaying the onset and progression
of diabetic neuropathy, but may not be eﬀective in reversing pre-existing diabetic
neuropathy.87, 90, 91
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The importance of diabetic neuropathy should not be understated, as it is
associated with significantly elevated levels of morbidity and mortality within the
diabetic population, through the potentially debilitating nature of its symptoms, the
elevated risk of iǌury, burns and foot ulceration as a result of sensory loss and the
dysfunction it exerts on many tissues and organ systems within the body.87, 92, 93
Macrovascular Complications of Diabetes
Coronary Heart Disease
Atherosclerosis of the coronary arteries supplying the heart can lead to
myocardial ischaemia and myocardial infarction which, in turn, can lead to
subsequent heart dysfunction, heart failure or death depending on the nature of the
myocardial iǌury sustained.
Diabetes is a major risk factor for the development of and death from coronary
heart disease (CHD); Individuals with diabetes are almost twice as likely to develop
CHD, 131% more likely to die from CHD and 82% more likely to experience a non-
fatal myocardial infarction than individuals without diabetes.76 The proportion of
CHD deaths that can be attributed to diabetes varies by age and sex, but has been
estimated as 77% in men and 89% in women across all ages, with a greater
proportion of CHD deaths at younger ages attributable to diabetes.94
The increased risks of CHD and CHD-related death in diabetes mean that
adequate control of serum glucose and early primary and/or secondary prevention
of CHD are of key importance in reducing morbidity and mortality within the diabetic
population. 
Glycaemic control has been shown to reduce the risk of cardiovascular and
CHD events. Intensive control of diabetes in patients with T1DM is estimated to
reduce cardiovascular event rates by 42%95 and fasting blood glucose
concentrations of ≥ 7 mmol/L and 5.6 - 7 mmol/L have been shown to confer a
136% and 61% excess hazard of CHD respectively in comparison to individuals
with diabetes with fasting blood glucose concentrations of 5.0 - 5.5 mmol/L.76
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Risk of CHD is amenable to lifestyle changes and control of known
cardiovascular risk factors such as hypertension and hypercholesterolaemia, both
of which are of particular importance in the increased atherogenic state associated
with diabetes.76 Control of blood pressure has been shown to be protective of
CHD76, 96, 97, with ACEis and ARBs conferring additional levels of protection in
comparison to other antihypertensive agents22, 98, 99 likely as a result of the beneficial
eﬀects on the risks of progression of diabetic nephropathy associated with these
classes of drugs.73 However, some degree of care is required when commencing
patients with diabetes on ACEis and ARBs, as these classes of drugs can lead to a
worsening of renal function in patients with renal artery stenosis (RAS). Patients with
RAS have suboptimal renal perfusion pressures due to the restriction on arterial
renal blood flow; the introduction of ACEis or ARBs will reduce intra-glomerular
blood pressure and, in the context of RAS, consequently degrade glomerular
filtration even further. It is therefore recommended that all patients with diabetes
who are commenced on ACEis or ARBs have their renal function closely monitored
and should be switched to another class of antihypertensive agent should renal
function deteriorate.70
It should be noted that the relationship between blood pressure and risk of CHD
events is continuous and non-linear, exhibiting a U-shaped relationship between
systolic and diastolic blood pressure and mortality in patients with diabetes, with
both extremes of blood pressure exhibiting increased hazards of death.100, 101
Management of blood pressure can also be more diﬃcult in individuals with
diabetes as a result of impaired renal function, which may entail the use of multiple
antihypertensive agents to adequately control blood pressure.70, 76
Cerebrovascular Disease
The underlying pathogenic mechanisms of cerebrovascular disease in diabetes
are similar to those for CHD, namely the promotion of atherogenesis as a result of
the metabolic disturbances associated with diabetes.
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The presence of diabetes is associated with an increase in atherosclerosis
aﬀecting the extra-cranial arteries supplying the brain102, 103, thereby restricting blood
flow. As with coronary heart disease, this can lead to a transient insuﬃciency of
blood flow, resulting in transient ischaemic attacks (TIAs), or infarction of tissues
distal to an atherosclerotic plaque should it rupture, leading to a stroke;
accordingly, strokes in patients with diabetes tend to be of the ischaemic rather
than haemorrhagic type. The signs and symptoms associated with TIAs and strokes
are dependent on which area of the brain has been subjected to ischaemia or
infarction. 
Diabetes is a major risk factor for the occurrence of stroke, with men and
women exhibiting a 83% and 128% excess risk of stroke respectively compared to
individuals without diabetes104; as with other vascular complications of diabetes, the
quality of glycaemic control is also associated with increased stroke risk.22
The increased risk of stroke associated with diabetes is particularly evident in
groups who would otherwise be considered at a low risk of cerebrovascular events.
The presence of diabetes can increase the odds of stroke by more than 10-fold in
individuals younger than 55 years of age105 and has been associated with an
increase in the odds of stroke in individuals aged 18-44 years with ORs ranging
from 3.3 in black females to 22.9 in caucasian males.106
In addition to the excess risk of experiencing a stroke, people with diabetes also
experience worse outcomes following a stroke, associated with a relative risk of 3.4
for stroke-related dementia107, a hazard ratio of 2.1 for experiencing recurrent
strokes108 and a relative risk of death following a stroke of 4.84.109 Additionally,
diabetes is associated with an twofold increase in the incidence of dementia,
Alzheimer’s-type dementia and vascular dementia.110
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Peripheral Arterial Disease
Peripheral arterial disease (PAD) is disorder that primarily manifests as an
insuﬃciency of blood supply to the lower limb, that can result in intermittent
claudication, indicating ischaemia of leg muscles during exertion, increased
susceptibility to foot ulcers and subsequent infection that can progress to gangrene
and osteomyelitis and an increased risk of non-traumatic lower limb amputation.
People with diabetes are more likely to develop PAD than people without
diabetes, exhibiting a relative risk of PAD between 2.6-2.9111, tend to have more
severe PAD than people without diabetes and are 5 times as likely to require an
amputation due to PAD than people without diabetes with PAD.112 Prognosis for
diabetics with PAD with foot ulcers or previous amputations are also poor, with high
rates of revision amputations and increased mortality.23, 113
For people with diabetes, the lifetime risk of developing a foot ulcer can
approach 25%.114 In the context of concomitant neuropathy and impaired wound
healing secondary to poor vascular supply of the lower limb and resultant peripheral
oedema, foot ulcers can progress to limb and life-threatening infection if not
appropriately managed; approximately 85% of lower limb amputations in people
with diabetes are preceded by a foot ulcer that has failed to heal and deteriorated to
the stage of either severe infection or gangrene.115 
The risks of both foot ulcers and lower limb amputation in diabetes increase with
both the duration of diabetes and the presence of other complications of diabetes23,
indicating that surveillance for foot ulcers in those with long-standing or
complicated diabetes mellitus is key to reducing the morbidity and mortality
associated with PAD.
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As with other vascular complications of diabetes, optimisation of glycaemic
control, hypertension and hyperlipidaemia are of importance with respect to
reducing the risk of onset or progression of PAD.113 In the case of an established
foot ulcer, management should focus on eradication of infection and maximising the
chance of healing. This may be achieved through a mixture of medical and surgical
approaches, such as broad-spectrum antibiotics, orthotic devices to reduce weight-
bearing on the aﬀected limb, stenting or bypass of proximal lower limb arteries
aﬀected by PAD, wound debridement or, as a last resort, amputation.22, 113
Early detection of foot ulcers is of great importance for the maximisation of
outcomes in diabetes and may reduce the incidence of limb- or life-threatening
PAD.116 Systematic surveillance of all people with diabetes who, by the atherogenic
nature of the disease, are at risk of foot ulcer development allows for opportunities
to deliver primary and secondary preventative care and to prompt referral to
specialist services should additional medical or surgical input be required.
Achieving the best outcomes for PAD in the context of diabetes mellitus requires
a systematic approach, and it has been suggested that the amputation rate in
people with diabetes can be reduced by between 49-85% through implementation
of the following strategies:115, 117
• Inspection of foot and footwear during routine reviews
• Preventative foot and shoe care in high-risk feet
• Structured education for patients, carers and healthcare providers
• A multifactorial and multidisciplinary approach to established foot ulcers
• Early diagnosis of and vascular intervention for PAD
• Continuous follow-up of patients with a history of foot ulcers
• Registration of amputations and foot ulcers
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Other Chronic Complications of Diabetes
Cataracts
Cataracts are considered a major cause of visual impairment in people with
diabetes; diabetes is associated with increased incidence, progression and earlier
age of onset of cataracts.118-120 The 10-year cumulative incidence of cataracts in
people with diabetes has been estimated at 8.3% for T1DM and 24.9% in T2DM.118,
120
Cataracts result from the progressive thickening and opacification of the ocular
lens due to glycation of and oxidative stress incurred by its proteins.120 Individuals
without diabetes may develop cataracts with age; in diabetes, chronic
hyperglycaemia results in sorbitol accumulation within and subsequent osmotic
changes of the lens, leading to denaturing of lens proteins, lens opacification and
visual loss.120, 121
Although the procedure most commonly used for cataract removal –
phaeoemulsification – does not diﬀer between people with and without diabetes,
people with diabetes may experience poorer visual outcomes post-surgery than
people without diabetes. Cataract surgery may induce a rapid acceleration of
diabetic retinopathy or may precipitate macular oedema, both of which may impair
or further threaten sight.120
There is some evidence that the incidence and progression of cataracts in
people with diabetes can be reduced through optimisation of glucose control,119,
120,however, with the sole exception of some juvenile cataracts observed in young
patients with T1DM, surgical cataract removal is currently the only approved
therapy to restore sight.120, 121
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Infection and Immunity
Certain infections are more common in people with diabetes and can occur with
increased severity and risk of complications.122 Certain aspects of the immune
response to infection – particularly cell-mediated immunity – may be depressed in
diabetes as a result of prevailing hyperglycaemia, however response to vaccines
appears to be largely normal in people with diabetes.122
Infection Characteristics of Note
Community-acquired pneumonia Pneumococcal infection associated with increased risk of 
death in people with diabetes
Influenza Increased mortality, risk of bacterial superinfection and 
ketoacidosis in diabetic patients
Acute bacterial cystitis Bacteriuria more common in diabetic vs. non-diabetic 
women
Acute pyelonephritis May become complicated by emphysematous infection or 
perinephric abscess formation
Fungal cystitis Colonisation may be indistinguishable from infection
Necrotising fasciitis Very high mortality, requires urgent surgical debridement
Invasive otitis externa Prompt ear, nose and throat review recommended
Emphysematous cholecystitis High mortality, emergency cystectomy required
Table 3. Features of Selected Infections in the Context of Diabetes (after Joshi et al., 1999).122
Prompt diagnosis and treatment of infection is essential to maximising outcomes
in patients with diabetes and, where appropriate, vaccination should be oﬀered to
minimise the risk of infection; in the UK, annual vaccinations for seasonal influenza
and pneumococcus are oﬀered to people with diabetes123 in light of the increased
risks of severe disease and mortality that they face should they become infected.
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Primary Care Quality
Diabetes Mellitus as an Ambulatory Care Sensitive 
Condition
ACSCs are defined as conditions for which primary care can reduce the risk of
hospitalisations, complications or more severe disease.4 The risk of these outcomes
in patients with diabetes mellitus are modifiable through control of blood glucose
concentrations, blood pressure and serum cholesterol in addition to lifestyle and
diet modifications and structured patient education.33, 71, 73, 73-76, 78, 87, 88, 90, 91, 113
Furthermore, regular, scheduled review of diabetic patients enables early
detection of and timely commencement of therapy for chronic complications of
diabetes, slowing the progression of end-organ disease, ensuring specialist review
when appropriate and reducing morbidity, mortality and potentially avoidable
healthcare resource use related to chronic complications.76, 76, 87, 95-97, 113, 115-117, 119, 120
Glycaemic control, blood pressure management, lowering of serum cholesterol,
weight checks, foot checks, immunisations and determining eligibility for
retinopathy screening are all achievable through high quality primary care. Quality
primary care, as opposed to predominantly specialist-driven secondary and tertiary
care, should take a ‘person-centred’ approach, providing holistic, continuous
personalised health care rather than delivery of problem-based episodic care (Table
4).6
Clinic or Outpatient-Based Ambulatory Care People-Centred Primary Care
Focus on illness and cure Focus on health needs
Relationship limited to moment of consultation Enduring personal relationship
Episodic curative care Comprehensive, continuous and person-
centred care
Responsibility to the patient limited to moment 
of consultation
Responsibility for health along the life cycle and 
tackling determinants of ill-health
Patients are users and consumers of the care 
they purchase
People are partners in managing their own 
health
Table 4. Comparison of conventional health care from people-centred primary care (after WHO,
2008).6
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Many of the key aspects of quality primary care as defined by the WHO6 align
closely with what would be desired for high-quality diabetes care. Diabetes,
although broadly categorised into sub-types, is a condition that exhibits a certain
degree of heterogeneity insofar as individual risks, responses to treatment and
health care needs are concerned, necessitating an individualised, yet evidence-
based and clinically sound, approach to the delivery of diabetes care.124
Measurement of Primary Care Quality
Ensuring that a health care system, or the quality of the services delivered by
health care institutions or organisations within that system, delivers high quality care
is central to ensuring that the care delivered is both clinically and cost eﬀective.
However, what defines quality in health care depends on the role that a given
stakeholder plays within that system. For example, a clinician may define quality in
terms of speed of access to diagnostic services or referrals to secondary or tertiary
care, a patient may define quality in terms of appointment availability and continuity
of care and commissioners of health care may define quality in terms of cost-
eﬀectiveness.
In a health care system such as the NHS, what defines quality and how it is
measured is tempered by the wider socio-political and economic contexts in which
the system exists. Financial constraints, particularly for publicly-funded systems,
may mean that certain aspects of quality have to be prioritised over others.
Furthermore, the perceived importance and public visibility of certain aspects of
care quality also need to be taken into account – those which are easily
recognisable and tangible to end-users of the service, such as waiting times, are
likely to remain a priority on political grounds.125
A reductionist view of quality measurement, whereby clinical outcomes are the
sole metric of interest, could be argued to be appropriate on the grounds that
patient outcomes summate the eﬀectiveness of services across all its component
parts for a given condition. Indeed, as discussed on page 2, emergency admission
rates for ACSCs are increasingly considered an outcome reflective of primary care
quality, under the prior assumption that such admissions would be predominantly
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driven by factors solely related to the quality of delivered care. However, such
approaches sideline many aspects of high quality care, such as assessing whether
the right action is being taken for the right person at the right time, ensuring equity
of services oﬀered and completely ignores the wider context in which a health
service itself exists.
Figure 4. The Donabedian model of health services and evaluation of health care quality.
Adapted from Donabedian (1966)126
The Donabedian framework126 (Figure 4) is a widely accepted approach to the
assessment of health care quality, considering a health care system in terms of its
structure, its processes and its outcomes. This framework is hierarchical in nature,
meaning that distal components can be aﬀected by proximal ones; for example, a
health care system that lacks appropriate equipment is likely to have suboptimal
processes and outcomes.
The conceptual framework proposed by Donabedian has been expanded upon
by a number of individuals and organisations since its publication in 1966,
identifying myriad domains across which the quality of care could be assessed
(Table 5). There is considerable variation between frameworks as to which domains
of patient care are considered measurable components of high-quality care, with
patient-centeredness or patient experience being the sole domain present in all of
the commonly utilised quality assessment frameworks. 
Structure Process Outcome
Patient satisfaction
Health status 
Examples
Facilities
Equipment
Personnel
Administration
Protocols
Management
Records
Diagnosis
Treatment plans
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Domains IoM OECD Quest forQuality
Performance
Assessment
Framework
NHS Next
Stage Review CQC
Safety • • • • •
Eﬀectiveness • • • • •
Outcomes of 
care • •
Patient-
centred / 
experience
• • • • • •
Timely • •
Access • • •
Eﬃcient • •
Value for 
money •
Capacity •
Equity • •
Healthy, 
independent 
living
•
Health 
improvement •
Table 5. Summary of quality domains utilised across various quality assessment frameworks.
After Goodwin et al. (2011)125 and Raleigh & Foot (2010)127.
CQC = Care Quality Commission; IoM = Institute of Medicine; OECD = Organisation for Economic Co-operation
and Development
The way in which quality of a health care system can or should be measured is
highly dependent on the context in which that information will be used. Diﬀerent
audiences for quality information are likely to have diﬀering opinions on both how
quality should be measured and even what they consider quality to be. 
Furthermore, the data that is readily available from a healthcare provider is likely
to diﬀer according to its function within the health system as a whole – for example,
providers of primary care tend to record symptoms, diagnoses and treatments,
whereas secondary and tertiary care providers tend to primarily focus on clinical
outcomes.125 There may also be elements of high-quality care, such as the doctor-
patient relationship, that are not amenable to quantification despite their perceived
importance in promoting favourable health care outcomes.
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Defining and measuring quality can become even more problematic for
individuals with chronic diseases, such as diabetes, as their care is delivered across
multiple providers, necessitating co-ordinated responses with respect to disease
management.128 Additional diﬃculties in determining what represents quality for
such patients may also arise from the impact that external factors and co-
morbidities may have on outcomes; certain aspects of high-quality care, such as
patient education and support of self-management may also be challenging to
reliably measure. In real terms, whilst quality indicators can useful information with
regards to the relationship between their attainment and long-term outcomes, they
may not encapsulate all aspects of what would be considered to be high-quality
care.125
Quality of delivered primary care is routinely measured in England using
completion rates of certain activities, either as part of a clinical incentive scheme,
such as the Quality and Outcomes Framework (QOF), or for the purposes of clinical
audit, such as the National Diabetes Audit (NDA). Whilst such quality targets have
notional or biologically sound links to ‘hard’ clinical outcomes such as hospital
admissions or mortality, explicit links between the two are seldom made for the
purposes of remuneration or audit. As such, these notional measures of quality may
be more accurately described as process or intermediate measures.
The data collected by QOF is primarily used for the purposes of rewarding
practices for their performance; annual QOF attainment by practices is also
nationally reported and utilised for benchmarking of primary care providers against
their peers. Use of such data outside of these specific contexts requires explicit
recognition of the implicit limitations and shortcomings that are likely to be present,
such as the lack of correction for case-mix and population characteristics in the
assessment of the performance of a specific practice and the potential of disease
diagnosis and coding within and between practices, meaning that direct
comparisons of practices without further adjustment would be inherently flawed.
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The use of process measures – as is commonplace in QOF – as opposed to
clinical outcomes for the assessment of quality of care confers a number of
advantages and disadvantages that must be borne in mind when reviewing,
analysing and comparing data pertaining to quality of care (Table 6).129
Advantages Disadvantages
• Provide actionable data for quality 
improvement initiatives
• In order to be valid, must be strong evidence 
that links the process to an outcome
• Data can often be obtained from existing 
electronic patient records, reducing need for 
additional data collection
• Where an explicit link between process and 
outcome is missing, demonstration of such a 
link is often diﬃcult and expensive
• Majority of process measures, especially if 
they are applied to an eligible subset of 
patients, tend to require minimal risk 
adjustment
• Lack of relevance in comparison to outcome 
measures to patients and non-clinicians
• Data on process measures can be collected 
quickly, avoiding issues associated with data 
collection for outcomes that are rare or 
measure status over a protracted period of 
time
• Majority of feasible process measures 
provide information on a specific component 
of care delivery rather than reporting a 
comprehensive measure of how well care is 
delivered
Table 6. Summary of advantages and disadvantages of process measures for the assessment of
healthcare quality.
After Rubin et al. (2001)129
In addition to the points discussed above, process measures can be subject to
confounding by indication, whereby paradoxical associations of good care with
poorer outcomes are observed.129 Such a phenomenon arises as a result of more
unwell patients – who have an increased likelihood of poorer outcomes – are more
likely to seek or receive care in comparison to those who are relatively well.
There is also potential for the adoption of new process measures to be based on
the availability of data within patient records as opposed to their clinical importance,
a possibility that is of particular relevance to a publicly-funded health system such
as the NHS. Development of new process measures that require collection of
additional information from and potential redesign of electronic patient records
could be prohibitively expensive, especially when compared to an alternative that
utilises existing data.129
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Accordingly, the bank of indicators utilised to judge quality of care is likely to
have been tempered by a degree of pragmatism and feasibility. In short, this may
mean that a given suite of process measures may not comprehensively cover all the
component processes that could aﬀect outcomes – meaning that considerable care
must be taken in how they are interpreted and how they are reported to the general
public.
In terms of relevance to the care of individuals with diabetes, the Quality and
Outcomes Framework (QOF) and the National Diabetes Audit (NDA) both describe
the quality of care delivered through a selection of process measures and are
discussed in greater detail below.
The Quality and Outcomes Framework
The Quality and Outcomes Framework (QOF) is a voluntary incentivisation
scheme oﬀered under the General Medical Services contract held between the NHS
and general practices. Since its introduction in 2004, QOF has incentivised a range
of general practice activities considered to be reflective of high quality primary care,
remunerating practices according to how well these activities were performed. In
QOF, performance is assessed according to a series of indicators that are grouped
into domains, originally clinical, organisational, patient experience and additional
services, considered to be reflective of a particular aspect of the functioning of a
general practice.130 For the 2015/16 QOF, the number of domains has been reduced
to two – clinical and public health.131
QOF indicators are ideally designed in a manner that reflects contemporaneous,
evidence-based practice. Since 2008, the National Institute for Health and Care
Excellence (NICE) has been charged with the development and maintenance of
QOF indicators. New QOF indicators are proposed by NICE as part of an indicator
‘menu’ which are presented to NHS England on an annual basis. The final list of
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QOF indicators for that year are decided upon through negotiation between NHS
England and the General Practitioners’ Committee of the British Medical
Association; this process not only reviewed proposals for new indicators, but also
considers whether existing indicators should be adjusted or removed from QOF
entirely.132
Prior to 2014/15, the indicator domains for QOF were clinical, public health,
patient experience and quality and productivity; the domains for patient experience
and quality and productivity, and the indicators within these domains, have since
been removed from QOF. The domains for 2014/15 and the indicator groupings
within them are presented in Table 7.
Clinical Domain Public Health Domain
Asthma Hypertension Blood pressure Contraception
Atrial fibrillation Hypothyroidism Cardiovascular disease - 
primary prevention
Obesity
Cancer Learning disability Cervical screening Smoking
Chronic kidney disease Mental health
Chronic obstructive 
pulmonary disease
Osteoporosis
Dementia Palliative care
Depression Peripheral arterial 
disease
Diabetes mellitus Rheumatoid arthritis
Epilepsy Secondary prevention of 
coronary heart disease
Heart failure Stroke and transient 
ischaemic attack
Table 7. Indicator domains for QOF 2014/15 for England.130
Each indicator group consists of a series of indicators that address separate
aspects of care for a particular clinical issue or disease. The performance for
indicators that pertain to treatment targets are calculated as the proportion of
patients from the relevant eligible population who have achieved the target in
question. Other indicators, such as those that require a practice to produce a
disease register, merely require a task to be completed and therefore do not have
achievement thresholds. 
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Target achievement is translated into points, the total number of which defines
the QOF income for a practice for that year; the total number of points available
across all QOF domains for 2014/15 was 559, each worth £156.92 and representing
a maximum practice QOF income of £87,718.28.133
The points value of indicators varies, broadly reflecting the diﬃculty of achieving
a specific indicator; for target-based indicators, points are awarded on a sliding
scale, with maximum and minimum levels of achievement reflecting the thresholds
for being awarded the maximum number of points and no points respectively (see
Table 8 for the 2014/15 QOF diabetes mellitus indicators).
The maximum and minimum levels of achievement also vary by indicator, with
the number of points awarded for that indicator calculated in the following manner,
where A is the calculated proportion of eligible patients achieving the target, B is the
minimum points threshold, C is the maximum points threshold and D is the total
number of points available for that target:134
Number achieving target
Number eligible for target ×100 = A
Points awarded =
A− B( )
C − B( ) ×D
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Indicator Description Points AchievementThresholds
DM017
The contractor establishes and maintains a register of all 
patients aged 17 or over with diabetes mellitus, which 
specifies the type of diabetes where a diagnosis has been 
confirmed
6 N/A
DM002
he percentage of patients with diabetes, on the register, in 
whom the last blood pressure reading (measured in the 
preceding 12 months) is 150/90 mmHg or less
8 53-93%
DM003
The percentage of patients with diabetes, on the register, in 
whom the last blood pressure reading (measured in the 
preceding 12 months) is 140/80 mmHg or less
10 38-78%
DM004
The percentage of patients with diabetes, on the register, 
whose last measured total cholesterol (measured within the 
preceding 12 months) is 5 mmol/l or less
6 40-75%
DM006
The percentage of patients with diabetes, on the register, 
with a diagnosis of nephropathy (clinical proteinuria) or micro-
albuminuria who are currently treated with an ACE-I (or ARBs)
3 57-97%
DM007
The percentage of patients with diabetes, on the register, in 
whom the last IFCC-HbA1c is 59 mmol/mol or less in the 
preceding 12 months
17 35-75%
DM008
The percentage of patients with diabetes, on the register, in 
whom the last IFCC-HbA1c is 64 mmol/mol or less in the 
preceding 12 months
8 43-83%
DM009
he percentage of patients with diabetes, on the register, in 
whom the last IFCC-HbA1c is 75 mmol/mol or less in the 
preceding 12 months
10 52-92%
DM012
The percentage of patients with diabetes, on the register, 
with a record of a foot examination and risk classification: 1) 
low risk (normal sensation, palpable pulses), 2) increased risk 
(neuropathy or absent pulses), 3) high risk (neuropathy or 
absent pulses plus deformity or skin changes in previous 
ulcer) or 4) ulcerated foot within the preceding 12 months
4 50-90%
DM014
The percentage of patients newly diagnosed with diabetes, 
on the register, in the preceding 1 April to 31 March who have
a record of being referred to a structured education 
programme within 9 months after entry on to the diabetes 
register
11 40-90%
DM018
The percentage of patients with diabetes, on the register, 
who have had influenza immunisation in the preceding 1 
August to 31 March
3 55-95%
Table 8. QOF indicators specific to diabetes mellitus, 2014/15.
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Using indicator DM007 as an example, consider a hypothetical practice that has
5,000 people with diabetes cited as eligible for this target of whom 2,000 achieve an
IFCC-HbA1c of 59 mmol/mol or less:
For DM007, the hypothetical achievement of 40% would therefore be worth
approximately £333.46. It should be noted that practices are not remunerated for
achievement that exceeds the maximum points threshold – therefore, for DM007, a
practice achieving 90% would not receive more income for this indicator than one
who achieved 75%. Furthermore, the number of registered (and indicator-eligible)
patients are not taken into account for the purposes of QOF calculation, meaning
that a practice achieving DM007 for 20 of its 50 eligible patients would receive the
same QOF income for this indicator as one achieving this target for 2,000 of its
5,000 eligible patients.
In addition to the restriction of some QOF indicators to certain patient groups
practices can elect to exclude certain patients from the eligible population for QOF
clinical indicators in a process termed exception reporting. Although declaration of
a patient as an exception is at the discretion of practice, there are only a limited
number of permitted reasons for a practice to do so:135, 136
• Refusing to attend review despite being invited on at least three occasions
during the preceding twelve months
• Not appropriate to review the chronic disease parameters due to particular
circumstances (e.g. terminal illness, extreme frailty)
Number achieving target
Number eligible for target ×100 = A
Points awarded =
A− B( )
C − B( ) ×D
2,000
5,000 ×100 = 40%
Points awarded =
40%− 35%( )
75%− 35%( ) ×17 = 2.125
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• Diagnosed within the practice or have only registered with the practice in the
preceding three months (for measurement indicators) or nine months (for
treatment and outcomes indicators)
• On maximum tolerated doses of medication whose levels remain sub-optimal
• Where prescribing a medication is not clinically appropriate (e.g. allergy, other
contraindication or adverse reaction)
• Where a given medication has not been tolerated
• The patient has exercised their right to informed dissent
• The patient has a supervening condition which makes treatment of their
condition inappropriate
• Where an investigative service or secondary care service is unavailable
A number of the criteria above by which practices can declare an individual as
an exception, in addition to setting the maximum threshold for indicator
achievement at less than 100%, respects the rights of patients to decline treatment
which their practice is financially incentivised to deliver. Despite the limited list of
reasons by which practices can declare exceptions, there are concerns that
excessive exception reporting may mask suboptimal care.137-140
The National Diabetes Audit
The National Diabetes Audit (NDA), whilst not part of a monetary incentivisation
scheme, is a major national audit that measures the eﬀectiveness of diabetes
management in England and Wales, allowing for local benchmarking of
performance and identification of best practice. In 2012/13, 70.6% of practices in
England and Wales participated in the NDA (5,980 of 8,476), representing 2,058,321
registrations of patients with diabetes.
The NDA is primarily aimed at exploring four aspects of the diabetes National
Service Framework (NSF):
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• Is everyone with diabetes diagnosed and recorded on a practice diabetes
register?
• What percentage of people registered with diabetes received the nine NICE key
processes of diabetes care?
• What percentage of people registered with diabetes achieved NICE defined
treatment targets for glucose control, blood pressure and blood cholesterol?
• For people with registered diabetes what are the rates of acute and long term
complications (disease outcomes)?
Unlike QOF, which predominantly reports on intermediate targets for diabetes,
the NDA links data pertaining to primary care performance at the level of practices
with secondary care utilisation, allowing for the assessment of whether actions
taken in primary care influence, for example, the risks of unscheduled
hospitalisations and mortality.
The targets and care process recommendations for primary care in the NDA
closely reflect NICE recommendations for diabetes; although many of these targets
are submitted for consideration of inclusion of QOF, not all of them are included
after the vetting process conducted by NHS Employers and the BMA General
Practitioners’ Committee. The NDA care processes and targets are described in
Table 9.27
Care Processes Treatment Targets Patient Support
Blood pressure BP ≤ 140/80 Delivery of structured education
BMI Cholesterol < 4mmol/L
Cholesterol Cholesterol < 5mmol/L
Foot surveillance HbA1c < 48mmol/mol (6.5%)
HbA1c¶ HbA1c ≤ 58mmol/mol (7.5%)
Retinopathy screening§ HbA1c ≤ 86mmol/mol (10.0%)
Serum creatinine
Smoking
Urine albumin
Table 9. National Diabetes Audit recommendations for care processes, treatment targets and patient
support.27
Compliance with all recommendations checked every 12 months. ¶ HbA1c is the only care process
recommended for patients aged < 12 years; § Organised by NHS Diabetes Eye Screening rather than by the
practice.
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Primary Care Quality and Ambulatory 
Care Sensitive Conditions
The QOF clinical domain includes a number of the conditions cited as ACSCs by
the NHS8, allowing for assessment of the impact that quality of care – as measured
by QOF – may have on a number of intermediate and hard clinical outcomes.
QOF, as currently reported, implies that the ability of general practices to deliver
high quality primary care is not subject to external influences, thereby considering
healthcare as a closed system. Socioeconomic factors such as population age,
ethnicity and deprivation exert a considerable influence on the ability of local
primary care services to maximise achievement of quality indicators and may
influence the impact that delivered quality may have on their population for a
number of ACSCs.13, 141-145 Whilst a number of factors aﬀecting demand and need
for primary care services are taken into account for the calculation of the global sum
allocated to individual practices146, it is likely that practices located in the most
deprived areas are likely to have to expend more resources in order to attain a
comparable level of quality target achievement, raising the possibility that practices
in areas with the highest needs are less likely to receive the highest levels of funding
via QOF.147
The introduction of QOF has led to an increase in delivered care quality for the
activities that it incentivises, albeit at the slight expense of non-incentivised
activities.148 The focused attention of practices as a result of the implementation of
QOF is also evident in the way that practices are remunerated for their performance,
with maximal pay for performance being delivered to a practice at achievement
levels that are often considerably less than 100%.130 This aspect of QOF leads to a
‘ceiling eﬀect’ in achievement levels; once practices reach the proportion of patients
achieving a specific target, there is no additional financial incentive to strive for
higher levels of achievement, potentially reducing QOF’s impact on improving
health outcomes.149 Exception reporting of patients could be argued to further
compound the issue of the implicit acceptance of maximal rewards for sub-maximal
delivery of quality care.150
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Accordingly, for the purposes of analysing associations between primary care
quality and outcomes, utilising practice QOF point scores as a metric of quality may
mask the eﬀect of performance levels that exceed the maximum points thresholds,
as considerable variation in practice performance exists above this threshold (see
Table 10 and Figure 5). Furthermore, in the context of generally high levels of QOF
point achievement149, usage of the underlying achievement for QOF indicators may
provide a more appropriate metric of quality and avoid assumptions that
performance of practices achieving the highest number of points for a given
indicator is homogenous.
Indicator
Practices
Achieving Max
Points¶
% of
Practices§
Underlying Achievement
Median IQR Mean SD
DM23 6,054 73.4% 53.79% 10.10% 54.41% 9.49%
DM24 7,277 88.3% 78.69% 8.26% 77.58% 7.52%
DM25 3,842 46.6% 89.53% 6.30% 88.05% 6.11%
Table 10. Practices achieving maximum points for QOF indicators DM23 (HbA1c ≤ 7% / 53.0 mmol/
mol), DM24 (HbA1c ≤ 8% / 63.1 mmol/mol) or DM25 (HbA1c ≤ 9% / 74.9% mmol/mol) in 2010/11.
¶ Maximum points rounded down to integer; § Total number of practices participating in QOF for 2010/11 was
8,246, 1 practice had missing data and was not included in the denominator.
Figure 5. Distribution of practice achievement for QOF indicator DM24 for 2010/11.
Graph on left shows achievement for all practices in 2010/11; graph on right shows achievement for practices at
maximum points threshold. Dotted red line denotes the maximum points threshold (70% for DM24 in 2010/11).
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Concerns have also been raised regarding the predominantly process-focused
nature of QOF and the use of intermediate outcomes as opposed to hard clinical
outcomes; the only QOF indicator that utilised a hard clinical outcome (Epilepsy 8,
recording as seizure-free for the past 12 months) is no longer part of QOF.130, 151 In
general terms, the volume of evidence that evaluates the relationship between QOF
performance and hard outcomes is limited and requires further evaluation to ensure
clinical and cost-eﬀectiveness.143, 149, 152, 153 There is also concern that the nature of
incentivised activity in QOF scores may encourage practices to simply improve
recording of patient activity as opposed to meaningfully improving their quality of
care.149
Despite the debate regarding whether the measurement of quality in QOF is
appropriate and represents an accurate estimate of the quality of care delivered by
a practice, some aspects of QOF are desirable with respect to the management of
chronic diseases such as diabetes, especially in the context of multi-morbidity.154
The introduction of QOF also led to improvements in intermediate outcomes across
all ethnic and deprivation groups, but may have increased inequality between strata
of these groups.150, 152, 155-157
Two aspects of QOF may, to a degree, contribute to the widening inequality gap
observed in a number of studies; awarding maximal pay for sub-maximal
performance and the ability of practices to exclude patients from achievement
calculations does pose the possibility of gaming that may bias against individuals
from ethnic minorities and deprived backgrounds. These groups may experience a
relative lack of accessibility to primary health care services or may perceive that
such services do not cater to the prevalent societal barriers that preclude
accessible and appropriate primary care.
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To date, much of the existing literature discussing the relationship between
measured quality of care and hard outcomes has generally found statistically
significant but arguably clinically marginal benefits for some patient groups.141, 145, 158
Generally, other practice and population characteristics have stronger associations
that measured primary care quality with health outcomes, particularly primary care
access and deprivation – although the possibility of potential autocorrelation
between deprivation, certain ethnic groups and age and QOF attainment cannot be
excluded.141, 142, 144, 159, 160
Access to primary care is a particularly important aspect of eﬀective, high-
quality primary care, albeit an aspect of primary care that is no longer assessed in
QOF. A lack of adequate patient access to services is associated with increased
attendances at emergency departments161, the incidence of ESRF in patients with
diabetes162, detection of chronic disease163 and admission rates for ACSCs144, 164, 165;
insuﬃcient access to primary care may also exacerbate the eﬀects of social
inequality on health outcomes.166
Access to primary care may also decrease where there demand for it, such as
deprived areas, areas with a high proportion of elderly residents and areas with a
prevalence of chronic disease, is highest.163 This may create a vicious cycle for
many practices with high caseloads and objectively higher need for services are
inadequately resourced to provided the highest levels of care quality and, as a
result of suboptimal performance on incentivisation schemes such QOF receive less
income than practices with lower demand for services. In turn, eﬀorts to increase
accessibility – and provide services that are appropriately tailored to specific
groups167 – may simply not be aﬀordable and achievable.
The introduction of QOF has led to improved recording of disease prevalence
and clinical activities and may indirectly inform practices of the needs of their
population.149 However, the manner of QOF incentivisation has been argued to
promote high-workload activities of marginal eﬀectiveness as opposed to
encouraging practices to address the needs of their registered population and the
provision of preventative services.168
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Further research is needed to explore whether QOF, and schemes analogous to
it, provide clinical and cost-eﬀectiveness. Despite positive associations between
incentivisation schemes and intermediate clinical outcomes,157, 169-171 performance in
these schemes has been shown in some studies to only have, at best, modest
associations with hospital admissions for diabetes mellitus141, 158, 172, COPD144 and
epilepsy.173 emergency department attendance rates159, admissions for coronary
heart disease143, admissions for strokes145 and admissions for primary care sensitive
conditions.174 A 2011 Cochrane review concluded that there was insuﬃcient
evidence to determine whether or not incentivisation schemes truly increased the
quality of primary care153 However, it should be noted that there is a lack of
agreement as to what defines quality with respect to ongoing management of
diabetes175 and that the ability of practices to deliver care that is deemed to be of
high quality is subject to external influences, particularly the levels of deprivation in
the population that they serve.142
As demands on primary care stand to increase, through population ageing,
changes in lifestyle and increased prevalence of chronic disease, incentivisation
schemes must be reactive to the challenges faced by primary care and encourage
delivery of eﬀective, timely and accessible care to the whole population rather than
to a subset of individuals who have the means and ability to avail themselves of
primary care.
Research Aims and Objectives
As discussed above, whilst there is evidence supporting the positive eﬀect that
quality improvement schemes such as QOF have had on attainment of intermediate
clinical outcomes, the eﬀects of the quality of diabetes management in primary care
have on ‘hard’ clinical outcomes require further exploration.
Whilst it is both logical and pathophysiologically sound to assume that attaining
the myriad intermediate outcomes in QOF would lead to improved outcomes, there
is relatively little evidence to support such an association; there is also the implicit
assumption that QOF is a reliable instrument to measure and quantify quality.
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In order to assess whether actions taken in primary care can aﬀect the
occurrence of outcomes such as unscheduled hospital admissions, a potential
downstream marker of sub-optimal care, and mortality, this thesis will examine not
only the quality of care delivered by practices to its patients, but also that which is
received by patients themselves on these outcomes.
Practice-Level Analyses
The first series of analyses will concentrate on practice-level analyses and the
count of emergency hospital admissions. Previous studies have tended to limit
themselves to emergency admissions where diabetes is the direct cause of
admission (i.e. the primary diagnosis). As diabetes is a chronic condition that can
lead to dysfunction of a number of organ systems which may take priority in the
description of presenting complaints and diagnoses, there is potential for this
method of admission selection to grossly underestimate the true burden of
emergency admissions arising from the population with diabetes.
Use of QOF points attained is also common in previous studies that aim to
examine what associations may exist between primary care quality and outcomes.
As the maximal levels of remuneration are awarded at sub-maximal levels of
practice performance, utilisation of points attained may mask diﬀerences in the
actual underlying achievement between practices. As such, the practice-level
analyses presented in this thesis will utilise underlying achievement of QOF
indicators. Furthermore, as there is potential for declared levels of performance
under QOF to be confounded by exception reporting, the eﬀects of exception
reporting will also be investigated.
The main research aims of the practice-level analyses will be:
• To assess the degree to which reliance on the primary diagnosis field alone to
identify admissions related to diabetes may underestimate the true burden of
emergency admissions from the population with diabetes;
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• To explore the associations between underlying achievement of selected QOF
indicators – those that are diabetes-specific and those that describe aspects of
practice accessibility – has on emergency admissions from the registered
population with diabetes.
Patient-Level Analyses
Although practice-level analyses will enable exploration of the eﬀect that the
levels of primary care quality reported by general practices has on their registered
population with diabetes, the nature of such analyses preclude inferring what the
eﬀects of quality may be at the individual level.
The second set of analyses in this thesis will be relatively unique through their
utilisation of patient-level data that links primary care activity with age-sex
standardised hospital admissions, examining the links between the quality of care
received by a patient and the outcomes that they experience, allowing for direct
assessment of the eﬀectiveness of receiving high quality care with respect to
emergency admissions, readmissions and mortality. 
The metrics of quality to be assessed will include patient achievement of a
number of diabetes-specific QOF intermediate outcome measures and receipt of
the nine NDA care processes. In addition to the analyses of receipt of high-quality
care, diﬀerences in the impact of co-morbidity between people with and without
diabetes will also be examined.
The main research aims of the practice-level analyses will be to assess:
• Whether achievement of intermediate outcomes and receipt of care processes
are associated with changes in emergency admission and readmission rates;
• Whether achievement of intermediate outcomes and receipt of care processes
are associated with mortality and the likelihood of death resulting from a
diabetes-related cause.
• Whether the presence and degree of co-morbidity presents diﬀerential levels of
risk with respect to all-cause mortality according to whether a given patient has
or does not have diabetes.
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Practice-Level Analyses
Identification of Admissions from The 
Population With Diabetes
Background
Many existing studies that utilise Hospital Episode Statistics (HES) for
examination of admission rates for ACSCs such as diabetes tend to identify such
admissions from the first diagnosis field alone, under the assumption that this is the
diagnosis directly precipitating the need for admission.144, 145, 158
As diabetes is a known risk factor for cardiovascular disease, cerebrovascular
disease, peripheral arterial disease, visual loss and renal failure, it is likely that
diabetes may be cited as a supporting diagnosis as opposed to the diagnosis that
directly led to admission. For example, a person with diabetes who is admitted to
hospital as a result of a myocardial infarction is more likely to (and, it could be
argued, more appropriately) have myocardial infarction recorded as a primary
diagnosis even though the diabetes is a likely precipitant of atherosclerotic coronary
artery disease.
As such, quantifying hospital admissions due to diabetes through the primary
diagnosis alone is likely to grossly underestimate the true burden of diabetes and its
complications on secondary and tertiary care providers.
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Methodology
Data Sources
Information on hospital admissions in England is available through Hospital
Episode Statistics (HES). HES provides data on all admissions, outpatient and
Accident and Emergency (A&E) attendances. As HES data has the potential to be
patient-identifiable, only aggregate data pertaining to admissions and attendances
across England is available to the public; data describing hospital-level activity is
only available to approved individuals and institutions who are able to comply with
Data Protection legislation.
With respect to hospital admissions, HES presents data as a series of episodes
and spells. Episodes are defined as a period of contiguous care under the
management of a single Consultant, whereas spells are a period spent within a
single secondary or tertiary care provider. Thus, spells can be comprised of multiple
episodes; admissions in which a patient is transferred from one provider for another
are referred to as ‘super-spells’, where a single admission is comprised of multiple
spells.
At the present time, little of the HES data pertaining to admissions is input
automatically; information regarding diagnoses and procedures performed are
retrospectively entered from the physical copy of patient notes by a team of Clinical
Coders, administrators who have been trained on the processes and methods of
coding (see Figure 6). Diagnoses for individual episodes, in addition to those
recorded at admission, are recorded using the 10th Revision of the International
Statistical Classification of Diseases and Related Health Problems (ICD-10).176 Up to
20 diagnoses for each episode can be recorded, with the diagnoses assigned on
admission considered representative of the presenting complaint(s) and current
diagnoses that a patient has.
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Figure 6. Overview of the clinical coding process.
Data pertaining to hospital admissions in England for the period 1st April 2005 to
QOF, in and of itself, does not currently contain any ‘hard’ clinical outcomes in its
assessment of the quality of delivered care, relying instead on intermediate
outcomes that may reflect engagement with care (both on the part of the patient
and the primary care team), recording of data to support eﬃcient delivery of care
and attainment of physiological goals, such as specific blood pressure and serum
cholesterol targets, that imply eﬀective treatment (HES field names are presented in
italics):
Patient notes
Diagnoses
Main complaint or 
condition treated in 
episode
Other diagnoses
Find matching 
ICD-10 code
Find matching 
ICD-10 code
Assign 
primary 
diagnosis 
code
Assign 
codes for 
other 
diagnoses
Continue reviewing 
notes
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• Citation of diabetes mellitus (ICD-10 codes E10, E11, E13 and E14 in line with
WHO recommendations177) in any diagnosis field (diag_01 to diag_20 inclusive)
• Method of admission recorded as an emergency (admimeth = 21, 22, 23, 34 or
28)
• Age on admission (startage) ≥ 17 years and ≤ 120 years (as values > 120 are
used to denote neonatal ages in HES)
• Admission date (admidate) in the range 1st April 2005 - 31st March 2011
inclusive
To take account of multiple-episode spells, only data pertaining to the first
episode of any given spell (epiorder = 1) was utilised so as to capture the diagnoses
on admission and to avoid double-counting of diagnoses. Admissions where the
recorded discharge date (disdate) preceded the admission date (admidate) were
excluded.
Admissions were classified according to the type of diabetes cited in any
diagnosis position; ICD-10 codes of E10 and E11 were assumed to be analogous to
T1DM and T2DM respectively; ICD-10 codes E13 (other specified diabetes mellitus)
and E14 (unspecified diabetes mellitus) were grouped as ‘other and unspecified
diabetes mellitus.
For admissions that cited diabetes multiple times across diagnosis fields, those
that utilised the same ICD-10 classification for diabetes type were classified
accordingly (i.e. an admission that cited E10 twice would be classified as T1DM);
admissions that cited diﬀerent diabetes types were classified as ‘other and
unspecified diabetes mellitus’.
In addition to diabetes type, derived from the first three characters of the ICD-10
code, data on diabetes complications were also available. All diabetes types share
a common suﬃx that denotes which complication was present at the time of
diagnosis (see Table 11).
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ICD-10 Suﬃx Description
.0 With coma
.1 With ketoacidosis
.2 With renal complications
.3 With ophthalmic complications
.4 With neurological complications
.5 With peripheral circulatory complications
.6 With other specified complications
.7 With multiple complications
.8 With unspecified complications
.9 Without complications
Table 11. ICD-10 suﬃxes used to denote complications of diabetes mellitus.
For admissions where diabetes was cited multiple times, a similar approach to
that used for classifying diabetes type was used for complications, whereby
admissions with concordant complications were coded as such. For admissions
with multiple citations of diabetes, a suﬃx of .9 was superseded by the first suﬃx
that denoted a specific complication unless the only other suﬃx was also .9; those
with multiple suﬃxes denoting specified complications were classified as ‘mixed’
complications.
Primary diagnoses for admissions citing diabetes were also determined and
ranked according to their frequency. Descriptions for each ICD-10 code were
incorporated into the dataset via a 1:1 merge. The ranking of diagnoses was
performed twice; one ranking included ICD-10 symptom codes (Rxx.x) and the
other excluded these codes. Data were cleaned, managed and tabulated in STATA
IC version 12.1 (StataCorp, TX, USA) for Mac OS X.
Results
A total of 2,136,084 emergency admissions citing diabetes mellitus (E10, E11,
E13 or E14) in any diagnosis position were identified in individuals aged ≥ 17 years
and ≤ 120 years during the period 1st April 2005 – 31st March 2011 inclusive. 
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The maximum number of diagnoses used across all admissions was 14.
Diabetes was most commonly cited first in the third diagnostic position (516,833
admissions / 24.20%) and was the first diagnosis in 6.26% (133,791) of admissions.
The mean and median diagnostic positions were 3.860 and 4 respectively (see
Figure 7 and Table 12). 
Diagnosis Position
Diabetes First Cited
Minimum 1
p25 2
p50 4
p75 5
Maximum 14
Mean 3.860
SD 1.948
Variance 3.796
Table 12. Descriptive statistics of diagnosis position in which diabetes was first cited in HES
emergency admissions, 2004/05-2010/11.
p25 = 25th centile; p50 = 50th centile; p75 = 75th centile; SD = standard deviation
Figure 7. Distribution of diagnosis position in which diabetes was first cited in HES emergency
admissions, 2004/05-2010/11.
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The most common type of diabetes cited was T2DM (1,789,802 admissions /
83.79%); T1DM was the next most common (280,255 admissions / 13.12%) and
other & unspecified diabetes comprised the remainder of admissions (66,027
admissions / 3.09%) (Table 13). T2DM was the most commonly cited diabetes type
in all bar the first diagnosis position, where T1DM was marginally more common
(47.10% versus 47.06%; 63,010 versus 62,962 admissions) (Figure 8). Diabetes was
cited multiple times in 44,290 (2.07%) admissions; 41,973 (94.77%) of these did so
in a concordant manner and 2,315 (5.23%) cited discordant diabetes types.
DM Type n %
T1DM 280,255 13.12%
T2DM 1,789,802 83.79%
Other & Unspecified 66,027 3.09%
TOTAL 2,136,084 100.00%
Table 13. Diabetes types cited in HES emergency admissions, 2005/06 - 2010/11.
T1DM = Type 1 diabetes mellitus; T2DM = Type 2 diabetes mellitus
Figure 8. Diabetes types by diagnosis position in which diabetes was first cited in HES emergency
admissions, 2005/06 - 2010/11.
Percentages shown are the proportion of diabetes citations declared as T2DM for a given diagnosis position.
T1DM = Type 1 diabetes mellitus; T2DM = Type 2 diabetes mellitus
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The overwhelming majority of diabetes citations were made with the suﬃx .9
(1,918,633 admissions / 89.82%), denoting no complications (Table 14). Suﬃx .9
was the most common suﬃx used across all diagnostic positions where diabetes
was first cited, although the greatest diﬀerentiation in suﬃxes was observed in
diagnosis position 1, where suﬃx .9 accounted for 40.07% (53,613) of diabetes
citations, suﬃx .1 (ketoacidosis) accounted for 31.09% (41,594) of diabetes
citations and suﬃx .5 (peripheral circulatory) accounted for 12.82% (17,147) of
diabetes citations (Figure 9). 
Diabetes Complication n %
x.0 Coma 7,654 0.4%
x.1 Ketoacidosis 47,794 2.2%
x.2 Renal 33,375 1.6%
x.3 Ophthalmic 44,260 2.1%
x.4 Neurological 24,172 1.1%
x.5 Peripheral circulatory 40,131 1.9%
x.6 Other specified 4,781 0.2%
x.7 Multiple 1,249 0.1%
x.8 Unspecified 4,328 0.2%
x.9 No complications 1,918,633 89.8%
≥ 2 complications 9,707 0.5%
TOTAL 2,136,084 100.0%
Table 14. Diabetes complications cited in HES emergency admissions, 2005/06 - 2010/11.
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Figure 9. Diabetes complications by position in which diabetes was first cited in HES emergency
admissions, 2004/05 - 2010/11.
Percentages shown are the proportion of diabetes citations with a suﬃx of .9 for a given diagnosis position;
.0 = coma; .1 = ketoacidosis; .2 = renal; .3 = ophthalmic; .4 = neurological; .5 = peripheral circulatory; .6 = other
specified complications; .7 = multiple complications; .8 = unspecified complications; .9 = no complications
The most common suﬃx across all diabetes types was .9, with 71.97%
(201,705) of T1DM, 92.75% (1,660,081) of T2DM and 86.10% (56,847) of other and
unspecified diabetes being cited in this manner. T1DM showed the greatest
diﬀerentiation with respect to recorded complications, with 13.14% (36,829) cited
as complicated by ketoacidosis, 3.95% (11,074) cited ophthalmic complications
and 3.15% (8,830) cited renal complications (Figure 10)
The most common first diagnosis, including ICD-10 codes denoting symptoms
(Rxx.x), across all emergency admissions citing diabetes was ‘chest pain,
unspecified’ (R07.4), accounting for 98,167 (4.60%) emergency admissions. Three
of the top 30 primary diagnoses were coded as diabetes – E10.1, E11.9 and E10.9,
ranked 9th (34,096, 1.60%), 11th (32,111, 1.50%) and 23rd (18,975, 0.89%)
respectively.
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Figure 10. Diabetes complications by diabetes type in HES emergency admissions, 2005/06 -
2010/11.
Percentages shown are the proportion of diabetes citations with a suﬃx of .9 for a given diagnosis position;
.0 = coma; .1 = ketoacidosis; .2 = renal; .3 = ophthalmic; .4 = neurological; .5 = peripheral circulatory; .6 = other
specified complications; .7 = multiple complications; .8 = unspecified complications; .9 = no complications
Once first diagnoses citing ICD-10 symptom codes were discounted and
superseded by the first non-symptom diagnosis in relevant admissions, the most
common first diagnosis was ‘non-insulin-dependent diabetes mellitus without
complications’ (E11.9), accounting for 114,232 (5.35%) emergency admissions
(Table 15).
Of note, ‘hypoglycaemia, unspecified’ (E16.2) placed highly in the lists including
and excluding symptom codes, ranked 5th (39,275, 1.84%) and 7th (41,082, 1.92%)
respectively.
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Rank
Including Symptom Codes (Rxx.x) Excluding Symptom Codes (Rxx.x)
ICD-10 Code n % ICD-10 Code n %
1 R07.4 Chest pain, unspecified 98,167 4.60% E11.9
Non-insulin-
dependent diabetes 
mellitus
114,232 5.35%
2 N39.0 Urinary tract infection,site not specified 67,958 3.18% N39.0
Urinary tract 
infection, site not 
specified
73,100 3.42%
3 R55.X Syncope and collapse 46,728 2.19% I20.9 Angina pectoris, unspecified 47,485 2.22%
4 J22.X
Unspecified acute 
lower respiratory 
infection
40,320 1.89% I10.X Essential (primary) hypertension 42,596 1.99%
5 E16.2 Hypoglycaemia, unspecified 39,275 1.84% J22.X
Unspecified acute 
lower respiratory 
infection
41,818 1.96%
6 I20.0 Unstable angina 37,030 1.73% I48.X Atrial fibrillation and flutter 41,209 1.93%
7 I50.0 Congestive heart failure 35,438 1.66% E16.2
Hypoglycaemia, 
unspecified 41,082 1.92%
8 R07.3 Other chest pain 34,734 1.63% I50.0 Congestive heart failure 38,116 1.78%
9 E10.1 Insulin-dependent diabetes mellitus 34,096 1.60% I20.0 Unstable angina 37,694 1.76%
10 K52.9
Non-infective 
gastroenteritis and 
colitis, unspecified
33,583 1.57% K52.9
Non-infective 
gastroenteritis and 
colitis, unspecified
37,587 1.76%
Table 15. Top 10 first diagnoses, including and excluding ICD-10 symptom codes, across all
emergency admissions citing diabetes mellitus in HES 2005/06 - 2010/11.
ICD-10 = International Classification of Diseases, 10th Revision
Discussion
From the data presented above, it is evident that sole reliance on the first
diagnosis field to identify potentially diabetes-related emergency admissions is far
from optimal; only 6.26% of HES emergency admissions citing diabetes and,
therefore, have the potential to be related to diabetes, in the period 1st April 2005 -
31st March 2011 would have been identified by such an approach. Failing to
identify a considerable proportion of admissions that may be related to diabetes is
likely to introduce bias and reduce statistical power.
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The only diagnostic position that demonstrated a meaningful diﬀerentiation of
suﬃxes denoting complications of diabetes was the first, where coma and
peripheral circulatory complications featured prominently. It is conceivable that
patients who present with complications that may be considered pathognomonic of
diabetes to clinicians are more likely to have their current condition directly ascribed
to diabetes. Conversely, emergency admissions that arise from conditions for which
diabetes confers an excess risk but are relatively common in the general population
are likely to take precedence over diabetes insofar as assigning the first diagnosis
(which could well be considered as the proximal cause) for an admission.
There are also indications that the suﬃx .9, denoting diabetes without
complications, is grossly overused in HES; .9 was the most common suﬃx across
all diagnosis positions, including the first, and was consistently used in over 90% of
all diabetes citations in diagnosis positions 2 to 14. This raises two issues; first, it is
evident that the suﬃx .9 is being utilised as the ‘default’ code for diabetes and may
more accurately reflect that diabetes has been recorded without mention of
complications rather than there being a de facto absence of them; secondly, this
finding implies that utilisation of suﬃxes in HES data to identify specific
complications of diabetes would be subject to poor sensitivity.
The proportion of admissions citing diabetes multiple times was relatively small
(44,290, 2.07%). The majority of instances of multiple diabetes citations did so
using concordant diabetes types (41,975, 94.77%), but this finding may indicate a
lack of clarity insofar as the procedure for defining diabetes types or diabetes
complications is concerned.
The accuracy of diabetes diagnoses in HES may also be related to a particular
shortcoming of the ICD-10 coding schema; the present version of ICD-10 has no
suﬃx for denoting diabetes complicated by cardiovascular disease, for which
diabetes confers a considerable excess risk. The addition of such a suﬃx may aid
the accuracy of diabetes complication coding and may, in some cases, promote
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diabetes to a higher diagnosis position, thereby potentially aiding identification of
emergency admissions that are diabetes-related. The frequency of primary
diagnoses citing cardiovascular disorders in the context of the presence of diabetes
in emergency admissions (Table 15) highlights the need for consideration of this
issue.
It should be noted that, whilst identifying emergency admissions attributable to
diabetes from the first diagnosis field alone is subject to poor sensitivity, the other
extreme – classing an emergency admission as attributable to diabetes if diabetes
is cited anywhere – is also far from ideal and subject to poor specificity. A ‘middle-
ground’ approach, whereby an emergency admission is classed as resulting from
diabetes if a known complication of diabetes is cited as the first diagnosis in the
context of diabetes with any suﬃx being cited in any other diagnostic position, may
be a potential solution to this problem. Of course, this is a moot point for studies
that are analysing outcomes from a known cohort of people with diabetes.178, 179
One important aspect of clinical coding is that Coders, whilst trained in the
extraction and classification of data from medical notes, are not clinically trained; as
such, the quality of coding that they can output is intrinsically linked to the clarity
and completeness of the information recorded in patient notes. Accordingly, if a
clinician has not specified the inter-relationship between the condition that has
precipitated an emergency admission and chronic disease, this information is
unlikely to be reflected in the diagnosis codes – both in terms of their presence and
order – assigned to a particular episode of care.
Whilst the use of datasets such as HES for research enables large-scale
ecological studies linking primary care with outcomes, it should be borne in mind
that the primary use for HES data is for quantifying hospital activity, where the
presence of diagnosis codes is more important than their explicit order. Regardless,
accurate identification of secondary and tertiary care utilisation resulting from
chronic diseases such as diabetes will be of increasing importance. Accurately
monitoring the rate of emergency admissions ascribable to diabetes will allow for
assessment of healthcare quality, secondary and tertiary prevention activities, aid
allocation of resources and strengthen the robustness of studies examining
predictors of unscheduled care usage.
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Practice QOF Performance and 
Emergency Admissions
Background
One of the primary goals of QOF, through remuneration of general practices for
specified activities, is to improve the quality of delivered healthcare. By extension,
improved outcomes – such as a reduced burden of potentially avoidable
unscheduled care – should result from improvements in primary care activity.
QOF is a voluntary incentivisation scheme that rewards general practices for
certain activities; practices are remunerated for their performance against a number
of indicators, with tiers of payment for a given indicator being awarded at specific
achievement levels. In order to prevent atypical patients, or those with terminal
diagnoses in whom aggressive treatment would not be considered appropriate,
impacting negatively on practice income, general practices can cite patients as an
‘exception’ to a specific indicator under a specific set of circumstances135, thereby
removing them from the eligible population for the purposes of calculating practice
achievement.
QOF, in and of itself, does not currently contain any ‘hard’ clinical outcomes in
its assessment of the quality of delivered care, relying instead on intermediate
outcomes that may reflect engagement with care (both on the part of the patient
and the primary care team), recording of data to support eﬃcient delivery of care
and attainment of physiological goals, such as specific blood pressure and serum
cholesterol targets, that imply eﬀective treatment.
- 64 -
The evidence that exists to support QOF driving improvements in population
health – as opposed to the mere act of attaining targets – is somewhat limited and
inconsistent in its findings. Studies have indicated an association between
decreased emergency hospital admission rates for conditions incentivised in
QOF,180 others have observed that relatively few clinically-based indicators are
associated with reduced admissions;145 however, access to primary care services is
an important, and somewhat more consistent, determinant of unscheduled care
utilisation.144, 145, 161, 162
It should be noted, however, that other studies observed that primary care
quality, as measured by QOF, showed no evidence of an association with
decreased admission rates143 or, where such an association was present, the
estimated diﬀerence in admission rates was of questionable clinical significance.143
The public health impact of the quality measures in QOF has also been called into
question149, 153, 160, 168, as has the lack of equity across ethnic groups and in deprived
communities.142, 155-157, 181 The ability of practices to declare patients as an
‘exception’ with respect to specific targets, combined with the fact that maximum
payment for a given indicator is awarded at achievement levels often considerably
less than 100%, may further disenfranchise minorities and other patient groups who
are subject to poor access to, or lack of appropriateness of, services in a bid to
protect practice income.136, 139, 150
In order to further explore the impact of the various potential determinants of
unscheduled hospital care utilisation described above, this analysis will explore a
number of relationships between reported QOF performance, practice and
population characteristics and emergency admissions from the registered
population with diabetes in England over a period of six years.
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Methodology
Data Sources
Multiple data sources were utilised for this analysis; Hospital Episode Statistics
data for England (HES), practice QOF returns, practice population age and sex
structure, practice population ethnicity estimates, practice workforce data, English
Index of Multiple Deprivation (IMD) data, rural-urban area classification data and
age-sex specific estimates of diabetes prevalence. All data were linked via the
unique practice identifier as reported in QOF.
Quality and Outcomes Framework Data
All general practices in England are required to submit their QOF data to the
Health & Social Care Information Centre (HSCIC) at the end of each financial year
(1st April - 31st March inclusive) for the purposes of determining QOF payments to
practices and calculation of aspiration payments, a monthly payment related to
expected levels of achievement in the coming financial year.134, 182, 183
QOF results for each practice for each financial year are published by the
H&SCIC as publicly-available data184, providing data on points awarded, underlying
achievement and exceptions declared for all indicators.
Data for practice-level achievement and exception reporting in England was
obtained from the H&SCIC184 for QOF years 2005/06 – 2010/11 inclusive. The
presence of individual indicators in QOF varied by year and, in order to maximise
comparability between years and the degree of variation between performance of
individual general practices, diabetes indicators were thematically grouped into
process measures, intermediate cardiovascular outcomes (blood pressure and total
cholesterol targets) and stringent, intermediate and moderate glycaemic control
(see Table 16). These indicator groupings were utilised for both underlying
achievement and exception rates.
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The rationale for combining the indicators for attainment of blood pressure and
total cholesterol targets, aside from the advantages of maximising inter-practice
variability in performance, was to arrive at a single predictor that summarised
activities taken to minimise cardiovascular risk other than glycaemic control.
Patient experience indicators PE07 (proportion of patients able to obtain a
consultation within 2 working days) and PE08 (proportion of patients able to obtain
a consultation more than two days ahead), available from QOF years 2008/09 to
2010/11 inclusive, were considered as separate indicators.
Indicator 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
Process Measures
DM02 BMI record ✓ ✓ ✓ ✓ ✓ ✓
DM03 Smoking record ✓ ✗ ✗ ✗ ✗ ✗
DM04 Smoking cessation ✓ ✗ ✗ ✗ ✗ ✗
DM08 Retinal screening record ✓ ✗ ✗ ✗ ✗ ✗
DM09 Peripheral pulses record ✓ ✓ ✓ ✓ ✓ ✓
DM10 Neuropathy record ✓ ✓ ✓ ✓ ✓ ✓
DM11 BP record ✓ ✓ ✓ ✓ ✓ ✓
DM13 Microalbuminuria record ✓ ✓ ✓ ✓ ✗ ✗
DM14 Serum creatinine record ✓ ✗ ✗ ✗ ✗ ✗
DM15 ACEi / A2A treatment for proteinuria ✓ ✓ ✓ ✓ ✓ ✓
DM16 Total cholesterol record ✓ ✗ ✗ ✗ ✗ ✗
DM18 Influenza immunisation ✓ ✓ ✓ ✓ ✓ ✓
DM21 Retinal screening record ✗ ✓ ✓ ✓ ✓ ✓
DM22 Serum creatinine / eGFR record ✗ ✓ ✓ ✓ ✓ ✓
Cardiovascular Intermediate Outcomes
DM12 BP ≤ 145/85 mmHg ✓ ✓ ✓ ✓ ✓ ✓
DM17 Total cholesterol ≤ 5.0 mmol/L ✓ ✓ ✓ ✓ ✓ ✓
Stringent Glycaemic Control
DM06 HbA1c ≤ 7.4% ✓ ✗ ✗ ✗ ✗ ✗
DM20 HbA1c ≤ 7.5% ✗ ✓ ✓ ✓ ✗ ✗
DM23 HbA1c ≤ 7.0% ✗ ✗ ✗ ✗ ✓ ✓
Intermediate Glycaemic Control
DM24 HbA1c ≤ 8.0% ✗ ✗ ✗ ✗ ✓ ✓
Moderate Glycaemic Control
DM07 HbA1c ≤ 10.0% ✓ ✓ ✓ ✓ ✗ ✗
DM25 HbA1c ≤ 9.0% ✗ ✗ ✗ ✗ ✓ ✓
Table 16. Thematic groupings of diabetes-specific QOF indicators and their availability by QOF year,
2005/06 - 2010/11.
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Assessment of practice level performance was based on the underlying
achievement for each group of diabetes indicators and separately for each patient
experience indicator (PE07 and PE08). Underlying achievement was calculated as
follows:
The number of patients achieving a given target equates to the total number of
patients meeting or exceeding a given target; the target denominator is the number
of patients who are eligible for consideration for a given target, less those that have
been declared as an exception. 
Indicator-level exception rates are only publicly available for the QOF year
2007/08 onwards and do not apply to the patient experience indicators chosen for
this analysis (PE07 and PE08). Exception ‘rates’ are defined as the proportion of
potentially eligible patients who have been declared as exceptions out of the entire
population who would be potentially eligible for the indicator in question.185
When considering groups of indicators, as with the calculations for underlying
achievement, indicator numerators and denominators were summed in order to
arrive at an overall exception rate, thus:
The distributions of practice underlying achievement and exception rates for
each group of diabetes indicators and for indicators PE07 and PE08 for each QOF
year were split into fifths according to quintiles of the relevant distribution, with the
first fifth denoting those practices with the lowest relative levels of underlying
achievement or exception proportion.
Underlying Achievement = Patients Achieving Target i∑ Indicator Denominatori∑
Exception Rate = Number of Exceptionsi∑
Number of Exceptionsi + Indicator Denominatori( )∑
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For this analysis, the list sizes of registered patients for each general practice
were categorised into three groups – ≤ 4,000 patients, 4,000 – 7,999 patients and ≥
8,000 patients – as detailed in the GP Workload Survey.186 List size was also
utilised, in coǌunction with reported numbers of people with diabetes, to calculate
each practice’s prevalence of diabetes mellitus. Practices were excluded if they had
a list size less than 1,000 patients or declared that they had no patients with
diabetes on their diabetes register.
Hospital Episode Statistics Data
The nature of HES data has been previously described in this chapter (see page
52). The criteria for the selection of eligible episodes for this analyses were as
follows (HES field names given in italics):
• Admission date in the range 1st April 2005 – 31st March 2011 inclusive
(admidate)
• Restriction to the first episode in a given spell (epiorder = 1)
• Patient aged ≥ 17 years but ≤ 120 years (startage)
• Citation of diabetes (ICD-10 classifications E10, E11, E13, E14) in any diagnostic
position (diag_01 to diag_20)
• Patients were admitted as an emergency (admimeth = 21, 22, 23, 34 or 28)
These criteria will identify diabetes-citing emergency admissions, hereafter
referred to as emergency admissions. The first episode of a spell was considered
representative of the state of a given patient at the time of admission.
Admissions were broadly categorised by diabetes type according to ICD-10
classification; E10 (insulin-dependent diabetes mellitus) was considered analogous
to Type 1 diabetes mellitus (T1DM), E11 (non-insulin-dependent diabetes mellitus)
was considered analogous to Type 2 diabetes mellitus (T2DM) and E13 (other
specified diabetes mellitus) and E14 (unspecified diabetes mellitus) were grouped
together as ‘other or unspecified diabetes mellitus’.
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Admissions that cited the same classification of diabetes multiple times were
classified accordingly; those that cited diﬀerent classifications of diabetes were
classified as ‘other or unspecified diabetes mellitus’.
In addition to diabetes type, each admission was classified by patient gender,
broad age band (15 – 44y, 45 – 64y, 65 – 74y and ≥ 75y) and the QOF year in which
the admission occurred (based on admission date), with QOF years running from
1st April – 31st March inclusive.
All admissions within HES denote the practice, using the standard unique
general practice identifier, that has responsibility for the delivery of primary care
services to a given patient (gpprac). As HES data describes episodes by patient,
aggregates of admissions (total and age-sex specific) were generated for each
practice for each QOF year.
Practice Population Structure, Ethnicity and GP Workforce
Data on practice population structure covering the period 2000 – 2010 was
obtained from the NHS Information Centre (now superseded by the H&SCIC)187; this
data describes, by QOF year, the proportion of the total registered population of a
practice that falls into a specific gender and age band (0 – 4 years, 5 – 14 years,
15 – 44 years, 45 – 64 years, 65 – 74 years, 75 – 84 years and ≥ 85 years).
The original data on population structure for each practice was presented as
numerical totals for each age-sex stratum; for the purposes of analysis, these totals
were converted into proportions of the total registered population for each QOF
year.
The ethnic composition of practice populations were estimated from pooled
HES hospital attendance data for the period 2004 – 2010 inclusive. This approach
has been demonstrated to be more closely aligned to the ethnic structure of
practice populations, based on self-reporting of ethnicity by patients, than the
assignation of ethnic structure of practice populations via postcode attribution from
the national census, a method used for the construction of the Attribution Data
Set.188
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For this analysis, patient ethnicity was grouped as white, non-white and not
recorded and, as values were pooled estimates from multiple years of data, these
ethnicity proportions were static for each practice across QOF years. Further
subdivision of ethnicity was considered, but in light of the considerable number of
existing variables, many of which were categorical and further described socio-
economic deprivation, to be included in the models, a parsimonious approach with
respect to ethnicity data was decided upon.
Data pertaining to the size of general practitioner workforce, based on pooled
estimates from the period 2002 – 2012 inclusive, for each general practice was
obtained from H&SCIC.189 Total GP full-time equivalents (FTEs) were determined as
the sum of FTEs for GP providers, other GPs, GP Registrars and GP retainers. For
the purposes of analysis, GP workforce was expressed as the total FTEs per 1,000
registered patients; as workforce data was determined from pooled data, FTEs per
1,000 patients were static across all QOF years in the analysis dataset.
Estimates of The Population Structure of People With Diabetes
At present, there are no datasets publicly available that describe the age-sex
structure of the population of people with diabetes at the level of general practices.
Estimates of age-sex specific prevalence of diabetes mellitus for England as a
whole (Table 17), based on patient reports of doctor-diagnosed diabetes, have been
reported as part of the Health Survey for England (HSfE).30, 190 
These estimates were applied to the relevant age-sex bands of each practice
population, using the arithmetic mean of multiple HSfE age groups to match the
age-bands given for practice population age data where appropriate.
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2003 2006 2009 2010
Males 16 – 24y 0.4% 0.8% 0.5% 0.5%
25 – 34y 0.3% 1.2% 1.0% 1.3%
35 – 44y 2.8% 2.4% 1.9% 2.5%
45 – 54y 3.6% 6.0% 8.1% 7.0%
55 – 64y 8.1% 8.5% 10.5% 11.1%
65 – 74y 11.9% 15.7% 15.7% 15.2%
≥ 75y 10.0% 13.5% 19.5% 15.9%
Females 16 – 24y 0.9% 0.9% 0.4% 0.4%
25 – 34y 0.9% 1.2% 0.8% 1.7%
35 – 44y 1.5% 1.2% 3.2% 2.5%
45 – 54y 2.6% 3.6% 3.5% 4.1%
55 – 64y 4.7% 6.0% 6.3% 8.0%
65 – 74y 8.4% 10.4% 902% 12.2%
≥ 75y 8.9% 10.6% 12.7% 13.2%
Table 17. Age-sex specific estimates of diabetes prevalence in England from HSfE 2003 - 2010.
The number of individuals in the various age-sex-specific bands for a practice
was determined from the reported proportion of individuals within that band (see
page 70) by the total registered population for that year. These estimates of
numbers of individuals in a age-sex-specific band were then multiplied by the
estimated prevalence of diabetes for that age-sex band; the estimated numbers of
people with diabetes were then converted into proportions and the final age-sex
specific estimates of numbers of individuals with diabetes were derived by
multiplying these estimated proportions by the total diabetes register size for that
practice.
Where nall = estimates of whole practice numbers, pall = proportion of practice population, ndm = interim
estimated numbers of individuals in an age-sex stratum, phsfe = HSfE-reported diabetes prevalence for an age-
sex stratum, pdm = estimated proportion of a practice’s population with diabetes that falls into an age-sex
stratum, Ndm = final estimated numbers of individuals with diabetes in an age-sex stratum.
nall age-sex( )i = pall age-sex( )i × nall registered( )
→ ndm age-sex( )i = nall age-sex( )i × phsfe age-sex( )i
→ pdm age-sex( )i =
ndm age-sex( )i
ndm age-sex( )i∑
→ Ndm age-sex( )i = pdm age-sex( )i × ndm registered( )
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It should be noted that the minimum ages of the various data sources to arrive at
the final estimate of numbers of people with diabetes in the youngest strata of age
did not quite match; 17 years for practice diabetes registers, 16 years for HSfE age-
sex prevalence estimates and 15 years for the proportions of practice populations.
As more granular detail, such as single-age specific prevalences and proportions,
was not available, the bottom limit of age for the relevant groups in each data
source had to be assumed to be equivalent.
Index of Multiple Deprivation and Rurality Classification
The English Index of Multiple Deprivation (IMD) is a measure that describes the
relative deprivation of one area in comparison to another. IMD scores and ranks are
available up to the resolution of Lower Super Output Areas (LSOAs) which comprise
of between 1,000 to 3,000 residents and 400 to 1,200 residences; from 2001 –
2010, there were 32,482 LSOAs in England.191
IMD scores are a composite measure that summarises the level of deprivation
across seven separate domains (income, employment, health and disability,
education, skills and training, barriers to housing and services, crime and living
environment). As such, a given IMD score can be arrived at through a number of
diﬀerent ways and are non-linear in their measurement of deprivation – for example,
an area with an IMD score of 100 is not necessarily twice as deprived as an area
with an IMD score of 50.
To avoid any potential issues with directly comparing IMD scores, LSOA IMD
ranks were utilised in this analysis. The scores for all 32,482 LSOAs were obtained
for the IMD assessments of 2004192, 2007193 and 2010194 and ranked in descending
order for each IMD assessment; LSOAs were then allocated to tenths of the
distribution of IMD scores, based on their IMD rank, with the first tenth (containing
the highest IMD scores) representing the most deprived LSOAs in England. 
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Categorisation of IMD ranks was considered preferable to utilisation of this
information as a continuous variable on the grounds of clarity with respect to
reporting of results; it is likely that the eﬀect sizes associated with a unitary increase
in rank would be minimal and, accordingly, potentially diﬃcult to interpret.
Furthermore, one cannot discount the possibility of deprivation measurement error
between LSOAs, meaning that a single rank diﬀerence could potentially result from
bias as opposed to a true diﬀerence; use of IMD deprivation scores as a continuous
variable would also be problematic, as a particular IMD score could be arrived at
through a number of diﬀerent ways depending on a LSOA’s IMD domain scores.
The LSOA for each general practice was determined from the practice’s
postcode via the GeoConvert tool provided by the UK Data Service.195 Practice
LSOAs were then cross-referenced with LSOA-level IMD scores and ranks to
determine which tenth of the distribution of deprivation in England that a given
practice fell into. IMD 2004 scores and ranks were utilised for the QOF year of
2005/06, IMD 2007 for QOF years 2007/08 to 2009/10 inclusive and IMD 2010 for
the QOF year 2010/11.
The Oﬃce for National Statistics (ONS) rural/urban area classifications for
LSOAs196 were also utilised for this analysis as a proxy for concentration of and
potential access to primary care services. Area classifications were aggregated to
rural and urban as per ONS guidance.197 Practices were matched to their LSOA via
postcode conversion in the same manner as detailed above.
Standardised Emergency Admission Ratios
In order to take account of potential diﬀerentials in the age-sex structure of the
populations of people with diabetes between practices, standardised emergency
admission ratios (SEARs) were calculated for each practice by means of indirect
standardisation.
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The reference population utilised was the entire registered diabetic population
for a given QOF year. The size of each age-sex group was defined as the sum of
that age-sex group across all practices. The total number of admissions arising
from each age-sex stratum were also determined and the admission rate for that
age-sex stratum was calculated accordingly.
To determine the expected number of emergency admissions for a given
practice, the number of people with diabetes in each age-sex stratum was
multiplied by the overall admission rate for that age-sex stratum; the expected
numbers of admissions for all age-sex strata were summed to give the expected
number of admissions for each practice. SEARs were calculated for each practice
by dividing the observed number of admissions by the expected number of
admissions and multiplying the result by 100.
Statistical Analysis
The primary outcome measure for this analysis was practice SEAR. Models were
constructed using negative binomial regression on the grounds of the variance of
admission counts greatly exceeding the mean (see Table 18).
QOF Year Mean Variance
2005/06 33.28 761.08
2006/07 35.74 892.88
2007/08 35.79 913.83
2008/09 40.26 1,144.68
2009/10 42.93 1,292.58
2010/11 45.44 1,494.32
Table 18. Mean and variance of admission counts per English general practice, QOF years 2005/06 -
2010/11.
QOF = Quality and Outcomes Framework
O = ai∑
E = (niri )∑
SEAR = OE
⎛
⎝⎜
⎞
⎠⎟
×100
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For all models, the dependent variable was the observed number of emergency
admissions, with the log-transformed expected number of admissions included as
the oﬀset term.
Where SEAR = standardised emergency admission ratio; O = observed admissions; E = expected
admissions.
Practices with no registered diabetics or a list size less than 1,000 patients were
excluded from analysis, as were non-English general practices; all regression
analyses clustered practices by Primary Care Trust (PCT) in order to take account of
local similarities in commissioning of services, healthcare infrastructure and
unmeasured population and environmental characteristics.
Initially, analyses of the following predictors were performed to assess
associations with SEARs:
• Practice list size category (≤ 4,000, 4,000 – 7,999, ≥ 8,000)
• GP FTEs per 1,000 patients
• Practice diabetes prevalence
• National tenth of IMD rank (2004, 2007 or 2010 as appropriate)
• Rural/urban area classification
• Fifth of achievement for each diabetes QOF indicator group (all years)
• Fifth of exception reporting for each diabetes QOF indicator group (2007/08
onwards)
• Fifth of achievement for PE07 (2008/09 onwards)
ln SEAR( ) = ln OE
⎛
⎝⎜
⎞
⎠⎟
ln OE
⎛
⎝⎜
⎞
⎠⎟
= β1x1 +!+ βnxn + c
→ ln O( )− ln(E ) = β1x1 +!+ βnxn + c
→ ln O( ) = β1x1 +!+ βnxn + c + ln(E )
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• Fifth of achievement for PE08 (2008/09 onwards)
Following univariate modelling, multiple variable models were separately
constructed for both underlying achievement and exception rate for each indicator
or indicator group; these models were additionally adjusted for practice list size
category, GP FTEs per 1,000 patients, practice diabetes prevalence, national tenth
of IMD rank and rural/urban area classification. Final models, containing all
predictors were then constructed in order to examine the robustness of
associations that may have been observed in previous models once adjusted for
levels of performance in other indicators and indicator groups.
For ease of interpretation, coeﬃcients from negative binomial models have been
reported as incidence rate ratios (IRRs), with an IRR greater than 1 denoting an
association with increased emergency admission rates and an IRR less than 1
denoting an association with decreased admission rates.
Statistical significance was assumed at α = 0.05; the datasets utilised in this
analysis were linked using the practice identifier as the key field and aggregate data
for analysis generated with FileMaker Pro Advanced version 13 (Apple Incorporated,
CA, USA) for Mac OS X; analyses were performed in STATA IC version 12.1
(StataCorp, TX, USA) for Mac OS X.
Results
The characteristics of the practices eligible for inclusion in this analysis are
shown in Table 19. A total of 2,074,628 emergency admissions were observed
during QOF years 2005/06 – 2010/11, with a peak of 2,409,268 registered people
with diabetes in 2010/11. Crude emergency admission rates from the registered
population with diabetes increased from 157.77 per 1,000 in 2005/06 to 167.60 per
1,000 in 2010/11 (Figure 11).
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
n /
Mean % / SD
n /
Mean % / SD
n /
Mean % / SD
n /
Mean % / SD
n /
Mean % / SD
n /
Mean % / SD
Practices 8,237 8,186 8,091 7,664 7,931 7,834
Admissions 35.44 27.32 38.39 29.48 38.86 29.74 45.23 33.29 47.65 34.98 51.08 37.51
Age 
(years)
0 - 4 5.49% 1.59% 5.56% 1.61% 5.66% 1.62% 5.80% 1.64% 5.86% 1.69% 5.91% 1.68%
5 - 14 12.18% 2.56% 11.93% 2.51% 11.67% 2.47% 11.51% 2.40% 11.37% 2.42% 11.27% 2.42%
15 - 44 43.17% 8.10% 43.13% 8.17% 42.94% 8.27% 42.55% 8.27% 42.28% 8.38% 41.83% 8.52%
45 - 64 24.06% 4.57% 24.36% 4.61% 24.65% 4.63% 24.90% 4.61% 25.10% 4.62% 25.36% 4.62%
65 - 74 7.94% 2.46% 7.85% 2.47% 7.85% 2.50% 7.97% 2.56% 8.11% 2.71% 8.25% 2.83%
≥ 75 7.16% 3.05% 7.18% 3.07% 7.22% 3.08% 7.25% 3.08% 7.27% 3.12% 7.37% 3.26%
Sex % Male 50.41% 2.77% 50.41% 2.68% 50.38% 2.69% 50.26% 2.59% 50.32% 2.62% 50.35% 2.74%
Ethnicity
White 71.45% 19.45% 71.50% 19.40% 71.63% 19.30% 71.94% 19.12% 71.80% 19.22% 71.86% 19.16%
Non-
White 9.22% 14.97% 9.22% 14.95% 9.14% 14.84% 8.94% 14.69% 9.04% 14.80% 9.00% 14.76%
Unknown 9.00% 14.76% 19.33% 10.40% 19.28% 10.34% 19.23% 10.31% 19.12% 10.28% 19.14% 10.27%
List Size 
Category
< 4,000 2,815 34.18% 2,722 33.25% 2,591 32.02% 2,223 29.01% 2,420 30.51% 2,323 29.65%
4,000 – 
7,999 2,945 35.75% 2,935 35.85% 2,851 35.24% 2,851 37.20% 2,847 35.90% 2,829 36.11%
≥ 8,000 2,477 30.07% 2,529 30.89% 2,590 32.01% 2,590 33.79% 2,664 33.59% 2,682 34.24%
GP FTEs per 1,000 
patients 0.671 0.298 0.663 0.288 0.657 0.285 0.651 0.275 0.644 0.274 0.639 0.260
Diabetes Prevalence 3.65% 1.05% 3.73% 1.07% 3.96% 1.10% 4.18% 1.14% 4.40% 1.28% 4.60% 1.25%
IMD 
Tenth
(1 = Most
Deprived)
1 1,340 16.27% 1,329 16.24% 1,332 16.46% 1,236 16.13% 1,293 16.30% 1,256 16.03%
2 1,110 13.48% 1,105 13.50% 1,040 12.85% 968 12.63% 1,013 12.77% 1,011 12.91%
3 967 11.74% 960 11.73% 927 11.46% 875 11.42% 909 11.46% 889 11.35%
4 832 10.10% 828 10.11% 876 10.83% 816 10.65% 851 10.73% 888 11.34%
5 852 10.34% 845 10.32% 782 9.67% 738 9.63% 762 9.61% 760 9.70%
6 724 8.79% 722 8.82% 745 9.21% 725 9.46% 740 9.33% 716 9.14%
7 704 8.55% 702 8.58% 691 8.54% 658 8.59% 680 8.57% 669 8.54%
8 585 7.10% 579 7.07% 597 7.38% 574 7.49% 590 7.44% 585 7.47%
9 590 7.16% 589 7.20% 575 7.11% 555 7.24% 571 7.20% 559 7.14%
10 509 6.18% 506 6.18% 512 6.33% 489 6.38% 504 6.35% 484 6.18%
Missing 
Data 24 0.29% 21 0.26% 14 0.17% 30 0.39% 18 0.23% 17 0.22%
QOF Process UA 91.61% 6.93% 91.92% 6.20% 92.42% 5.26% 92.68% 4.52% 93.34% 4.18% 93.71% 3.72%
QOF CVS UA 76.86% 8.10% 81.01% 7.25% 81.33% 6.25% 81.35% 5.91% 81.85% 5.79% 82.01% 5.61%
QOF Strict 
Glycaemic Control 
UA
61.71% 10.69% 67.67% 10.68% 66.62% 9.40% 66.22% 8.65% 53.79% 9.66% 54.18% 8.98%
QOF Intermediate 
Glycaemic Control 
UA
N/A N/A N/A N/A 77.11% 7.60% 77.70% 7.04%
QOF Moderate 
Glycaemic Control 
UA
91.04% 6.07% 92.31% 5.25% 92.01% 4.77% 91.96% 4.35% 87.65% 6.13% 88.07% 5.51%
QOF PE07 UA N/A N/A N/A 84.23% 13.95% 82.22% 13.64% 82.21% 13.47%
QOF PE08 UA N/A N/A N/A 76.91% 17.52% 74.89% 16.89% 75.35% 16.61%
QOF Process ER N/A N/A 5.86% 3.33% 5.96% 3.58% 5.67% 3.03% 5.81% 3.34%
QOF CVS ER N/A N/A 7.83% 4.13% 7.40% 3.72% 7.69% 3.91% 7.58% 4.12%
QOF Strict 
Glycaemic Control 
ER
N/A N/A 10.33% 7.02% 9.43% 6.22% 12.96% 8.60% 13.31% 8.88%
QOF Intermediate 
Glycaemic Control 
ER
N/A N/A N/A N/A 9.42% 6.43% 9.57% 6.55%
QOF Moderate 
Glycaemic Control 
ER
N/A N/A 5.58% 4.07% 5.15% 3.47% 7.31% 5.02% 7.34% 5.15%
Table 19. Descriptive statistics of general practices included in practice-level analysis.
GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple Deprivation; UA = underlying
achievement; ER = exception rate; N/A denotes variable not available in given QOF year
- 78 -
Figure 11. Emergency admissions and crude admission rate per 1,000 registered people with
diabetes in England, 2005/06 to 2010/11.
Numbers on bars represent the count of emergency admissions for each QOF year; numbers above data points
denote the crude emergency admission rate for that QOF year.
The estimated structure of the registered population with diabetes diﬀered
considerably to that of the general registered population; the estimated population
with diabetes was older (Figure 12) and had an excess of males (Figure 13) in
comparison to the general registered population.
Figure 12. Proportion of patients by age-band in the general registered population and the estimated
registered population with diabetes, QOF 2005/06 - 2010/11.
Proportions given exclude patients aged ≤ 14 years; the lower limit for age in HSfE age-specific prevalences
was 16, whereas the equivalent age-band for the registered population was 15.
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Figure 13. Proportion of patients by gender in the general registered population and the estimated
registered population with diabetes, QOF 2005/06 - 2010/11.
Overall, crude emergency admission rates generally rose with increasing age
(Table 14) and females experienced a higher crude emergency admission rate than
males (Table 15). Standardised emergency admission ratios (SEARs) showed a wide
distribution across all years; distribution characteristics, box and scatter plots of
SEAR (excluding outliers) are shown in Table 20, Figure 16 and Table 17
respectively.
Figure 14. Crude emergency admission ratios by age-band, QOF 2005/06 - 2010/11.
* = the lower age limit of HSfE prevalence estimates was 16 and the lower age limit of eligible emergency
admissions was 17.
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Figure 15. Crude emergency admission rates by gender, QOF 2005/06 - 2010/11.
Quoted numbers indicate crude admission rate (per 1,000) for each gender during the given QOF year.
QOF Year Mean Median IQR(p25– p75)
Total
Practices Total Outliers
2005/06 102.19 94.22 62.55(66.00–128.54) 8,237 268
2006/07 104.65 94.23 60.50(67.48–127.98) 8,186 302
2007/08 102.69 93.20 58.33(67.72–126.05) 8,091 309
2008/09 100.27 91.27 54.68(68.03–122.71) 7,664 248
2009/10 103.17 93.52 54.17(71.01–125.19) 7,931 243
2010/11 103.20 93.19 52.89(71.27–124.16) 7,834 262
Table 20. Characteristics of distribution of standardised emergency admission ratios (SEARs) for
English general practices, QOF 2005/06 - 2010/11.
IQR = interquartile range; p25 = 25th centile; p75 = 75th centile. Low outliers were defined as observations
where the SEAR was less than p25 – (1.5 × IQR); high outliers were defined as observations where the SEAR
was less than p75 + (1.5 × IQR).
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Figure 16. Box plots of standardised emergency admission ratios (SEARs) for English general
practices, QOF 2005/06 - 2010/11.
Figure 17. Scatter plot of practice SEARs versus practice diabetes register size for English practices,
QOF 2005/06 - 2010/11.
Blue markers denote individual practices; red line denotes a SEAR of 100
IRRs resulting from univariate regression for all candidate predictors are shown
in Table 21, Table 22 and Table 23. All candidate predictors, bar proportions of
practice registered population in age-bands and practice performance in the
cardiovascular QOF indicator group, showed significant associations with SEAR
across all QOF years in univariate analysis. 
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Practices with a higher proportion of males and non-white patients generally
experienced higher admission rates in univariate analyses; larger practice list sizes,
higher practice diabetes prevalences, practices located in more aﬄuent areas and
practices located in urban areas generally experienced lower admission rates in
univariate analyses (Table 21).
With regards to practice QOF performance, the most consistent associations
with a decreased admission rate in univariate analyses were with underlying
achievement for the process group of diabetes QOF indicators, the intermediate
and moderate glycaemic control groups of diabetes QOF indicators and patient
access indicators (Table 22). Practices in the highest fifth of exception rates for the
majority of QOF indicator groups experienced higher admission rates in univariate
analyses (Table 23).
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference Reference Reference Reference
5 - 14 1.039 < 0.001 1.013 0.129 1.010 0.251 1.007 0.991 0.985 0.044 0.958 < 0.001
15 - 44 1.023 < 0.001 1.006 0.337 1.009 0.146 1.007 0.996 0.994 0.234 0.975 < 0.001
45 - 64 1.004 0.469 0.988 0.030 0.995 0.353 0.994 0.984 0.986 0.004 0.972 < 0.001
65 - 74 1.029 < 0.001 1.016 0.021 0.998 0.758 0.996 0.983 0.975 < 0.001 0.954 < 0.001
≥ 75 1.011 0.084 0.991 0.155 1.001 0.898 0.996 0.985 0.987 0.026 0.965 < 0.001
Proportion male 1.014 < 0.001 1.023 < 0.001 1.023 < 0.001 1.024 < 0.001 1.022 < 0.001 1.022 < 0.001
Ethnicity
White Reference Reference Reference Reference Reference Reference
Non-
White 1.001 0.078 1.002 < 0.001 1.001 < 0.001 1.002 < 0.001 1.001 < 0.001 1.002 < 0.001
Unknown 0.998 < 0.001 0.997 < 0.001 0.999 0.165 1.031 < 0.001 0.998 < 0.001 1.000 0.751
List Size
< 4,000 Reference Reference Reference Reference Reference Reference
4,000 – 
7,999 0.962 0.003 0.951 < 0.001 0.956 < 0.001 0.954 < 0.001 0.954 < 0.001 0.963 0.001
≥ 8,000 0.917 < 0.001 0.889 < 0.001 0.913 < 0.001 0.917 < 0.001 0.917 < 0.001 0.930 < 0.001
GP FTEs per 1,000 
patients 0.929 < 0.001 0.906 < 0.001 0.935 < 0.001 0.927 < 0.001 0.940 0.001 0.935 < 0.001
Diabetes Prevalence 0.983 0.001 0.964 < 0.001 0.983 < 0.001 0.993 < 0.001 0.979 < 0.001 0.981 < 0.001
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference Reference Reference Reference
2 0.824 < 0.001 0.820 < 0.001 0.842 < 0.001 0.841 < 0.001 0.856 < 0.001 0.893 < 0.001
3 0.790 < 0.001 0.810 < 0.001 0.812 < 0.001 0.825 < 0.001 0.828 < 0.001 0.842 < 0.001
4 0.727 < 0.001 0.737 < 0.001 0.769 < 0.001 0.775 < 0.001 0.774 < 0.001 0.804 < 0.001
5 0.714 < 0.001 0.699 < 0.001 0.746 < 0.001 0.737 < 0.001 0.745 < 0.001 0.762 < 0.001
6 0.700 < 0.001 0.698 < 0.001 0.705 < 0.001 0.729 < 0.001 0.729 < 0.001 0.729 < 0.001
7 0.687 < 0.001 0.677 < 0.001 0.693 < 0.001 0.705 < 0.001 0.710 < 0.001 0.732 < 0.001
8 0.661 < 0.001 0.659 < 0.001 0.687 < 0.001 0.690 < 0.001 0.687 < 0.001 0.696 < 0.001
9 0.644 < 0.001 0.636 < 0.001 0.668 < 0.001 0.692 < 0.001 0.697 < 0.001 0.683 < 0.001
10 0.655 < 0.001 0.627 < 0.001 0.646 < 0.001 0.663 < 0.001 0.694 < 0.001 0.678 < 0.001
Area 
Classification
Rural Reference Reference Reference Reference Reference Reference
Urban 0.817 < 0.001 0.810 < 0.001 0.780 < 0.001 0.787 < 0.001 0.776 < 0.001 0.780 < 0.001
Table 21. Results of univariate negative binomial regression for variables describing practice
characteristics, QOF 2005/06 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Process UA 
Fifth
1 Reference Reference Reference Reference Reference Reference
2 0.949 0.001 0.911 < 0.001 0.936 < 0.001 0.940 < 0.001 0.908 < 0.001 0.936 < 0.001
3 0.945 0.001 0.903 < 0.001 0.926 < 0.001 0.912 < 0.001 0.908 < 0.001 0.921 < 0.001
4 0.930 < 0.001 0.907 < 0.001 0.898 < 0.001 0.907 < 0.001 0.888 < 0.001 0.936 < 0.001
5 0.947 0.001 0.927 < 0.001 0.926 < 0.001 0.902 < 0.001 0.911 < 0.001 0.926 < 0.001
CVS UA Fifth
1 Reference Reference Reference Reference Reference Reference
2 0.987 0.435 0.971 0.073 0.968 0.041 0.987 0.410 0.997 0.841 0.993 0.643
3 0.994 0.715 0.987 0.429 1.000 0.990 1.012 0.426 0.989 0.445 0.987 0.375
4 0.994 0.727 0.996 0.784 0.990 0.541 0.998 0.891 0.994 0.690 1.006 0.694
5 1.001 0.951 0.998 0.902 0.991 0.591 1.020 0.193 1.034 0.023 1.019 0.198
Strict 
Glycaemic 
Control UA 
Fifth
1 Reference Reference Reference Reference Reference Reference
2 0.971 0.071 0.955 0.005 1.005 0.768 0.980 0.195 0.933 < 0.001 0.947 < 0.001
3 0.966 0.036 0.968 0.048 0.989 0.475 0.944 < 0.001 0.923 < 0.001 0.942 < 0.001
4 0.975 0.118 0.996 0.787 0.991 0.581 0.953 0.002 0.952 0.001 0.973 0.058
5 0.975 0.119 0.988 0.472 1.037 0.023 0.969 0.042 1.010 0.501 1.019 0.190
Intermediate 
Glycaemic 
Control UA 
Fifth
1
N/A N/A N/A N/A
Reference Reference
2 0.924 < 0.001 0.915 < 0.001
3 0.892 < 0.001 0.919 < 0.001
4 0.899 < 0.001 0.893 < 0.001
5 0.925 < 0.001 0.939 < 0.001
Moderate 
Glycaemic 
Control UA 
Fifth
1 Reference Reference Reference Reference Reference Reference
2 0.970 0.059 0.959 0.011 0.950 0.001 0.960 0.008 0.940 < 0.001 0.909 < 0.001
3 0.962 0.017 0.888 < 0.001 0.922 < 0.001 0.913 < 0.001 0.887 < 0.001 0.888 < 0.001
4 0.903 < 0.001 0.911 < 0.001 0.894 < 0.001 0.902 < 0.001 0.897 < 0.001 0.894 < 0.001
5 0.905 < 0.001 0.906 < 0.001 0.924 < 0.001 0.879 < 0.001 0.881 < 0.001 0.911 < 0.001
PE07 UA 
Fifth
1
N/A N/A N/A
Reference Reference Reference
2 0.955 0.002 0.934 < 0.001 0.948 < 0.001
3 0.911 < 0.001 0.915 < 0.001 0.934 < 0.001
4 0.881 < 0.001 0.897 < 0.001 0.893 < 0.001
5 0.877 < 0.001 0.875 < 0.001 0.856 < 0.001
PE08 UA 
Fifth
1
N/A N/A N/A
Reference Reference Reference
2 0.946 < 0.001 1.002 0.893 0.986 0.329
3 0.924 < 0.001 0.973 0.054 0.962 0.007
4 0.886 < 0.001 0.925 < 0.001 0.930 < 0.001
5 0.872 < 0.001 0.920 < 0.001 0.888 < 0.001
Table 22. Results of univariate negative binomial regression for variables describing underlying QOF
performance, QOF 2005/06 - 2010/11.
CVS = cardiovascular system (includes targets pertaining to blood pressure and total cholesterol); UA =
underlying achievement.
Regression coeﬃcients converted to IRRs; practices assigned to fifth of underlying achievement (UA) for each
indicator / indicator group; the lowest fifth (1) denotes those practices with the worst performances in that
indicator / indicator group; N/A denotes that the indicator / indicator group was not present for that QOF year.
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Process ER 
Fifth
1
N/A N/A
Reference Reference Reference Reference
2 0.990 0.506 0.996 0.807 1.003 0.861 1.012 0.411
3 0.994 0.680 1.037 0.019 1.026 0.081 1.036 0.016
4 1.044 0.006 1.055 < 0.001 1.047 0.002 1.049 0.001
5 1.110 < 0.001 1.116 < 0.001 1.129 < 0.001 1.127 < 0.001
CVS ER Fifth
1
N/A N/A
Reference Reference Reference Reference
2 0.961 0.013 0.994 0.701 0.977 0.112 0.999 0.936
3 0.964 0.021 0.987 0.381 1.001 0.935 0.997 0.842
4 0.968 0.039 0.984 0.293 0.985 0.292 1.021 0.149
5 1.022 0.165 1.036 0.024 1.055 < 0.001 1.074 < 0.001
Strict 
Glycaemic 
Control ER 
Fifth
1
N/A N/A
Reference Reference Reference Reference
2 0.992 0.622 1.017 0.271 1.008 0.596 1.029 0.052
3 1.007 0.644 1.034 0.027 1.020 0.177 1.052 < 0.001
4 1.042 0.009 1.054 0.001 1.062 < 0.001 1.063 < 0.001
5 1.089 < 0.001 1.122 < 0.001 1.122 < 0.001 1.142 < 0.001
Intermediate 
Glycaemic 
Control ER 
Fifth
1
N/A N/A N/A N/A
Reference Reference
2 1.020 0.172 1.025 0.091
3 1.030 0.041 1.052 0.001
4 1.067 < 0.001 1.057 < 0.001
5 1.142 < 0.001 1.167 < 0.001
Moderate 
Glycaemic 
Control ER 
Fifth
1
N/A N/A
Reference Reference Reference Reference
2 0.974 0.090 1.003 0.844 0.994 0.683 1.031 0.035
3 0.976 0.127 1.009 0.550 1.033 0.026 1.055 < 0.001
4 1.008 0.634 1.043 0.005 1.059 < 0.001 1.071 < 0.001
5 1.100 < 0.001 1.126 < 0.001 1.148 < 0.001 1.166 < 0.001
Table 23. Results of univariate negative binomial regression for variables describing QOF exception
rates, QOF 2005/06 - 2010/11.
CVS = cardiovascular system (includes targets pertaining to blood pressure and total cholesterol); ER =
exception rate.
Regression coeﬃcients converted to IRRs; practices assigned to fifth of exception rate (ER) for each indicator /
indicator group; the lowest fifth (1) denotes those practices with the least exception reports in that indicator /
indicator group; N/A denotes that the indicator / indicator group was not present for that QOF year.
Multiple variable models, adjusted for practice list size category, GP FTEs per
1,000 patients, practice diabetes prevalence, tenth of IMD rank and rural/urban area
classification, that were separately constructed for the underlying achievement or
exception rate for each indicator or indicator group for each QOF year,
demonstrated some attenuation of the estimated eﬀects from the univariate models
for the majority of performance and exception measures. Results for the multiple
variable models are shown in Tables 24 – 35.
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The most consistent association of performance with emergency admission
rates were observed for the process group of indicators, where the best performing
practices experienced emergency admission rates 2.8% – 7.5% lower than the
worst performing practices (Table 24), and for indicators PE07 (Table 34) and PE08
(Table 35), where the best performing practices were subject to admission rates
5.5% – 9.7% lower and 6.3% – 10.3% lower respectively.
Exception reporting for a number of indicator groups were consistently
associated with an increase in emergency admissions across observed QOF years.
Practices with the highest levels of exception reporting for the process group of
indicators (Table 25), strict glycaemic control indicators (Table 29), intermediate
glycaemic control indicators (Table 31) and moderate glycaemic control indicators
(Table 33) experienced emergency admission rates that were higher by 5.7% –
7.8%, 5.5% – 7.9%, 6.6% – 9.3% and 5.4 – 8.7% respectively in comparison to
those practices with the lowest levels of exception reporting. 
Of particular interest, there appeared to be no association between achievement
in the cardiovascular indicator group and emergency admission rates (Table 26);
exception reporting for this indicator group generally showed no association with
emergency admission rates, with the exception of QOF year 2010/11, where
practices with the highest levels of exception reporting experienced emergency
admission rates 5.6% higher than those with the lowest levels of exception
reporting (Table 27).
Of the variables describing practice characteristics, the most consistent
associations with emergency admission rates across all models were observed for
practice LSOA deprivation, where those located in the most aﬄuent areas
experienced emergency admission rates 26.3% – 38.3% lower than those in the
most deprived areas, and practice location, where practices in urban areas were
subject to emergency admission rates 7.9% – 12.0% lower than those located in
rural areas.
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference Reference Reference Reference
5 - 14 1.015 0.139 1.010 0.368 1.012 0.249 1.017 0.125 1.002 0.828 0.986 0.158
15 - 44 1.006 0.473 0.997 0.742 1.006 0.409 1.010 0.162 1.002 0.727 0.990 0.177
45 - 64 1.000 0.953 0.994 0.390 1.004 0.608 1.003 0.641 0.997 0.651 0.989 0.103
65 - 74 1.016 0.144 1.019 0.136 1.007 0.518 1.011 0.258 0.996 0.673 0.982 0.080
≥ 75 0.991 0.391 0.985 0.143 0.993 0.526 0.996 0.682 0.991 0.339 0.977 0.015
Sex % Male 1.003 0.496 1.009 0.045 1.005 0.432 1.003 0.632 1.006 0.187 1.004 0.470
Ethnicity
White Reference Reference Reference Reference Reference Reference
Non-
White 0.997 0.006 0.999 0.360 0.997 0.060 0.998 0.081 0.996 0.001 0.997 0.010
Unknown 0.999 0.418 0.998 0.276 0.999 0.715 0.996 0.109 0.998 0.264 0.999 0.607
List Size
< 4,000 Reference Reference Reference Reference Reference Reference
4,000 – 
7,999 0.991 0.517 0.990 0.477 0.983 0.280 0.972 0.077 0.984 0.265 0.985 0.369
≥ 8,000 0.966 0.056 0.955 0.018 0.959 0.046 0.952 0.010 0.959 0.017 0.968 0.092
GP FTEs per 1,000 
patients 0.958 0.084 0.945 0.055 0.981 0.524 0.972 0.433 1.002 0.957 0.988 0.760
Diabetes Prevalence 0.957 0.001 0.917 < 0.001 0.960 0.003 0.974 0.036 0.976 0.013 0.971 0.015
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference Reference Reference Reference
2 0.832 < 0.001 0.834 < 0.001 0.850 < 0.001 0.860 < 0.001 0.864 < 0.001 0.887 < 0.001
3 0.797 < 0.001 0.817 < 0.001 0.819 < 0.001 0.844 < 0.001 0.835 < 0.001 0.850 < 0.001
4 0.743 < 0.001 0.757 < 0.001 0.781 < 0.001 0.809 < 0.001 0.800 < 0.001 0.821 < 0.001
5 0.732 < 0.001 0.720 < 0.001 0.764 < 0.001 0.778 < 0.001 0.778 < 0.001 0.791 < 0.001
6 0.717 < 0.001 0.714 < 0.001 0.726 < 0.001 0.772 < 0.001 0.767 < 0.001 0.762 < 0.001
7 0.700 < 0.001 0.691 < 0.001 0.723 < 0.001 0.759 < 0.001 0.756 < 0.001 0.773 < 0.001
8 0.679 < 0.001 0.673 < 0.001 0.707 < 0.001 0.739 < 0.001 0.734 < 0.001 0.731 < 0.001
9 0.656 < 0.001 0.641 < 0.001 0.692 < 0.001 0.741 < 0.001 0.744 < 0.001 0.719 < 0.001
10 0.660 < 0.001 0.618 < 0.001 0.657 < 0.001 0.704 < 0.001 0.729 < 0.001 0.704 < 0.001
Area 
Classification
Rural Reference Reference Reference Reference Reference Reference
Urban 0.920 0.004 0.914 0.005 0.881 < 0.001 0.896 < 0.001 0.889 < 0.001 0.914 0.001
Process UA 
Fifth
1 Reference Reference Reference Reference Reference Reference
2 0.976 0.217 0.938 < 0.001 0.965 0.020 0.966 0.022 0.939 < 0.001 0.964 0.009
3 0.991 0.661 0.956 0.017 0.978 0.209 0.952 0.010 0.956 0.007 0.968 0.040
4 0.983 0.436 0.947 0.010 0.952 0.002 0.941 0.002 0.929 < 0.001 0.966 0.043
5 0.980 0.361 0.950 0.009 0.959 0.039 0.925 < 0.001 0.932 < 0.001 0.953 0.010
Table 24. Results of multi-variable negative binomial regression for underlying achievement of QOF
process indicator group, QOF 2005/06 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; UA = underlying achievement.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference Reference
5 - 14 1.013 0.236 1.018 0.106 1.005 0.645 0.988 0.247
15 - 44 1.006 0.393 1.011 0.144 1.004 0.538 0.993 0.304
45 - 64 1.004 0.586 1.004 0.600 0.999 0.861 0.991 0.187
65 - 74 1.009 0.434 1.013 0.198 0.998 0.853 0.985 0.133
≥ 75 0.993 0.533 0.996 0.719 0.992 0.434 0.979 0.024
Sex % Male 1.005 0.382 1.003 0.579 1.007 0.178 1.004 0.475
Ethnicity
White Reference Reference Reference Reference
Non-
White 0.997 0.069 0.998 0.118 0.997 0.002 0.997 0.017
Unknown 0.999 0.714 0.996 0.108 0.998 0.283 0.999 0.654
List Size
< 4,000 Reference Reference Reference Reference
4,000 – 
7,999 0.983 0.285 0.975 0.102 0.984 0.257 0.985 0.355
≥ 8,000 0.958 0.036 0.953 0.011 0.955 0.007 0.964 0.051
GP FTEs per 1,000 patients 0.978 0.473 0.967 0.369 0.996 0.907 0.983 0.645
Diabetes Prevalence 0.962 0.006 0.976 0.054 0.978 0.021 0.973 0.023
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference Reference
2 0.851 < 0.001 0.861 < 0.001 0.864 < 0.001 0.891 < 0.001
3 0.819 < 0.001 0.847 < 0.001 0.839 < 0.001 0.853 < 0.001
4 0.781 < 0.001 0.811 < 0.001 0.802 < 0.001 0.825 < 0.001
5 0.765 < 0.001 0.780 < 0.001 0.780 < 0.001 0.793 < 0.001
6 0.726 < 0.001 0.772 < 0.001 0.767 < 0.001 0.764 < 0.001
7 0.723 < 0.001 0.760 < 0.001 0.757 < 0.001 0.775 < 0.001
8 0.708 < 0.001 0.739 < 0.001 0.735 < 0.001 0.734 < 0.001
9 0.693 < 0.001 0.743 < 0.001 0.746 < 0.001 0.722 < 0.001
10 0.656 < 0.001 0.703 < 0.001 0.727 < 0.001 0.706 < 0.001
Area 
Classification
Rural Reference Reference Reference Reference
Urban 0.882 < 0.001 0.896 < 0.001 0.888 < 0.001 0.913 0.001
Process ER 
Fifth
1 Reference Reference Reference Reference
2 0.997 0.837 0.994 0.650 1.007 0.651 1.015 0.371
3 1.000 0.996 1.034 0.066 1.015 0.334 1.031 0.059
4 1.025 0.227 1.052 0.006 1.030 0.081 1.047 0.010
5 1.057 0.010 1.067 0.001 1.078 < 0.001 1.076 < 0.001
Table 25. Results of multi-variable negative binomial regression for exception rates for QOF process
indicator group, QOF 2007/08 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; ER = exception rate.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference Reference Reference Reference
5 - 14 1.016 0.132 1.009 0.405 1.012 0.267 1.016 0.138 1.003 0.809 0.986 0.162
15 - 44 1.006 0.460 0.997 0.690 1.005 0.438 1.010 0.191 1.003 0.715 0.991 0.182
45 - 64 1.000 0.968 0.993 0.350 1.003 0.663 1.003 0.717 0.997 0.653 0.989 0.104
65 - 74 1.016 0.141 1.019 0.150 1.007 0.549 1.010 0.288 0.995 0.659 0.982 0.076
≥ 75 0.991 0.407 0.984 0.143 0.993 0.523 0.996 0.678 0.991 0.374 0.977 0.016
Sex % Male 1.003 0.458 1.010 0.033 1.005 0.396 1.003 0.571 1.007 0.154 1.004 0.463
Ethnicity
White Reference Reference Reference Reference Reference Reference
Non-
White 0.997 0.007 0.999 0.391 0.997 0.060 0.998 0.091 0.996 0.001 0.997 0.013
Unknown 0.999 0.418 0.998 0.277 0.999 0.712 0.996 0.113 0.998 0.281 0.999 0.635
List Size
< 4,000 Reference Reference Reference Reference Reference Reference
4,000 – 
7,999 0.990 0.486 0.989 0.441 0.983 0.279 0.975 0.111 0.985 0.310 0.987 0.437
≥ 8,000 0.965 0.045 0.953 0.013 0.960 0.048 0.957 0.023 0.961 0.021 0.970 0.111
GP FTEs per 1,000 patients 0.956 0.069 0.942 0.042 0.978 0.466 0.968 0.380 0.998 0.951 0.985 0.694
Diabetes Prevalence 0.957 0.001 0.917 < 0.001 0.960 0.003 0.974 0.035 0.976 0.013 0.971 0.014
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference Reference Reference Reference
2 0.833 < 0.001 0.834 < 0.001 0.850 < 0.001 0.860 < 0.001 0.864 < 0.001 0.888 < 0.001
3 0.797 < 0.001 0.818 < 0.001 0.819 < 0.001 0.845 < 0.001 0.837 < 0.001 0.852 < 0.001
4 0.743 < 0.001 0.757 < 0.001 0.780 < 0.001 0.809 < 0.001 0.801 < 0.001 0.822 < 0.001
5 0.731 < 0.001 0.719 < 0.001 0.763 < 0.001 0.778 < 0.001 0.778 < 0.001 0.791 < 0.001
6 0.717 < 0.001 0.713 < 0.001 0.724 < 0.001 0.768 < 0.001 0.765 < 0.001 0.761 < 0.001
7 0.699 < 0.001 0.689 < 0.001 0.721 < 0.001 0.757 < 0.001 0.755 < 0.001 0.772 < 0.001
8 0.679 < 0.001 0.672 < 0.001 0.706 < 0.001 0.736 < 0.001 0.732 < 0.001 0.731 < 0.001
9 0.656 < 0.001 0.640 < 0.001 0.690 < 0.001 0.740 < 0.001 0.744 < 0.001 0.719 < 0.001
10 0.659 < 0.001 0.617 < 0.001 0.655 < 0.001 0.702 < 0.001 0.728 < 0.001 0.703 < 0.001
Area 
Classification
Rural Reference Reference Reference Reference Reference Reference
Urban 0.919 0.004 0.913 0.004 0.881 < 0.001 0.895 < 0.001 0.886 < 0.001 0.913 0.001
CVS UA Fifth
1 Reference Reference Reference Reference Reference Reference
2 1.003 0.873 0.986 0.451 0.984 0.339 0.991 0.515 1.005 0.716 1.003 0.824
3 1.017 0.401 0.993 0.693 0.997 0.866 1.008 0.632 0.993 0.643 0.993 0.614
4 1.004 0.820 0.995 0.781 0.989 0.528 0.992 0.634 0.996 0.823 1.004 0.815
5 1.008 0.727 0.986 0.515 0.989 0.605 1.002 0.906 1.017 0.396 1.009 0.651
Table 26. Results of multi-variable negative binomial regression for underlying achievement of QOF
cardiovascular indicator group, QOF 2005/06 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; CVS = cardiovascular system (includes targets pertaining to blood pressure and total cholesterol);
UA = underlying achievement.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference Reference
5 - 14 1.011 0.299 1.017 0.130 1.004 0.720 0.987 0.217
15 - 44 1.005 0.488 1.010 0.178 1.004 0.621 0.992 0.253
45 - 64 1.003 0.711 1.003 0.697 0.998 0.756 0.990 0.152
65 - 74 1.006 0.581 1.011 0.259 0.997 0.745 0.984 0.106
≥ 75 0.993 0.498 0.995 0.668 0.992 0.399 0.978 0.019
Sex % Male 1.005 0.389 1.003 0.575 1.007 0.188 1.004 0.462
Ethnicity
White Reference Reference Reference Reference
Non-
White 0.997 0.056 0.998 0.093 0.996 0.002 0.997 0.013
Unknown 0.999 0.722 0.996 0.112 0.998 0.277 0.999 0.621
List Size
< 4,000 Reference Reference Reference Reference
4,000 – 
7,999 0.985 0.349 0.975 0.105 0.985 0.295 0.985 0.329
≥ 8,000 0.963 0.068 0.956 0.018 0.958 0.012 0.965 0.050
GP FTEs per 1,000 patients 0.978 0.472 0.967 0.369 0.996 0.907 0.982 0.628
Diabetes Prevalence 0.961 0.004 0.975 0.045 0.977 0.018 0.974 0.024
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference Reference
2 0.850 < 0.001 0.860 < 0.001 0.863 < 0.001 0.890 < 0.001
3 0.818 < 0.001 0.845 < 0.001 0.837 < 0.001 0.852 < 0.001
4 0.779 < 0.001 0.809 < 0.001 0.799 < 0.001 0.823 < 0.001
5 0.762 < 0.001 0.778 < 0.001 0.778 < 0.001 0.792 < 0.001
6 0.724 < 0.001 0.770 < 0.001 0.764 < 0.001 0.763 < 0.001
7 0.721 < 0.001 0.757 < 0.001 0.755 < 0.001 0.773 < 0.001
8 0.706 < 0.001 0.736 < 0.001 0.731 < 0.001 0.732 < 0.001
9 0.691 < 0.001 0.740 < 0.001 0.743 < 0.001 0.720 < 0.001
10 0.655 < 0.001 0.701 < 0.001 0.726 < 0.001 0.704 < 0.001
Area 
Classification
Rural Reference Reference Reference Reference
Urban 0.881 < 0.001 0.894 < 0.001 0.887 < 0.001 0.913 0.001
CVS ER Fifth
1 Reference Reference Reference Reference
2 0.969 0.045 1.009 0.543 0.986 0.359 1.018 0.238
3 0.978 0.217 1.008 0.627 1.014 0.314 1.015 0.355
4 0.968 0.079 1.003 0.861 0.989 0.532 1.040 0.022
5 0.996 0.870 1.023 0.269 1.028 0.173 1.056 0.010
Table 27. Results of multi-variable negative binomial regression for exception reporting for QOF
cardiovascular indicator group, QOF 2007/08 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; CVS = cardiovascular system (includes targets pertaining to blood pressure and total cholesterol);
ER = exception rate.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference Reference Reference Reference
5 - 14 1.016 0.137 1.010 0.361 1.012 0.238 1.016 0.145 1.003 0.772 0.986 0.161
15 - 44 1.006 0.465 0.997 0.701 1.005 0.460 1.010 0.192 1.003 0.677 0.990 0.163
45 - 64 1.000 0.957 0.993 0.355 1.003 0.698 1.003 0.723 0.997 0.693 0.988 0.096
65 - 74 1.016 0.142 1.019 0.144 1.007 0.542 1.010 0.291 0.996 0.669 0.982 0.073
≥ 75 0.991 0.397 0.985 0.145 0.993 0.507 0.995 0.676 0.992 0.410 0.977 0.014
Sex % Male 1.003 0.475 1.011 0.023 1.006 0.317 1.003 0.566 1.007 0.148 1.005 0.410
Ethnicity
White Reference Reference Reference Reference Reference Reference
Non-
White 0.997 0.007 0.999 0.491 0.998 0.106 0.998 0.086 0.996 0.002 0.997 0.016
Unknown 0.999 0.409 0.998 0.290 0.999 0.773 0.996 0.114 0.998 0.290 0.999 0.651
List Size
< 4,000 Reference Reference Reference Reference Reference Reference
4,000 – 
7,999 0.990 0.480 0.990 0.468 0.984 0.304 0.975 0.110 0.988 0.390 0.992 0.595
≥ 8,000 0.964 0.042 0.956 0.016 0.963 0.062 0.958 0.022 0.965 0.031 0.976 0.176
GP FTEs per 1,000 patients 0.957 0.073 0.940 0.037 0.976 0.430 0.968 0.384 0.998 0.965 0.988 0.745
Diabetes Prevalence 0.958 0.001 0.916 < 0.001 0.957 0.001 0.974 0.035 0.976 0.011 0.969 0.007
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference Reference Reference Reference
2 0.833 < 0.001 0.835 < 0.001 0.852 < 0.001 0.861 < 0.001 0.865 < 0.001 0.889 < 0.001
3 0.797 < 0.001 0.819 < 0.001 0.820 < 0.001 0.845 < 0.001 0.838 < 0.001 0.854 < 0.001
4 0.742 < 0.001 0.759 < 0.001 0.781 < 0.001 0.810 < 0.001 0.802 < 0.001 0.823 < 0.001
5 0.731 < 0.001 0.720 < 0.001 0.763 < 0.001 0.778 < 0.001 0.779 < 0.001 0.790 < 0.001
6 0.717 < 0.001 0.712 < 0.001 0.723 < 0.001 0.768 < 0.001 0.766 < 0.001 0.762 < 0.001
7 0.700 < 0.001 0.689 < 0.001 0.720 < 0.001 0.758 < 0.001 0.757 < 0.001 0.774 < 0.001
8 0.679 < 0.001 0.671 < 0.001 0.704 < 0.001 0.736 < 0.001 0.733 < 0.001 0.730 < 0.001
9 0.656 < 0.001 0.640 < 0.001 0.689 < 0.001 0.740 < 0.001 0.744 < 0.001 0.718 < 0.001
10 0.660 < 0.001 0.617 < 0.001 0.652 < 0.001 0.702 < 0.001 0.729 < 0.001 0.702 < 0.001
Area 
Classification
Rural Reference Reference Reference Reference Reference Reference
Urban 0.919 0.003 0.914 0.004 0.884 < 0.001 0.894 < 0.001 0.888 < 0.001 0.914 0.001
Strict 
Glycaemic 
Control UA 
Fifth
1 Reference Reference Reference Reference Reference Reference
2 1.002 0.925 0.990 0.640 1.035 0.135 1.000 0.987 0.969 0.079 0.980 0.157
3 1.002 0.929 1.015 0.546 1.029 0.271 0.976 0.218 0.958 0.053 0.980 0.186
4 1.002 0.950 1.037 0.249 1.037 0.267 0.995 0.827 0.983 0.524 1.010 0.626
5 0.994 0.840 1.034 0.348 1.092 0.017 1.000 0.995 1.015 0.666 1.034 0.248
Table 28. Results of multi-variable negative binomial regression for underlying achievement of QOF
strict glycaemic control indicator group, QOF 2005/06 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; UA = underlying achievement.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference Reference
5 - 14 1.011 0.275 1.017 0.115 1.004 0.711 0.987 0.202
15 - 44 1.005 0.452 1.010 0.167 1.004 0.601 0.992 0.247
45 - 64 1.003 0.654 1.004 0.634 0.998 0.810 0.990 0.156
65 - 74 1.007 0.536 1.012 0.242 0.997 0.752 0.983 0.103
≥ 75 0.993 0.515 0.996 0.699 0.992 0.413 0.978 0.019
Sex % Male 1.005 0.381 1.003 0.574 1.007 0.180 1.004 0.513
Ethnicity
White Reference Reference Reference Reference
Non-
White 0.997 0.055 0.998 0.081 0.996 0.001 0.997 0.008
Unknown 0.999 0.715 0.996 0.111 0.998 0.272 0.999 0.640
List Size
< 4,000 Reference Reference Reference Reference
4,000 – 
7,999 0.985 0.337 0.976 0.121 0.986 0.304 0.986 0.373
≥ 8,000 0.961 0.054 0.957 0.019 0.958 0.012 0.967 0.063
GP FTEs per 1,000 patients 0.977 0.464 0.967 0.363 0.993 0.842 0.980 0.597
Diabetes Prevalence 0.962 0.005 0.976 0.057 0.979 0.025 0.974 0.028
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference Reference
2 0.849 < 0.001 0.860 < 0.001 0.862 < 0.001 0.890 < 0.001
3 0.818 < 0.001 0.846 < 0.001 0.838 < 0.001 0.852 < 0.001
4 0.779 < 0.001 0.810 < 0.001 0.801 < 0.001 0.823 < 0.001
5 0.762 < 0.001 0.779 < 0.001 0.779 < 0.001 0.792 < 0.001
6 0.725 < 0.001 0.772 < 0.001 0.764 < 0.001 0.763 < 0.001
7 0.722 < 0.001 0.760 < 0.001 0.756 < 0.001 0.773 < 0.001
8 0.706 < 0.001 0.737 < 0.001 0.734 < 0.001 0.734 < 0.001
9 0.691 < 0.001 0.742 < 0.001 0.746 < 0.001 0.722 < 0.001
10 0.655 < 0.001 0.702 < 0.001 0.728 < 0.001 0.706 < 0.001
Area 
Classification
Rural Reference Reference Reference Reference
Urban 0.880 < 0.001 0.895 < 0.001 0.886 < 0.001 0.912 0.001
Strict 
Glycaemic 
Control ER 
Fifth
1 Reference Reference Reference Reference
2 0.991 0.528 1.012 0.418 0.987 0.315 1.010 0.552
3 0.983 0.347 1.020 0.225 0.998 0.915 1.023 0.129
4 1.001 0.955 1.023 0.171 1.024 0.185 1.024 0.202
5 1.025 0.326 1.055 0.012 1.059 0.015 1.079 0.002
Table 29. Results of multi-variable negative binomial regression for exception reporting for QOF
strict glycaemic control indicator group, QOF 2007/08 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; ER = exception rate.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2009/10 2010/11
IRR p IRR p
Age (years)
0 - 4 Reference Reference
5 - 14 1.002 0.861 0.985 0.137
15 - 44 1.002 0.750 0.990 0.150
45 - 64 0.996 0.618 0.988 0.087
65 - 74 0.995 0.635 0.981 0.061
≥ 75 0.991 0.360 0.976 0.012
Sex % Male 1.007 0.169 1.004 0.471
Ethnicity
White Reference Reference
Non-
White 0.996 0.001 0.997 0.010
Unknown 0.998 0.269 0.999 0.622
List Size
< 4,000 Reference Reference
4,000 – 
7,999 0.987 0.377 0.990 0.554
≥ 8,000 0.964 0.034 0.974 0.161
GP FTEs per 1,000 patients 0.999 0.976 0.987 0.735
Diabetes Prevalence 0.976 0.015 0.972 0.014
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference
2 0.865 < 0.001 0.888 < 0.001
3 0.838 < 0.001 0.852 < 0.001
4 0.801 < 0.001 0.823 < 0.001
5 0.779 < 0.001 0.790 < 0.001
6 0.767 < 0.001 0.761 < 0.001
7 0.757 < 0.001 0.772 < 0.001
8 0.733 < 0.001 0.731 < 0.001
9 0.744 < 0.001 0.719 < 0.001
10 0.729 < 0.001 0.702 < 0.001
Area 
Classification
Rural Reference Reference
Urban 0.888 < 0.001 0.914 0.001
Intermediate 
Glycaemic 
Control UA 
Fifth
1 Reference Reference
2 0.966 0.027 0.958 0.003
3 0.955 0.010 0.991 0.594
4 0.971 0.126 0.970 0.098
5 0.992 0.720 1.014 0.538
Table 30. Results of multi-variable negative binomial regression for underlying achievement of QOF
intermediate glycaemic control indicator group, QOF 2009/10 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; UA = underlying achievement.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2009/10 2010/11
IRR p IRR p
Age (years)
0 - 4 Reference Reference
5 - 14 1.004 0.689 0.987 0.200
15 - 44 1.004 0.587 0.992 0.242
45 - 64 0.999 0.838 0.990 0.159
65 - 74 0.997 0.778 0.984 0.109
≥ 75 0.992 0.427 0.978 0.019
Sex % Male 1.007 0.173 1.004 0.512
Ethnicity
White Reference Reference
Non-
White 0.996 0.001 0.997 0.009
Unknown 0.998 0.268 0.999 0.636
List Size
< 4,000 Reference Reference
4,000 – 
7,999 0.986 0.316 0.986 0.385
≥ 8,000 0.958 0.013 0.966 0.062
GP FTEs per 1,000 patients 0.994 0.865 0.981 0.617
Diabetes Prevalence 0.978 0.023 0.974 0.030
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference
2 0.862 < 0.001 0.890 < 0.001
3 0.837 < 0.001 0.852 < 0.001
4 0.800 < 0.001 0.823 < 0.001
5 0.779 < 0.001 0.794 < 0.001
6 0.765 < 0.001 0.764 < 0.001
7 0.757 < 0.001 0.775 < 0.001
8 0.734 < 0.001 0.737 < 0.001
9 0.745 < 0.001 0.724 < 0.001
10 0.728 < 0.001 0.707 < 0.001
Area 
Classification
Rural Reference Reference
Urban 0.887 < 0.001 0.912 0.001
Intermediate 
Glycaemic 
Control ER 
Fifth
1 Reference Reference
2 1.001 0.965 1.012 0.408
3 1.008 0.602 1.038 0.014
4 1.032 0.086 1.027 0.149
5 1.066 0.006 1.093 < 0.001
Table 31. Results of multi-variable negative binomial regression for exception reporting for QOF
intermediate glycaemic control indicator group, QOF 2009/10 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; ER = exception rate.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference Reference Reference Reference
5 - 14 1.016 0.133 1.009 0.435 1.011 0.299 1.016 0.146 1.002 0.858 0.985 0.153
15 - 44 1.006 0.453 0.996 0.673 1.005 0.495 1.010 0.190 1.002 0.731 0.990 0.167
45 - 64 1.000 0.996 0.993 0.346 1.002 0.717 1.003 0.703 0.997 0.643 0.988 0.096
65 - 74 1.017 0.136 1.019 0.153 1.005 0.617 1.011 0.262 0.996 0.674 0.981 0.063
≥ 75 0.991 0.417 0.984 0.142 0.993 0.501 0.995 0.672 0.991 0.361 0.977 0.014
Sex % Male 1.003 0.526 1.010 0.039 1.005 0.382 1.003 0.621 1.007 0.186 1.004 0.450
Ethnicity
White Reference Reference Reference Reference Reference Reference
Non-White 0.997 0.006 0.999 0.359 0.997 0.060 0.998 0.081 0.996 0.001 0.997 0.009
Unknown 0.999 0.394 0.998 0.266 0.999 0.722 0.996 0.108 0.998 0.261 0.999 0.620
List Size
< 4,000 Reference Reference Reference Reference Reference Reference
4,000 – 
7,999 0.990 0.496 0.990 0.493 0.985 0.348 0.975 0.114 0.985 0.307 0.991 0.592
≥ 8,000 0.964 0.041 0.955 0.017 0.965 0.082 0.958 0.025 0.961 0.022 0.977 0.205
GP FTEs per 1,000 patients 0.959 0.091 0.942 0.044 0.977 0.452 0.971 0.427 1.000 0.992 0.986 0.713
Diabetes Prevalence 0.957 0.001 0.917 < 0.001 0.960 0.003 0.974 0.036 0.976 0.013 0.972 0.017
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference Reference Reference Reference
2 0.832 < 0.001 0.833 < 0.001 0.851 < 0.001 0.859 < 0.001 0.864 < 0.001 0.889 < 0.001
3 0.797 < 0.001 0.818 < 0.001 0.818 < 0.001 0.845 < 0.001 0.838 < 0.001 0.853 < 0.001
4 0.742 < 0.001 0.759 < 0.001 0.780 < 0.001 0.809 < 0.001 0.800 < 0.001 0.822 < 0.001
5 0.732 < 0.001 0.719 < 0.001 0.762 < 0.001 0.779 < 0.001 0.778 < 0.001 0.791 < 0.001
6 0.718 < 0.001 0.713 < 0.001 0.723 < 0.001 0.770 < 0.001 0.766 < 0.001 0.761 < 0.001
7 0.702 < 0.001 0.691 < 0.001 0.720 < 0.001 0.758 < 0.001 0.756 < 0.001 0.772 < 0.001
8 0.680 < 0.001 0.673 < 0.001 0.705 < 0.001 0.738 < 0.001 0.734 < 0.001 0.731 < 0.001
9 0.658 < 0.001 0.641 < 0.001 0.690 < 0.001 0.742 < 0.001 0.745 < 0.001 0.720 < 0.001
10 0.661 < 0.001 0.619 < 0.001 0.653 < 0.001 0.704 < 0.001 0.730 < 0.001 0.703 < 0.001
Area 
Classification
Rural Reference Reference Reference Reference Reference Reference
Urban 0.921 0.005 0.913 0.004 0.880 < 0.001 0.896 < 0.001 0.888 < 0.001 0.912 0.001
Moderate 
Glycaemic 
Control  UA 
Fifth
1 Reference Reference Reference Reference Reference Reference
2 1.003 0.889 1.001 0.953 0.986 0.443 0.991 0.505 0.988 0.487 0.955 0.004
3 1.006 0.794 0.949 0.012 0.992 0.707 0.971 0.109 0.962 0.029 0.970 0.107
4 0.971 0.193 0.990 0.667 0.974 0.313 0.976 0.179 0.980 0.318 0.982 0.366
5 0.980 0.448 0.980 0.442 1.024 0.366 0.969 0.150 0.977 0.250 1.008 0.687
Table 32. Results of multi-variable negative binomial regression for underlying achievement of QOF
moderate glycaemic control indicator group, QOF 2005/06 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; UA = underlying achievement.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference Reference
5 - 14 1.011 0.285 1.017 0.115 1.005 0.658 0.987 0.210
15 - 44 1.005 0.475 1.010 0.167 1.004 0.549 0.992 0.258
45 - 64 1.003 0.677 1.004 0.630 0.999 0.876 0.990 0.172
65 - 74 1.007 0.543 1.012 0.223 0.998 0.833 0.984 0.119
≥ 75 0.993 0.503 0.996 0.686 0.993 0.453 0.978 0.021
Sex % Male 1.006 0.366 1.003 0.587 1.007 0.172 1.004 0.510
Ethnicity
White Reference Reference Reference Reference
Non-White 0.997 0.055 0.998 0.089 0.996 0.001 0.997 0.011
Unknown 0.999 0.718 0.996 0.108 0.998 0.268 0.999 0.632
List Size
< 4,000 Reference Reference Reference Reference
4,000 – 
7,999 0.987 0.400 0.977 0.137 0.986 0.326 0.984 0.327
≥ 8,000 0.964 0.077 0.957 0.021 0.958 0.013 0.965 0.050
GP FTEs per 1,000 patients 0.978 0.466 0.968 0.387 0.994 0.881 0.981 0.621
Diabetes Prevalence 0.962 0.005 0.976 0.052 0.978 0.021 0.973 0.024
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference Reference
2 0.849 < 0.001 0.859 < 0.001 0.863 < 0.001 0.890 < 0.001
3 0.818 < 0.001 0.846 < 0.001 0.838 < 0.001 0.852 < 0.001
4 0.780 < 0.001 0.809 < 0.001 0.800 < 0.001 0.823 < 0.001
5 0.763 < 0.001 0.780 < 0.001 0.780 < 0.001 0.793 < 0.001
6 0.726 < 0.001 0.771 < 0.001 0.766 < 0.001 0.764 < 0.001
7 0.722 < 0.001 0.760 < 0.001 0.757 < 0.001 0.774 < 0.001
8 0.707 < 0.001 0.738 < 0.001 0.734 < 0.001 0.735 < 0.001
9 0.692 < 0.001 0.741 < 0.001 0.746 < 0.001 0.723 < 0.001
10 0.656 < 0.001 0.702 < 0.001 0.728 < 0.001 0.706 < 0.001
Area 
Classification
Rural Reference Reference Reference Reference
Urban 0.880 < 0.001 0.895 < 0.001 0.887 < 0.001 0.913 0.001
Moderate 
Glycaemic 
Control ER 
Fifth
1 Reference Reference Reference Reference
2 0.971 0.080 0.997 0.829 0.989 0.412 1.023 0.116
3 0.975 0.121 1.003 0.865 1.017 0.236 1.046 0.002
4 0.975 0.222 1.016 0.332 1.027 0.169 1.043 0.045
5 1.021 0.400 1.054 0.017 1.064 0.004 1.087 < 0.001
Table 33. Results of multi-variable negative binomial regression for exception reporting for QOF
moderate glycaemic control indicator group, QOF 2007/08 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; ER = exception rate.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2008/09 2009/10 2010/11
IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference
5 - 14 1.019 0.081 1.005 0.610 0.989 0.302
15 - 44 1.011 0.127 1.004 0.532 0.993 0.319
45 - 64 1.005 0.539 0.999 0.864 0.991 0.208
65 - 74 1.012 0.241 0.997 0.784 0.984 0.114
≥ 75 0.998 0.862 0.994 0.524 0.981 0.045
Sex % Male 1.004 0.468 1.008 0.118 1.006 0.336
Ethnicity
White Reference Reference Reference
Non-White 0.997 0.064 0.996 0.001 0.997 0.007
Unknown 0.996 0.112 0.998 0.272 0.999 0.614
List Size
< 4,000 Reference Reference Reference
4,000 – 
7,999 0.969 0.054 0.978 0.120 0.977 0.164
≥ 8,000 0.950 0.009 0.948 0.003 0.952 0.014
GP FTEs per 1,000 patients 0.974 0.482 1.004 0.912 0.995 0.896
Diabetes Prevalence 0.973 0.026 0.974 0.007 0.969 0.007
IMD Tenth
(1 = Most 
Deprived)
1 Reference Reference Reference
2 0.861 < 0.001 0.865 < 0.001 0.889 < 0.001
3 0.845 < 0.001 0.838 < 0.001 0.854 < 0.001
4 0.812 < 0.001 0.803 < 0.001 0.825 < 0.001
5 0.781 < 0.001 0.782 < 0.001 0.793 < 0.001
6 0.772 < 0.001 0.769 < 0.001 0.765 < 0.001
7 0.761 < 0.001 0.757 < 0.001 0.776 < 0.001
8 0.739 < 0.001 0.736 < 0.001 0.734 < 0.001
9 0.744 < 0.001 0.748 < 0.001 0.722 < 0.001
10 0.707 < 0.001 0.732 < 0.001 0.708 < 0.001
Area 
Classification
Rural Reference Reference Reference
Urban 0.898 < 0.001 0.890 < 0.001 0.918 0.001
PE07 UA Fifth
1 Reference Reference Reference
2 0.981 0.244 0.958 0.008 0.962 0.060
3 0.957 0.019 0.963 0.079 0.964 0.084
4 0.941 0.002 0.946 0.007 0.937 0.006
5 0.945 0.008 0.928 0.001 0.903 < 0.001
Table 34. Results of multi-variable negative binomial regression for underlying achievement of QOF
indicator PE07, QOF 2008/09 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; UA = underlying achievement.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
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2008/09 2009/10 2010/11
IRR p IRR p IRR p
Age (years)
0 - 4 Reference Reference Reference
5 - 14 1.018 0.090 1.004 0.697 0.987 0.192
15 - 44 1.012 0.100 1.004 0.530 0.992 0.262
45 - 64 1.005 0.476 0.999 0.847 0.991 0.177
65 - 74 1.012 0.211 0.997 0.756 0.983 0.093
≥ 75 0.998 0.878 0.993 0.506 0.980 0.028
Sex % Male 1.004 0.462 1.008 0.115 1.005 0.363
Ethnicity
White Reference Reference Reference
Non-
White 0.998 0.077 0.996 0.001 0.997 0.010
Unknown 0.996 0.099 0.998 0.253 0.999 0.593
List Size
< 4,000 Reference Reference Reference
4,000 – 
7,999 0.959 0.013 0.972 0.056 0.971 0.088
≥ 8,000 0.932 < 0.001 0.938 0.001 0.943 0.003
GP FTEs per 1,000 
patients 0.974 0.465 1.004 0.921 0.993 0.843
Diabetes Prevalence 0.969 0.010 0.973 0.006 0.966 0.005
IMD Decile
( 1 = Most 
Deprived)
1 Reference Reference Reference
2 0.864 < 0.001 0.866 < 0.001 0.889 < 0.001
3 0.848 < 0.001 0.839 < 0.001 0.854 < 0.001
4 0.813 < 0.001 0.803 < 0.001 0.825 < 0.001
5 0.781 < 0.001 0.781 < 0.001 0.794 < 0.001
6 0.774 < 0.001 0.769 < 0.001 0.765 < 0.001
7 0.762 < 0.001 0.759 < 0.001 0.777 < 0.001
8 0.742 < 0.001 0.738 < 0.001 0.735 < 0.001
9 0.748 < 0.001 0.750 < 0.001 0.723 < 0.001
10 0.712 < 0.001 0.737 < 0.001 0.710 < 0.001
Area 
Classification
Rural Reference Reference Reference
Urban 0.901 < 0.001 0.891 < 0.001 0.919 0.002
PE08 UA Fifth
1 Reference Reference Reference
2 0.948 0.002 0.995 0.770 0.981 0.322
3 0.937 0.001 0.971 0.112 0.954 0.021
4 0.905 < 0.001 0.937 0.001 0.938 0.005
5 0.897 < 0.001 0.937 0.005 0.909 < 0.001
Table 35. Results of multi-variable negative binomial regression for underlying achievement of QOF
indicator PE08, QOF 2008/09 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; UA = underlying achievement.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase.
- 99 -
For the model containing all predictors – that is, all variables describing practice
population characteristics, practice characteristics, deprivation, rurality, fifths of
underlying achievement for all selected QOF indicators and indicator groups and
fifths of exception rates, where available, for all QOF indicators and indicator
groups – significant associations with emergency admission rates remained for a
number of predictors (Table 36).
Increasing practice diabetes prevalence was associated with decreased
emergency admissions across all QOF years, with a 1% increase in prevalence
conferring a relative reduction in emergency admissions between 2.8% – 8.5%. 
Deprivation, as with previous models, was associated with significant changes in
emergency admission rates across all QOF years, with practices in the most aﬄuent
areas experiencing emergency admission rates that were 25.2% – 38.0% lower
than those located in the most deprived areas; all levels of decreasing deprivation
were associated with significantly lower emergency admission rates in comparison
to practices located in the most deprived areas across all QOF years. Likewise,
practices located in urban areas were associated with lower emergency admission
rates in comparison to those located in rural areas across all QOF years, with
relative reductions in the range 7.7% – 11.2%. 
Insofar as QOF performance is concerned, the most consistent associations
with changes in emergency admission rates in the full model were observed for
underlying achievement for the process group of indicators and indicator PE08
(ability to book an appointment more than two days in advance), with relative
emergency admission rate reductions ranging between 4.7% – 9.1% and 6.0% –
8.8% respectively for the best-performing fifth of practices in comparison to the
worst performing fifth.
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For indicator and indicator group exception rates, relatively consistent
associations with changes in emergency admission rates were observed for the
process and for the intermediate cardiovascular outcome groups of indicators. In
QOF years 2007/08 to 2009/10, practices in the highest fifth of exception reporting
for the process group of indicators were associated with relative increases in
emergency admission rates of between 8.9% – 12.7% in comparison to practices in
the lowest fifth of exception reporting for the process group of indicators.
Practices that were in the highest fifth of exception reporting for the
cardiovascular intermediate outcome group of indicators were associated with
emergency admission rates that were 7.1% – 11.0% lower than practices with the
lowest levels of exception reporting; of interest, practices in the highest fifth of
performance for this indicator group tended to have elevated emergency admission
rates, with a significant relative increase of 4.9% in 2008/09 and 2009/10 in
comparison to the worst-performing fifth of practices.
Some other significant associations were also observed, albeit not with the
degree of consistency observed for the predictors already discussed. Practices with
list sizes of 8,000 or more patients were associated with relative reductions in
emergency admission rates ranging between 4.1% – 6.9% for 2006/07 and
2008/09 – 2010/11 in comparison to practices with list sizes less than 4,000
patients. Sporadic associations between the proportion of practice populations
recorded as non-white and reduced emergency admission rates were observed in
2005/06 and 2009/10 – 2010/11, although the clinical significance of such a finding
may be marginal, as each 1% increase of the non-white population was only
associated with a 0.3% – 0.4% relative decrease in emergency admission rates.
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age (years)
0 - 4 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
5 - 14 1.017 0.131 1.014 0.186 1.013 0.211 1.022 0.037 1.007 0.489 0.990 0.354
15 - 44 1.007 0.432 1.000 0.956 1.006 0.401 1.014 0.051 1.006 0.391 0.994 0.405
45 - 64 1.001 0.928 0.996 0.545 1.004 0.583 1.008 0.250 1.002 0.766 0.993 0.334
65 - 74 1.017 0.155 1.023 0.073 1.009 0.407 1.015 0.128 1.000 0.995 0.987 0.193
≥ 75 0.992 0.473 0.987 0.191 0.993 0.520 1.001 0.917 0.996 0.675 0.982 0.051
Sex % Male 1.002 0.630 1.009 0.054 1.006 0.371 1.004 0.485 1.007 0.145 1.005 0.342
Ethnicity
White Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Non-
White 0.997 0.011 0.999 0.539 0.998 0.112 0.998 0.087 0.996 0.002 0.997 0.008
Unknown 0.999 0.484 0.998 0.281 0.999 0.811 0.996 0.108 0.998 0.302 0.999 0.636
List Size
< 4,000 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
4,000 – 
7,999 0.991 0.491 0.992 0.575 0.989 0.497 0.964 0.023 0.980 0.156 0.974 0.103
≥ 8,000 0.966 0.065 0.959 0.024 0.968 0.120 0.931 < 0.001 0.948 0.004 0.943 0.002
GP FTEs per 1,000 
patients 0.959 0.124 0.945 0.049 0.987 0.655 0.981 0.576 1.013 0.712 1.004 0.914
Diabetes Prevalence 0.956 0.001 0.915 < 0.001 0.958 0.001 0.969 0.010 0.972 0.003 0.967 0.003
IMD Tenth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.832 < 0.001 0.835 < 0.001 0.853 < 0.001 0.867 < 0.001 0.868 < 0.001 0.892 < 0.001
3 0.797 < 0.001 0.818 < 0.001 0.821 < 0.001 0.850 < 0.001 0.845 < 0.001 0.856 < 0.001
4 0.743 < 0.001 0.761 < 0.001 0.782 < 0.001 0.821 < 0.001 0.812 < 0.001 0.832 < 0.001
5 0.734 < 0.001 0.722 < 0.001 0.767 < 0.001 0.788 < 0.001 0.791 < 0.001 0.801 < 0.001
6 0.719 < 0.001 0.714 < 0.001 0.731 < 0.001 0.785 < 0.001 0.782 < 0.001 0.774 < 0.001
7 0.702 < 0.001 0.693 < 0.001 0.725 < 0.001 0.773 < 0.001 0.772 < 0.001 0.787 < 0.001
8 0.680 < 0.001 0.674 < 0.001 0.712 < 0.001 0.754 < 0.001 0.751 < 0.001 0.746 < 0.001
9 0.658 < 0.001 0.642 < 0.001 0.697 < 0.001 0.759 < 0.001 0.764 < 0.001 0.733 < 0.001
10 0.662 < 0.001 0.620 < 0.001 0.659 < 0.001 0.723 < 0.001 0.748 < 0.001 0.717 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Urban 0.923 0.008 0.920 0.005 0.888 < 0.001 0.903 < 0.001 0.897 < 0.001 0.919 0.002
Process UA 
Fifth
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.975 0.219 0.938 < 0.001 0.961 0.016 0.961 0.012 0.939 < 0.001 0.961 0.007
3 0.990 0.632 0.955 0.027 0.974 0.165 0.947 0.012 0.949 0.004 0.960 0.014
4 0.983 0.520 0.949 0.023 0.947 0.005 0.931 0.002 0.919 < 0.001 0.954 0.014
5 0.982 0.497 0.953 0.034 0.945 0.014 0.909 < 0.001 0.917 < 0.001 0.930 0.001
CVS UA Fifth
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.011 0.532 1.000 0.990 0.986 0.377 1.006 0.640 1.017 0.256 1.018 0.176
3 1.028 0.176 1.006 0.737 0.995 0.777 1.031 0.065 1.015 0.351 1.008 0.600
4 1.020 0.372 1.008 0.657 0.982 0.318 1.025 0.183 1.024 0.146 1.023 0.195
5 1.028 0.295 0.996 0.867 0.976 0.262 1.049 0.040 1.049 0.034 1.028 0.231
Strict 
Glycaemic 
Control UA 
Fifth
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.004 0.820 1.008 0.711 1.051 0.040 1.005 0.780 0.992 0.750 0.994 0.699
3 1.010 0.723 1.049 0.098 1.056 0.064 0.986 0.555 0.987 0.662 1.001 0.978
4 1.015 0.671 1.084 0.037 1.073 0.056 1.010 0.727 1.018 0.652 1.042 0.147
5 1.015 0.737 1.092 0.056 1.130 0.007 1.016 0.710 1.056 0.275 1.068 0.072
(continued...)
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Strict 
Glycaemic 
Control UA 
Fifth
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.004 0.820 1.008 0.711 1.051 0.040 1.005 0.780 0.992 0.750 0.994 0.699
3 1.010 0.723 1.049 0.098 1.056 0.064 0.986 0.555 0.987 0.662 1.001 0.978
4 1.015 0.671 1.084 0.037 1.073 0.056 1.010 0.727 1.018 0.652 1.042 0.147
5 1.015 0.737 1.092 0.056 1.130 0.007 1.016 0.710 1.056 0.275 1.068 0.072
Intermediate 
Glycaemic 
Control UA 
Fifth
1
N/A N/A N/A N/A
Reference Group Reference Group
2 0.970 0.135 0.965 0.064
3 0.964 0.115 0.977 0.360
4 0.971 0.346 0.933 0.016
5 0.970 0.352 0.939 0.063
Moderate 
Glycaemic 
Control UA 
Fifth
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.998 0.932 1.001 0.942 0.983 0.400 1.004 0.787 1.010 0.631 0.974 0.171
3 0.996 0.890 0.934 0.004 0.982 0.455 0.985 0.498 0.984 0.516 0.989 0.655
4 0.958 0.167 0.962 0.160 0.952 0.101 0.992 0.730 0.990 0.733 1.002 0.950
5 0.964 0.296 0.939 0.063 0.985 0.625 0.983 0.569 0.966 0.295 1.018 0.581
PE07 UA 
Fifth
1
N/A N/A N/A
Reference Group Reference Group Reference Group
2 1.004 0.827 0.973 0.079 0.974 0.209
3 0.985 0.399 0.982 0.405 0.981 0.370
4 0.973 0.173 0.970 0.145 0.960 0.096
5 0.985 0.531 0.956 0.065 0.932 0.011
PE08 UA 
Fifth
1
N/A N/A N/A
Reference Group Reference Group Reference Group
2 0.949 0.002 0.998 0.885 0.983 0.376
3 0.939 0.001 0.979 0.229 0.962 0.051
4 0.913 < 0.001 0.949 0.008 0.952 0.028
5 0.912 < 0.001 0.961 0.077 0.940 0.015
Process ER 
Fifth
1
N/A N/A
Reference Group Reference Group Reference Group Reference Group
2 1.021 0.178 1.004 0.768 1.018 0.259 1.008 0.646
3 1.041 0.053 1.058 0.006 1.030 0.115 1.020 0.309
4 1.087 0.003 1.086 0.001 1.047 0.039 1.034 0.190
5 1.127 < 0.001 1.105 0.001 1.089 0.004 1.047 0.103
(continued...)
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2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
CVS ER Fifth
1
N/A N/A
Reference Group Reference Group Reference Group Reference Group
2 0.957 0.011 0.995 0.732 0.973 0.134 1.002 0.903
3 0.951 0.034 0.976 0.223 0.981 0.280 0.986 0.508
4 0.910 0.001 0.946 0.023 0.934 0.005 0.991 0.739
5 0.890 0.001 0.929 0.013 0.925 0.007 0.975 0.414
Strict 
Glycaemic 
Control ER 
Fifth
1
N/A N/A
Reference Group Reference Group Reference Group Reference Group
2 1.025 0.130 1.017 0.315 0.983 0.421 0.986 0.542
3 1.030 0.228 1.026 0.272 0.994 0.853 0.976 0.380
4 1.046 0.150 1.024 0.394 1.019 0.602 0.971 0.450
5 1.049 0.229 1.044 0.184 1.048 0.273 0.991 0.860
Intermediate 
Glycaemic 
Control ER 
Fifth
1
N/A N/A N/A N/A
Reference Group Reference Group
2 1.016 0.506 0.995 0.840
3 1.004 0.910 1.024 0.486
4 1.009 0.808 1.026 0.538
5 1.014 0.758 1.089 0.096
Moderate 
Glycaemic 
Control ER 
Fifth
1
N/A N/A
Reference Group Reference Group Reference Group Reference Group
2 0.964 0.030 0.979 0.156 0.984 0.439 1.027 0.171
3 0.955 0.031 0.968 0.121 1.013 0.596 1.038 0.170
4 0.944 0.039 0.971 0.273 1.010 0.765 1.019 0.578
5 0.979 0.541 0.997 0.939 1.026 0.467 1.008 0.864
Table 36. Results of multi-variable negative binomial regression for all selected predictors, QOF
2008/09 - 2010/11.
IRR = Incidence rate ratio;  GP = General practitioner; FTE = Full-time equivalent; IMD = Index of Multiple
Deprivation; CVS = cardiovascular system (includes targets pertaining to blood pressure and total cholesterol);
UA = underlying achievement; ER = exception rate.
Regression coeﬃcients converted to IRRs; practice population age structure and ethnicity described as the
proportion of the registered population falling within a given category; IRRs for practice population age-bands,
proportion male, ethnicities and diabetes prevalence denote the magnitude of estimated eﬀect of a 1%
increase; N/A denotes that the indicator / indicator group was not present for that QOF year.
Whilst direct calculation of the degree of variability in emergency admissions
attributable to the full model was precluded through use of clustering by PCT,
pseudo-R2 values were calculated for an unclustered variant of the full model for
each QOF year (Table 37). For the unclustered models, the degree of variation
between practices attributable to models was relatively low, with pseudo-R2 values
ranging between 0.0175 – 0.0231.
2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
Pseudo-R2 0.0175 0.0210 0.0196 0.0203 0.0223 0.0231
Table 37. Pseudo-R2 values, by QOF year, for unclustered versions of the full emergency admissions
model.
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Discussion
Principal Findings
Over the period 2005/06 to 2010/11, the prevalence of diabetes rose from
3.55% to 4.45% in the English registered population, representing an increase in
the number of people with diabetes by over 565,000.
Over the same period, emergency admissions in people with diabetes increased
from a crude rate of 157.77 per 1,000 registered people with diabetes to a crude
rate of 167.60 per 1,000; the mean emergency admissions per practice increased
from 35.44 to 51.08. Such observations could be due to a true increase in risk of
disease requiring emergency admission (likely due to an ageing population of
people with diabetes) or improvements in clinical coding, whereby a person who
has diabetes is more likely to be reported as such.
Crude emergency admission rates for people younger than 65 years remained
relatively static over the observation period, whereas those for people aged 65 or
older increased. This may well reflect the impact of multi-morbidity in older
members of the population, but further investigation of how appropriate existing
quality targets for older people with diabetes are with respect to minimising the risk
of emergency hospital admissions. 
Crude emergency admission rates increased with age, likely representing the
elevated risk of co-morbidity in older individuals. The greatest changes in admission
rates over the observation period were observed in the youngest (15 – 44 years) and
oldest (≥ 75 years) age groups, where crude emergency admission rates rose from
106.35 to 125.84 per 1,000 people with diabetes and 283.18 to 300.11 per 1,000
people with diabetes respectively. Females were consistently subject to a higher
emergency admission rates than males; this could be due to diﬀerences in health-
seeking behaviour or the under-diagnosis and under-treatment of cardiovascular
disease in women.198, 199
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In order to control for the eﬀects of practice population age and gender on
emergency admission rates, SEARs for each practice were generated. There was
considerable variability in SEARs across practices, which would imply that there are
variations in underlying determinants of emergency admission rates of people with
diabetes.
Although quantification of residual confounding in the full negative binomial
models is precluded by use of clustering, adjusted R2 values for unclustered models
indicate that there is considerable residual confounding, meaning that additional
factors, some of which may not be adequately captured by the available data, also
have a role to play when considering determinants of emergency admissions in
people with diabetes. That aside, all of the negative binomial models demonstrated
significant eﬀects of the selected predictors on practice emergency admissions,
likely as a result of the large sample size used for model construction.
It should be noted that the population structure of people with diabetes, and
hence the derived SEARs, are based on estimates from HSfE rather than known
counts. This would mean that there is likely to be a degree of error in the SEARs;
however, all practices would be subject to such errors, meaning that any resulting
bias would be likely to be non-diﬀerential in nature.
A number of associations between predictors and emergency admission rates
were relatively robust and persisted across increasingly verbose models, most
notably practice deprivation, practice rurality, diabetes prevalence and underlying
achievement for the process group of QOF indicators and underlying achievement
for indicator PE08 (ability to book an appointment two or more days in advance).
The majority of indicators and indicator groups based upon intermediate clinical
targets (cardiovascular intermediate outcomes and glycaemic control indicator
groups) failed to show any consistent associations with emergency admission rates.
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The findings from the full model with regards to practice deprivation – that the
most aﬄuent practices are subject to relative reductions in emergency admission
rates estimated to be in the range of 25.2% – 38.0% in comparison to the most
deprived – and practice rurality – where urban practices were estimated to have
emergency admission rates 7.7% – 11.2% lower than their rural counterparts – is in
keeping with a number of existing studies.13, 159, 160, 172, 200 Such diﬀerences are likely
to represent diﬀerences in risk factor distribution, health-seeking behaviours, de-
prioritisation of one’s own health and accessibility of services.
Increasing practice diabetes prevalence was associated with decreased
emergency admission rates across all QOF years for the full model, with relative
reductions in emergency admissions ranging between 2.8% – 8.5% with every 1%
increase in practice diabetes prevalence. This may indicate that more frequent
exposure of the primary care workforce to people with diabetes increases familiarity
with the ongoing management of diabetes, promoting delivery of care that is timely,
comprehensive and eﬃcacious. Practice list size had no discernible association
with emergency admission rates.
In the full model, achievement for diabetes-specific process indicators was
significantly associated with decreased emergency admission rates for five of the
six years observed (2006/07 – 2010/11 inclusive), with the best performing fifth of
practices estimated to have emergency admission rates 4.7% – 9.1% lower than
those observed for the worst performing practices. This finding may reflect that
practices who are able to attain high levels of achievement for this group of
indicators have a higher level of engagement with their patients who have diabetes;
success in the process group of indicators is dependent on regular patient review,
which would promote discussion of secondary and tertiary prevention measures
that may, in turn, reduce the risk of emergency admission at the patient level.
The ability of individuals to book appointments more than two days in advance,
as measured by indicator PE08, was associated with a decreased emergency
admission rate for two of the three years this indicator was available in the full
model (2008/09 and 2010/11, 6.0% – 8.8% reduction for the best performing fifth of
practices in comparison to the worst). Ease of booking appointments less than two
days in advance (indicator PE07) only demonstrated an association with reduced
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admission rates for QOF year 2010/11 in the full model, with an estimate of the
magnitude less than the maximum observed for PE08, with the best performing fifth
of practices experiencing emergency admission rates 6.8% lower than the worst
performing fifth. In particular, the findings for PE08 highlight the central role that
proactive, planned care has in the maximisation of health outcomes in the
population with diabetes, as opposed to reactive care for acute illnesses and
complications. The removal of all indicators pertaining to patient experience and
access from QOF in recent years130 is, therefore, of considerable concern, as
improved accessibility and appointment availability are strongly associated with a
decreased rate of emergency admissions from the population with diabetes.
The general lack of associations between underlying achievement for the
indicators and indicator groups based on intermediate targets and emergency
admissions in the full model may be attributable to a number of factors. Firstly,
engagement with care – to a certain degree – on behalf of the patient is necessary
to obtain a measurement of blood pressure, total cholesterol or HbA1c; the
adjusted incidence rate ratios for emergency admissions for these indicators and
indicator groups may well have been non-significant as achievement for the process
group of indicators had already been accounted for. 
However, few of these indicators and indicator groups exhibited significant
associations in models in which the eﬀects of performance for these indicators and
indicator groups was unadjusted for practice performance in other indicators. This
raises the question of whether the blood pressure, total cholesterol and HbA1c QOF
targets are suitably stringent to exert a meaningful eﬀect on emergency
admissions.201
Another potential explanation for the lack of consistent associations between
achievement in indicators and indicator groups based upon intermediate targets is
heterogeneity of patients and the degree to which their blood pressure, total
cholesterol and HbA1c is lowered. There is a need for personalisation of treatment
targets for people with diabetes124, 202 that concentrate on the attributes and risks to
individual patients as opposed to incentivisation of physician behaviour, introducing
the possibility that the gains realised with respect to improved outcomes for some
patients is masked by the lack of benefit in those for whom these targets are not
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suitable. It is also likely that individuals who have achieved the targets stipulated
exhibit a range of values for blood pressure, total cholesterol and HbA1c. A number
of recent studies have described a U-shaped relationship between these variables
and outcomes such as mortality and unscheduled admissions, with values above
and below a certain range conferring elevated levels of risk100, 101, 203, 204; patients who
are in receipt of intensive treatment may have exceeded treatment targets and have
values that lie below the optimal range and, therefore, exhibit increased risks of
emergency admissions that may eclipse the benefits realised for individuals who
have met intermediate targets but still have values within the optimal range.
The potentially deleterious eﬀects of overtly aggressive treatment of
hypertension and hypercholesterolaemia discussed above may also partially explain
the seemingly counterintuitive associations between increased emergency
admission rates for practices in the best performing fifth of the cardiovascular
intermediate outcome indicator group in 2008/09 – 2009/10 and for the decreased
emergency admission rates associated with practices in the highest fifth of
exception reporting in 2007/08 – 2009/10.
Aside from the associations between levels of exception reporting for the
cardiovascular intermediate outcome indicator group and emergency admissions,
the only other significant associations observed for exception reporting was for the
process indicator group. For QOF years 2007/08 – 2009/10, practices in the highest
fifth of exception reporting were subject to emergency admission rates estimated to
be 8.9% – 12.7% higher than those with the lowest levels of exception reporting.
This finding could result from practices with the highest levels of exception
reporting having a larger proportion of individuals with co-existing terminal disease
for whom it may not be appropriate to continue regular diabetes reviews, a
considerable number of individuals who cannot access services due to problems
with mobility, individuals who are disinclined to access services on the grounds of
perceived societal barriers, patients already on maximal therapy or that these
practices serve a population which does not engage well with the services oﬀered
by primary care. 
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Whilst QOF business rules allow for declaration of patients as exceptions for
many of the above reasons, there is considerable variation in exception reporting
rates between practices that could be argued to be above and beyond that which
would be expected from varying practice populations (Figure 18). Such an
observation could result from ‘gaming’ of the exception reporting system139, thereby
disenfranchising patients for whom services are inaccessible or inappropriate.
Exploration of this potential issue is beyond the scope of this analysis; however, the
role of exception reporting with respect to ascertainment of quality of primary care
is worthy of further investigation with respect to people with diabetes.
Figure 18. Box plots of exception rates for diabetes-specific QOF indicator groups for English
practices, QOF 2010/11.
For the process group of indicators, and for indicator PE08, the estimated
improvements in emergency admission rates for those practices attaining the
highest levels of performance are both statistically and clinically significant in the full
model. For the purposes of illustration, the potential reductions in the number of
emergency admissions in QOF year 2010/11 should the lowest performing fifth
attain the performance of the highest fifth for the process indicator group and for
PE08 are shown in Table 38.
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Estimated IRR
for Best
Performing Fifth
Number of
Emergency
Admissions From
Worst
Performing Fifth
Total Diabetes
Register Size of
Worst
Performing Fifth
Crude Admission
Rate per 1,000
for Worst
Performing Fifth
Potential
Reduction in
Admissions
Process 0.930 78,634 453,979 173.21 5,474.41
PE08 0.940 104,033 600,455 173.26 6,250.12
Table 38. Potential reductions in emergency admissions from the worst performing fifth of practices
should they attain the levels of performance observed in the best performing fifth of practices, QOF
2010/11.
Strengths and Limitations
Despite the large sample size of practices, analysis over multiple QOF years and
adjustment for multiple measures of primary care quality, these analyses are subject
to a number of potential limitations. For such analyses, ecological bias is highly
likely; metrics of care quality, such as those reported in QOF, are an aggregate of
the care actually delivered to individual patients. That is to say that we cannot state
with certainty that a given patient did or did not attain a given quality target –
furthermore, as emergency admission data was aggregated to the level of practices,
no direct correlations can be made between the quality of care actually received
and the outcome of interest at the patient level.
Whist the decision to combine indicators into thematic groups was taken to
maximise diﬀerences in performance between practices, this approach may have
masked associations with individual indicators and does imply that all component
indicators in a group have a similar impact with respect to modulation of emergency
admission rates.
Ecological bias is also likely to be present in estimates of deprivation and
rurality. Practices were assigned deprivation and rurality scores on the basis of the
postcode, and hence LSOA, in which they were located. Such measures of
accessibility and deprivation may not necessarily apply to the registered population
of a practice; a practice located in an aﬄuent area may serve a large lumber of
individuals from an adjoining area that is subject to high levels of deprivation, for
example.
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The decision to group the data pertaining to the ethnic composition of practice
populations into ‘white’ and ‘non-white’ may have masked important eﬀects on
outcomes between the ethnic subgroups within these categories. In their current
state, these analyses make the assumption that the risk profile – be it cultural,
societal or genetic – of the subgroups that comprise a particular ethnic category is
identical; this was an approach that was taken on the grounds of parsimony that, in
hindsight, was not appropriate and worthy of further investigation.
As previously discussed (see pages 51-63), the accuracy of clinical coding of
hospital admissions with respect to determining whether or not diabetes is the
direct cause is questionable. Therefore, this analysis took the approach of capturing
all emergency admissions from HES that cited diabetes in any diagnostic position. 
This approach assumes that a patient has received a diagnosis of diabetes prior
to the emergency admission in question; if a large number of individuals were only
diagnosed with diabetes at the time of admission to hospital, estimates of
admission rates could be falsely inflated.
Furthermore, this approach means that it is impossible to delineate between
emergency admissions directly due to diabetes as opposed to admissions that have
arisen from the registered diabetic population, meaning that assessment of
variations in admission rates is not limited to conditions that are explicitly linked to
diabetes mellitus. However, as diabetes, and the adequacy of its management, is
associated with an increased risk of a number of acute illnesses, this approach may
be more reasonable than only considering admissions where diabetes has been
cited as the first diagnosis and may give a more accurate indication of the total
burden of emergency hospital admissions arising from the population with diabetes.
Following on from the use of emergency admissions that cite diabetes in any
diagnosis position, there is also an assumption that all causes of emergency
admissions are equally modifiable by the selected markers of primary care quality.
This issue is likely to be more pertinent for certain groupings of indicators
(specifically glycaemic control and intermediate cardiovascular outcomes), but may
be of lesser importance when considering more general markers of quality such as
achievement in the process indicator group and patient access.
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It is also likely that there is considerable residual confounding in this analysis,
stemming, to some degree, from the use of aggregate data, the limitations of
available datasets and the impact of ecological bias. Although practice emergency
admission rates have been adjusted for age and sex, the actual case-mix and
prevalence of additional risk factors of emergency hospital admission could not be
ascertained.
Use of patient-level data to further explore the relationship between the quality
of care received, individual risk factors, co-morbidities and clinical outcomes would
allow for a more granular analysis that may be less subject to bias and confounding.
Closing Summary
These analyses have indicated that the rates of emergency hospital admissions
from the population with diabetes vary considerably and that emergency admission
rates may, to an extent, be modifiable by some aspects of primary care quality, in
particular process measures of care and patient access. Deprivation has been
shown to have strong, consistent associations with emergency admission rates,
with associated eﬀect sizes commonly outstripping those observed for the highest
levels of QOF attainment, emphasising the importance of factors that lie outside of
the sphere of influence of medicine may have on influencing outcomes of care.
- 113 -
Patient-Level Analyses
Background
Practice-level data, such as that used in the previous chapter, is of considerable
use when profiling the performance of individual practices and geographic regions
within England; however, use of such data is subject to ecological bias. That being
said, for certain applications and research questions, use of aggregate data is both
sound and appropriate.
In terms of QOF, reports of practice-level performance only provide information
on the practice as a whole as opposed to supplying data on what care a given
patient actually received. This issue also extends to use of additional aggregate
data sources which may describe other characteristics, such as age and ethnicity,
of a population; it is impossible to deduce the characteristics of an individual from
the characteristics of the group to which they belong.
Use of patient-level data for exploring relationships between quality of care
received and clinical outcomes obviates these concerns; furthermore, longitudinal
patient-level data permits temporal sequencing of events, allowing assessment of
whether a change in clinical state (or risk profile) subsequently led to an event of
interest.
Another advantage of using patient-level data, as opposed to QOF data, to
assess the impact quality of care on outcomes is that the issue of exception
reporting becomes moot. Patient-level data allows for determination of the level of
care received and their attainment of intermediate treatment targets, regardless of
exception status – ensuring that the entire population of interest is sampled and
their outcomes tracked rather than a subgroup of individuals who have been
deemed to be compliant with and amenable to management provided in primary
care.
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In England, patient-level data is a available as a commercial product via the
Clinical Practice Research Datalink (CPRD) from the Medicines & Healthcare
Products Regulatory Agency (MHRA) and the National Institute for Health Research
(NIHR). The CPRD dataset contains data on all primary care patient events, directly
extracted from electronic patient record systems, from a nationally representative
sample of English general practices. CPRD datasets are subject to quality checks at
the level of the patient and the source general practice as a whole prior to delivery
to customers.
The following analyses utilise a bespoke dataset purchased from CPRD that was
originally requested for the examination of clinical outcomes in people with
diabetes. Primary care data was linked to HES, ONS mortality and IMD data by
CPRD prior to delivery.
Methodology
Data Sources
The dataset utilised for this analysis was a custom extract from the CPRD
dataset, linked to HES data. The CPRD dataset contains longitudinal data on
patients registered to a representative sample of English General Practices. HES
data pertaining to hospital admissions, diagnoses and procedures was linked to the
main CPRD dataset on a patient-by-patient basis, allowing for analysis of
associations between primary care and in-patient activities at the level of individual
patients. All CPRD data linkage, cleaning and preparation was performed by the
MHRA prior to delivery of the final research dataset.
All patients were anonymised by the MHRA; accordingly, information on place of
residence was only available at the resolution of region of England and only the year
of birth (as opposed to the full date of birth) was available for each patient.
Furthermore, the identity of individual general practices was also pseudonymised,
precluding linkage of additional datasets describing further practice attributes.
- 115 -
Deprivation data, expressed as the Index of Multiple Deprivation (IMD) 2007 quintile
for the LSOA in which the postcode of a given patient’s last known address is
located, was also linked to the dataset by the MHRA; more granular deprivation
data (e.g. LSOA deprivation rank) was not available in the CPRD-HES dataset
utilised for these analyses.
Patient events, such as consultations, investigation results, diagnoses in
addition to patient characteristics such as occupation and social circumstances are
recorded in primary care patient notes using Read codes, a hierarchical clinical
coding system that have been in use in the NHS since 1985.
The CPRD-HES dataset provided by the MHRA contained a randomly selected
sample of 125,000 people, aged 17 years or older with a recorded diagnosis of
diabetes; supplied data covered the period 2003 – 2010. These 125,000 individuals
with diabetes were matched to 125,000 patients without diabetes (defined as no
mention of diabetes or receipt of hypoglycaemic agents).
The patients included in the dataset as supplied were randomly selected from
the pool of individuals with records deemed to be of an acceptable standard from
practices participating in the HES and ONS linkage scheme, with a valid postcode
and with at least one episode of care – defined as a record of BP, cholesterol or
HbA1c – between 2003 and 2009.
The Read codes used by MHRA to define the presence of diabetes are given in
Table 39. Whilst the list of codes is likely to capture the majority of people with
diabetes, certain codes – such as “Type I diabetes mellitus with diabetic cataract”
or “Type 1 diabetes mellitus with neuropathic arthropathy” or “Unstable type 1
diabetes mellitus” and “Insulin dose changed” – that are strongly suggestive of
diabetes are not included in this list. In addition to these codes, individuals with a
record of at least one prescription for a hypoglycaemic agent between 2003 and
2009 were also considered as having a diagnosis of diabetes. A total of 155,372
individuals were identified, from which the sample of 125,000 patients with diabetes
were drawn (see Figure 19 for selection flowchart).
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Table 39. Read codes used by the MHRA to identify patients with diabetes in the CPRD-HES
dataset.
Read Code Description Read Code Description Read Code Description
66A..00 Diabetic monitoring C100000 Diabetes mellitus, juvenile type, no mention of complication C109C00 Non-insulin dependent diabetes mellitus with nephropathy
66A1.00 Initial diabetic assessment C100011 Insulin dependent diabetes mellitus C109J00 Insulin treated Type 2 diabetes mellitus
66A2.00 Follow-up diabetic assessment C100100 Diabetes mellitus, adult onset, no mention of complication C10A100 Malnutrition-related diabetes mellitus with ketoacidosis
66A3.00 Diabetic on diet only C100111 Maturity onset diabetes C10B.00 Diabetes mellitus induced by steroids
66A4.00 Diabetic on oral treatment C100112 Non-insulin dependent diabetes mellitus C10B000 Steroid induced diabetes mellitus without complication
66A5.00 Diabetic on insulin C100z00 Diabetes mellitus NOS with no mention of complication C10C.11 Maturity onset diabetes in youth
66A8.00 Has seen dietician - diabetes C101.00 Diabetes mellitus with ketoacidosis C10D.00 Diabetes mellitus autosomal dominant type 2
66A9.00 Understands diet - diabetes C101000 Diabetes mellitus, juvenile type, with ketoacidosis C10E.00 Type 1 diabetes mellitus
66Aa.00 Diabetic diet - poor compliance C101z00 Diabetes mellitus NOS with ketoacidosis C10E.11 Type I diabetes mellitus
66AA.11 Injection sites - diabetic C102.00 Diabetes mellitus with hyperosmolar coma C10E.12 Insulin dependent diabetes mellitus
66Ab.00 Diabetic foot examination C103.00 Diabetes mellitus with ketoacidotic coma C10E700 Type 1 diabetes mellitus with retinopathy
66Ac.00 Diabetic peripheral neuropathy screening C104.00 Diabetes mellitus with renal manifestation C10E800 Type 1 diabetes mellitus - poor control
66AD.00 Fundoscopy - diabetic check C104.11 Diabetic nephropathy C10ED00 Type 1 diabetes mellitus with nephropathy
66Af.00 Patient diabetes education review C104z00 Diabetes mellitus with nephropathy NOS C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma
66AG.00 Diabetic drug side eﬀects C105.00 Diabetes mellitus with ophthalmic manifestation C10EK00 Type 1 diabetes mellitus with persistent proteinuria
66AH.00 Diabetic treatment changed C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria
66AI.00 Diabetic - good control C105z00 Diabetes mellitus NOS with ophthalmic manifestation C10EM00 Type 1 diabetes mellitus with ketoacidosis
66Ai.00 Diabetic 6 month review C106.00 Diabetes mellitus with neurological manifestation C10EN00 Type 1 diabetes mellitus with ketoacidotic coma
66AJ.00 Diabetic - poor control C106.12 Diabetes mellitus with neuropathy C10EQ00 Type 1 diabetes mellitus with gastroparesis
66AJ.11 Unstable diabetes C106.13 Diabetes mellitus with polyneuropathy C10F.00 Type 2 diabetes mellitus
66AJz00 Diabetic - poor control NOS C106100 Diabetes mellitus, adult onset, + neurological manifestation C10F.11 Type II diabetes mellitus
66AK.00 Diabetic - cooperative patient C106z00 Diabetes mellitus NOS with neurological manifestation C10F000 Type 2 diabetes mellitus with renal complications
66Ak.00 Diabetic monitoring - lower risk albumin excretion C107.00 Diabetes mellitus with peripheral circulatory disorder C10F100 Type 2 diabetes mellitus with ophthalmic complications
66AL.00 Diabetic-uncooperative patient C107.11 Diabetes mellitus with gangrene C10F200 Type 2 diabetes mellitus with neurological complications
66Al.00 Diabetic monitoring - higher risk albumin excretion C107.12 Diabetes with gangrene C10F400 Type 2 diabetes mellitus with ulcer
66AM.00 Diabetic - follow-up default C107z00 Diabetes mellitus NOS with peripheral circulatory disorder C10F600 Type 2 diabetes mellitus with retinopathy
66An.00 Diabetes type 1 review C108.00 Insulin dependent diabetes mellitus C10F700 Type 2 diabetes mellitus - poor control
66AN.00 Date diabetic treatment start C108.11 IDDM-Insulin dependent diabetes mellitus C10F711 Type II diabetes mellitus - poor control
66Ao.00 Diabetes type 2 review C108.12 Type 1 diabetes mellitus C10F900 Type 2 diabetes mellitus without complication
66AO.00 Date diabetic treatment stopp. C108.13 Type I diabetes mellitus C10F911 Type II diabetes mellitus without complication
66AP.00 Diabetes: practice programme C108400 Unstable insulin dependent diabetes mellitus C10FB00 Type 2 diabetes mellitus with polyneuropathy
66Aq.00 Diabetic foot screen C108500 Insulin dependent diabetes mellitus with ulcer C10FC00 Type 2 diabetes mellitus with nephropathy
66AQ.00 Diabetes: shared care programme C108700 Insulin dependent diabetes mellitus with retinopathy C10FE00 Type 2 diabetes mellitus with diabetic cataract
66AR.00 Diabetes management plan given C108800 Insulin dependent diabetes mellitus - poor control C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy
66AS.00 Diabetic annual review C108900 Insulin dependent diabetes maturity onset C10FJ00 Insulin treated Type 2 diabetes mellitus
66AT.00 Annual diabetic blood test C109.00 Non-insulin dependent diabetes mellitus C10FJ11 Insulin treated Type II diabetes mellitus
66AU.00 Diabetes care by hospital only C109.11 NIDDM - Non-insulin dependent diabetes mellitus C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus
66AV.00 Diabetic on insulin and oral treatment C109.12 Type 2 diabetes mellitus C10FL00 Type 2 diabetes mellitus with persistent proteinuria
66AW.00 Diabetic foot risk assessment C109.13 Type II diabetes mellitus C10FL11 Type II diabetes mellitus with persistent proteinuria
66AY.00 Diabetic diet - good compliance C109400 Non-insulin dependent diabetes mellitus with ulcer C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria
66AZ.00 Diabetic monitoring NOS C109600 Non-insulin-dependent diabetes mellitus with retinopathy C10FN00 Type 2 diabetes mellitus with ketoacidosis
C10..00 Diabetes mellitus C109700 Non-insulin dependent diabetes mellitus - poor control C10FQ00 Type 2 diabetes mellitus with exudative maculopathy
C100.00 Diabetes mellitus with no mention of complication C109900 Non-insulin-dependent diabetes mellitus without complication C10z.00 Diabetes mellitus with unspecified complication
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Figure 19. Flowchart of selection process undertaken by the MHRA to identify eligible patients with
diabetes from the CPRD dataset.
Preparation of Data
As supplied, the CPRD-HES data consisted of a large number of individual
datasets describing a number of aspects of patients’ care, primary care encounters
and secondary care utilisation (see Table 40) in addition to datasets describing
mortality, and socioeconomic status. A number of data dictionaries, used to
enhance human readability of the data, were also included with the CPRD-HES
dataset.
Acceptable Patients
11,503,844
5,356,524
Participating 
Practice?
4,761,564
4,757,037
Valid postcode?
2,228,691
≥ 1 Episode of 
Care Between 
2003-2009?
Record of 
Diabetes During 
2003-2009?
156,622
Aged ≥ 17y at 
Time of First 
Record?
155,372
Data during 
ONS/HES 
Collection?
Random 
Selection
Sample for Analysis
125,000
6,147,320 excluded
594,960 excluded
4,527 excluded
2,528,346 excluded 2,072,069 excluded
1,250 excluded
30,372 discarded
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All data tables were imported into FileMaker Pro Advanced V13 (FileMaker Inc.,
CA, USA), a database system allowing for the creation of complex relationships
between tables (see Figure 20 for simplified version of database structure, fields
provided in each table available in Appendices).
Sources Data File Number ofRecords* Description
Primary Care
(CPRD)
Patient 250,000 Basic patient demographics and registration details
Practice 300 Basic practice details, including region
Staﬀ 864,782 Basic Practice staﬀ details
Consultation 89,789,150 Describes type of consultation as entered by the GP
Clinical 66,953,678 Describes medical history; contains symptoms, signs and diagnoses
Additional 
Clinical Details 20,814,560
Contains information entered in the structured data areas in the GP 
patient records
Referral 2,662,350 Describes referrals to external care centres, including specialty and referral type
Immunisation 2,399,603 Contains details of immunisation records
Test 66,410,566
Contains records of test data on the GP system; three types of test 
records, involving 4, 7 or 8 data fields; data can denote either 
qualitative text based results or quantitative results involving a numeric 
value
Therapy 109,650,559 Contains details of all prescriptions (both drugs and appliances) on the GP system
Secondary 
Care (HES)
Patient 194,861 Contains details of patients with both a primary care and secondary care record
Augmented Care 20,635 Describes utilisation of augmented care (if any) during a spell
Critical Care 4,065 Describes utilisation of critical care (if any) during a spell
Diagnosis by 
Episode 5,161,269 Describes unique diagnoses associated with each in-patient episode
Diagnosis by 
Hospitalisation 4,162,836 Describes unique diagnoses associated with each hospitalisation
Primary 
Diagnosis by 
Hospitalisation
1,288,296 Describes primary diagnosis associated with each hospitalisation
Episodes 1,461,652 Describes characteristics of each hospital episode
Hospitalisations 1,245,139 Describes characteristics of each hospitalisation
Maternity 66,508 Describes characteristics of pregnancies and births
Procedures by 
Episode 1,797,149 Describes procedures performed during an episode
TOTAL 375,197,958
Table 40. Data included in the CPRD-HES dataset utilised for analysis.
* = number of records incorporate both patients with and without diabetes
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Figure 20. Simplified database structure for CPRD-HES data.
Fields in italics denote fields used to link tables; not all fields shown (see Appendix). Not all data dictionaries
shown; no tables of data generated post hoc shown.
Assigning Diabetes Type
Although patients had been flagged as having a prior diagnosis of diabetes by
the MHRA, according to the presence of any of the Read codes outlined in Table
39, no clear delineation was made between patients with T1DM and T2DM.
Secondary Care (HES) Data
Primary Care (CPRD) Data
Patient ID
Practice ID
Patient List
Patient ID
Patients with 
Diabetes
Patient ID
Cause
Mortality
Patient ID
Consultation ID
Consultation Type
Consultation
Patient ID
Consultation ID
Read Code
Clinical
Patient ID
Consultation ID
Specialty
Urgency
Referral
Patient ID
Consultation ID
Immunisation Type
Immunisation
Patient ID
Consultation ID
Entity Type
Additional
Patient ID
Consultation ID
Entity Type
Test
Patient ID
Consultation ID
Product ID
Quantity
Therapy
Entity Type
Entity Data Spec
Entities
Read Code
Read Description
Read Codes
Patient ID
Spell ID
Hospitalisations
Patient ID
Spell ID
Episode ID
Episode Order
Episodes
Patient ID
Spell ID
ICD-10 Code
Diagnoses by 
Hospitalisation
Patient ID
Episode ID
ICD-10 Code
Diagnoses by 
Episode
Patient ID
Spell ID
ICD-10 Code
Primary Diagnosis 
by Hospitalisation
Patient ID
Episode ID
OPCS Code
Procedures by 
Episode
Patient ID
Episode ID
Critical Care
Patient ID
Episode ID
Augmented Care
OPCS Code
OPCS Description
Procedures 
Dictionary 
ICD-10 Code
ICD Description
ICD-10 Dictionary 
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The list of diagnoses deemed by CPRD to reflect a diagnosis of diabetes was
initially reviewed by myself (DCG) and Dr Panagiotis Anagnwstis (PA), an
Endocrinology specialist. Both PA and myself independently assigned a code to
each diagnosis to reflect whether it supported a diagnosis of T1DM, T2DM, either
T1DM or T2DM or not T1DM or T2DM. Any disagreements were reviewed and
adjudicated by Professor Azeem Majeed (AM); the agreed typing of CPRD diabetes
diagnosis codes is shown in Table 41. Bar classification of Read codes, PA had no
further role in data management, analysis or interpretation.
Table 41. Classification of diabetes diagnoses used by the MHRA to identify people with diabetes in
the CPRD-HES dataset.
Read Code Description Read Code Description Read Code Description
C10E.00 Type 1 diabetes mellitus T1DM C109700 Non-insulin dependent diabetes mellitus - 
poor control
T2DM 66Ac.00 Diabetic peripheral neuropathy screening T1DM or T2DM
C100011 Insulin dependent diabetes mellitus T1DM C10FC00 Type 2 diabetes mellitus with nephropathy T2DM 66Aq.00 Diabetic foot screen T1DM or T2DM
C108.00 Insulin dependent diabetes mellitus T1DM C10F600 Type 2 diabetes mellitus with retinopathy T2DM 66AR.00 Diabetes management plan given T1DM or T2DM
C108.11 IDDM-Insulin dependent diabetes mellitus T1DM C10F700 Type 2 diabetes mellitus - poor control T2DM 66A5.00 Diabetic on insulin T1DM or T2DM
C108.12 Type 1 diabetes mellitus T1DM C10F900 Type 2 diabetes mellitus without 
complication
T2DM 66AI.00 Diabetic - good control T1DM or T2DM
C10EM00 Type 1 diabetes mellitus with ketoacidosis T1DM C10FN00 Type 2 diabetes mellitus with ketoacidosis T2DM 66AQ.00 Diabetes: shared care programme T1DM or T2DM
66An.00 Diabetes type 1 review T1DM C10FK00 Hyperosmolar non-ketotic state in type 2 
diabetes mellitus
T2DM 66AD.00 Fundoscopy - diabetic check T1DM or T2DM
C100000 Diabetes mellitus, juvenile type, no 
mention of complication
T1DM C109400 Non-insulin dependent diabetes mellitus 
with ulcer
T2DM 66Ai.00 Diabetic 6 month review T1DM or T2DM
C108.13 Type I diabetes mellitus T1DM C109900 Non-insulin-dependent diabetes mellitus 
without complication
T2DM 66A9.00 Understands diet - diabetes T1DM or T2DM
C10E.12 Insulin dependent diabetes mellitus T1DM C102.00 Diabetes mellitus with hyperosmolar 
coma
T2DM 66Ab.00 Diabetic foot examination T1DM or T2DM
C108900 Insulin dependent diabetes maturity onset T1DM C10FQ00 Type 2 diabetes mellitus with exudative 
maculopathy
T2DM 66AU.00 Diabetes care by hospital only T1DM or T2DM
C108800 Insulin dependent diabetes mellitus - poor 
control
T1DM C10F000 Type 2 diabetes mellitus with renal 
complications
T2DM 66A1.00 Initial diabetic assessment T1DM or T2DM
C10EK00 Type 1 diabetes mellitus with persistent 
proteinuria
T1DM C10F911 Type II diabetes mellitus without 
complication
T2DM 66AW.00 Diabetic foot risk assessment T1DM or T2DM
C10ED00 Type 1 diabetes mellitus with nephropathy T1DM C106100 Diabetes mellitus, adult onset, + 
neurological manifestation
T2DM 66A8.00 Has seen dietician - diabetes T1DM or T2DM
C10E700 Type 1 diabetes mellitus with retinopathy T1DM C10FB00 Type 2 diabetes mellitus with 
polyneuropathy
T2DM 66AA.11 Injection sites - diabetic T1DM or T2DM
C10EL00 Type 1 diabetes mellitus with persistent 
microalbuminuria
T1DM C10F200 Type 2 diabetes mellitus with neurological 
complications
T2DM 66AH.00 Diabetic treatment changed T1DM or T2DM
C108700 Insulin dependent diabetes mellitus with 
retinopathy
T1DM C10FH00 Type 2 diabetes mellitus with neuropathic 
arthropathy
T2DM C106.12 Diabetes mellitus with neuropathy T1DM or T2DM
C108500 Insulin dependent diabetes mellitus with 
ulcer
T1DM C109600 Non-insulin-dependent diabetes mellitus 
with retinopathy
T2DM C106.00 Diabetes mellitus with neurological 
manifestation
T1DM or T2DM
C10E800 Type 1 diabetes mellitus - poor control T1DM C10FE00 Type 2 diabetes mellitus with diabetic 
cataract
T2DM 66Af.00 Patient diabetes education review T1DM or T2DM
C10E.11 Type I diabetes mellitus T1DM C105100 Diabetes mellitus, adult onset, + 
ophthalmic manifestation
T2DM C104.11 Diabetic nephropathy T1DM or T2DM
C10EN00 Type 1 diabetes mellitus with ketoacidotic 
coma
T1DM C10F400 Type 2 diabetes mellitus with ulcer T2DM C100.00 Diabetes mellitus with no mention of 
complication
T1DM or T2DM
C10EQ00 Type 1 diabetes mellitus with 
gastroparesis
T1DM C10FJ11 Insulin treated Type II diabetes mellitus T2DM 66AM.00 Diabetic - follow-up default T1DM or T2DM
C101000 Diabetes mellitus, juvenile type, with 
ketoacidosis
T1DM C10F711 Type II diabetes mellitus - poor control T2DM C105.00 Diabetes mellitus with ophthalmic 
manifestation
T1DM or T2DM
C10EE00 Type 1 diabetes mellitus with 
hypoglycaemic coma
T1DM C10FL11 Type II diabetes mellitus with persistent 
proteinuria
T2DM C104.00 Diabetes mellitus with renal manifestation T1DM or T2DM
C108400 Unstable insulin dependent diabetes 
mellitus
T1DM C109C00 Non-insulin dependent diabetes mellitus 
with nephropathy
T2DM 66AJz00 Diabetic - poor control NOS T1DM or T2DM
66A4.00 Diabetic on oral treatment T2DM C10F100 Type 2 diabetes mellitus with ophthalmic 
complications
T2DM 66AJ.11 Unstable diabetes T1DM or T2DM
66A3.00 Diabetic on diet only T2DM 66AS.00 Diabetic annual review T1DM or T2DM 66AK.00 Diabetic - cooperative patient T1DM or T2DM
C100111 Maturity onset diabetes T2DM C101.00 Diabetes mellitus with ketoacidosis T1DM or T2DM C100z00 Diabetes mellitus NOS with no mention of 
complication
T1DM or T2DM
66AV.00 Diabetic on insulin and oral treatment T2DM 66AT.00 Annual diabetic blood test T1DM or T2DM 66AN.00 Date diabetic treatment start T1DM or T2DM
C10C.11 Maturity onset diabetes in youth T2DM 66AY.00 Diabetic diet - good compliance T1DM or T2DM 66Ak.00 Diabetic monitoring - lower risk albumin 
excretion
T1DM or T2DM
C10F.00 Type 2 diabetes mellitus T2DM 66Aa.00 Diabetic diet - poor compliance T1DM or T2DM C104z00 Diabetes mellitus with nephropathy NOS T1DM or T2DM
C100112 Non-insulin dependent diabetes mellitus T2DM C107.00 Diabetes mellitus with peripheral 
circulatory disorder
T1DM or T2DM C107.11 Diabetes mellitus with gangrene T1DM or T2DM
C109.00 Non-insulin dependent diabetes mellitus T2DM C103.00 Diabetes mellitus with ketoacidotic coma T1DM or T2DM 66AL.00 Diabetic-uncooperative patient T1DM or T2DM
C109.12 Type 2 diabetes mellitus T2DM C10D.00 Diabetes mellitus autosomal dominant 
type 2
T1DM or T2DM C106z00 Diabetes mellitus NOS with neurological 
manifestation
T1DM or T2DM
C100100 Diabetes mellitus, adult onset, no mention 
of complication
T2DM C101z00 Diabetes mellitus NOS with ketoacidosis T1DM or T2DM 66Al.00 Diabetic monitoring - higher risk albumin 
excretion
T1DM or T2DM
66Ao.00 Diabetes type 2 review T2DM 66AG.00 Diabetic drug side effects T1DM or T2DM C105z00 Diabetes mellitus NOS with ophthalmic 
manifestation
T1DM or T2DM
C10FJ00 Insulin treated Type 2 diabetes mellitus T2DM C107z00 Diabetes mellitus NOS with peripheral 
circulatory disorder
T1DM or T2DM 66AO.00 Date diabetic treatment stopp. T1DM or T2DM
C10FM00 Type 2 diabetes mellitus with persistent 
microalbuminuria
T2DM 66A..00 Diabetic monitoring T1DM or T2DM C107.12 Diabetes with gangrene T1DM or T2DM
C109.13 Type II diabetes mellitus T2DM C10..00 Diabetes mellitus T1DM or T2DM C106.13 Diabetes mellitus with polyneuropathy T1DM or T2DM
C109.11 NIDDM - Non-insulin dependent diabetes 
mellitus
T2DM 66A2.00 Follow-up diabetic assessment T1DM or T2DM C10z.00 Diabetes mellitus with unspecified 
complication
T1DM or T2DM
C109J00 Insulin treated Type 2 diabetes mellitus T2DM 66AP.00 Diabetes: practice programme T1DM or T2DM C10B.00 Diabetes mellitus induced by steroids Not T1DM or 
T2DM
C10FL00 Type 2 diabetes mellitus with persistent 
proteinuria
T2DM 66AZ.00 Diabetic monitoring NOS T1DM or T2DM C10B000 Steroid induced diabetes mellitus without 
complication
Not T1DM or 
T2DM
C10F.11 Type II diabetes mellitus T2DM 66AJ.00 Diabetic - poor control T1DM or T2DM C10A100 Malnutrition-related diabetes mellitus with 
ketoacidosis
Not T1DM or 
T2DM
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Patients were assigned the diabetes type according to the presence of the
various Read codes discussed above in their medical history as cited in the
‘Clinical’ CPRD table; patients who had codes that all indicated the same diagnosis
type were classified as such. Patients with codes suggesting more than one
diabetes type or solely had codes denoting ‘either T1DM or T2DM’ were classified
as per Figure 21.
Figure 21. Algorithm for assigning diabetes type in individuals for whom diagnosis codes are
inconclusive.
The accuracy of the algorithm for determining diabetes type in individuals where
there was uncertainty of their diabetes type was validated against the pool of
patients of a known diabetes type.
Determination of Smoking Status and History
Details on smoking status are recorded as entity type 4 in the ‘Additional Clinical
Details’ table of the CPRD-HES dataset. The data associated with smoking status is
recorded using the following codes: 1 = current smoker; 2 = ex-smoker; 3 = non-
smoker; 4 = not asked.
There was considerable potential for inconsistent recording of smoking status,
which may not reflect a patient’s historical smoking status – for example, an
individual who used to smoke has the potential to be recorded as either an ex-
smoker or a non-smoker.
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Accordingly, and to maximise data accuracy, the entire recorded smoking
histories for each patient were reviewed and their smoking status determined as of
1st April 2005 according to the algorithm detailed in Figure 22. Patients whose most
recent smoking status was recorded as ‘not asked’ had their smoking status
determined according to their most recent specified smoking status; patients who
had no other classification of smoking statuses of ‘not asked’ or had missing data
were classified as being of unknown smoking status.
Figure 22. Algorithm for assigning smoking status.
Determination of Co-Morbidities
The presence of diabetes is associated with a markedly elevated risk of a
number of other chronic diseases, such as coronary heart disease, peripheral
arterial disease and chronic renal failure.76, 94 Individuals with diabetes are also
subject to the same risks and development of other diseases which may impact on
an individual’s health and quality of life. The net eﬀect for people with diabetes is
that they are likely to face increased levels of co-morbidity over time, which may be
in excess of that which would be expected from their age, gender and ethnicity
alone.
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Increasing levels of co-morbidity have been demonstrated to be associated with
an elevated risk of death in the adult population across a number of developed
countries205-207 and are associated with greater use of primary care resources.208 In
individuals with diabetes, co-morbidity has been shown to be associated with
increased risks of preventable hospital admissions and mortality.209-211
The Charlson Comorbidity Index (CCI)205 is one method by which the level of co-
morbidity can be quantified for a patient through summation of weighted scores for
categories of chronic conditions. The CCI was initially developed in the 1980s and
was primarily calibrated for patients admitted to hospital; the CCI has subsequently
been adapted and validated for use in English primary care services.206 It could be
argued that the disease weights in the CCI are no longer representative of the
outcomes that could be expected from contemporary medical practice, particularly
for diseases such as acquired auto- immune deficiency syndrome (AIDS); as such,
an updated series of weights has recently been developed and validated.207 CCI
disease categories and their weights are described in Table 42.
Condition Original Weight Updated Weight Change
Myocardial infarction 1 0 -1
Congestive heart failure 1 2 +1
Peripheral arterial disease 1 0 -1
Cerebrovascular disease 1 0 -1
Dementia 1 2 +1
Chronic pulmonary disease 1 1 0
Rheumatological disease 1 1 0
Peptic ulcer disease 1 0 -1
Mild liver disease 1 2 +1
Diabetes mellitus without chronic complications 1 0 -1
Hemi- or paraplegia 2 2 0
Renal disease 2 1 -1
Diabetes mellitus with chronic complications 2 1 -1
Any malignancy, including leukaemia and 
lymphoma 2 2 0
Moderate / severe liver disease 3 4 +1
Metastatic solid tumour(s) 6 6 0
AIDS / HIV 6 4 -2
Maximum Possible Score 29 24 -5
Table 42. Charlson co-morbidity index disease categories and their associated original and updated
weights.
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For the purposes of investigating the impact of co-morbidity on mortality in
diabetic and non-diabetic cohorts, the observation start date for the entire cohort
was determined as 1st April 2005; the failure variable was set as the occurrence of
death (of any cause), with patients being censored at the last data collection date
from their practice.
Patients were classified as diabetic according to whether their clinical records
contained Read codes, determined by CPRD, that were deemed indicative of a
diagnosis of diabetes (see Table 39). Patients with diabetes were further classified
as prevalent or incident cases according to whether their diabetes diagnosis date
was before or after their observation start date. All patients identified as having
diabetes were matched 1:1 with individuals deemed to be non-diabetic by age (± 2
years), gender and practice by the MHRA.
As only the year of birth was available for each patient, and to take account of
the likelihood of a non-linear relationship between age and hazard of death, patients
were grouped into age bands for their approximate age at the start of observation
(< 25y, 25–44y, 45—54y, 55—64y, 65—74y and ≥ 75y). It should be noted that, as
only the year of birth was available for each patient, calculated ages may be up to ±
1 year of their true value. In order to quantify socioeconomic deprivation, patients
were assigned to the English national fifth of IMD score into which their LSOA of
residence fell, with the first fifth representing the most deprived LSOAs in England.
The burden of co-morbidity for each patient was determined from cross-
referencing all recorded primary care diagnoses (entries with an entity type of
‘diagnosis’ entered into the clinical table of the CPRD dataset) with a validated list
of Medical Codes mapped to CCI diagnosis categories206 with updated co-
morbidity weights derived from a recent multi-national study (Table 42).207 Disease
categories for each patient were only counted once even if multiple diagnoses
within a given category were recorded; it was assumed that co-morbid diseases
were non-reversible.
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Each patient’s CCI score at the start of observation was recorded; additionally,
all diagnoses following the start of observation were reviewed and, should the
diagnosis of a new condition alter their CCI score, dates of change and updated
CCI scores were also recorded. Two pairs of categories implied progression from
one disease state to another, more advanced state. The pairs in question were mild
liver disease and moderate/severe liver disease and cancer and metastatic tumour;
in order to avoid double-counting of CCI should such progression occur, the CCI
score of the less severe form of condition was subtracted from a patient’s total CCI
score before adding the score associated with the more severe version.
Figure 23. Algorithm for calculating running totals of Charlson co-morbidity score (using updated
weights) for individual patients.
All diagnoses sorted by date prior to execution of algorithm; $id = temporary variable for storage of patient ID;
$pt_liv = flag for identification of a patient with mild liver disease; $pt_can = flag for identification of a patient
with cancer
Due to the relatively small count of patients with higher CCI scores, patients
were allocated to CCI groups of CCI = 0, CCI = 1, CCI = 2, CCI = 3 and CCI ≥ 4;
dates of change of CCI group were also recorded.
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Defining Emergency Admissions and Readmissions
Emergency admissions and readmissions are both examples of unscheduled
and potentially preventable secondary care utilisation that may indicate the receipt
of suboptimal care or a lack of engagement with, or access to, services.9, 158, 172, 212-215
Potentially preventable emergency admissions and readmissions are both costly
and prevalent and represent a significant opportunity cost to the health service216
and negatively impact quality of life for patients and their families.217, 218 As it could
be argued that some readmissions result from inadequate discharge planning or
other failures in care quantity or quality within hospitals, current NHS policy is not to
reimburse secondary and tertiary care providers for the care delivered for
admissions classed as readmissions, pending a clinical review of the avoidability of
such admissions.219
As with the other analyses discussed in this chapter, the primary data source for
defining emergency admissions and readmissions is the bespoke CPRD-HES
dataset supplied by the MHRA. Emergency admissions were defined as those
admissions cited with an admission method (admimeth) of 21 – 24 or 28220;
readmissions were defined in accordance with the Payment by Results business
rules as set out by the Department of Health.
For the purposes of these analyses, a readmission is defined as an emergency
admission (admimeth = 21 – 24, 28) within 30 days of a prior admission, except
those with any of the following criteria (see Figure 24 for algorithm used to identify
such admissions), adapted from the PbR rules in order to fit the constraints of
recorded data:
• Cancer, where the initial admission / readmission has a primary diagnosis of
cancer (ICD-10 codes C00 – C97 and D37 – D48, primary diagnosis field of HES
primary diagnosis by hospitalisation table); admissions for cancer were not
considered as an index event from which time to the next admission was
calculated
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• Patients who are readmitted following self-discharge against medical advice
(dismeth = 2 in HES hospitalisations table)
• Patient is in receipt of renal replacement therapy (ICD-10 codes N180, Z490,
Z491, Z492, Z992 in primary diagnosis field of HES primary diagnosis by
hospitalisation table or OPCS codes M011-M015, M018, M019, X401-X409 in
HES procedures by episode table); admissions for RRT were not considered as
an index event from which time to the next admission was calculated
• Patient is still in hospital (dismeth = 8 in HES hospitalisations table)
Figure 24. Algorithm for identifying readmissions by patient from CPRD-HES data.
Admissions were sorted by patient ID and admission date prior to running this algorithm; $selfdis = flag for prior
admission ending in self-discharge; $cancer = flag for presence of cancer; $rrt = flag for admission for renal
replacement therapy; $in_hosp = flag for indicating patient is still in hospital
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Measures of Diabetes Care Quality
The CPRD data supplied by the MHRA contains all primary care events for all of
the included patients, allowing for quantification of whether a given patient has met
a particular treatment target, from which the quality of care received by a patient
can be inferred.
Whilst the CPRD data is an excellent tool for measuring events at the level of
patients, the data only contains a randomised sample of patients, which may not be
representative of practice populations as a whole, and has replaced the standard
practice identifiers with anonymised codes. Overall practice performance with
respect to markers of quality cannot be aggregated from available data nor be
matched from additional datasets describing practice-level performance.
For the purposes of these analyses, quality of care received by a patient was
according to whether specific 2005/06 QOF targets were met and National Diabetes
Audit (NDA) care processes were performed. 
The following QOF targets were examined: DM06 (HbA1c ≤ 7.4% / 57.4 mmol/
mol), DM12 (BP ≤ 145/85) and DM17 (TC ≤ 5.0 mmol/L). For these QOF indicators,
the most recent value in the 15 months prior to the end of the QOF year (1st
January 2005 - 31st March 2006 inclusive) were utilised for the purposes of
determining whether a given target was met; individuals with missing
measurements or no measurements relevant to a given target within the eligibility
timeframe were assumed to have not met the target for the 2005/06 QOF year. Data
pertaining to achievement of the selected QOF indicators was extracted from the
CPRD data as detailed in Table 43.
All 9 NDA care processes, pertaining to whether certain annual checks had
taken place (HbA1c, BP, cholesterol, serum creatinine, urine albumin, foot
surveillance, BMI, smoking status and retinopathy screening) were also analysed.
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Although there are similarities between the NDA care processes and a number
of QOF indicators describing processes of care (see Table 16, page 67), NDA
process measures were chosen in preference to QOF indicators for the following
reasons:
The primary purpose of the NDA is to report on the care received by patients;
the primary purpose of QOF, which measures practice-level performance based on
aggregated patient data, is for incentivisation of and remuneration for specific
clinical activities;
• The NDA process measures consider all individuals with diabetes as opposed to
QOF, which allows for exceptions;
• The associated Read codes for identification of completion of certain NDA
processes are more stringent than their QOF counterparts – for example, the
NDA foot check process specifies checking of peripheral pulses and sensory
loss;
• NDA recording of smoking status is diabetes-specific. In QOF, recording of
smoking status is for patients with one of many chronic diseases, of which
diabetes is one, precluding isolation of diabetes-specific data;
• All NDA care processes require the specified action to have been carried out in
the past 12 months as opposed to within the last 15 months, necessitating
annual review of people with diabetes.
Indicator Source DataTable
Source Entity
Type
Read Codes
Cited by Entity
Type
DM06 HbA1c ≤ 7.4% / 57.4 mmol/mol Test 275
44TB.00, 42W..00,
42W4.00, 42W..11,
42W..12, 42W5.00
DM12 BP ≤ 145/85 Additional ClinicalDetails 1 N/A
DM17 TC ≤ 5.0 mmol/L Test 163
44P9.00, 44OE.00,
44P..00, 44P3.00,
44P1.00, 44PK.00,
44P2.00, 44P4.00,
44PJ.00, 44PH.00,
44PZ.00
Table 43. Description of data sources for determination of patient-level attainment of selected QOF
targets.
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The Read codes utilised by the NDA to identify whether a patient had
experienced specific processes were used to identify pertinent clinical events from
the clinical table of the CPRD dataset that had occurred within the 12 months prior
to the end of the 2005/06 QOF year (1st April 2005 – 31st March 2006).221
For the purposes of this study, additional Read codes were utilised to identify
patients who had had their HbA1c checked (42W..11, 42W..12, 42W..00, 42W4.00,
44TC.00, 66Ae.00, 66Ae000) to maximise event capture rates. Furthermore,
examination of weight (Read codes 22A..00, 22A4.00, 22AZ.00, 22A3.00, 22A1.00,
22A2.00, 22A5.0) was assumed to equate to measurement of BMI, as BMI values
may be calculated on demand when patient records are accessed and not formally
recorded as a BMI value in some electronic patient record systems (Table 44).
Individuals who did not have records containing the Read codes relevant to a
particular care process within the eligibility timeframe were assumed to have not
met that care process for 2005/06. A comparison of the proportion of people with
diabetes receiving individual NDA care processes from the cohort used for analysis
and that which was observed nationally in the 2005/06 NDA is shown in Table 45.
Identifying and Classifying Death
Data pertaining to patient deaths was extracted from the Oﬃce for National
Statistics mortality dataset that was included as part of the bespoke CPRD-HES
utilised for analysis. The ONS mortality dataset, as supplied, contains data
specifying the date of death and up to 15 causes of death coded using the ICD-10
scheme, one of which is cited as the proximal cause of death (i.e. that condition
which directly led to death). The data contained within the ONS dataset is drawn
directly from death certificates; however, the ONS were unable to provide
clarification on how the 15 cause of death fields map to the fields on a standard
English death certificate prior to analysis.222
The date of death, recorded as the date of death entered on the death
certificate, and proximal cause of death was extracted for all patients with diabetes.
Deaths were flagged as potentially diabetes-related if the proximal cause of death
contained any of the ICD-10 codes listed in Table 46.
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Deaths as recorded in the ONS dataset were cross-checked with CPRD primary
care records; the ONS date of death took primacy over the date of death recorded
in CPRD should the dates not match. Patients who were recorded as having died in
the CPRD data but were not present in the ONS mortality dataset were completely
excluded from analysis.
NDA Process Read Codes Used by NDA Additional ReadCodes
Blood Pressure 
Measurement
246.., 2461., 2462., 2463., 2464., 2465., 2466., 2467., 2468., 2469., 246A., 246B.,
246C., 246D., 246E., 246F., 246G., 246H., 246I., 246J., 246N., 246P., 246Q.,
246R., 246S., 246T., 246V., 246W., 246X., 246Y., 246Z., 246a., 246b., 246c.,
246d., 246e., 246f., 246g.
None
BMI 
Measurement
22K.., 22K1., 22K2., 22K3., 22K4., 22K5., 22K6., 22K7., 22K8., 22K9., 22K90,
22KB.
22A..00, 22A4.00,
22AZ.00, 22A3.00,
22A1.00, 22A2.00,
22A5.0
Foot Check
24E1., 24E6., 24E7., 24E8., 24E9., 24EA., 24EB., 24EC., 24ED., 24EE., 24EF.,
24F1., 24F6., 24F7., 24F8., 24F9., 24FA., 24FB., 24FC., 24FD., 24FE., 24FF.,
29B1., 29B2., 29B20 29B21 29B3., 29B7., 29B8., 29B9., 29BA., 29BB., 29BC.,
29BD., 29BE., 29BF., 29BG., 29BH., 29BJ., 29BK., 29BL., 29BM., 29BN., 29BP.,
29BQ., 29BR., 29BS., 29BT., 29BV., 29H1., 29H2., 29H3., 29H4., 29H5., 29H6.,
29H7., 29H8., 29H9., 29HA., 29HB., 2G5A., 2G5B., 2G5E., 2G5F., 2G5G., 2G5H.,
2G5I., 2G5J., 2G5K., 2G5L., 585V., 585W., 585X., 585Y., 585a., 585b., 585c.,
585d., 585e., 66AE., 66AW., 66Ab., 66Ac., 66Aq., 8H7r., 9NND., 2G5d., 2G5e.
None
HbA1c 
Measurement 42W5.
42W..11, 42W..12,
42W..00, 42W4.00,
44TC.00, 66Ae.00,
66Ae000
Retinopathy 
Screening 31283, 3129., 312F., 58C1., 68A7., 68A8., 9N2f. None
Serum 
Cholesterol 
Measurement
44P.., 44P1., 44P2., 44P3., 44P4., 44PH., 44OE., 44PJ., 44PK None
Serum 
Creatinine 
Measurement
44J3., 44J30, 44J31, 44J32, 44J33, 44J3z, 44JC., 44JD., 44JF. None
Smoking Status 
Review
137.., 1371., 1372., 1373., 1374., 1375., 1376., 1377., 1378., 1379., 137A., 137B.,
137C., 137D., 137F., 137G., 137H., 137J., 137K., 137K0 137L., 137M., 137N.,
137O., 137P., 137Q., 137R., 137S., 137T., 137V., 137X., 137Y., 137Z., 137a.,
137b., 137c., 137d., 137e., 137f., 137h., 137j., 137l., 137m., 137o.
None
Urinary Albumin
Measurement 44J6., 44J7., 44lD., 46N4., 46N5., 46N6., 44JG., 46TC., 46TD. None
Table 44. Read codes used to extract data pertaining to NDA care process achievement, 2005/06.
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England CPRD-HES Data
NDA BMI 80.76% 75.77%
NDA BP 86.45% 83.00%
NDA Cholesterol 81.05% 77.13%
NDA Creatinine 82.67% 78.76%
NDA Foot 63.76% 68.40%
NDA HbA1c 82.54% 58.45%
NDA Retinal Screen 60.66% 23.51%
NDA Smoking Status 79.38% 39.92%
NDA Urinary Albumin 48.20% 16.74%
Table 45. Comparison of receipt of NDA care process in England and in CPRD-HES dataset,
2005/06.
Disease Category ICD-10 Codes
Diabetes Mellitus E10, E11, E13, E14
Hypoglycaemia E16.0, E16.1
Vascular Syndromes of Brain G45, G46
Cardio- and Other Cerebrovascular Disease I10 – I79, I95 – I99
Renal Failure N17 – N19
Hyperglycaemia R73.9
Poisoning by Insulin or Oral Hypoglycaemic agents T38.3
Table 46. ICD-10 codes used to identify deaths potentially related to diabetes mellitus from proximal
causes of death.
Statistical Analysis
Co-Morbidity and Survival
For this analysis, all 250,000 patients (125,000 individuals with diabetes and the
125,000 controls) were included; of these, 9,112 (3.64%) could not be included in
the co-morbidity analysis dataset due to missing data with respect to date of death,
death prior to the observation start date, death after the observation end date or an
age at death that was less than their age at the start of observation 
The final dataset of 240,888 patients was analysed using Cox regression utilising
the Breslow method for ties. Models were adjusted for age group, diabetes status
(none, incident, prevalent), gender, deprivation fifth and smoking status.
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Two analyses were performed; one that utilised each patient’s CCI score at the
start of observation and a series of separate models for strata of CCI score to take
account of potential increases in CCI score over time for each patient. For the
second series of models, utilising strata of CCI, patient observation start and end
dates were recalculated according to the dates where a CCI score change led to a
change in their CCI grouping; the patient in question would be censored from their
original CCI model on a date one day prior to their CCI change and entered into the
relevant CCI model with an observation start date that is equal to the date of their
CCI change.
In addition to CCI score, the other independent variables included in this model
were diabetes status (non-diabetic, incident or prevalent diabetes), gender, smoking
status as of 1st April 2005 (determined using the methodology discussed on page
123), the age group of the patient at their observation start date, IMD fifth and broad
region of residence. Statistical significance was assumed at α = 0.05. The database
was stored on and records extracted from FileMaker Pro Advanced V13 for Mac OS
X (FileMaker Inc., CA, USA) and analyses were performed using STATA/MP V12.1
for Mac OS X (StataCorp, TX, USA).
Quality of Primary Care Diabetes Management, Emergency
Admissions and Readmissions
The eﬀects of quality of diabetes management in primary care on emergency
admissions and readmissions were modelled via zero-inflated negative binomial
regression. The source population for this analysis was the 125,000 individuals
identified as having diabetes. Patients were eligible for inclusion in this analysis if
they had received a diagnosis of diabetes before and were alive on 1st April 2005.
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The count of emergency admissions and readmissions were tallied over a
number of time periods that were aligned with the start and end dates of the QOF
year (1st April - 31st March); the time periods used were 2005/06 (index year),
2005/06 - 2006/07 (index year + 1), 2005/06 - 2007/08 (index year + 2), 2005/06 -
2008/09 (index year + 3) and 2005/06 - 2009/10 (index year + 4). Quality of care was
defined as whether a patient achieved the aforementioned QOF targets and NDA
processes during QOF year 2005/06 (pages 129 – 131), each expressed as a binary
variable.
Zero-inflated negative binomial models were utilised as opposed to standard
negative binomial models and Poisson models on the grounds of the variance of
admission counts exceeding the mean and the predominance of patients who
experienced zero admissions in all years of observation (Table 47). Predictors of
zero counts were set as all independent variables bar quality targets. The quality of
fit for all models were assessed relative to standard negative binomial and zero-
inflated Poisson models.
Models were constructed a priori, with the dependent variable set as either
emergency admission or readmission count, the independent variables set as the
quality target of interest, patient gender, age group, diabetes type (T1DM, T2DM),
years since diagnosis of diabetes, smoking status (non-smoker, ex-smoker, current
smoker, unknown, CCI score category (CCI = 0, CCI = 1, CCI = 2, CCI = 3 or CCI ≥
4) and fifth of IMD quintile. Where relevant, calculation of independent variables was
as previously described in this chapter.
Univariate models for each predictor were constructed prior to multiple-variable
modelling. Separate multiple-variable models were then constructed for each
combination of admission type (emergency admissions / readmissions), time period
and quality target. Finally, full models were constructed that included all predictor
variables; four separate versions of these models were constructed, utilising the
various combinations of the chosen individual QOF targets versus attainment of all
three QOF targets and receipt of individual NDA care processes versus the count of
NDA care processes received.
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The database was stored on and records extracted from FileMaker Pro
Advanced V13 for Mac OS X (FileMaker Inc., CA, USA) and analyses were
performed using STATA/MP V12.1 for Mac OS X (StataCorp, TX, USA).
2005/06 2005/06 – 2006/07
Mean Variance ZeroAdm
% Zero
Adm* Mean Variance
Zero
Adm
% Zero
Adm*
Emergency Admissions 0.396 0.999 35,510 49.52% 0.782 2.533 28,811 40.18%
Readmissions 0.090 0.264 43,439 60.58% 0.176 0.640 41,529 57.92%
2005/06 – 2007/08 2005/06 – 2008/09
Mean Variance ZeroAdm
% Zero
Adm* Mean Variance
Zero
Adm
% Zero
Adm*
Emergency Admissions 1.160 4.417 23,581 32.89% 1.557 6.579 19,058 26.58%
Readmissions 0.261 1.155 39,783 55.48% 0.353 1.761 37,980 52.97%
2005/06 – 2009/10
Mean Variance ZeroAdm
% Zero
Adm*
Emergency Admissions 1.954 8.925 15,230 21.24%
Readmissions 0.445 2.332 36,385 50.74%
Table 47. Distribution characteristics of emergency admissions and readmissions, cumulative totals,
CPRD-HES dataset 2005/06 - 2009/10.
* = Number of people with diabetes by 1st April 2005 = 71,703
Quality of Primary Care Diabetes Management and 
Mortality
The eﬀects of quality of diabetes management in primary care on the odds of
mortality, both all-cause and potentially diabetes-related, were modelled via logistic
regression. The source population for this analysis was the 125,000 individuals
identified as having diabetes. Patients were eligible for inclusion in this analysis if
they had received a diagnosis of diabetes before and were alive on 1st April 2005.
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The occurrence of death due to any cause or death due to a cause potentially
related to diabetes were recorded according to which time period of interest in
which they occurred; these time periods were the same as for the analyses
examining emergency admissions and readmissions (page 134). Quality of care,
was defined as whether a patient achieved the aforementioned QOF targets and
NDA processes during QOF year 2005/06 (pages 129 – 131), each expressed as a
binary variable.
Logistic regression, modelling the odds of death, was chosen in preference to
modelling of survival with Cox regression on the grounds of visual inspection of log-
log plots of survival for each of the QOF indicators and NDA care processes
indicating non-proportional hazards, thereby violating the assumptions of Cox
regression (see Appendix). The calculated odds ratios for the death due to any
cause models relates to the odds of dying during the various follow-up periods, with
an OR > 1 denoting increased odds of death and an OR < 1 denoted decreased
odds of death.
Those quoted for the models examining deaths potentially related to diabetes
express the odds of dying from a cause related to diabetes versus death due to
another cause; as such, an OR > 1 for these models indicates an association with
increased odds of dying of a potentially diabetes-related cause, whereas an OR < 1
indicates that patients with a particular characteristic may have decreased odds of
dying of a potentially diabetes-related cause (i.e. they are more likely to die of
something unrelated to diabetes).
Univariate models for each predictor were constructed prior to multiple-variable
modelling. Separate multiple-variable models were constructed for all-cause and
potentially diabetes-related mortality, time period and quality target. Models were
constructed a priori, with the independent variables set as the quality target of
interest, patient gender, age group, diabetes type (T1DM, T2DM), years since
diagnosis of diabetes, smoking status (non-smoker, ex-smoker, current smoker,
unknown), CCI score category (CCI = 0, CCI = 1, CCI = 2, CCI = 3 or CCI ≥ 4) and
fifth of IMD quintile. Finally, full models were constructed that included all predictor
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variables; four separate versions of these models were constructed, utilising the
various combinations of the chosen individual QOF targets versus attainment of all
three QOF targets and receipt of individual NDA care processes versus the count of
NDA care processes received. Where relevant, calculation of independent variables
was as previously described in this chapter.
The database was stored on and records extracted from FileMaker Pro
Advanced V13 for Mac OS X (FileMaker Inc., CA, USA) and analyses were
performed using STATA/MP V12.1 for Mac OS X (StataCorp, TX, USA).
Results
Allocation of Diabetes Type
Of the 125,000 patients identified as having a diagnosis of diabetes, a total of
118,971 had diagnosis Read codes that matched the list used by the MHRA; the
remainder (6,029) were assumed to have diabetes by virtue of their medication
history alone and were therefore not suitable for the algorithm used to allocate
diabetes type in these analyses.
109,938 (92.4%) of the eligible patients identified as having diabetes had codes
that all agreed upon either T1DM or T2DM; 9,033 (7.6%) patients had codes that
either did not specify a diabetes type or had multiple diabetes types indicated by
the codes present in their medical history. Only 219 patients had codes that did not
indicate a diabetes type of interest.
The algorithm used to assign diabetes type for patients in whom diabetes type
was uncertain was validated against the 109,938 patients of known diabetes type;
this yielded a positive predictive value of 96.22% for T1DM and 94.94% for T2DM
(Table 48).
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Original Type
T1DM T2DM TOTAL
Type from
Algorithm
T1DM 3,664 144 3,808
T2DM 5,375 100,755 106,130
TOTAL 9,039 100,899 109,938
Table 48. Validation of algorithm to assign patients a diabetes against patients with a known
diabetes type.
Of the 9,033 patients who could be assigned a diabetes type via the algorithm,
8,756 (96.9%) were declared as T2DM, with the remaining 277 (3.1%) patients
assigned as T1DM (Table 49).
Before After Delta
T1DM 9,039 9,316 277
T2DM 100,899 109,655 8,756
Mixed/Unknown 9,033 0 -9,033
Table 49. Diabetes type assignation and final totals by diabetes type for CPRD-HES dataset.
Co-Morbidity and Diabetes Status
A total of 240,888 patients were eligible for this analysis; characteristics of each
patient group are shown in Table 50. Of these, 121,445 (50.42%) had received no
diagnosis of diabetes mellitus, 66,942 (27.79%) had received a diagnosis of
diabetes mellitus before 1st April 2005 and 52,501 (21.79%) were diagnosed with
diabetes after 1st April 2005 but before the end of observation; total observation
times for each group were 721,407.6, 374,737.3 and 315,800.4 person-years
respectively. During the observation period, 13,458 people without diabetes died,
13,435 people with prevalent diabetes died and 5,276 people with incident diabetes
died, giving rise to crude death rates (per 1,000 PY) of 18.655, 5.852 and 16.707
respectively (Table 51). 
Crude death rates for each stratum of diabetes status and co-morbidity
grouping are shown in Table 52 and Figure 25. Crude death rates increased with
increasing co-morbidity across all patient groups; patients with prevalent diabetes
had the highest crude mortality rates across all levels of co-morbidity and those
with incident diabetes had the lowest crude mortality rates across all levels of co-
morbidity.
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In the multiple-variable Cox regression where the co-morbidity of patients was
determined at the start of observation (1st April 2005) and remained fixed (Table 53),
individuals with prevalent diabetes were subject to a significantly increased hazard
of death compared to individuals without diabetes (HR = 1.459, p ≤ 0.001).
Adjusted hazard ratios for co-morbidity maintained the pattern observed in
crude mortality rates, namely increased hazard of death with increased burden of
co-morbidity. There was some evidence of a dose-response relationship between
increasing co-morbidity and hazard of death, with the hazard of death for
individuals with a CCI of 4 or more was approximately 238% that of those with a
CCI of 0 (Table 53).
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No DM Prevalent DM Incident DM
Co-Morbidity 
Grouping
CCI = 0
n 98,639 46,055 41,590
% 81.22% 68.80% 79.22%
CCI = 1
n 15,338 13,265 7,598
% 12.63% 19.82% 14.47%
CCI = 2
n 5,593 5,127 2,427
% 4.61% 7.66% 4.62%
CCI = 3
n 1,375 1,718 636
% 1.13% 2.57% 1.21%
CCI ≥ 4
n 500 777 250
% 0.41% 1.16% 0.48%
Male
n 64,625 36,813 26,876
% 53.21% 54.99% 51.19%
Age Group
< 25y
n 2,521 778 1,722
% 2.08% 1.16% 3.28%
25 - 44y
n 16,990 6,905 9,946
% 13.99% 10.31% 18.94%
45 - 64y
n 45,844 23,898 21,367
% 37.75% 35.70% 40.70%
65 - 74y
n 29,312 17,778 11,159
% 24.14% 26.56% 21.25%
≥ 75y
n 26,778 17,583 8,307
% 22.05% 26.27% 15.82%
IMD Fifth
(1 = Most 
Deprived)
1
n 17,006 10,820 9,140
% 14.00% 16.16% 17.41%
2
n 23,271 14,108 11,141
% 19.16% 21.07% 21.22%
3
n 24,984 13,685 10,518
% 20.57% 20.44% 20.03%
4
n 28,689 15,129 11,398
% 23.62% 22.60% 21.71%
5
n 27,212 13,016 10,083
% 22.41% 19.44% 19.21%
Smoking 
Status
Non-Smoker
n 54,192 24,881 17,523
% 44.62% 37.17% 33.38%
Ex-Smoker
n 34,118 26,662 13,908
% 28.09% 39.83% 26.49%
Current Smoker
n 21,828 9,564 8,476
% 17.97% 14.29% 16.14%
Unknown
n 11,307 5,835 12,594
% 9.31% 8.72% 23.99%
(table continued on next page)
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No DM Prevalent DM Incident DM
Region
North East
n 2,833 1,486 1,305
% 2.33% 2.22% 2.49%
North West
n 20,696 11,495 8,874
% 17.04% 17.17% 16.90%
Yorkshire
n 5,823 3,057 2,635
% 4.79% 4.57% 5.02%
East Midlands
n 3,857 2,156 1,642
% 3.18% 3.22% 3.13%
West Midlands
n 14,404 7,625 6,553
% 11.86% 11.39% 12.48%
East of England
n 13,586 7,890 5,446
% 11.19% 11.79% 10.37%
South West
n 15,559 8,630 6,647
% 12.81% 12.89% 12.66%
South Central
n 13,687 7,553 5,894
% 11.27% 11.28% 11.23%
London
n 16,388 9,110 7,070
% 13.49% 13.61% 13.47%
South East
n 14,612 7,940 6,435
% 12.03% 11.86% 12.26%
Table 50. Characteristics of patients included in co-morbidity survival analysis.
No DM Prevalent DM Incident DM
Patients
n 121,445 66,942 52,501
% 50.42% 27.79% 21.79%
Observation 
Time (Years)
Total 721,407.6 374,737.3 315,800.4
Mean 5.940 5.598 6.015
Minimum 0.003 0.003 0.008
Maximum 6.478 6.478 6.478
Deaths
n 13,458 13,435 5,276
% 11.08% 20.07% 10.05%
Crude Death Rate per 1,000 PY 18.655 35.852 16.707
Table 51. Total patients, observation times and deaths by diabetes status.
The hazard of death for individuals who developed diabetes during the
observation period did not significantly diﬀer from that of individuals without
diabetes (HR = 1.003, p = 0.835). Increasing hazard of death was also associated
with a history of smoking, increasing age, deprivation and with residence in some,
but not all, regions of England (Table 53).
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As described earlier, additional analyses were performed that allowed for the
movement of patients between co-morbidity groupings – and hence diﬀerent
stratified models – over time. Crude death rates and Cox regression results for co-
morbidity groupings and diabetes status where patient co-morbidity could change
over time are presented in Table 54 and Table 55.
Comorbidity
No DM Prevalent DM Incident DM
Deaths
Person-
Years
(1,000)
Rate per
1,000 PY Deaths
Person-
Years
Rate per
1,000 PY Deaths
Person-
Years
Rate per
1,000 PY
CCI = 0 8,820 593.377 14.864 7,224 265.475 27.212 3,481 252.274 13.798
CCI = 1 2,124 89.764 23.662 2,839 73.871 38.432 865 45.466 19.025
CCI = 2 1,751 29.126 60.118 2,042 24.819 82.275 631 13.412 47.047
CCI = 3 543 6.765 80.264 860 7.528 114.241 206 3.383 60.887
CCI ≥ 4 220 2.376 92.605 470 3.044 154.403 93 1.265 73.532
Table 52. Crude death rates by diabetes status and co-morbidity grouping.
Figure 25. Crude death rates by diabetes status and co-morbidity grouping.
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HR p
Diabetes Status
No DM Reference Group
Prevalent DM 1.459 < 0.001
Incident DM 1.003 0.835
Gender
Male Reference Group
Female 0.853 < 0.001
Smoking Status
Non-smoker Reference Group
Ex-Smoker 1.135 < 0.001
Current Smoker 1.735 < 0.001
Unknown 1.314 < 0.001
Age Group
< 25y Reference Group
25 - 44y 2.912 < 0.001
45 - 64y 10.450 < 0.001
65 - 74y 31.745 < 0.001
≥ 75y 105.815 < 0.001
IMD Fifth 
(1 = Most 
Deprived)
1 Reference Group
2 0.898 < 0.001
3 0.850 < 0.001
4 0.795 < 0.001
5 0.729 < 0.001
Region of 
England
North East Reference Group
North West 1.089 0.025
Yorkshire 1.136 0.003
East Midlands 1.038 0.441
West Midlands 1.040 0.314
East of England 1.043 0.286
South West 1.028 0.478
South Central 1.070 0.090
London 0.913 0.023
South East 1.015 0.704
Co-morbidity 
Grouping
CCI = 0 Reference Group
CCI = 1 1.084 < 0.001
CCI = 2 2.001 < 0.001
CCI = 3 2.402 < 0.001
CCI ≥ 4 3.383 < 0.001
Table 53. Results of multiple-variable Cox regression examining the eﬀects of diabetes status and
co-morbidity on hazard of death.
HR = Hazard ratio; CCI = Charlson Co-morbidity Index
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No DM Prevalent DM Incident DM
Comorbidity Deaths
Person-
Years
(1,000)
Rate per
1,000 PY Deaths
Person-
Years
Rate per
1,000 PY Deaths
Person-
Years
Rate per
1,000 PY
CCI = 0 7,916 582.502 13.590 4,446 205.630 21.621 2,876 238.554 12.056
CCI = 1 1,223 76.699 15.945 1,536 53.162 28.893 410 35.308 11.612
CCI = 2 1,204 23.827 50.532 1,259 17.002 74.052 364 9.520 38.237
CCI = 3 391 5.612 69.677 583 5.292 110.158 120 2.389 50.225
CCI ≥ 4 220 2.376 92.605 470 3.044 154.403 93 1.265 73.532
Table 54. Crude death rates by co-morbidity grouping and diabetes status for analysis where patient
co-morbidity was not fixed over time.
CCI = Charlson Co-morbidity Index; PY = Person-Years
CCI = 0 CCI = 1 CCI = 2 CCI = 3 CCI ≥ 4
HR p HR p HR p HR p HR p
Diabetes 
Status
No DM Reference Group Reference Group Reference Group Reference Group Reference Group
Prevalent DM 1.559 < 0.001 1.767 < 0.001 1.586 < 0.001 1.651 < 0.001 1.570 < 0.001
Incident DM 1.104 < 0.001 0.953 0.409 0.917 0.154 0.857 0.142 0.817 0.106
Table 55. Results for multiple-variable Cox regression for strata of co-morbidity grouping examining
the eﬀect of diabetes status on hazard of death.
Estimates of hazard ratios additionally adjusted, but coeﬃcients not shown, for gender, smoking status at start
of observation (non-, ex-, current smoker or unknown), age group (< 25y, 25 -44y, 45 -64y, 65 - 74y, ≥ 75y), fifth
of IMD score for LSOA of residence and broad region of England.
HR = Hazard ratio; CCI = Charlson Co-morbidity Index
As with the analysis where patient CCI was fixed at the start of observation,
patients with prevalent diabetes experienced both higher crude mortality rates and
adjusted hazards of death across all levels of co-morbidity. Patients who developed
diabetes during the observation period experienced a higher adjusted hazard of
death in comparison to individuals without diabetes where CCI was 0, but were
subject to hazards of death similar to individuals without diabetes for all other
groupings of co-morbidity.
Quality of Primary Care Diabetes Management and 
Emergency Admissions
A total of 68,002 individuals had received a diagnosis of diabetes by 1st April
2005; of these, 67,919 (99.9%) had been determined to have either T1DM or T2DM
and were therefore eligible for analysis. Details of patient demographics, years with
diabetes, deprivation, smoking status and co-morbidity are shown in Table 56.
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DM17 (TC ≤ 5.0mmol/L) was the most commonly achieved target, attained by
44,310 (65.24%) patients; 41,185 patients (60.64%) achieved DM12 (BP ≤ 145/85),
31,818 (46.85%) achieved DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) and 18,970
(27.67%) achieving all three of these targets (Table 57).
n / Mean %
DM Type
T1DM 6,760 9.94%
T2DM 61,159 89.94%
Unknown* 83 0.12%
Age (years) 63.957 N/A
Age Group
< 25y 778 1.15%
25 – 44y 6,913 10.18%
45 – 64y 24,081 35.46%
65 – 74y 18,086 26.63%
≥ 75y 18,061 26.59%
Gender
Male 37,342 54.98%
Female 30,577 45.02%
Years With DM 5.743 N/A
Deprivation Fifth 
(1 = Most 
Deprived)
1 10,982 16.17%
2 14,320 21.08%
3 13,914 20.49%
4 15,337 22.58%
5 13,180 19.41%
Missing 186 0.27%
Smoking Status
Non-Smoker 25,177 37.07%
Ex-Smoker 27,079 39.87%
Current Smoker 9,728 14.32%
Unknown 5,935 8.74%
CCI Group
CCI = 0 43,114 63.48%
CCI = 1 14,452 21.28%
CCI = 2 6,348 9.35%
CCI = 3 2,578 3.80%
CCI ≥ 4 1,427 2.10%
Table 56. Demographics, smoking status and co-morbidity for patients included in analysis of
emergency admissions, readmissions and mortality as of 1st April 2005.
* = The 83 patients of unknown diabetes type were not included in any analyses or taken account of in any of
the other subtotals in this table; this total is simply presented for information
T1DM = Type 1 diabetes mellitus; T2DM = Type 2 diabetes mellitus; CCI = Charlson co-morbidity index
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QOF Indicator(s) n %
DM06 (HbA1c ≤ 7.4% / 
57.4 mmol/mol)
Not achieved 36,101 53.15%
Achieved 31,818 46.85%
DM12 (BP ≤ 145/85)
Not achieved 26,734 39.36%
Achieved 41,185 60.64%
DM17 (TC ≤ 5.0 mmol/L)
Not achieved 23,609 34.76%
Achieved 44,310 65.24%
DM06 + DM12 + DM17
Not achieved 49,129 72.33%
Achieved 18,790 27.67%
Table 57. Achievement of selected QOF targets by patients included in analysis of emergency
admissions, readmissions and mortality, 2005/06.
QOF = Quality and outcomes framework; HbA1c = Glycated haemoglobin; BP = Blood pressure; TC = Total
cholesterol
Relatively few patients achieved all 9 NDA care processes, with only 1,343
patients (1.98%) doing so in 2005/06; the modal number of processes achieved
was 7 (Table 58 and Figure 26). The most commonly achieved NDA care processes
was checking of blood pressure, with 56,372 patients (83.00%) receiving this care
process; the least commonly achieved was checking of urinary albumin, with only
11,372 (16.74%) receiving this process (Table 58).
Figure 26. NDA care processes achieved by patients, 2005/06.
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NDA Process(es) of Care n %
Number of NDA 
Processes Met
0 9,348 13.76%
1 1,509 2.22%
2 1,476 2.17%
3 2,053 3.02%
4 3,111 4.58%
5 7,200 10.60%
6 16,909 24.90%
7 18,044 26.57%
8 6,926 10.20%
9 1,343 1.98%
NDA BMI
Not achieved 16,459 24.23%
Achieved 51,460 75.77%
NDA BP
Not achieved 11,547 17.00%
Achieved 56,372 83.00%
NDA Cholesterol
Not achieved 15,531 22.87%
Achieved 52,388 77.13%
NDA Creatinine
Not achieved 14,425 21.24%
Achieved 53,494 78.76%
NDA Foot
Not achieved 21,465 31.60%
Achieved 46,454 68.40%
NDA HbA1c
Not achieved 28,218 41.55%
Achieved 39,701 58.45%
NDA Retinal 
Screen
Not achieved 51,952 76.49%
Achieved 15,967 23.51%
NDA Smoking 
Status
Not achieved 40,806 60.08%
Achieved 27,113 39.92%
NDA Urinary 
Albumin
Not achieved 56,547 83.26%
Achieved 11,372 16.74%
Table 58. Achievement of NDA care processes by patients included in analysis of emergency
admissions, readmissions and mortality, 2005/06.
NDA = National Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin
During the first year of observation (2005/06), the mean number of emergency
admissions per patient was 0.266, rising to 1.315 over the longest follow-up period
(2005/06 – 2009/10); the proportion of patients experiencing zero emergency
admissions was 84.83% in 2005/06 and 55.03% in 2005/06 – 2009/10 (Table 59).
All zero-inflated negative binomial models presented in this section exhibited a
significantly superior fit in comparison to Poisson and standard negative binomial
models (p < 0.001 for both).
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Univariate analyses of all predictor variables indicated that increased emergency
admission rates across all lengths of follow-up were associated with T1DM, number
of years with diabetes mellitus, female gender, increasing deprivation, increasing
co-morbidity and having any smoking status other than non-smoker (Table 60).
Achieving any of the QOF targets in 2005/06 was associated with decreased
emergency admissions, with the exception of DM12 (BP ≤ 145/85) for emergency
admissions occurring in 2005/06 and 2005/06 – 2006/07; attaining all of the
selected QOF targets did not seem to yield any additional benefit versus attainment
of individual targets in univariate analyses (Table 60).
2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
Mean 0.266 0.526 0.780 1.047 1.315
Zero 
Emergency 
Admissions
n 57,618 50,934 45,712 41,200 37,374
% 84.83% 74.99% 67.30% 60.66% 55.03%
Table 59. Emergency admissions from individuals with diabetes by 1st April 2005 by follow-up
period.
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2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.882 0.011 0.828 < 0.001 0.828 < 0.001 0.845 < 0.001 0.856 < 0.001
Years With DM 1.008 < 0.001 1.010 < 0.001 1.011 < 0.001 1.011 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.036 0.224 1.064 0.003 1.071 < 0.001 1.065 < 0.001 1.068 < 0.001
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.023 0.886 0.895 0.305 0.928 0.408 0.904 0.206 0.862 0.043
45 – 64y 0.874 0.364 0.766 0.010 0.771 0.002 0.765 < 0.001 0.756 < 0.001
65 – 74y 0.988 0.935 0.858 0.136 0.858 0.072 0.849 0.031 0.832 0.009
≥ 75y 1.165 0.297 1.031 0.767 1.063 0.468 1.060 0.438 1.032 0.652
Deprivation
Fifth 
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.822 < 0.001 0.816 < 0.001 0.821 < 0.001 0.838 < 0.001 0.840 < 0.001
3 0.815 < 0.001 0.768 < 0.001 0.770 < 0.001 0.780 < 0.001 0.796 < 0.001
4 0.819 < 0.001 0.769 < 0.001 0.765 < 0.001 0.778 < 0.001 0.783 < 0.001
5 0.765 < 0.001 0.729 < 0.001 0.718 < 0.001 0.712 < 0.001 0.713 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.227 < 0.001 1.305 < 0.001 1.335 < 0.001 1.324 < 0.001 1.318 < 0.001
CCI = 2 1.448 < 0.001 1.474 < 0.001 1.512 < 0.001 1.491 < 0.001 1.437 < 0.001
CCI = 3 1.733 < 0.001 1.848 < 0.001 1.824 < 0.001 1.779 < 0.001 1.709 < 0.001
CCI ≥ 4 2.059 < 0.001 2.064 < 0.001 2.047 < 0.001 1.962 < 0.001 1.817 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.069 0.049 1.123 < 0.001 1.130 < 0.001 1.126 < 0.001 1.106 < 0.001
Current 
Smoker 1.086 0.070 1.152 < 0.001 1.147 < 0.001 1.153 < 0.001 1.165 < 0.001
Unknown 1.158 0.007 1.290 < 0.001 1.367 < 0.001 1.404 < 0.001 1.399 < 0.001
DM06 (HbA1c ≤ 7.4% /
57.4 mmol/mol) 0.820 < 0.001 0.822 < 0.001 0.831 < 0.001 0.830 < 0.001 0.833 < 0.001
DM12 (BP ≤ 145/85) 0.987 0.588 0.973 0.134 0.955 0.003 0.927 < 0.001 0.920 < 0.001
DM17 (TC ≤ 5.0 mmol/
L) 0.769 < 0.001 0.819 < 0.001 0.831 < 0.001 0.834 < 0.001 0.847 < 0.001
DM06 + DM12 + DM17 0.858 < 0.001 0.863 < 0.001 0.867 < 0.001 0.857 < 0.001 0.854 < 0.001
(continued on next page...)
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2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
Number of 
NDA 
Processes 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.506 < 0.001 1.272 < 0.001 1.136 0.012 1.031 0.513 0.990 0.811
2 1.725 < 0.001 1.412 < 0.001 1.249 < 0.001 1.139 0.005 1.080 0.079
3 1.476 < 0.001 1.326 < 0.001 1.178 < 0.001 1.081 0.060 1.036 0.364
4 1.379 < 0.001 1.313 < 0.001 1.186 < 0.001 1.089 0.016 1.062 0.070
5 0.936 0.144 0.989 0.756 0.944 0.064 0.907 < 0.001 0.897 < 0.001
6 0.715 < 0.001 0.819 < 0.001 0.828 < 0.001 0.823 < 0.001 0.828 < 0.001
7 0.626 < 0.001 0.748 < 0.001 0.791 < 0.001 0.800 < 0.001 0.821 < 0.001
8 0.588 < 0.001 0.709 < 0.001 0.734 < 0.001 0.759 < 0.001 0.791 < 0.001
9 0.470 < 0.001 0.627 < 0.001 0.713 < 0.001 0.743 < 0.001 0.784 < 0.001
NDA BMI 0.546 < 0.001 0.655 < 0.001 0.712 < 0.001 0.745 < 0.001 0.775 < 0.001
NDA BP 0.763 < 0.001 0.840 < 0.001 0.856 < 0.001 0.859 < 0.001 0.869 < 0.001
NDA Cholesterol 0.597 < 0.001 0.728 < 0.001 0.779 < 0.001 0.804 < 0.001 0.829 < 0.001
NDA Creatinine 0.757 < 0.001 0.848 < 0.001 0.873 < 0.001 0.878 < 0.001 0.889 < 0.001
NDA Foot 0.559 < 0.001 0.680 < 0.001 0.741 < 0.001 0.774 < 0.001 0.805 < 0.001
NDA HbA1c 0.780 < 0.001 0.853 < 0.001 0.874 < 0.001 0.888 < 0.001 0.905 < 0.001
NDA Retinal Screen 0.667 < 0.001 0.738 < 0.001 0.785 < 0.001 0.814 < 0.001 0.834 < 0.001
NDA Smoking Status 0.862 < 0.001 0.973 0.149 1.001 0.954 1.018 0.207 1.033 0.013
NDA Urinary Albumin 0.768 < 0.001 0.863 < 0.001 0.905 < 0.001 0.936 < 0.001 0.961 0.021
Table 60. Results, by follow-up period, of univariate zero-inflated negative binomial regression
modelling of emergency admission counts.
T1DM = Type 1 diabetes mellitus; T2DM = Type 2 diabetes mellitus; CCI = Charlson co-morbidity index; NDA =
National Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin
The total number of NDA processes achieved in 2005/06 exhibited a somewhat
unexpected relationship with emergency admission rates in univariate analyses,
with patients achieving 1 – 4 processes exhibiting increased emergency admission
rates (versus achieving no processes) for admissions occurring in the first three
follow-up periods. Receiving any of the individual care processes in 2005/06 was
generally protective of emergency admissions across all follow-up periods, with the
exception of smoking status review (Table 60).
Multiple-variable analysis of attainment of QOF targets in isolation in 2005/06
indicated that reaching the targets for DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) and
DM17 (TC ≤ 5.0 mmol/L) were protective of emergency admissions across all
follow-up periods; the benefits of attaining DM12 (BP ≤145/85) did not demonstrate
a significant association with reduced emergency admission rates until the follow-
up period was extended to three or more years.
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Attaining multiple QOF targets in 2005/06 did not appear to confer markedly
improved benefits versus attainment of single targets for the majority of follow-up
periods in these multiple-variable models. As expected, associations of QOF target
achievement with reduced admission rates experienced some dilution with
increasing follow-up period (Table 61, full regression tables available in
Appendices).
2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
IRR p IRR p IRR p IRR p IRR p
DM06 (HbA1c ≤ 7.4% / 
57.4 mmol/mol) 0.826 < 0.001 0.830 < 0.001 0.845 < 0.001 0.847* < 0.001 0.849 < 0.001
DM12 (BP ≤ 145/85) 0.981 0.430 0.976 0.185 0.968 0.044 0.942 < 0.001 0.939 < 0.001
DM17 (TC ≤ 5.0 mmol/L) 0.761 < 0.001 0.817 < 0.001 0.840 < 0.001 0.850 < 0.001 0.869 < 0.001
DM06 + DM12 + DM17 0.861 < 0.001 0.867 < 0.001 0.878 < 0.001 0.870 < 0.001 0.868 < 0.001
Table 61. Results from multiple-variable zero-inflated negative binomial regression of selected QOF
indicators against emergency admissions.
* = Model failed to converge after 1,000 iterations
Results denote separate models for each QOF indicator(s) and follow-up period; all models also adjusted, but
coeﬃcients not shown, for diabetes type, gender, years post-diabetes diagnosis, age group, IMD fifth, smoking
status and co-morbidity grouping.
IRR = Incidence rate ratio; HbA1c = Glycated haemoglobin; BP = Blood pressure; TC = Total cholesterol
Associations between receiving NDA processes of care in 2005/06 and
emergency admission rates in multiple-variable analysis were similar to those
observed in univariate analysis. Receiving 1 – 4 processes was associated with a
significant increase in emergency admission rates versus receiving no NDA
processes; however, receiving 6 – 9 processes was associated with decreased
emergency admission rates, with evidence of a dose-response relationship between
increasing process attainment and decreasing emergency admission rates.
Receipt of the NDA care processes pertaining to cholesterol checks, creatinine
checks, foot checks, HbA1c measurement and retinopathy screening in 2005/06
were significantly associated with decreased emergency admission rates across all
follow-up periods, with the greatest benefits associated with BMI and foot checks;
review of smoking status in 2005/06 was associated with decreased emergency
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admission rates for up to two years of follow-up and checking of urinary albumin in
2005/06 was associated with decreased emergency admission rates for up to three
years of follow-up. As expected, associations of receiving NDA care processes in
2005/06 with emergency admission rates experienced some dilution with increasing
follow-up period (Table 62, full tables available in Appendix).
2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
Number of 
NDA 
Processes 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.484 < 0.001 1.286 < 0.001 1.164 0.003 1.055 0.264 1.011 0.810
2 1.745 < 0.001 1.449 < 0.001 1.284 < 0.001 1.178 0.001 1.115 0.015
3 1.447 < 0.001 1.330 < 0.001 1.194 < 0.001 1.106 0.019 1.068 0.099
4 1.351 < 0.001 1.317 < 0.001 1.217 < 0.001 1.135 0.001 1.115 0.002
5 0.926 0.099 1.013 0.720 0.996 0.891 0.972 0.348 0.970 0.279
6 0.707 < 0.001 0.838 < 0.001 0.873 < 0.001 0.883 < 0.001 0.897 < 0.001
7 0.604 < 0.001 0.743 < 0.001 0.813 < 0.001 0.834 < 0.001 0.866 < 0.001
8 0.574 < 0.001 0.713 < 0.001 0.769 < 0.001 0.803 < 0.001 0.847 < 0.001
9 0.458 < 0.001 0.631 < 0.001 0.741 < 0.001 0.784 < 0.001 0.829 < 0.001
NDA BMI 0.548 < 0.001 0.666 < 0.001 0.739 < 0.001 0.782 < 0.001 0.819 < 0.001
NDA BP 0.762 < 0.001 0.864 < 0.001 0.902 < 0.001 0.917 < 0.001 0.934 < 0.001
NDA Cholesterol 0.592 < 0.001 0.734 < 0.001 0.805 < 0.001 0.843 < 0.001 0.875 < 0.001
NDA Creatinine 0.747 < 0.001 0.857 < 0.001 0.905 < 0.001 0.922 < 0.001 0.941 0.001
NDA Foot 0.557 < 0.001 0.688 < 0.001 0.763 < 0.001 0.806 < 0.001 0.843 < 0.001
NDA HbA1c 0.784 < 0.001 0.859 < 0.001 0.891 < 0.001 0.909 < 0.001 0.929 < 0.001
NDA Retinal 
Screen 0.683 < 0.001 0.760 < 0.001 0.819 < 0.001 0.852 < 0.001 0.874 < 0.001
NDA Smoking 
Status 0.824 < 0.001 0.936 0.003 0.977 0.236 1.000 0.989 1.024 0.142
NDA Urinary 
Albumin 0.782 < 0.001 0.886 < 0.001 0.934 0.001 0.965 0.061 0.991 0.585
Table 62. Results from multiple-variable zero-inflated negative binomial regression of total NDA
processes achieved and individual NDA processes against emergency admissions.
Results denote separate models for each QOF indicator(s) and follow-up period; all models also adjusted, but
coeﬃcients not shown, for diabetes type, gender, years post-diabetes diagnosis, age group, IMD fifth, smoking
status and co-morbidity grouping.
IRR = Incidence rate ratio; NDA = National Diabetes Audit; BMI = Body mass index; BP = Blood pressure;
HbA1c = Glycated haemoglobin; TC = Total cholesterol
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In addition to the multiple-variable models that examined QOF indicators or NDA
process in isolation, full models were run that included all predictors of interest
(Tables 63 – 66). The findings of these full models, where the eﬀect of individual
quality measures will have been adjusted for the eﬀects of attainment of others
amongst all other predictors of interest, diverged somewhat from the previous
multiple-variable analysis with respect to some indicators and processes.
Attainment of DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) in 2005/06 maintained a
significantly protective association with respect to emergency admission rates
across all follow-up periods in all fully-adjusted models, albeit with some
attenuation of eﬀect (IRR 0.868 – 0.924). DM12 (BP ≤ 145/85) was no longer
associated with a protective eﬀect with respect to emergency admissions in the full
models and instead was associated with an increased emergency admission rate
for the first two years of follow-up (IRR 1.054 – 1.123). The associations observed
for DM17 (TC ≤ 5.0 mmol/L) and attainment of all selected QOF indicators in the
fully-adjusted models were similar in nature to those observed in the previous
multiple-variable analysis, albeit only statistically significant for follow-up periods of
two to five years with some attenuation of eﬀect (IRR 0.901 – 0.939 and IRR 0.891 –
0.936 respectively).
Associations between the receipt of a number of NDA care processes in
2005/06 in the fully-adjusted model were similar to those observed in the previous
multiple-variable analysis for BMI checks, cholesterol checks, foot checks and
retinal screening. The associations observed between emergency admission rates
and receipt of the NDA BP check and creatinine check were reversed in comparison
to the previous multiple-variable models, with receipt of these processes being
associated with an increased emergency admission rate in the fully-adjusted
analysis (IRR 1.189 – 1.557 and IRR 1.190 – 1.483 respectively). Receipt of the
urinary albumin check care process was associated with an increased emergency
admission rate in the fifth year of follow-up (IRR 1.040 – 1.044) and no significant
associations between the NDA HbA1c check and emergency admissions were
observed in the fully-adjusted model.
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Associations in the fully-adjusted models between the total number of NDA care
processes received in 2005/06 and emergency admission rates were broadly similar
to those observed in the previous multiple-variable analysis for the first three years
of follow-up, with receipt of four or fewer care processes being associated with
increased emergency admission rates (IRR 1.167 – 1.745) and receipt of seven or
more care processes having an association with decreased admission rates (IRR
0.459 – 0.910) in comparison to receiving no care processes.
In the fully-adjusted model utilising achievement of individual QOF indicators,
the protective associations with decreased emergency admission rates for patients
achieving seven or more NDA care processes became, for the most part,
insignificant. Associations between the number of NDA care processes achieved for
the fully-adjusted model utilising achievement of all three selected QOF indicators
were broadly compatible with those from the partially adjusted multiple-variable
models.
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.868 0.016 0.813 < 0.001 0.819 < 0.001 0.835 < 0.001 0.850 < 0.001
Years With DM 1.004 0.023 1.004 0.002 1.005 < 0.001 1.004 0.001 1.004 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.005 0.869 1.036 0.101 1.032 0.080 1.025 0.121 1.027 0.069
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.160 0.380 1.018 0.879 1.060 0.545 1.034 0.690 0.971 0.701
45 – 64y 1.082 0.638 0.967 0.775 0.982 0.852 0.968 0.696 0.935 0.380
65 – 74y 1.157 0.389 1.077 0.531 1.094 0.351 1.084 0.344 1.044 0.580
≥ 75y 1.190 0.303 1.178 0.163 1.287 0.009 1.328 0.001 1.307 0.001
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.833 < 0.001 0.817 < 0.001 0.819 < 0.001 0.838 < 0.001 0.839 < 0.001
3 0.799 < 0.001 0.753 < 0.001 0.754 < 0.001 0.766 < 0.001 0.785 < 0.001
4 0.795 < 0.001 0.743 < 0.001 0.742 < 0.001 0.753 < 0.001 0.759 < 0.001
5 0.767 < 0.001 0.715 < 0.001 0.707 < 0.001 0.707 < 0.001 0.710 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.225 < 0.001 1.320 < 0.001 1.327 < 0.001 1.317 < 0.001 1.316 < 0.001
CCI = 2 1.412 < 0.001 1.483 < 0.001 1.478 < 0.001 1.449 < 0.001 1.404 < 0.001
CCI = 3 1.703 < 0.001 1.874 < 0.001 1.765 < 0.001 1.705 < 0.001 1.648 < 0.001
CCI ≥ 4 1.957 < 0.001 2.067 < 0.001 1.969 < 0.001 1.869 < 0.001 1.746 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.022 0.558 1.066 0.020 1.071 0.003 1.069 0.002 1.044 0.027
Current 
Smoker 1.089 0.100 1.148 < 0.001 1.142 < 0.001 1.147 < 0.001 1.149 < 0.001
Unknown 1.026 0.652 1.203 < 0.001 1.294 < 0.001 1.338 < 0.001 1.334 < 0.001
QOF 
Indicator 
Achievement
DM06 0.922 0.001 0.878 < 0.001 0.878 < 0.001 0.873 < 0.001 0.868 < 0.001
DM12 1.123 < 0.001 1.058 0.005 1.025 0.153 0.984 0.323 0.972 0.052
DM17 0.984 0.589 0.939 0.006 0.920 < 0.001 0.912 < 0.001 0.917 < 0.001
Individual 
NDA 
Processes
BMI 
Check 0.625 < 0.001 0.675 < 0.001 0.730 < 0.001 0.768 < 0.001 0.797 < 0.001
BP Check 1.496 < 0.001 1.424 < 0.001 1.326 < 0.001 1.279 < 0.001 1.236 < 0.001
TC Check 0.626 < 0.001 0.765 < 0.001 0.833 < 0.001 0.877 < 0.001 0.904 0.001
Creatinine
Check 1.483 < 0.001 1.382 < 0.001 1.321 < 0.001 1.263 < 0.001 1.220 < 0.001
Foot 
Check 0.680 < 0.001 0.779 < 0.001 0.835 < 0.001 0.869 < 0.001 0.895 < 0.001
HbA1c 
Check 0.967 0.220 0.964 0.087 0.964 0.044 0.969 0.058 0.979 0.166
Retinal 
Screen 0.784 < 0.001 0.820 < 0.001 0.865 < 0.001 0.888 < 0.001 0.902 < 0.001
Smoking 
Status 
Check
1.101 0.002 1.122 < 0.001 1.117 < 0.001 1.117 < 0.001 1.124 < 0.001
Urinary 
Albumin 0.940 0.054 0.993 0.788 1.011 0.619 1.029 0.136 1.044 0.016
Table 63. Results from full multiple-variable zero-inflated negative binomial regression of patient
characteristics, QOF indicators achieved and individual NDA processes received against emergency
admissions.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National
Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.851 0.006 0.799 < 0.001 0.805 < 0.001 0.824 < 0.001 0.840 < 0.001
Years With DM 1.005 0.011 1.005 < 0.001 1.005 < 0.001 1.004 < 0.001 1.004 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.003 0.933 1.037 0.090 1.035 0.055 1.029 0.071 1.030 0.043
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.160 0.382 1.022 0.853 1.066 0.508 1.042 0.625 0.979 0.779
45 – 64y 1.081 0.645 0.964 0.757 0.981 0.845 0.969 0.707 0.938 0.398
65 – 74y 1.150 0.409 1.060 0.623 1.078 0.436 1.069 0.432 1.032 0.683
≥ 75y 1.181 0.324 1.157 0.215 1.264 0.015 1.306 0.002 1.287 0.001
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.831 < 0.001 0.817 < 0.001 0.820 < 0.001 0.839 < 0.001 0.840 < 0.001
3 0.798 < 0.001 0.754 < 0.001 0.755 < 0.001 0.766 < 0.001 0.785 < 0.001
4 0.793 < 0.001 0.741 < 0.001 0.742 < 0.001 0.753 < 0.001 0.759 < 0.001
5 0.765 < 0.001 0.715 < 0.001 0.706 < 0.001 0.706 < 0.001 0.709 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.232 < 0.001 1.325 < 0.001 1.333 < 0.001 1.324 < 0.001 1.322 < 0.001
CCI = 2 1.415 < 0.001 1.482 < 0.001 1.480 < 0.001 1.450 < 0.001 1.405 < 0.001
CCI = 3 1.721 < 0.001 1.888 < 0.001 1.777 < 0.001 1.717 < 0.001 1.661 < 0.001
CCI ≥ 4 1.974 < 0.001 2.074 < 0.001 1.973 < 0.001 1.870 < 0.001 1.746 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.024 0.521 1.067 0.017 1.072 0.003 1.068 0.002 1.043 0.029
Current 
Smoker 1.095 0.082 1.153 < 0.001 1.148 < 0.001 1.152 < 0.001 1.153 < 0.001
Unknown 1.027 0.649 1.214 < 0.001 1.311 < 0.001 1.360 < 0.001 1.357 < 0.001
All Selected QOF 
Indicators 0.999 0.971 0.936 0.002 0.924 < 0.001 0.902 < 0.001 0.891 < 0.001
Individual 
NDA 
Processes
BMI 
Check 0.625 < 0.001 0.673 < 0.001 0.728 < 0.001 0.766 < 0.001 0.795 < 0.001
BP Check 1.557 < 0.001 1.429 < 0.001 1.309 < 0.001 1.238 < 0.001 1.189 < 0.001
TC Check 0.621 < 0.001 0.749 < 0.001 0.810 < 0.001 0.852 < 0.001 0.881 < 0.001
Creatinine
Check 1.472 < 0.001 1.356 < 0.001 1.294 < 0.001 1.233 < 0.001 1.190 < 0.001
Foot 
Check 0.680 < 0.001 0.777 < 0.001 0.832 < 0.001 0.866 < 0.001 0.892 < 0.001
HbA1c 
Check 0.963 0.164 0.957 0.037 0.956 0.014 0.961 0.015 0.971 0.054
Retinal 
Screen 0.784 < 0.001 0.819 < 0.001 0.863 < 0.001 0.886 < 0.001 0.901 < 0.001
Smoking 
Status 
Check
1.101 0.002 1.121 < 0.001 1.115 < 0.001 1.114 < 0.001 1.121 < 0.001
Urinary 
Albumin 0.938 0.046 0.990 0.675 1.007 0.732 1.026 0.185 1.040 0.026
Table 64. Results from full multiple-variable zero-inflated negative binomial regression of patient
characteristics, attainment of all three selected QOF indicators and individual NDA processes
received against emergency admissions.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National
Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.868 0.016 0.817 < 0.001 0.822 < 0.001 0.837 < 0.001 0.851 < 0.001
Years With DM 1.004 0.031 1.004 0.004 1.005 < 0.001 1.004 0.001 1.004 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.989 0.705 1.025 0.250 1.026 0.154 1.021 0.201 1.023 0.114
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.207 0.267 1.076 0.531 1.097 0.337 1.062 0.481 0.995 0.947
45 – 64y 1.155 0.392 1.054 0.651 1.036 0.708 1.012 0.889 0.970 0.695
65 – 74y 1.259 0.174 1.193 0.134 1.171 0.103 1.146 0.110 1.096 0.235
≥ 75y 1.296 0.123 1.321 0.018 1.384 0.001 1.412 < 0.001 1.377 < 0.001
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.832 < 0.001 0.813 < 0.001 0.816 < 0.001 0.834 < 0.001 0.833 < 0.001
3 0.810 < 0.001 0.757 < 0.001 0.757 < 0.001 0.766 < 0.001 0.784 < 0.001
4 0.791 < 0.001 0.740 < 0.001 0.740 < 0.001 0.751 < 0.001 0.757 < 0.001
5 0.757 < 0.001 0.707 < 0.001 0.699 < 0.001 0.700 < 0.001 0.703 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.243 < 0.001 1.327 < 0.001 1.336 < 0.001 1.323 < 0.001 1.319 < 0.001
CCI = 2 1.443 < 0.001 1.501 < 0.001 1.500 < 0.001 1.465 < 0.001 1.415 < 0.001
CCI = 3 1.735 < 0.001 1.891 < 0.001 1.791 < 0.001 1.726 < 0.001 1.665 < 0.001
CCI ≥ 4 1.998 < 0.001 2.096 < 0.001 2.009 < 0.001 1.906 < 0.001 1.775 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.156 < 0.001 1.193 < 0.001 1.178 < 0.001 1.164 < 0.001 1.131 < 0.001
Current 
Smoker 1.286 < 0.001 1.338 < 0.001 1.295 < 0.001 1.284 < 0.001 1.276 < 0.001
Unknown 1.115 0.057 1.307 < 0.001 1.377 < 0.001 1.408 < 0.001 1.397 < 0.001
QOF 
Indicator 
Achievement
DM06 0.924 0.002 0.880 < 0.001 0.881 < 0.001 0.876 < 0.001 0.871 < 0.001
DM12 1.111 < 0.001 1.054 0.009 1.027 0.135 0.988 0.461 0.976 0.098
DM17 0.947 0.058 0.918 < 0.001 0.906 < 0.001 0.901 < 0.001 0.909 < 0.001
NDA 
Processes 
Received
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.453 < 0.001 1.298 < 0.001 1.185 0.001 1.090 0.071 1.048 0.302
2 1.702 < 0.001 1.480 < 0.001 1.335 < 0.001 1.253 < 0.001 1.195 < 0.001
3 1.439 < 0.001 1.399 < 0.001 1.280 < 0.001 1.215 < 0.001 1.181 < 0.001
4 1.354 < 0.001 1.412 < 0.001 1.331 < 0.001 1.275 < 0.001 1.257 < 0.001
5 0.935 0.197 1.099 0.024 1.103 0.008 1.108 0.002 1.110 0.001
6 0.714 < 0.001 0.911 0.014 0.973 0.408 1.013 0.665 1.034 0.235
7 0.611 < 0.001 0.812 < 0.001 0.910 0.005 0.963 0.215 1.004 0.887
8 0.582 < 0.001 0.784 < 0.001 0.866 < 0.001 0.932 0.049 0.989 0.729
9 0.463 < 0.001 0.695 < 0.001 0.836 0.005 0.913 0.111 0.971 0.572
Table 65. Results from full multiple-variable zero-inflated negative binomial regression of patient
characteristics, QOF indicators achieved and total number of NDA processes received against
emergency admissions.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National
Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.853 0.007 0.803 < 0.001 0.808 < 0.001 0.825 < 0.001 0.840 < 0.001
Years With DM 1.005 0.016 1.005 0.001 1.005 < 0.001 1.004 < 0.001 1.004 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.989 0.726 1.028 0.195 1.030 0.098 1.025 0.115 1.027 0.068
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.210 0.261 1.083 0.499 1.104 0.304 1.068 0.441 1.000 0.996
45 – 64y 1.153 0.397 1.049 0.678 1.034 0.727 1.008 0.921 0.968 0.667
65 – 74y 1.246 0.193 1.170 0.181 1.150 0.147 1.125 0.168 1.078 0.332
≥ 75y 1.282 0.140 1.293 0.028 1.356 0.002 1.382 < 0.001 1.349 < 0.001
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.830 < 0.001 0.812 < 0.001 0.817 < 0.001 0.835 < 0.001 0.834 < 0.001
3 0.809 < 0.001 0.757 < 0.001 0.758 < 0.001 0.767 < 0.001 0.784 < 0.001
4 0.790 < 0.001 0.739 < 0.001 0.740 < 0.001 0.751 < 0.001 0.757 < 0.001
5 0.755 < 0.001 0.707 < 0.001 0.698 < 0.001 0.699 < 0.001 0.702 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.249 < 0.001 1.332 < 0.001 1.341 < 0.001 1.330 < 0.001 1.326 < 0.001
CCI = 2 1.447 < 0.001 1.500 < 0.001 1.501 < 0.001 1.466 < 0.001 1.416 < 0.001
CCI = 3 1.752 < 0.001 1.904 < 0.001 1.802 < 0.001 1.738 < 0.001 1.677 < 0.001
CCI ≥ 4 2.009 < 0.001 2.100 < 0.001 2.012 < 0.001 1.906 < 0.001 1.775 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.158 < 0.001 1.196 < 0.001 1.179 < 0.001 1.164 < 0.001 1.131 < 0.001
Current 
Smoker 1.293 < 0.001 1.346 < 0.001 1.304 < 0.001 1.291 < 0.001 1.282 < 0.001
Unknown 1.120 0.048 1.321 < 0.001 1.394 < 0.001 1.428 < 0.001 1.416 < 0.001
All Selected QOF 
Indicators 0.993 0.784 0.936 0.001 0.924 < 0.001 0.902 < 0.001 0.891 < 0.001
NDA 
Processes 
Received
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.485 < 0.001 1.289 < 0.001 1.167 0.003 1.058 0.233 1.015 0.745
2 1.745 < 0.001 1.455 < 0.001 1.290 < 0.001 1.185 < 0.001 1.124 0.010
3 1.448 < 0.001 1.340 < 0.001 1.205 < 0.001 1.119 0.009 1.083 0.048
4 1.353 < 0.001 1.335 < 0.001 1.235 < 0.001 1.158 < 0.001 1.139 < 0.001
5 0.928 0.111 1.030 0.427 1.015 0.650 0.997 0.913 0.997 0.913
6 0.708 < 0.001 0.853 < 0.001 0.892 < 0.001 0.908 < 0.001 0.926 0.002
7 0.605 < 0.001 0.758 < 0.001 0.833 < 0.001 0.861 < 0.001 0.896 < 0.001
8 0.575 < 0.001 0.729 < 0.001 0.789 < 0.001 0.831 < 0.001 0.880 < 0.001
9 0.459 < 0.001 0.648 < 0.001 0.763 < 0.001 0.813 < 0.001 0.864 0.004
Table 66. Results from full multiple-variable zero-inflated negative binomial regression of patient
characteristics, attainment of all three selected QOF indicators and total number of NDA processes
received against emergency admissions.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National
Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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Quality of Primary Care Diabetes Management and 
Readmissions
The same patients that were eligible for the emergency admissions analysis
were eligible for this analysis; their characteristics, QOF attainment and NDA
process receipt are described in Table 56, Table 57 and Table 58 respectively. The
vast majority of patients diagnosed with diabetes by 1st April 2005 experienced no
readmissions over all lengths of follow up, with 58,492 (86.12%) not experiencing a
readmission over the longest follow-up period (Table 67).
2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
Mean 0.060 0.118 0.175 0.237 0.300
Zero Readmissions
n 65,528 63,626 61,884 60,084 58,492
% 96.48% 93.68% 91.11% 88.46% 86.12%
Table 67. Readmissions from individuals with diabetes by 1st April 2005 by follow-up period.
All zero-inflated negative binomial models presented in this section exhibited a
significantly superior fit in comparison to Poisson and standard negative binomial
models (p < 0.001 for both).
Univariate analyses of all predictor variables indicated that increased
readmission rates across all lengths of follow-up were associated with T1DM and
increasing deprivation. Increasing time with diabetes was associated with increased
readmission rates for follow-up periods of 2 years and longer; patients in the
highest co-morbidity group experienced an increased rate of readmissions across
all years. Paradoxically, individuals in the older age groups, relative to the youngest,
generally experienced fewer readmissions for follow-up periods of 2 years and
longer (Table 68).
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Achievement of DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) and DM17 (TC ≤ 5.0
mmol/L) in 2005/06 were associated with reduced readmission rates across all
follow-up periods in univariate analyses, whereas achievement of DM12 (BP ≤
145/85) in 2005/06 was associated with reduced admission rates over follow-up
periods longer than two years. As with the univariate analyses of emergency
admission counts, achievement of all three QOF targets in 2005/06 did not seem to
confer additional benefits with respect to readmissions (Table 68).
The total number of NDA processes achieved in 2005/06 exhibited a similar
relationship to that observed with emergency admission rates in univariate analyses
of readmissions, insofar as associations between patients achieving 6 or more
processes and reduced rates of readmissions was concerned across all follow-up
periods. Receiving any of the individual care processes in 2005/06 was generally
protective of readmissions across all follow-up periods, with the exception of
receiving a smoking status review in 2005/06 and readmissions occurring over the
longest follow-up period (Table 68).
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2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.692 0.004 0.612 < 0.001 0.565 < 0.001 0.572 < 0.001 0.611 < 0.001
Years With DM 1.002 0.563 1.006 0.045 1.008 0.003 1.007 0.001 1.007 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.995 0.950 1.062 0.236 1.081 0.059 1.037 0.304 1.024 0.452
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.762 0.547 0.818 0.512 0.880 0.610 0.892 0.597 0.865 0.453
45 – 64y 0.526 0.139 0.510 0.022 0.525 0.008 0.528 0.002 0.523 < 0.001
65 – 74y 0.432 0.052 0.455 0.007 0.450 0.001 0.446 < 0.001 0.451 < 0.001
≥ 75y 0.441 0.056 0.421 0.003 0.449 0.001 0.464 < 0.001 0.455 < 0.001
Deprivation
Fifth 
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.789 0.026 0.822 0.011 0.792 < 0.001 0.817 < 0.001 0.800 < 0.001
3 0.731 0.005 0.668 < 0.001 0.679 < 0.001 0.700 < 0.001 0.702 < 0.001
4 0.794 0.042 0.708 < 0.001 0.662 < 0.001 0.698 < 0.001 0.723 < 0.001
5 0.646 < 0.001 0.649 < 0.001 0.637 < 0.001 0.657 < 0.001 0.669 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.087 0.396 1.263 0.001 1.256 < 0.001 1.298 < 0.001 1.266 < 0.001
CCI = 2 1.067 0.553 1.133 0.106 1.129 0.054 1.184 0.002 1.169 0.001
CCI = 3 1.232 0.115 1.332 0.003 1.347 < 0.001 1.384 < 0.001 1.406 < 0.001
CCI ≥ 4 1.559 0.002 1.660 < 0.001 1.672 < 0.001 1.636 < 0.001 1.587 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.059 0.499 1.151 0.017 1.129 0.012 1.110 0.011 1.100 0.009
Current 
Smoker 1.044 0.704 1.214 0.015 1.158 0.025 1.111 0.057 1.180 0.001
Unknown 1.384 0.017 1.500 < 0.001 1.582 < 0.001 1.614 < 0.001 1.662 < 0.001
DM06 (HbA1c ≤ 7.4% / 
57.4 mmol/mol) 0.729 < 0.001 0.710 < 0.001 0.730 < 0.001 0.732 < 0.001 0.743 < 0.001
DM12 (BP ≤ 145/85) 0.955 0.371 0.949 < 0.001 0.898 0.001 0.863 < 0.001 0.864 < 0.001
DM17 (TC ≤ 5.0 mmol/L) 0.690 < 0.001 0.764 < 0.001 0.764 < 0.001 0.760 < 0.001 0.777 < 0.001
DM06 + DM12 + DM17 0.796 < 0.001 0.806 < 0.001 0.816 < 0.001 0.796 < 0.001 0.799 < 0.001
(continued on next page...)
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2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
Number of 
NDA 
Processes 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.339 0.051 1.100 0.431 0.962 0.715 0.840 0.064 0.816 0.020
2 1.446 0.013 1.212 0.110 0.978 0.837 0.845 0.075 0.803 0.013
3 1.324 0.038 1.232 0.055 1.078 0.427 0.992 0.928 0.979 0.789
4 1.431 0.002 1.330 0.002 1.150 0.084 1.021 0.774 0.964 0.583
5 0.747 0.003 0.863 0.056 0.816 0.002 0.789 < 0.001 0.765 < 0.001
6 0.574 < 0.001 0.714 < 0.001 0.699 < 0.001 0.684 < 0.001 0.685 < 0.001
7 0.460 < 0.001 0.613 < 0.001 0.648 < 0.001 0.661 < 0.001 0.696 < 0.001
8 0.359 < 0.001 0.494 < 0.001 0.537 < 0.001 0.563 < 0.001 0.602 < 0.001
9 0.290 < 0.001 0.417 < 0.001 0.470 < 0.001 0.475 < 0.001 0.517 < 0.001
NDA BMI 0.432 < 0.001 0.569 < 0.001 0.625 < 0.001 0.666 < 0.001 0.702 < 0.001
NDA BP 0.617 < 0.001 0.728 < 0.001 0.729 < 0.001 0.734 < 0.001 0.741 < 0.001
NDA Cholesterol 0.495 < 0.001 0.656 < 0.001 0.695 < 0.001 0.715 < 0.001 0.738 < 0.001
NDA Creatinine 0.641 < 0.001 0.749 < 0.001 0.763 < 0.001 0.765 < 0.001 0.779 < 0.001
NDA Foot 0.455 < 0.001 0.599 < 0.001 0.659 < 0.001 0.696 < 0.001 0.724 < 0.001
NDA HbA1c 0.684 < 0.001 0.766 < 0.001 0.791 < 0.001 0.796 < 0.001 0.825 < 0.001
NDA Retinal Screen 0.575 < 0.001 0.661 < 0.001 0.736 < 0.001 0.770 < 0.001 0.795 < 0.001
NDA Smoking Status 0.786 < 0.001 0.906 0.018 0.922 0.022 0.935 0.029 0.971 0.289
NDA Urinary Albumin 0.674 < 0.001 0.789 < 0.001 0.832 < 0.001 0.869 < 0.001 0.889 0.001
Table 68. Results, by follow-up period, of univariate zero-inflated negative binomial regression
modelling of readmission counts.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA
= National Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC =
Total cholesterol
Multiple-variable analysis of attainment of QOF targets in 2005/06 in isolation
indicated that reaching the targets for DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) and
DM17 (TC ≤ 5.0 mmol/L) were protective of readmissions across all follow-up
periods; the benefits of attaining DM12 (BP ≤145/85) did not demonstrate a
significant association with reduced readmission rates until the follow-up period
was extended to three or more years. Attaining all three selected QOF targets in
2005/06 did not appear to confer improved benefits versus attainment of single
targets across all follow-up periods. As expected, associations of QOF target
achievement with reduced admission rates experienced some dilution with
increasing follow-up period (Table 69, full regression tables available in
Appendices).
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2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM06 (HbA1c ≤ 7.4%
/ 57.4 mmol/mol) 0.752 < 0.001 0.753 < 0.001 0.791 < 0.001 0.795 < 0.001 0.811 < 0.001
DM12 (BP ≤ 145/85) 0.976 0.640 0.981 0.631 0.950 0.125 0.916 0.003 0.922 0.003
DM17 (TC ≤ 5.0 
mmol/L) 0.703 < 0.001 0.804 < 0.001 0.826 < 0.001 0.826 < 0.001 0.851 < 0.001
DM06 + DM12 + 
DM17 0.816 < 0.001 0.845 < 0.001 0.876 < 0.001 0.855 < 0.001 0.861 < 0.001
Table 69. Results from multiple-variable zero-inflated negative binomial regression of selected QOF
indicators against readmissions.
Results denote separate models for each QOF indicator(s) and follow-up period; all models also adjusted, but
coeﬃcients not shown, for diabetes type, gender, years post-diabetes diagnosis, age group, IMD fifth, smoking
status and co-morbidity grouping.
IRR = Incidence rate ratio; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
Associations between receiving NDA processes of care in 2005/06 and
emergency admission rates in multiple-variable analysis were similar to those
observed in univariate analysis. Receiving 6 – 9 processes was associated with
decreased emergency admission rates, with evidence of a dose-response
relationship between increasing process attainment and decreasing emergency
admission rates.
For readmissions occurring in 2005/06, receiving 1 – 4 NDA processes in
2005/06 was associated with increased readmission rates. Receipt of the NDA care
processes pertaining to cholesterol checks, creatinine checks, foot checks, HbA1c
measurement and retinopathy screening in 2005/06 were significantly associated
with decreased readmission rates across all follow-up periods, with the greatest
benefits associated with BMI and foot checks; review of smoking status in 2005/06
was associated with decreased readmission rates for up to two years of follow-up
and checking of urinary albumin in 2005/06 was associated with decreased
emergency admission rates for up to four years of follow-up. As expected,
associations of receiving NDA care processes in 2005/06 with readmission rates
experienced some dilution with increasing follow-up period (Table 70, full regression
tables available in Appendices).
- 164 -
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
Number of 
NDA 
Processes 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.374 0.036 1.156 0.237 1.054 0.620 0.915 0.349 0.879 0.146
2 1.501 0.007 1.262 0.055 1.055 0.620 0.926 0.422 0.896 0.221
3 1.420 0.011 1.358 0.005 1.202 0.054 1.106 0.238 1.095 0.248
4 1.496 0.001 1.427 < 0.001 1.272 0.004 1.138 0.080 1.086 0.231
5 0.782 0.016 0.930 0.357 0.920 0.222 0.900 0.079 0.886 0.031
6 0.590 < 0.001 0.767 < 0.001 0.785 < 0.001 0.780 < 0.001 0.797 < 0.001
7 0.464 < 0.001 0.638 < 0.001 0.721 < 0.001 0.746 < 0.001 0.796 < 0.001
8 0.354 < 0.001 0.506 < 0.001 0.594 < 0.001 0.635 < 0.001 0.688 < 0.001
9 0.291 < 0.001 0.446 < 0.001 0.526 < 0.001 0.551 < 0.001 0.603 < 0.001
NDA BMI 0.429 < 0.001 0.571 < 0.001 0.652 < 0.001 0.705 < 0.001 0.753 < 0.001
NDA BP 0.639 < 0.001 0.781 < 0.001 0.816 < 0.001 0.836 < 0.001 0.854 < 0.001
NDA Cholesterol 0.500 < 0.001 0.682 < 0.001 0.750 < 0.001 0.784 < 0.001 0.823 < 0.001
NDA Creatinine 0.658 < 0.001 0.798 < 0.001 0.845 < 0.001 0.860 < 0.001 0.890 0.001
NDA Foot 0.453 < 0.001 0.607 < 0.001 0.692 < 0.001 0.742 < 0.001 0.778 < 0.001
NDA HbA1c 0.697 < 0.001 0.792 < 0.001 0.838 < 0.001 0.847 < 0.001 0.884 < 0.001
NDA Retinal Screen 0.590 < 0.001 0.684 < 0.001 0.778 < 0.001 0.815 < 0.001 0.840 < 0.001
NDA Smoking Status 0.763 < 0.001 0.882 0.007 0.926 0.055 0.956 0.205 0.998 0.946
NDA Urinary Albumin 0.673 < 0.001 0.815 < 0.001 0.873 0.002 0.921 0.031 0.946 0.111
Table 70. Results from multiple-variable zero-inflated negative binomial regression of total NDA
processes achieved and individual NDA processes against readmissions.
Results denote separate models for each NDA process / count and follow-up period; all models also adjusted,
but coeﬃcients not shown, for diabetes type, gender, years post-diabetes diagnosis, age group, IMD fifth,
smoking status and co-morbidity grouping.
IRR = Incidence rate ratio; NDA = National Diabetes Audit; BMI = Body mass index; BP = Blood pressure;
HbA1c = Glycated haemoglobin
In addition to the multiple-variable models run for each QOF indicator or NDA
process in isolation, full models were run that included all predictors of interest
(Tables 71 – 74). The findings of these full models, where the eﬀect of individual
quality measures will have been adjusted for the eﬀects of attainment of others
amongst all other predictors of interest, diverged somewhat from the previous
multiple-variable analysis with respect to some indicators and processes but were
broadly similar to the changes in eﬀect size and direction that were observed for the
models examining emergency admission rates (see previous section, pages 145-
159).
Attainment of DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) in 2005/06 maintained a
significantly protective association with respect to readmission rates across all
follow-up periods in all fully-adjusted models (IRR 0.803 – 0.872). DM12 (BP ≤
145/85) was no longer associated with a protective eﬀect with respect to
readmissions in the fully-adjusted models and instead was associated with an
increased emergency admission rate for the first two years of follow-up (IRR 1.103 –
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1.194). DM17 (TC ≤ 5.0 mmol/L) exhibited a statistically significant protective eﬀect
for follow-up periods of four and five years (IRR 0.920 – 0.927) in the fully-adjusted
model utilising the count of NDA processes received, but not for the model utilising
receipt of individual NDA care processes. Attainment of all selected QOF indicators
was associated with reductions in readmissions for the fourth and fifth years of
follow-up in all fully-adjusted models (IRR 0.900 – 0.905).
Associations between the receipt of a number of individual NDA care processes
in 2005/06 in the fully-adjusted model were similar to those observed in the
previous multiple-variable analysis for BMI checks, cholesterol checks, foot checks
and retinal screening. The associations observed between readmission rates and
receipt of the NDA BP check, creatinine check and smoking status check were
reversed in comparison to the previous multiple-variable models, with receipt of
these processes being associated with an increased readmission rate in the fully-
adjusted models (IRR 1.168 – 1.502, IRR 1.229 – 1.548 and IRR 1.120 – 1.171
respectively). Receipt of the urinary albumin check care process was not associated
with significant changes in readmission rates across any length of follow-up. Some
significant associations between the NDA HbA1c check and reduced readmission
rates were observed; patients receiving this care process exhibited reduced
readmission rates for follow-up periods of two to four years in the fully-adjusted
model utilising achievement of all three QOF indicators (IRR 0.908 – 0.925), but was
only significantly associated with reduced readmission rates in the fourth year of
follow-up in the model utilising achievement of individual QOF indicators (IRR =
0.929).
Associations in the fully-adjusted models between the total number of NDA care
processes received in 2005/06 and readmission rates were broadly similar to those
observed in the previous multiple-variable analysis insofar as receipt of six or more
NDA care processes being associated with reduced readmission rates for the first
three years of follow-up in the model utilising individual QOF indicators versus
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receiving no care processes (OR 0.286 – 0.862). Significant reductions in
emergency admission rates were observed for receipt of seven or more or eight or
more care processes versus receipt of no care process were observed only for
follow-up periods of four and five years in the fully-adjusted model utilising
individual QOF indicators (IRR 0.650 – 0.867 and IRR 0.706 – 0.798 respectively).
Associations between the number of NDA care processes achieved for the fully-
adjusted model utilising achievement of all three selected QOF indicators
consistently showed associations between receipt of six or more NDA care
processes in 2005/06 across all years of follow-up (IRR 0.291 – 0.822).
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.837 0.206 0.769 0.009 0.728 < 0.001 0.753 < 0.001 0.808 0.002
Years With DM 1.001 0.824 1.003 0.345 1.003 0.330 1.001 0.551 1.002 0.371
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.944 0.437 1.013 0.811 1.028 0.522 0.977 0.521 0.989 0.727
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.921 0.865 1.032 0.922 1.212 0.465 1.185 0.453 1.080 0.703
45 – 64y 0.629 0.335 0.683 0.234 0.833 0.484 0.792 0.297 0.728 0.113
65 – 74y 0.530 0.188 0.646 0.175 0.749 0.272 0.708 0.126 0.661 0.039
≥ 75y 0.478 0.125 0.545 0.059 0.703 0.180 0.704 0.119 0.648 0.031
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.951 0.632 0.879 0.089 0.829 0.003 0.844 0.001 0.829 < 0.001
3 0.825 0.080 0.700 < 0.001 0.701 < 0.001 0.732 < 0.001 0.736 < 0.001
4 0.953 0.676 0.795 0.004 0.729 < 0.001 0.738 < 0.001 0.759 < 0.001
5 0.757 0.020 0.737 < 0.001 0.701 < 0.001 0.697 < 0.001 0.708 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.040 0.684 1.233 0.002 1.209 < 0.001 1.275 < 0.001 1.271 < 0.001
CCI = 2 1.076 0.502 1.249 0.005 1.234 0.001 1.309 < 0.001 1.305 < 0.001
CCI = 3 1.346 0.023 1.477 < 0.001 1.484 < 0.001 1.519 < 0.001 1.568 < 0.001
CCI ≥ 4 1.561 0.002 1.740 < 0.001 1.755 < 0.001 1.735 < 0.001 1.719 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.011 0.905 1.130 0.060 1.108 0.057 1.081 0.095 1.058 0.175
Current 
Smoker 0.870 0.250 1.008 0.929 0.965 0.624 0.936 0.286 0.998 0.972
Unknown 1.032 0.824 1.265 0.020 1.344 < 0.001 1.365 < 0.001 1.416 < 0.001
QOF 
Indicator 
Achievement
DM06 0.867 0.009 0.803 < 0.001 0.834 < 0.001 0.835 < 0.001 0.841 < 0.001
DM12 1.194 0.002 1.107 0.018 1.035 0.349 0.982 0.569 0.978 0.455
DM17 1.025 0.702 0.993 0.887 0.964 0.384 0.933 0.060 0.938 0.057
NDA Process
BMI 
Check 0.532 < 0.001 0.601 < 0.001 0.666 < 0.001 0.717 < 0.001 0.767 < 0.001
BP Check 1.399 0.001 1.388 < 0.001 1.274 0.001 1.253 0.001 1.168 0.012
TC Check 0.615 < 0.001 0.789 0.002 0.845 0.014 0.880 0.037 0.901 0.069
Creatinine
Check 1.548 < 0.001 1.421 < 0.001 1.357 < 0.001 1.300 < 0.001 1.265 < 0.001
Foot 
Check 0.617 < 0.001 0.738 < 0.001 0.805 < 0.001 0.846 < 0.001 0.860 < 0.001
HbA1c 
Check 0.935 0.263 0.924 0.080 0.938 0.096 0.929 0.029 0.958 0.165
Retinal 
Screen 0.723 < 0.001 0.762 < 0.001 0.843 < 0.001 0.869 < 0.001 0.884 < 0.001
Smoking 
Status 
Check
1.171 0.019 1.130 0.017 1.125 0.007 1.128 0.002 1.151 < 0.001
Urinary 
Albumin 0.877 0.069 0.936 0.212 0.963 0.393 0.999 0.985 1.013 0.725
Table 71. Results from full multiple-variable zero-inflated negative binomial regression of patient
characteristics, QOF indicators achieved and individual NDA processes received against
readmissions.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA
= National Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC =
Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.805 0.124 0.750 0.004 0.711 < 0.001 0.740 < 0.001 0.794 0.001
Years With DM 1.002 0.668 1.004 0.178 1.004 0.182 1.002 0.350 1.003 0.209
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.938 0.391 1.010 0.842 1.030 0.492 0.982 0.625 0.993 0.820
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.932 0.885 1.052 0.876 1.228 0.435 1.202 0.415 1.092 0.662
45 – 64y 0.635 0.346 0.693 0.252 0.844 0.517 0.801 0.322 0.733 0.121
65 – 74y 0.540 0.203 0.650 0.181 0.750 0.273 0.704 0.120 0.656 0.036
≥ 75y 0.483 0.130 0.543 0.057 0.698 0.169 0.694 0.105 0.638 0.025
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.943 0.575 0.875 0.080 0.829 0.003 0.846 0.002 0.830 < 0.001
3 0.823 0.075 0.699 < 0.001 0.703 < 0.001 0.735 < 0.001 0.738 < 0.001
4 0.945 0.619 0.782 0.002 0.726 < 0.001 0.739 < 0.001 0.759 < 0.001
5 0.758 0.020 0.734 < 0.001 0.700 < 0.001 0.697 < 0.001 0.708 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.056 0.577 1.251 0.001 1.225 < 0.001 1.289 < 0.001 1.285 < 0.001
CCI = 2 1.080 0.479 1.258 0.004 1.238 0.001 1.310 < 0.001 1.306 < 0.001
CCI = 3 1.371 0.016 1.501 < 0.001 1.502 < 0.001 1.541 < 0.001 1.590 < 0.001
CCI ≥ 4 1.607 0.001 1.765 < 0.001 1.768 < 0.001 1.739 < 0.001 1.724 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.014 0.875 1.135 0.051 1.109 0.056 1.079 0.103 1.057 0.180
Current 
Smoker 0.871 0.254 1.016 0.857 0.971 0.682 0.939 0.313 1.002 0.971
Unknown 1.025 0.864 1.270 0.018 1.358 < 0.001 1.385 < 0.001 1.438 < 0.001
All Selected QOF 
Indicators 0.999 0.986 0.934 0.121 0.942 0.108 0.906 0.003 0.900 0.001
NDA Process
BMI 
Check 0.531 < 0.001 0.603 < 0.001 0.666 < 0.001 0.718 < 0.001 0.768 < 0.001
BP Check 1.502 < 0.001 1.424 < 0.001 1.267 0.001 1.210 0.003 1.126 0.050
TC Check 0.620 < 0.001 0.790 0.002 0.833 0.006 0.861 0.013 0.886 0.032
Creatinine
Check 1.524 < 0.001 1.379 < 0.001 1.318 < 0.001 1.258 0.001 1.229 0.001
Foot 
Check 0.617 < 0.001 0.734 < 0.001 0.801 < 0.001 0.841 < 0.001 0.855 < 0.001
HbA1c 
Check 0.926 0.197 0.908 0.032 0.925 0.040 0.916 0.009 0.945 0.068
Retinal 
Screen 0.722 < 0.001 0.762 < 0.001 0.841 < 0.001 0.867 < 0.001 0.883 < 0.001
Smoking 
Status 
Check
1.165 0.023 1.126 0.021 1.120 0.010 1.121 0.003 1.143 < 0.001
Urinary 
Albumin 0.874 0.064 0.930 0.175 0.958 0.334 0.994 0.868 1.008 0.829
Table 72. Results from full multiple-variable zero-inflated negative binomial regression of patient
characteristics, achievement of all three selected QOF indicators and individual NDA processes
received against readmissions.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA
= National Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC =
Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.863 0.295 0.796 0.023 0.748 0.001 0.767 < 0.001 0.818 0.003
Years With DM 0.999 0.899 1.002 0.583 1.002 0.394 1.001 0.600 1.002 0.368
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.897 0.146 0.984 0.756 1.012 0.787 0.968 0.367 0.983 0.585
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.876 0.785 1.019 0.953 1.173 0.546 1.158 0.517 1.097 0.647
45 – 64y 0.595 0.278 0.703 0.270 0.823 0.456 0.795 0.306 0.749 0.148
65 – 74y 0.520 0.174 0.672 0.217 0.752 0.279 0.721 0.148 0.691 0.066
≥ 75y 0.458 0.103 0.574 0.083 0.707 0.186 0.718 0.141 0.677 0.052
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.944 0.588 0.886 0.110 0.835 0.004 0.847 0.002 0.826 < 0.001
3 0.850 0.141 0.713 < 0.001 0.713 < 0.001 0.738 < 0.001 0.739 < 0.001
4 0.937 0.572 0.796 0.004 0.728 < 0.001 0.741 < 0.001 0.759 < 0.001
5 0.743 0.013 0.734 < 0.001 0.700 < 0.001 0.697 < 0.001 0.708 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.080 0.425 1.250 0.001 1.226 < 0.001 1.284 < 0.001 1.277 < 0.001
CCI = 2 1.121 0.290 1.259 0.004 1.247 0.001 1.315 < 0.001 1.305 < 0.001
CCI = 3 1.345 0.024 1.482 < 0.001 1.484 < 0.001 1.520 < 0.001 1.573 < 0.001
CCI ≥ 4 1.578 0.002 1.737 < 0.001 1.760 < 0.001 1.739 < 0.001 1.724 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.212 0.027 1.305 < 0.001 1.254 < 0.001 1.209 < 0.001 1.179 < 0.001
Current 
Smoker 1.080 0.508 1.220 0.016 1.128 0.076 1.073 0.220 1.141 0.011
Unknown 1.142 0.342 1.401 0.001 1.447 < 0.001 1.444 < 0.001 1.491 < 0.001
QOF 
Indicator 
Achievement
DM06 0.872 0.012 0.806 < 0.001 0.838 < 0.001 0.837 < 0.001 0.844 < 0.001
DM12 1.168 0.007 1.103 0.023 1.039 0.302 0.992 0.793 0.987 0.662
DM17 0.988 0.850 0.973 0.576 0.946 0.178 0.920 0.021 0.927 0.023
NDA 
Processes 
Received
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.324 0.066 1.156 0.240 1.069 0.531 0.946 0.561 0.906 0.267
2 1.423 0.022 1.254 0.068 1.084 0.461 0.985 0.881 0.957 0.629
3 1.383 0.023 1.394 0.003 1.278 0.013 1.221 0.023 1.207 0.021
4 1.458 0.004 1.498 < 0.001 1.377 < 0.001 1.289 0.001 1.221 0.006
5 0.769 0.022 0.987 0.882 1.008 0.913 1.030 0.665 1.007 0.905
6 0.578 < 0.001 0.810 0.008 0.862 0.030 0.899 0.078 0.911 0.096
7 0.454 < 0.001 0.676 < 0.001 0.796 0.001 0.867 0.019 0.917 0.122
8 0.348 < 0.001 0.541 < 0.001 0.659 < 0.001 0.741 < 0.001 0.798 0.001
9 0.286 < 0.001 0.480 < 0.001 0.590 < 0.001 0.650 < 0.001 0.706 0.001
Table 73. Results from full multiple-variable zero-inflated negative binomial regression of patient
characteristics, QOF indicators achieved and total NDA processes received against readmissions.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA
= National Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC =
Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.835 0.201 0.776 0.012 0.730 < 0.001 0.754 < 0.001 0.803 0.001
Years With DM 1.000 0.948 1.003 0.336 1.003 0.232 1.002 0.399 1.003 0.216
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.895 0.139 0.984 0.754 1.015 0.728 0.974 0.467 0.987 0.679
Age Group
< 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.896 0.821 1.051 0.877 1.196 0.497 1.176 0.474 1.106 0.617
45 – 64y 0.607 0.297 0.720 0.303 0.838 0.498 0.802 0.325 0.751 0.150
65 – 74y 0.532 0.189 0.681 0.232 0.755 0.286 0.716 0.138 0.683 0.058
≥ 75y 0.465 0.110 0.575 0.084 0.703 0.179 0.706 0.123 0.664 0.041
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.935 0.526 0.882 0.100 0.834 0.004 0.848 0.002 0.827 < 0.001
3 0.848 0.135 0.713 < 0.001 0.715 < 0.001 0.740 < 0.001 0.740 < 0.001
4 0.931 0.537 0.785 0.002 0.724 < 0.001 0.741 < 0.001 0.759 < 0.001
5 0.744 0.013 0.732 < 0.001 0.699 < 0.001 0.697 < 0.001 0.707 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.095 0.350 1.267 < 0.001 1.240 < 0.001 1.296 < 0.001 1.288 < 0.001
CCI = 2 1.126 0.273 1.267 0.003 1.251 < 0.001 1.315 < 0.001 1.306 < 0.001
CCI = 3 1.370 0.017 1.505 < 0.001 1.500 < 0.001 1.540 < 0.001 1.593 < 0.001
CCI ≥ 4 1.611 0.001 1.757 < 0.001 1.769 < 0.001 1.742 < 0.001 1.727 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.209 0.029 1.308 < 0.001 1.254 < 0.001 1.206 < 0.001 1.177 < 0.001
Current 
Smoker 1.079 0.516 1.229 0.012 1.134 0.063 1.077 0.200 1.144 0.009
Unknown 1.139 0.354 1.409 0.001 1.463 < 0.001 1.462 < 0.001 1.510 < 0.001
All Selected QOF 
Indicators 0.993 0.911 0.936 0.134 0.942 0.109 0.905 0.002 0.900 < 0.001
NDA 
Processes 
Received
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.375 0.036 1.158 0.231 1.055 0.614 0.916 0.361 0.881 0.153
2 1.501 0.007 1.265 0.053 1.057 0.607 0.930 0.449 0.901 0.248
3 1.421 0.010 1.367 0.004 1.210 0.047 1.117 0.196 1.106 0.200
4 1.498 0.001 1.450 < 0.001 1.289 0.002 1.164 0.041 1.110 0.131
5 0.783 0.018 0.946 0.488 0.934 0.324 0.921 0.179 0.908 0.088
6 0.591 < 0.001 0.780 < 0.001 0.797 < 0.001 0.801 < 0.001 0.819 < 0.001
7 0.465 < 0.001 0.651 < 0.001 0.735 < 0.001 0.770 < 0.001 0.822 < 0.001
8 0.355 < 0.001 0.517 < 0.001 0.606 < 0.001 0.656 < 0.001 0.712 < 0.001
9 0.291 < 0.001 0.460 < 0.001 0.539 < 0.001 0.572 < 0.001 0.627 < 0.001
Table 74. Results from full multiple-variable zero-inflated negative binomial regression of patient
characteristics, achievement of all three selected QOF indicators and total NDA processes received
against readmissions.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA
= National Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC =
Total cholesterol
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Quality of Primary Care Diabetes Management and 
Mortality
The same patients that were eligible for the analyses of emergency admission
and readmission rates analysis were eligible for analysis of odds of mortality; their
characteristics, QOF attainment and NDA process receipt are described Table 56,
Table 57 and Table 58 respectively. The numbers of patients who died, both due to
any cause and those that are potentially diabetes-related (Table 46, page 133),
during various lengths of follow-up are shown in Table 75. No deaths occurred in
the group of patients who were younger than 25 years of age in 2005/06, meaning
that these 778 individuals were excluded from the models for 2005/06.
2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
Died (all cause)
n 2,444 4,792 7,214 9,545 11,878
% 3.60% 7.06% 10.62% 14.05% 17.49%
Died (potentially
DM-related)
n 1,215 2,292 3,418 4,460 5,527
% (of patients) 1.79% 3.37% 5.03% 6.57% 8.14%
% (of deaths) 49.71% 47.83% 47.38% 46.73% 46.53%
Table 75. Deaths occurring by follow-up period from individuals diagnosed with diabetes mellitus by
1st April 2005.
Univariate analyses of all-cause mortality suggested associations between
T2DM, the number of years with diabetes, female gender increasing age, residence
in the most deprived fifth of England, increasing co-morbidity and being an ex-
smoker with increased odds of death across all follow-up periods (Table 76).
Attaining QOF target DM17 (TC ≤ 5.0 mmol/L) was most consistently associated
with decreased odds of death in univariate analyses. Attaining QOF targets DM06
(HbA1c ≤ 7.4% / 57.4 mmol/mol) and DM12 (BP ≤ 145/85) were both associated
with decreased odds of same-year death, but were only otherwise associated with
increased odds of death over four- and five-year follow-up and two- to four-year
follow-up respectively in univariate analyses (Table 76).
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Receipt of 6 or more NDA care processes was associated with decreased odds
of death compared to receiving no care processes across all time periods in
univariate analyses, whereas receiving 1 – 3 care processes was associated with
increased odds of death compared to receiving no care processes. Receipt of any
single NDA care process, with the exception of smoking status review, in 2005/06
was associated with decreased odds of death across all follow-up periods in
univariate analyses. Review of smoking status in 2005/06 was only associated with
decreased odds of death for follow-up periods covering 1 to 3 years in univariate
analyses (Table 76).
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 1.809 < 0.001 1.984 < 0.001 2.251 < 0.001 2.450 < 0.001 2.463 < 0.001
Years With DM 1.019 < 0.001 1.016 < 0.001 1.017 < 0.001 1.019 < 0.001 1.020 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.072 0.092 1.102 0.001 1.109 < 0.001 1.106 < 0.001 1.111 < 0.001
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.034 0.232 1.306 0.500 1.585 0.211 1.715 0.101
45 – 64y 3.726 < 0.001 5.556 0.003 3.677 0.001 4.559 < 0.001 4.773 < 0.001
65 – 74y 11.924 < 0.001 16.180 < 0.001 11.116 < 0.001 13.246 < 0.001 13.990 < 0.001
≥ 75y 38.462 < 0.001 54.826 < 0.001 38.633 < 0.001 49.670 < 0.001 54.800 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.007 0.917 0.904 0.034 0.890 0.004 0.912 0.010 0.916 0.007
3 1.076 0.271 0.897 0.025 0.895 0.006 0.898 0.003 0.909 0.004
4 0.952 0.467 0.868 0.003 0.896 0.005 0.920 0.017 0.926 0.017
5 0.830 0.009 0.746 < 0.001 0.750 < 0.001 0.758 < 0.001 0.777 < 0.001
CCI Group
CCI = 0 Reference Group¶ Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.503 < 0.001 1.436 < 0.001 1.498 < 0.001 1.480 < 0.001 1.490 < 0.001
CCI = 2 4.227 < 0.001 3.793 < 0.001 3.907 < 0.001 3.895 < 0.001 3.835 < 0.001
CCI = 3 5.732 < 0.001 5.908 < 0.001 6.018 < 0.001 6.050 < 0.001 6.001 < 0.001
CCI ≥ 4 10.034 < 0.001 9.326 < 0.001 9.449 < 0.001 9.924 < 0.001 10.147 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.234 < 0.001 1.305 < 0.001 1.354 < 0.001 1.379 < 0.001 1.388 < 0.001
Current 
Smoker 0.900 0.116 0.996 0.933 1.039 0.341 1.025 0.491 1.053 0.114
Unknown 0.321 < 0.001 0.422 < 0.001 0.601 < 0.001 0.740 < 0.001 0.867 0.001
DM06 (HbA1c ≤ 7.4% / 
57.4 mmol/mol) 0.780 < 0.001 0.962 0.198 1.044 0.088 1.083 < 0.001 1.117 < 0.001
DM12 (BP ≤ 145/85) 0.909 0.023 1.095 0.004 1.094 < 0.001 1.069 0.003 1.041 0.054
DM17 (TC ≤ 5.0 mmol/L) 0.474 < 0.001 0.702 < 0.001 0.785 < 0.001 0.828 < 0.001 0.857 < 0.001
DM06 + DM12 + DM17 0.674 < 0.001 0.897 0.002 0.965 0.203 0.996 0.870 1.012 0.589
(continued on next page...)
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2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
Number of 
NDA 
Processes 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 2.813 < 0.001 2.759 < 0.001 2.652 < 0.001 2.418 < 0.001 2.325 < 0.001
2 2.943 < 0.001 2.961 < 0.001 2.914 < 0.001 2.650 < 0.001 2.536 < 0.001
3 1.593 < 0.001 1.948 < 0.001 1.992 < 0.001 1.975 < 0.001 1.920 < 0.001
4 1.094 0.253 1.504 < 0.001 1.613 < 0.001 1.553 < 0.001 1.584 < 0.001
5 0.471 < 0.001 0.871 0.014 0.988 0.801 1.001 0.984 1.024 0.564
6 0.222 < 0.001 0.516 < 0.001 0.680 < 0.001 0.733 < 0.001 0.787 < 0.001
7 0.149 < 0.001 0.425 < 0.001 0.612 < 0.001 0.701 < 0.001 0.767 < 0.001
8 0.098 < 0.001 0.359 < 0.001 0.544 < 0.001 0.630 < 0.001 0.697 < 0.001
9 0.129 < 0.001 0.338 < 0.001 0.506 < 0.001 0.628 < 0.001 0.733 < 0.001
NDA BMI 0.173 < 0.001 0.322 < 0.001 0.413 < 0.001 0.463 < 0.001 0.506 < 0.001
NDA BP 0.306 < 0.001 0.545 < 0.001 0.676 < 0.001 0.739 < 0.001 0.794 < 0.001
NDA Cholesterol 0.188 < 0.001 0.388 < 0.001 0.510 < 0.001 0.574 < 0.001 0.625 < 0.001
NDA Creatinine 0.352 < 0.001 0.619 < 0.001 0.760 < 0.001 0.819 < 0.001 0.864 < 0.001
NDA Foot 0.166 < 0.001 0.352 < 0.001 0.467 < 0.001 0.528 < 0.001 0.576 < 0.001
NDA HbA1c 0.396 < 0.001 0.628 < 0.001 0.746 < 0.001 0.797 < 0.001 0.819 < 0.001
NDA Retinal Screen 0.293 < 0.001 0.472 < 0.001 0.570 < 0.001 0.627 < 0.001 0.661 < 0.001
NDA Smoking Status 0.416 < 0.001 0.740 < 0.001 0.884 < 0.001 0.961 0.081 1.016 0.441
NDA Urinary Albumin 0.293 < 0.001 0.548 < 0.001 0.658 < 0.001 0.724 < 0.001 0.783 < 0.001
Table 76. Results, by follow-up period, of univariate logistic regression modelling of deaths due to
any cause.
¶ = group declared as empty by STATA
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
In multiple-variable analyses of associations between attainment of individual
QOF indicators in 2005/06 in isolation and death due to any cause, separate
achievement of DM06 and DM12 were associated with decreased odds of death
across all follow-up periods, albeit with some attenuation of eﬀect with longer
periods of follow-up. Attaining DM12 in 2005/06 was associated with decreased
odds of same-year death, but associations were non-significant for all other follow-
up periods in multiple-variable regression. Attaining all three selected QOF
indicators in 2005/06 was associated with decreased odds of death across all time
periods, but the magnitude of eﬀect did not exceed the maximal eﬀect associated
with attaining one of the component indicators in isolation (Table 77, full regression
tables available in Appendices).
Multi-variable analyses of associations between receipt of NDA care processes
in 2005/06 in isolation and death due to any cause, receiving any individual care
process was associated with decreased odds of death across all follow-up periods
(Table 78, full regression tables available in Appendices).
- 174 -
As noted with the univariate analyses of total NDA care processes received and
the multiple-variable regressions for emergency admissions and readmissions, there
appeared to be a threshold of total NDA care processes below which associations
with increased odds of death were observed and past which associations with
decreased odds of death were seen. Receiving 5 or more NDA care processes in
2005/06 was associated with decreased odds of death across all follow-up periods
compared to receiving no NDA care processes, whereas receiving 1 – 2 care
processes in 2005/06 was associated with increased odds of death across all
follow-up periods (Table 78, full regression tables available in Appendices).
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM06 (HbA1c ≤ 7.4% / 
57.4 mmol/mol) 0.550 < 0.001 0.678 < 0.001 0.742 < 0.001 0.772 < 0.001 0.804 < 0.001
DM12 (BP ≤ 145/85) 0.777 < 0.001 0.961 0.228 0.984 0.569 0.977 0.362 0.963 0.113
DM17 (TC ≤ 5.0 mmol/L) 0.343 < 0.001 0.525 < 0.001 0.597 < 0.001 0.638 < 0.001 0.670 < 0.001
DM06 + DM12 + DM17 0.530 < 0.001 0.708 < 0.001 0.763 < 0.001 0.787 < 0.001 0.802 < 0.001
Table 77. Results from multiple-variable logistic regression of odds of death due to any cause for
selected QOF indicators.
Results denote separate models for each QOF indicator(s) and follow-up period; all models also adjusted, but
coeﬃcients not shown, for diabetes type, gender, years post-diabetes diagnosis, age group, IMD fifth, smoking
status and co-morbidity grouping.
BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
Number of 
NDA 
Processes 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.853 < 0.001 1.938 < 0.001 2.025 < 0.001 1.936 < 0.001 1.984 < 0.001
2 1.747 < 0.001 1.916 < 0.001 2.117 < 0.001 2.043 < 0.001 2.117 < 0.001
3 0.905 0.269 1.230 0.009 1.400 < 0.001 1.507 < 0.001 1.585 < 0.001
4 0.596 < 0.001 0.905 0.163 1.078 0.252 1.104 0.108 1.228 0.001
5 0.254 < 0.001 0.518 < 0.001 0.643 < 0.001 0.687 < 0.001 0.752 < 0.001
6 0.114 < 0.001 0.286 < 0.001 0.411 < 0.001 0.466 < 0.001 0.536 < 0.001
7 0.069 < 0.001 0.211 < 0.001 0.332 < 0.001 0.404 < 0.001 0.474 < 0.001
8 0.044 < 0.001 0.173 < 0.001 0.287 < 0.001 0.354 < 0.001 0.419 < 0.001
9 0.055 < 0.001 0.148 < 0.001 0.242 < 0.001 0.322 < 0.001 0.404 < 0.001
NDA BMI 0.136 < 0.001 0.253 < 0.001 0.329 < 0.001 0.374 < 0.001 0.417 < 0.001
NDA BP 0.168 < 0.001 0.318 < 0.001 0.421 < 0.001 0.481 < 0.001 0.548 < 0.001
NDA Cholesterol 0.123 < 0.001 0.260 < 0.001 0.354 < 0.001 0.408 < 0.001 0.458 < 0.001
NDA Creatinine 0.202 < 0.001 0.375 < 0.001 0.487 < 0.001 0.544 < 0.001 0.597 < 0.001
NDA Foot 0.124 < 0.001 0.262 < 0.001 0.352 < 0.001 0.402 < 0.001 0.445 < 0.001
NDA HbA1c 0.312 < 0.001 0.501 < 0.001 0.608 < 0.001 0.658 < 0.001 0.682 < 0.001
NDA Retinal Screen 0.290 < 0.001 0.464 < 0.001 0.563 < 0.001 0.623 < 0.001 0.658 < 0.001
NDA Smoking Status 0.236 < 0.001 0.477 < 0.001 0.608 < 0.001 0.700 < 0.001 0.772 < 0.001
NDA Urinary Albumin 0.268 < 0.001 0.497 < 0.001 0.597 < 0.001 0.658 < 0.001 0.717 < 0.001
Table 78. Results from multiple-variable logistic regression of odds of death due to any cause for
NDA care processes.
Results denote separate models for each NDA process / count and follow-up period; all models also adjusted,
but coeﬃcients not shown, for diabetes type, gender, years post-diabetes diagnosis, age group, IMD fifth,
smoking status and co-morbidity grouping.
In addition to the multiple-variable models examining the odds of death due to
any cause for each QOF indicator or NDA process in isolation, full models were run
that included all predictors of interest (Tables 79 – 82).
A number of significant associations persisted in the fully-adjusted models of
death due to any cause. Female gender and residing in the least deprived areas of
England were associated with decreased odds of death across all follow-up periods
in all models. Increasing levels of co-morbidity and being an ex- or current smoker
were both associated with increased odds of death across all time periods in all
models.
Individuals diagnosed with T2DM exhibited significantly decreased odds of
death over the first three years of follow-up, but were non-significant for longer
periods of follow-up. Increasing time with diabetes – measured as years with
diabetes – was significantly associated with increased odds of death for follow-up
periods of three to five years.
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In the fully-adjusted models, associations between receipt of QOF indicator
DM12 (BP ≤ 145/85) and increased odds of death were observed for all follow-up
periods (OR 1.214 – 1.840), with the greatest odds of death observed over the
shortest lengths of follow-up. In the full model considering receipt of individual NDA
processes, achievement of DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) was associated
with increased odds of death over one year of follow-up (OR = 1.116); DM17 (TC ≤
5.0 mmol/L) was associated with increased odds of death for the first two years of
follow-up in the full model utilising individual NDA processes (OR 1.099 – 1.224) and
with decreased odds of death for four and five years of follow-up in the full model
utilising the total number of NDA care processes received (OR 0.914 – 0.928).
Achievement of all three selected QOF targets in 2005/06 was associated with
increased odds of death over a follow-up period of one to two years in the fully-
adjusted model utilising individual NDA processes (OR 1.085 – 1.118) and with
borderline significance over a follow-up period of one year in the fully-adjusted
model utilising the total number of NDA care processes received (OR = 1.123).
Insofar as associations with individual NDA care processes in the fully-adjusted
models are concerned, BMI checks (OR 0.500 – 0.530), total cholesterol checks (OR
0.237 – 0.502), foot checks (OR 0.327 – 0.620), HbA1c checks (OR 0.779 – 0.896),
retinal screening (OR 0.525 – 0.782) and urinary albumin checks (OR 0.579 – 0.881)
were all associated with decreased odds of death across all follow-up periods; the
patterns and magnitude of estimated ORs were similar across the separate fully-
adjusted models utilising individual QOF targets and achievement of all three QOF
targets. 
Creatinine checks were associated with increased odds of death across all
follow-up periods (OR 1.928 – 2.247); blood pressure checks showed no significant
association with odds of death for follow-up periods of one and two years for the
fully-adjusted model utilising achievement of separate QOF indicators, but was
associated with increased odds of death for follow-up periods of three or more
years (OR 1.167 – 1.370) in the fully-adjusted model using separate QOF indicators
and was associated with an increased odds of death across all lengths of follow-up
in the fully-adjusted model examining achievement of all three QOF indicators (OR
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1.169 – 1.473). Review of smoking status was associated with significantly reduced
odds of death over one year of follow up in (OR 0.724 – 0.728), but was associated
with increased odds of death over four and five years of follow-up (OR 1.112 –
1.156) in both of the fully-adjusted models examining attainment of individual NDA
care processes.
For the full models examining odds of death due to any cause that utilised the
total number of NDA processes received (Table 81 and Table 82), a similar pattern
of associations as that for multiple-variable models examining the number of NDA
processes received without any additional adjustment for other quality metrics and
the univariate model was observed.
Compared to receiving no processes of care, receipt of between 1 – 2 care
processes (one year of follow-up) and 1 – 4 processes (five years of follow-up) were
associated with increased odds of death in both fully-adjusted models. Receipt of 5
or more care processes was associated with decreased odds of death across all
follow-up periods in comparison to receiving no NDA processes. Where a protective
association was observed, the greatest magnitudes of associations were observed
over the shortest period of follow-up; for individuals receiving all 9 processes,
considerable associations with reduced odds of death versus individuals receiving
no processes of care were observed over one year of follow-up (OR 0.035 – 0.052)
that remained both clinically and statistically meaningful over five years of follow-up
(OR 0.397 – 0.409).
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.702 0.001 0.741 < 0.001 0.844 0.017 0.925 0.227 0.909 0.106
Years With DM 1.003 0.325 1.001 0.546 1.005 0.007 1.008 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.788 < 0.001 0.830 < 0.001 0.833 < 0.001 0.823 < 0.001 0.820 < 0.001
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.414 0.140 1.415 0.383 1.639 0.182 1.777 0.082
45 – 64y 5.820 < 0.001 8.884 < 0.001 4.864 < 0.001 5.430 < 0.001 5.706 < 0.001
65 – 74y 19.990 < 0.001 26.560 < 0.001 14.882 < 0.001 15.835 < 0.001 16.988 < 0.001
≥ 75y 50.117 < 0.001 77.994 < 0.001 46.605 < 0.001 55.140 < 0.001 63.345 < 0.001
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.943 0.433 0.846 0.002 0.831 < 0.001 0.851 < 0.001 0.852 < 0.001
3 0.982 0.812 0.799 < 0.001 0.792 < 0.001 0.784 < 0.001 0.790 < 0.001
4 0.888 0.113 0.780 < 0.001 0.793 < 0.001 0.801 < 0.001 0.793 < 0.001
5 0.792 0.003 0.689 < 0.001 0.681 < 0.001 0.671 < 0.001 0.677 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.415 < 0.001 1.301 < 0.001 1.363 < 0.001 1.355 < 0.001 1.374 < 0.001
CCI = 2 2.452 < 0.001 2.261 < 0.001 2.411 < 0.001 2.459 < 0.001 2.459 < 0.001
CCI = 3 2.850 < 0.001 3.127 < 0.001 3.299 < 0.001 3.417 < 0.001 3.463 < 0.001
CCI ≥ 4 4.107 < 0.001 4.220 < 0.001 4.545 < 0.001 5.038 < 0.001 5.367 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.261 < 0.001 1.185 < 0.001 1.176 < 0.001 1.147 < 0.001 1.128 < 0.001
Current 
Smoker 1.556 < 0.001 1.590 < 0.001 1.674 < 0.001 1.613 < 0.001 1.681 < 0.001
Unknown 0.147 < 0.001 0.249 < 0.001 0.409 < 0.001 0.540 < 0.001 0.695 < 0.001
QOF 
Indicator 
Achievement
DM06 1.116 0.045 0.983 0.648 0.966 0.269 0.961 0.153 0.971 0.255
DM12 1.840 < 0.001 1.580 < 0.001 1.400 < 0.001 1.303 < 0.001 1.214 < 0.001
DM17 1.224 0.001 1.099 0.035 1.001 0.982 0.977 0.494 0.957 0.161
NDA Process
BMI 
Check 0.516 < 0.001 0.500 < 0.001 0.509 < 0.001 0.517 < 0.001 0.529 < 0.001
BP Check 0.868 0.068 1.055 0.411 1.167 0.010 1.237 < 0.001 1.370 < 0.001
TC Check 0.237 < 0.001 0.354 < 0.001 0.431 < 0.001 0.468 < 0.001 0.502 < 0.001
Creatinine
Check 2.040 < 0.001 2.142 < 0.001 2.093 < 0.001 2.002 < 0.001 1.928 < 0.001
Foot 
Check 0.327 < 0.001 0.484 < 0.001 0.565 < 0.001 0.597 < 0.001 0.618 < 0.001
HbA1c 
Check 0.779 < 0.001 0.832 < 0.001 0.877 < 0.001 0.896 < 0.001 0.876 < 0.001
Retinal 
Screen 0.525 < 0.001 0.647 < 0.001 0.719 < 0.001 0.764 < 0.001 0.782 < 0.001
Smoking 
Status 
Check
0.724 < 0.001 0.968 0.485 1.036 0.353 1.112 0.002 1.154 < 0.001
Urinary 
Albumin 0.579 < 0.001 0.749 < 0.001 0.798 < 0.001 0.836 < 0.001 0.878 < 0.001
Table 79. Results from full multiple-variable logistic regression of patient characteristics, QOF
indicators achieved and individual NDA processes received against death due to any cause.
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.690 < 0.001 0.724 < 0.001 0.829 0.008 0.911 0.147 0.899 0.073
Years With DM 1.002 0.465 1.001 0.544 1.005 0.006 1.008 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.768 < 0.001 0.816 < 0.001 0.826 < 0.001 0.819 < 0.001 0.818 < 0.001
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.309 0.161 1.374 0.425 1.603 0.203 1.748 0.091
45 – 64y 5.794 < 0.001 8.439 < 0.001 4.677 < 0.001 5.262 < 0.001 5.568 < 0.001
65 – 74y 20.093 < 0.001 25.279 < 0.001 14.283 < 0.001 15.305 < 0.001 16.540 < 0.001
≥ 75y 50.355 < 0.001 73.742 < 0.001 44.522 < 0.001 53.087 < 0.001 61.562 < 0.001
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.945 0.445 0.846 0.002 0.830 < 0.001 0.850 < 0.001 0.851 < 0.001
3 0.984 0.830 0.798 < 0.001 0.792 < 0.001 0.784 < 0.001 0.789 < 0.001
4 0.889 0.113 0.778 < 0.001 0.792 < 0.001 0.800 < 0.001 0.792 < 0.001
5 0.794 0.004 0.689 < 0.001 0.680 < 0.001 0.670 < 0.001 0.676 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.412 < 0.001 1.304 < 0.001 1.365 < 0.001 1.357 < 0.001 1.376 < 0.001
CCI = 2 2.487 < 0.001 2.291 < 0.001 2.433 < 0.001 2.478 < 0.001 2.473 < 0.001
CCI = 3 2.909 < 0.001 3.179 < 0.001 3.339 < 0.001 3.451 < 0.001 3.487 < 0.001
CCI ≥ 4 4.254 < 0.001 4.326 < 0.001 4.622 < 0.001 5.104 < 0.001 5.416 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.267 < 0.001 1.189 < 0.001 1.178 < 0.001 1.148 < 0.001 1.129 < 0.001
Current 
Smoker 1.545 < 0.001 1.592 < 0.001 1.679 < 0.001 1.618 < 0.001 1.685 < 0.001
Unknown 0.132 < 0.001 0.235 < 0.001 0.397 < 0.001 0.529 < 0.001 0.687 < 0.001
All Selected QOF 
Indicators 1.188 0.004 1.085 0.040 1.026 0.431 1.002 0.935 0.981 0.476
NDA
BMI 
Check 0.524 < 0.001 0.504 < 0.001 0.511 < 0.001 0.519 < 0.001 0.530 < 0.001
BP Check 1.169 0.035 1.291 < 0.001 1.338 < 0.001 1.371 < 0.001 1.473 < 0.001
TC Check 0.250 < 0.001 0.363 < 0.001 0.430 < 0.001 0.464 < 0.001 0.495 < 0.001
Creatinine
Check 2.247 < 0.001 2.243 < 0.001 2.141 < 0.001 2.028 < 0.001 1.941 < 0.001
Foot 
Check 0.332 < 0.001 0.488 < 0.001 0.567 < 0.001 0.599 < 0.001 0.620 < 0.001
HbA1c 
Check 0.794 < 0.001 0.832 < 0.001 0.875 < 0.001 0.894 < 0.001 0.875 < 0.001
Retinal 
Screen 0.537 < 0.001 0.651 < 0.001 0.720 < 0.001 0.765 < 0.001 0.781 < 0.001
Smoking 
Status 
Check
0.728 < 0.001 0.970 0.512 1.038 0.334 1.114 0.002 1.156 < 0.001
Urinary 
Albumin 0.593 < 0.001 0.756 < 0.001 0.803 < 0.001 0.840 < 0.001 0.881 < 0.001
Table 80. Results from full multiple-variable logistic regression of patient characteristics,
achievement of all three selected QOF indicators and individual NDA processes received against
death due to any cause.
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.709 0.001 0.749 < 0.001 0.852 0.023 0.933 0.283 0.919 0.152
Years With DM 1.003 0.333 1.002 0.521 1.006 0.006 1.009 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.767 < 0.001 0.817 < 0.001 0.824 < 0.001 0.815 < 0.001 0.811 < 0.001
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.488 0.127 1.472 0.332 1.706 0.149 1.850 0.063
45 – 64y 6.041 < 0.001 9.551 < 0.001 5.288 < 0.001 5.890 < 0.001 6.184 < 0.001
65 – 74y 21.943 < 0.001 29.925 < 0.001 16.844 < 0.001 17.787 < 0.001 19.018 < 0.001
≥ 75y 56.030 < 0.001 89.285 < 0.001 53.462 < 0.001 62.621 < 0.001 71.533 < 0.001
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.941 0.415 0.842 0.001 0.826 < 0.001 0.846 < 0.001 0.846 < 0.001
3 0.998 0.983 0.804 < 0.001 0.794 < 0.001 0.784 < 0.001 0.789 < 0.001
4 0.873 0.067 0.766 < 0.001 0.779 < 0.001 0.788 < 0.001 0.782 < 0.001
5 0.778 0.001 0.673 < 0.001 0.666 < 0.001 0.657 < 0.001 0.665 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.433 < 0.001 1.313 < 0.001 1.370 < 0.001 1.360 < 0.001 1.377 < 0.001
CCI = 2 2.522 < 0.001 2.317 < 0.001 2.457 < 0.001 2.500 < 0.001 2.496 < 0.001
CCI = 3 2.972 < 0.001 3.223 < 0.001 3.383 < 0.001 3.496 < 0.001 3.539 < 0.001
CCI ≥ 4 4.307 < 0.001 4.378 < 0.001 4.678 < 0.001 5.165 < 0.001 5.494 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.382 < 0.001 1.376 < 0.001 1.363 < 0.001 1.346 < 0.001 1.337 < 0.001
Current 
Smoker 1.761 < 0.001 1.940 < 0.001 2.037 < 0.001 1.993 < 0.001 2.098 < 0.001
Unknown 0.161 < 0.001 0.284 < 0.001 0.470 < 0.001 0.621 < 0.001 0.803 < 0.001
QOF 
Indicator 
Achievement
DM06 1.127 0.027 0.985 0.694 0.966 0.267 0.960 0.144 0.967 0.199
DM12 1.680 < 0.001 1.492 < 0.001 1.334 < 0.001 1.254 < 0.001 1.177 < 0.001
DM17 1.052 0.394 1.002 0.956 0.941 0.088 0.928 0.021 0.914 0.003
NDA 
Processes 
Received
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.488 < 0.001 1.683 < 0.001 1.862 < 0.001 1.827 < 0.001 1.918 < 0.001
2 1.280 0.011 1.577 < 0.001 1.891 < 0.001 1.895 < 0.001 2.030 < 0.001
3 0.641 < 0.001 1.003 0.974 1.256 0.003 1.409 < 0.001 1.537 < 0.001
4 0.409 < 0.001 0.729 < 0.001 0.969 0.653 1.038 0.579 1.201 0.004
5 0.171 < 0.001 0.413 < 0.001 0.577 < 0.001 0.647 < 0.001 0.739 < 0.001
6 0.075 < 0.001 0.226 < 0.001 0.368 < 0.001 0.438 < 0.001 0.527 < 0.001
7 0.045 < 0.001 0.166 < 0.001 0.297 < 0.001 0.380 < 0.001 0.466 < 0.001
8 0.028 < 0.001 0.136 < 0.001 0.256 < 0.001 0.333 < 0.001 0.413 < 0.001
9 0.035 < 0.001 0.116 < 0.001 0.215 < 0.001 0.301 < 0.001 0.397 < 0.001
Table 81. Results from full multiple-variable logistic regression of patient characteristics, QOF
indicators achieved and total NDA processes received against death due to any cause.
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.707 0.001 0.737 < 0.001 0.840 0.013 0.922 0.204 0.911 0.114
Years With DM 1.002 0.481 1.001 0.526 1.006 0.005 1.009 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.756 < 0.001 0.809 < 0.001 0.822 < 0.001 0.814 < 0.001 0.813 < 0.001
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.400 0.142 1.433 0.366 1.671 0.165 1.823 0.070
45 – 64y 5.965 < 0.001 9.105 < 0.001 5.087 < 0.001 5.706 < 0.001 6.030 < 0.001
65 – 74y 21.937 < 0.001 28.568 < 0.001 16.156 < 0.001 17.161 < 0.001 18.470 < 0.001
≥ 75y 56.093 < 0.001 84.828 < 0.001 51.129 < 0.001 60.275 < 0.001 69.435 < 0.001
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.943 0.433 0.842 0.001 0.825 < 0.001 0.845 < 0.001 0.845 < 0.001
3 1.002 0.982 0.804 < 0.001 0.793 < 0.001 0.784 < 0.001 0.788 < 0.001
4 0.873 0.067 0.765 < 0.001 0.778 < 0.001 0.787 < 0.001 0.782 < 0.001
5 0.778 0.001 0.672 < 0.001 0.664 < 0.001 0.655 < 0.001 0.663 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.429 < 0.001 1.316 < 0.001 1.372 < 0.001 1.363 < 0.001 1.379 < 0.001
CCI = 2 2.555 < 0.001 2.345 < 0.001 2.479 < 0.001 2.517 < 0.001 2.509 < 0.001
CCI = 3 3.019 < 0.001 3.269 < 0.001 3.417 < 0.001 3.523 < 0.001 3.558 < 0.001
CCI ≥ 4 4.411 < 0.001 4.462 < 0.001 4.740 < 0.001 5.218 < 0.001 5.533 < 0.001
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 1.380 < 0.001 1.376 < 0.001 1.363 < 0.001 1.347 < 0.001 1.337 < 0.001
Current 
Smoker 1.730 < 0.001 1.934 < 0.001 2.040 < 0.001 1.999 < 0.001 2.105 < 0.001
Unknown 0.149 < 0.001 0.273 < 0.001 0.461 < 0.001 0.614 < 0.001 0.800 < 0.001
All Selected QOF 
Indicators 1.123 0.050 1.056 0.170 1.008 0.809 0.988 0.668 0.969 0.245
NDA 
Processes 
Received
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.842 < 0.001 1.933 < 0.001 2.024 < 0.001 1.937 < 0.001 1.987 < 0.001
2 1.724 < 0.001 1.904 < 0.001 2.115 < 0.001 2.046 < 0.001 2.124 < 0.001
3 0.887 0.187 1.219 0.012 1.398 < 0.001 1.510 < 0.001 1.592 < 0.001
4 0.579 < 0.001 0.894 0.119 1.076 0.266 1.107 0.100 1.237 < 0.001
5 0.245 < 0.001 0.510 < 0.001 0.641 < 0.001 0.689 < 0.001 0.759 < 0.001
6 0.109 < 0.001 0.280 < 0.001 0.410 < 0.001 0.468 < 0.001 0.541 < 0.001
7 0.066 < 0.001 0.206 < 0.001 0.331 < 0.001 0.405 < 0.001 0.479 < 0.001
8 0.042 < 0.001 0.170 < 0.001 0.286 < 0.001 0.355 < 0.001 0.424 < 0.001
9 0.052 < 0.001 0.145 < 0.001 0.242 < 0.001 0.323 < 0.001 0.409 < 0.001
Table 82. Results from full multiple-variable logistic regression of patient characteristics,
achievement of all three selected QOF indicators and total NDA processes received against death
due to any cause.
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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For all the analyses pertaining to death due to a potentially-diabetes related
cause, it should be noted that the source population is individuals who have died.
Therefore the ORs reported pertain to the odds of dying due to a cause potentially
related to diabetes versus dying due to any other cause; an OR < 1 infers that the
presence of a given predictor is associated with decreased odds of death due to a
diabetes-related cause, whereas an OR > 1 infers an association with an increased
odds of death due to a diabetes-related cause.
Univariate analyses of potentially diabetes-related mortality indicated
associations favouring a non-diabetes cause of death for T2DM for follow-up
lengths of greater than 2 years, being an ex- or current smoker and for follow-up
lengths of greater than 2 years. The number of years with diabetes was associated
with increased odds of death due to a potentially diabetes-related cause (Table 83).
Attaining QOF targets DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) and DM12 (BP ≤
145/85) in 2005/06 were associated with decreased odds of death due to a
potentially diabetes-related cause for follow-up lengths of two or more and three or
more years respectively in univariate analyses. No significant associations between
achieving DM17 (TC ≤ 5.0 mmol/L) and the odds of potentially diabetes-related
death were observed. Unlike with other patient-level analyses, the estimated ORs
for achieving all three of the selected QOF targets indicated a protective eﬀect that
outstripped any of the individual targets in univariate analyses (Table 83).
The total number of NDA care processes received in 2005/06 appeared to have
no consistent association with the odds of death due to a potentially diabetes-
related cause in univariate analyses. Receiving the NDA cholesterol check process
in 2005/06 was, somewhat counterintuitively, associated with increased odds of
death from a potentially diabetes-related cause for follow-up lengths of 1 – 2 years;
any such associations were non-significant for longer follow-up periods. Receiving
the NDA smoking status check was associated with decreased odds of death due
to a potentially diabetes-related cause for follow-up periods of three or more years
(Table 83).
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Multiple-variable regression, where the eﬀects of each individual quality indicator
was adjusted for patient factors, for the odds of death due to a potentially diabetes-
related cause yielded similar results to that observed for univariate regression.
Associations with decreased odds of death due to a potentially diabetes-related
cause were observed for DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) and DM12 (BP ≤
145/85) for follow-up lengths of three or more and four or more years respectively.
Attaining all three selected QOF targets were associated with decreased odds of
potentially diabetes-related death for periods of follow-up exceeding three years. As
observed with the univariate analysis of diabetes-related death, the protective eﬀect
of achieving multiple targets generally exceeded those of the individual targets in
isolation (Table 84).
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.722 0.061 0.715 0.009 0.655 < 0.001 0.709 < 0.001 0.697 < 0.001
Years With DM 1.018 0.001 1.015 < 0.001 1.016 < 0.001 1.017 < 0.001 1.016 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.073 0.383 1.072 0.232 1.080 0.104 1.081 0.059 1.061 0.106
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.375 0.800 0.917 0.913 1.119 0.881 0.841 0.792
45 – 64y 1.683 0.314 1.701 0.665 1.125 0.878 1.379 0.661 0.793 0.714
65 – 74y 1.845 0.227 1.708 0.663 1.064 0.935 1.288 0.729 0.757 0.661
≥ 75y 2.084 0.144 1.911 0.597 1.272 0.753 1.553 0.547 0.932 0.912
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.058 0.669 1.059 0.534 1.013 0.867 1.011 0.863 0.986 0.811
3 1.075 0.579 1.063 0.512 1.049 0.524 1.052 0.444 1.032 0.596
4 0.918 0.517 0.934 0.457 0.967 0.655 0.941 0.350 0.918 0.143
5 0.867 0.310 0.843 0.083 0.858 0.056 0.902 0.140 0.894 0.074
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.770 0.023 0.927 0.343 0.947 0.398 0.973 0.623 1.004 0.932
CCI = 2 0.728 0.004 0.809 0.008 0.871 0.033 0.916 0.120 0.947 0.287
CCI = 3 0.965 0.791 1.124 0.226 1.177 0.042 1.192 0.013 1.245 0.001
CCI ≥ 4 0.649 0.002 0.830 0.082 0.855 0.084 0.900 0.195 0.922 0.280
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.901 0.241 0.852 0.013 0.886 0.022 0.890 0.012 0.913 0.029
Current 
Smoker 0.787 0.070 0.743 0.001 0.724 < 0.001 0.737 < 0.001 0.751 < 0.001
Unknown 1.149 0.581 0.870 0.385 1.004 0.971 1.024 0.793 0.992 0.919
DM06 (HbA1c ≤ 7.4% / 
57.4 mmol/mol) 0.900 0.198 0.888 0.041 0.847 < 0.001 0.857 < 0.001 0.857 < 0.001
DM12 (BP ≤ 145/85) 0.987 0.875 0.960 0.497 0.919 0.081 0.892 < 0.001 0.891 0.002
DM17 (TC ≤ 5.0 mmol/L) 1.077 0.358 1.061 0.312 0.995 0.916 0.963 0.368 0.948 0.157
DM06 + DM12 + DM17 0.856 0.121 0.881 0.057 0.828 < 0.001 0.834 < 0.001 0.836 < 0.001
(continued on next page...)
- 184 -
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
Number of 
NDA 
Processes 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 0.774 0.080 0.814 0.113 0.883 0.286 0.874 0.212 0.876 0.189
2 0.876 0.360 0.866 0.262 0.949 0.645 0.931 0.501 0.896 0.267
3 1.003 0.985 0.985 0.904 0.968 0.769 0.899 0.296 0.934 0.465
4 1.063 0.686 1.124 0.328 1.132 0.228 1.102 0.296 1.046 0.596
5 0.994 0.967 1.092 0.407 1.044 0.633 1.043 0.604 1.001 0.987
6 1.083 0.577 1.120 0.240 1.082 0.325 1.007 0.921 0.975 0.685
7 1.066 0.693 0.917 0.385 0.898 0.182 0.884 0.075 0.896 0.077
8 1.310 0.357 0.832 0.207 0.798 0.040 0.765 0.004 0.799 0.006
9 0.852 0.775 0.865 0.637 0.806 0.337 0.819 0.269 0.803 0.154
NDA BMI 1.085 0.332 0.998 0.966 0.922 0.090 0.906 0.019 0.910 0.015
NDA BP 1.044 0.601 1.040 0.549 0.999 0.982 0.979 0.671 0.982 0.690
NDA Cholesterol 1.224 0.014 1.150 0.017 1.093 0.074 1.047 0.298 1.013 0.748
NDA Creatinine 0.945 0.489 0.997 0.963 0.990 0.856 0.960 0.397 0.950 0.240
NDA Foot 1.144 0.138 1.036 0.537 0.964 0.440 0.936 0.109 0.938 0.087
NDA HbA1c 1.152 0.092 1.057 0.335 1.027 0.578 1.009 0.830 1.016 0.666
NDA Retinal Screen 0.992 0.953 0.927 0.377 0.903 0.117 0.886 0.027 0.925 0.107
NDA Smoking Status 1.079 0.433 0.903 0.095 0.848 0.001 0.860 < 0.001 0.866 < 0.001
NDA Urinary Albumin 1.178 0.348 0.992 0.936 0.961 0.581 0.938 0.293 0.951 0.341
Table 83. Results, by follow-up period, of univariate logistic regression modelling of deaths due to a
potentially diabetes-related cause.
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM06 (HbA1c ≤ 7.4% / 57.4 
mmol/mol) 0.924 0.347 0.911 0.117 0.869 0.004 0.882 0.003 0.881 0.001
DM12 (BP ≤ 145/85) 1.014 0.865 0.978 0.710 0.935 0.172 0.911 0.032 0.904 0.009
DM17 (TC ≤ 5.0 mmol/L) 1.112 0.200 1.093 0.137 1.030 0.558 1.001 0.986 0.979 0.597
DM06 + DM12 + DM17 0.889 0.248 0.906 0.142 0.851 0.003 0.860 0.001 0.858 < 0.001
Table 84. Results from multiple-variable logistic regression of odds of death due to a potentially
diabetes-related cause for selected QOF indicators.
Results denote separate models for each QOF indicator(s) and follow-up period; all models also adjusted, but
coeﬃcients not shown, for diabetes type, gender, years post-diabetes diagnosis, age group, IMD fifth, smoking
status and co-morbidity grouping.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA
= National Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC =
Total cholesterol
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Associations between receipt of NDA care processes in 2005/06 in multiple-
variable regression were similar to those observed for univariate regression. There
were no associations between the total number of NDA care processes received
and the odds of death due to a potentially diabetes-related cause over any of
lengths of follow-up in these analyses. Receipt of the NDA cholesterol check in
2005/06 was associated with increased odds of death due to a potentially diabetes-
related cause for follow-up lengths of one to three years; associations for longer
follow-up periods did not reach statistical significance.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
Number of 
NDA 
Processes 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 0.782 0.099 0.814 0.118 0.887 0.310 0.885 0.263 0.874 0.189
2 0.898 0.462 0.893 0.383 0.966 0.763 0.963 0.724 0.913 0.368
3 1.054 0.738 1.007 0.955 0.984 0.890 0.920 0.419 0.948 0.580
4 1.089 0.578 1.126 0.325 1.141 0.205 1.124 0.218 1.058 0.514
5 1.010 0.948 1.102 0.366 1.058 0.542 1.064 0.448 1.011 0.885
6 1.120 0.434 1.141 0.176 1.104 0.222 1.041 0.575 1.003 0.966
7 1.126 0.473 0.971 0.773 0.958 0.606 0.949 0.472 0.956 0.498
8 1.400 0.260 0.903 0.490 0.877 0.246 0.843 0.074 0.872 0.110
9 0.961 0.945 0.990 0.973 0.896 0.631 0.918 0.639 0.889 0.454
NDA BMI 1.102 0.256 1.016 0.784 0.949 0.291 0.939 0.148 0.942 0.135
NDA BP 1.069 0.433 1.067 0.334 1.030 0.606 1.018 0.731 1.021 0.664
NDA Cholesterol 1.247 0.009 1.174 0.007 1.132 0.015 1.091 0.054 1.056 0.189
NDA Creatinine 0.968 0.694 1.030 0.648 1.029 0.611 1.003 0.958 0.989 0.805
NDA Foot 1.176 0.077 1.055 0.367 0.989 0.821 0.963 0.377 0.968 0.395
NDA HbA1c 1.157 0.087 1.068 0.265 1.045 0.359 1.029 0.495 1.035 0.367
NDA Retinal Screen 1.006 0.970 0.958 0.620 0.938 0.332 0.919 0.131 0.959 0.391
NDA Smoking Status 1.176 0.126 0.990 0.885 0.916 0.124 0.934 0.175 0.932 0.120
NDA Urinary Albumin 1.189 0.326 1.002 0.981 0.977 0.746 0.956 0.468 0.969 0.553
Table 85. Results from multiple-variable logistic regression of odds of death due to a potentially
diabetes-related cause for NDA care processes.
Results denote separate models for each NDA process / count and follow-up period; all models also adjusted,
but coeﬃcients not shown, for diabetes type, gender, years post-diabetes diagnosis, age group, IMD fifth,
smoking status and co-morbidity grouping.
IRR = Incidence rate ratio; CCI = Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA
= National Diabetes Audit; BMI = Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC =
Total cholesterol
Full models, including all predictor variables, were also constructed for
examining associations with the odds of death due to a diabetes related cause. As
stated in the methodology section of this chapter, these models only contain
individuals who have died; hence the estimated odds ratios describe the odds of
dying from a diabetes-related cause versus death due to any other cause (Tables
86 – 89).
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For the full models utilising individual NDA care processes (Table 86 and Table
87), few predictors demonstrated consistent associations with the odds of death
due to a diabetes-related cause; only years with diabetes and the NDA total
cholesterol check process had significant associations with diﬀerences in the odds
of death due to a diabetes-related cause for all lengths of follow-up. Associations
between odds of death due to a diabetes-related cause and the total number of
NDA care processes received were, at best, sporadically statistically significant but
generally showed no consistent associations with changes in the odds of diabetes-
related death (Table 88 and Table 89).
Attaining DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) in 2005/06 was associated
with reduced odds of death due to a potentially diabetes-related cause for follow-
up lengths of two to five years (OR 0.838 – 0.870); receipt of DM12 (BP ≤ 145/85)
was associated with reduced odds of diabetes-related death for follow-up lasting
four or five years (OR 0.891 – 0.905). No significant associations were observed
between receipt of DM17 (TC ≤ 5.0 mmol/L) over any length of follow-up in any of
the full models.
Attaining all three of the selected QOF indicators in 2005/06 was associated with
reduced odds of death due to a potentially diabetes-related cause for follow-up
periods of two to five years across all fully-adjusted models (OR 0.811 – 0.866), with
estimates of the magnitude of eﬀect exceeding that associated with any of the
individual indicators.
Each additional year that a patient has had a diagnosis of diabetes for was
significantly associated with increased odds of death due to a diabetes-related
cause across all lengths of follow-up in all full models (OR 1.012 – 1.019). Receipt of
the NDA total cholesterol check process was associated with increased odds of
death due to a diabetes-related cause (OR 1.243 – 1.408).
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Patients who with a recorded diabetes type of T2DM were associated with lower
odds of death due to a diabetes-related cause than their peers with T1DM (OR
0.686 – 0.757) for follow-up periods of two or more years across all full models.
Associations, for follow-up periods of two or more years, were observed with
decreased odds of death due to a diabetes-related cause in patients residing in the
most aﬄuent fifth as compared to those in the least aﬄuent fifth (OR 0.804 – 0.858)
across all full models.
Sporadically statistically significant associations with increasing co-morbidity
and reduced odds of death due to a diabetes-related cause were observed, but
such associations were not consistent across lengths of follow-up; however,
patients with the highest levels of co-morbidity were associated with decreased
odds of death due to a diabetes-related cause for lengths of follow-up ranging from
one to three years (OR 0.621 – 0.819) across all full models. Being a current smoker
was also associated with decreased odds of death due to a diabetes-related cause;
significant associations were observed for follow-up lengths of two to five years (OR
0.766 – 0.821) across all full models.
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.726 0.083 0.747 0.032 0.693 0.002 0.752 0.006 0.738 0.001
Years With DM 1.017 0.003 1.013 0.002 1.013 < 0.001 1.013 < 0.001 1.013 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.043 0.631 1.010 0.871 1.012 0.810 1.011 0.796 0.998 0.966
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.412 0.786 0.921 0.919 1.140 0.864 0.896 0.868
45 – 64y 1.929 0.216 1.941 0.594 1.293 0.742 1.567 0.545 0.947 0.932
65 – 74y 2.140 0.147 2.000 0.577 1.247 0.777 1.480 0.598 0.912 0.886
≥ 75y 2.380 0.096 2.212 0.523 1.465 0.624 1.739 0.456 1.104 0.877
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.058 0.674 1.058 0.544 1.003 0.968 0.996 0.958 0.969 0.597
3 1.070 0.613 1.038 0.689 1.003 0.971 1.009 0.895 0.993 0.913
4 0.927 0.572 0.919 0.361 0.934 0.363 0.907 0.137 0.884 0.037
5 0.833 0.206 0.811 0.037 0.806 0.008 0.858 0.033 0.847 0.009
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.706 0.003 0.880 0.118 0.903 0.122 0.933 0.220 0.956 0.374
CCI = 2 0.696 0.001 0.788 0.003 0.851 0.014 0.895 0.055 0.921 0.111
CCI = 3 0.898 0.438 1.061 0.544 1.123 0.155 1.141 0.068 1.193 0.008
CCI ≥ 4 0.627 0.001 0.798 0.038 0.814 0.026 0.862 0.072 0.884 0.106
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 0.923 0.428 0.891 0.124 0.957 0.483 0.950 0.355 0.977 0.641
Current 
Smoker 0.784 0.100 0.782 0.021 0.797 0.010 0.801 0.004 0.821 0.005
Unknown 1.084 0.752 0.848 0.312 0.983 0.885 0.985 0.871 0.958 0.598
QOF 
Indicator 
Achievement
DM06 0.859 0.105 0.865 0.025 0.839 0.001 0.866 0.002 0.869 0.001
DM12 0.993 0.938 0.951 0.454 0.922 0.138 0.899 0.026 0.891 0.007
DM17 1.029 0.788 1.043 0.578 0.998 0.974 0.984 0.770 0.975 0.598
NDA Process
BMI 
Check 0.975 0.826 0.923 0.334 0.874 0.057 0.883 0.051 0.892 0.049
BP Check 1.022 0.852 1.088 0.389 1.122 0.182 1.150 0.077 1.180 0.025
TC Check 1.408 0.013 1.370 0.002 1.396 < 0.001 1.342 < 0.001 1.243 0.003
Creatinine
Check 0.716 0.006 0.846 0.098 0.908 0.280 0.902 0.207 0.906 0.193
Foot 
Check 1.069 0.582 1.019 0.812 0.984 0.807 0.961 0.496 0.977 0.665
HbA1c 
Check 1.148 0.210 1.034 0.645 1.035 0.555 1.032 0.530 1.053 0.252
Retinal 
Screen 0.930 0.634 0.929 0.412 0.932 0.300 0.922 0.155 0.963 0.454
Smoking 
Status 
Check
1.066 0.606 0.928 0.355 0.886 0.062 0.929 0.191 0.931 0.157
Urinary 
Albumin 1.117 0.547 0.975 0.802 0.971 0.698 0.965 0.571 0.983 0.762
Table 86. Results from full multiple-variable logistic regression of patient characteristics, QOF
indicators achieved and individual NDA processes received against death due to a potentially
diabetes-related cause.
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.725 0.081 0.742 0.028 0.687 0.001 0.748 0.005 0.735 0.001
Years With DM 1.018 0.002 1.013 0.001 1.013 < 0.001 1.014 < 0.001 1.013 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.034 0.703 1.000 0.996 1.003 0.954 1.007 0.866 0.996 0.918
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.357 0.810 0.890 0.885 1.116 0.886 0.889 0.858
45 – 64y 1.900 0.227 1.893 0.608 1.254 0.772 1.531 0.567 0.932 0.913
65 – 74y 2.100 0.158 1.949 0.591 1.209 0.808 1.446 0.619 0.898 0.867
≥ 75y 2.319 0.107 2.139 0.540 1.409 0.660 1.689 0.480 1.082 0.903
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.049 0.725 1.051 0.593 0.999 0.985 0.994 0.925 0.967 0.571
3 1.062 0.653 1.033 0.730 1.000 0.999 1.006 0.925 0.991 0.876
4 0.915 0.511 0.909 0.306 0.928 0.325 0.904 0.125 0.881 0.031
5 0.822 0.176 0.807 0.033 0.804 0.008 0.857 0.031 0.845 0.009
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.709 0.004 0.881 0.123 0.904 0.126 0.934 0.223 0.958 0.387
CCI = 2 0.706 0.002 0.790 0.004 0.850 0.014 0.894 0.050 0.919 0.104
CCI = 3 0.904 0.469 1.062 0.537 1.123 0.156 1.139 0.071 1.192 0.008
CCI ≥ 4 0.629 0.002 0.800 0.040 0.815 0.027 0.859 0.066 0.880 0.094
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 0.926 0.441 0.891 0.122 0.957 0.485 0.950 0.354 0.976 0.632
Current 
Smoker 0.783 0.098 0.780 0.020 0.795 0.009 0.800 0.004 0.819 0.004
Unknown 1.082 0.758 0.849 0.316 0.994 0.960 1.000 1.000 0.975 0.758
All Selected QOF 
Indicators 0.785 0.028 0.843 0.018 0.811 < 0.001 0.834 < 0.001 0.839 < 0.001
NDA Process
BMI 
Check 0.979 0.853 0.924 0.344 0.876 0.061 0.887 0.061 0.895 0.057
BP Check 1.027 0.815 1.068 0.484 1.079 0.359 1.092 0.249 1.114 0.130
TC Check 1.480 0.002 1.427 < 0.001 1.430 < 0.001 1.360 < 0.001 1.253 0.001
Creatinine 
Check 0.704 0.004 0.830 0.064 0.880 0.152 0.876 0.103 0.878 0.085
Foot 
Check 1.075 0.552 1.022 0.788 0.984 0.806 0.960 0.485 0.976 0.652
HbA1c 
Check 1.129 0.265 1.020 0.783 1.023 0.696 1.022 0.660 1.044 0.337
Retinal 
Screen 0.929 0.628 0.930 0.421 0.932 0.301 0.922 0.154 0.963 0.450
Smoking 
Status 
Check
1.066 0.606 0.932 0.384 0.889 0.070 0.931 0.206 0.932 0.164
Urinary 
Albumin 1.132 0.499 0.977 0.818 0.975 0.741 0.966 0.588 0.984 0.767
Table 87. Results from full multiple-variable logistic regression of patient characteristics,
achievement of all three selected QOF indicators and individual NDA processes received against
death due to a potentially diabetes-related cause.
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.745 0.111 0.751 0.035 0.693 0.002 0.757 0.008 0.743 0.001
Years With DM 1.018 0.002 1.013 0.002 1.012 < 0.001 1.013 < 0.001 1.013 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.060 0.504 1.028 0.658 1.027 0.595 1.022 0.629 1.007 0.854
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.410 0.787 0.963 0.963 1.205 0.807 0.910 0.887
45 – 64y 1.878 0.235 1.955 0.591 1.359 0.694 1.651 0.500 0.971 0.964
65 – 74y 2.052 0.170 2.007 0.576 1.310 0.730 1.560 0.550 0.937 0.920
≥ 75y 2.292 0.111 2.234 0.519 1.548 0.575 1.844 0.410 1.142 0.837
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.036 0.791 1.055 0.567 1.003 0.967 0.999 0.990 0.970 0.614
3 1.047 0.729 1.035 0.718 1.007 0.929 1.016 0.819 0.995 0.934
4 0.902 0.439 0.911 0.317 0.933 0.357 0.908 0.141 0.882 0.034
5 0.806 0.132 0.806 0.031 0.809 0.010 0.858 0.031 0.842 0.007
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.711 0.004 0.882 0.127 0.906 0.134 0.936 0.239 0.959 0.403
CCI = 2 0.695 0.001 0.789 0.003 0.849 0.013 0.894 0.051 0.920 0.107
CCI = 3 0.882 0.367 1.049 0.623 1.115 0.183 1.135 0.079 1.186 0.010
CCI ≥ 4 0.621 0.001 0.797 0.037 0.816 0.028 0.862 0.072 0.884 0.107
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 0.929 0.447 0.888 0.088 0.933 0.227 0.941 0.228 0.957 0.334
Current 
Smoker 0.788 0.092 0.770 0.009 0.770 0.001 0.791 0.001 0.800 0.001
Unknown 1.083 0.754 0.845 0.300 0.974 0.822 0.986 0.880 0.946 0.493
QOF 
Indicator 
Achievement
DM06 0.854 0.090 0.859 0.019 0.838 0.001 0.865 0.002 0.870 0.001
DM12 0.997 0.975 0.961 0.556 0.926 0.158 0.905 0.034 0.902 0.014
DM17 1.065 0.530 1.083 0.271 1.047 0.447 1.021 0.696 0.997 0.942
NDA 
Processes 
Received
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 0.793 0.127 0.836 0.181 0.928 0.530 0.932 0.521 0.922 0.432
2 0.922 0.596 0.927 0.568 1.035 0.774 1.043 0.704 0.996 0.967
3 1.090 0.606 1.044 0.754 1.063 0.607 1.009 0.932 1.052 0.612
4 1.125 0.483 1.172 0.226 1.248 0.050 1.245 0.033 1.189 0.066
5 1.050 0.770 1.148 0.255 1.162 0.146 1.185 0.066 1.142 0.116
6 1.150 0.395 1.184 0.139 1.212 0.043 1.161 0.077 1.139 0.092
7 1.157 0.428 1.004 0.974 1.056 0.581 1.064 0.469 1.092 0.260
8 1.438 0.241 0.942 0.710 0.968 0.798 0.943 0.586 0.994 0.950
9 1.028 0.961 1.034 0.917 0.991 0.970 1.037 0.847 1.025 0.880
Table 88. Results from full multiple-variable logistic regression of patient characteristics, QOF
indicators achieved and total number of NDA processes received against death due to a potentially
diabetes-related cause.
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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2005/06 2005/06 -2006/07
2005/06 -
2007/08
2005/06 -
2008/09
2005/06 -
2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.741 0.103 0.743 0.029 0.686 0.001 0.751 0.006 0.739 0.001
Years With DM 1.019 0.001 1.014 0.001 1.013 < 0.001 1.014 < 0.001 1.013 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.051 0.572 1.016 0.793 1.015 0.772 1.015 0.740 1.003 0.941
Age Group
< 25y No Events* Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.364 0.807 0.928 0.926 1.170 0.837 0.895 0.867
45 – 64y 1.863 0.241 1.931 0.598 1.321 0.722 1.605 0.525 0.949 0.936
65 – 74y 2.018 0.180 1.973 0.586 1.272 0.758 1.517 0.575 0.916 0.891
≥ 75y 2.234 0.122 2.174 0.534 1.487 0.611 1.779 0.438 1.108 0.873
Deprivation 
Fifth
(1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.028 0.834 1.048 0.614 0.998 0.984 0.996 0.952 0.968 0.588
3 1.038 0.780 1.027 0.773 1.003 0.971 1.012 0.862 0.992 0.893
4 0.891 0.390 0.903 0.270 0.928 0.323 0.906 0.131 0.880 0.030
5 0.798 0.116 0.804 0.029 0.808 0.009 0.857 0.030 0.841 0.007
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.715 0.005 0.885 0.137 0.908 0.141 0.937 0.245 0.960 0.417
CCI = 2 0.703 0.002 0.790 0.003 0.848 0.012 0.892 0.046 0.918 0.100
CCI = 3 0.890 0.399 1.052 0.602 1.116 0.177 1.135 0.079 1.186 0.010
CCI ≥ 4 0.626 0.001 0.802 0.042 0.819 0.030 0.862 0.070 0.883 0.101
Smoking 
Status
Non-
Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-
Smoker 0.928 0.436 0.887 0.084 0.933 0.229 0.942 0.233 0.957 0.336
Current 
Smoker 0.783 0.083 0.766 0.007 0.767 0.001 0.790 0.001 0.799 < 0.001
Unknown 1.079 0.764 0.844 0.295 0.980 0.862 0.995 0.958 0.958 0.596
All Selected QOF 
Indicators 0.811 0.054 0.866 0.043 0.830 0.001 0.848 0.001 0.848 < 0.001
NDA 
Processes 
Received
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 0.786 0.107 0.818 0.127 0.891 0.331 0.888 0.279 0.878 0.203
2 0.914 0.540 0.904 0.436 0.982 0.873 0.977 0.827 0.927 0.455
3 1.094 0.574 1.030 0.817 1.011 0.925 0.942 0.561 0.971 0.762
4 1.148 0.376 1.167 0.205 1.191 0.097 1.167 0.105 1.098 0.284
5 1.065 0.681 1.146 0.213 1.114 0.247 1.114 0.195 1.057 0.467
6 1.192 0.239 1.195 0.075 1.171 0.058 1.096 0.210 1.056 0.411
7 1.222 0.239 1.023 0.829 1.024 0.786 1.007 0.926 1.014 0.838
8 1.524 0.163 0.956 0.764 0.943 0.613 0.894 0.252 0.926 0.373
9 1.101 0.867 1.055 0.866 0.972 0.903 0.986 0.940 0.953 0.762
Table 89. Results from full multiple-variable logistic regression of patient characteristics,
achievement of all three selected QOF indicators and total number of NDA processes received
against death due to a potentially diabetes-related cause.
* = No deaths during follow-up period, 778 patients excluded for this year only; IRR = Incidence rate ratio; CCI =
Charlson Co-morbidity Index; QOF = Quality and Outcomes Framework; NDA = National Diabetes Audit; BMI =
Body mass index; BP = Blood pressure; HbA1c = Glycated haemoglobin; TC = Total cholesterol
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Discussion
These analyses of patient-level data indicate the presence of an association
between high-quality diabetes management in primary care and ‘hard’ clinical
outcomes such as emergency admission rates, readmission rates and all-cause
mortality over follow-up periods varying in length from one to five years. There is
also some limited evidence that specific aspects of diabetes care may modulate the
likelihood of death being due to causes linked to diabetes mellitus. Many of the
associations observed persisted across increasingly complex models, from
univariate models to fully-adjusted models. It is notable, however, that associations
with deprivation, a factor that is outside of the sphere of influence of primary care,
had the most consistent association with diﬀerences in survival, admission rates
and odds of death.
Findings of Comorbidity Analyses
The Cox models describing the survival of individuals with and without diabetes
indicated that prevalent diabetes – that is, diabetes diagnosed prior to the start of
observation – is associated with increased hazards of death in comparison to
individuals without diabetes. Individuals with newly-diagnosed diabetes were
associated with significantly increased hazard of death compared to individuals
without diabetes for Charlson Co-morbidity index of 0, but exhibited hazards of
death that did not significantly diﬀer from people without diabetes for all other levels
of co-morbidity.
These findings, adjusted for a number of patient factors, imply that prevalent
diabetes significantly impacts on survival regardless of the level of co-morbidity an
individual has. In coǌunction with evidence that newly-diagnosed diabetes has a
negative impact on survival for individuals deemed not to have significant co-
morbidity calls into question the rationale of diabetes (without complication) being
assigned a weight of 0 in the updated Charlson disease weights by Quan et al.207
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It should be noted that the selection of controls (i.e. individuals without a
recorded history of diabetes) by the MHRA in the supplied CPRD-HES dataset
could have favoured individuals who may be subject to an increased risk of vascular
disease as the selection criteria stipulated these individuals as having at least one
record of blood pressure, cholesterol, HbA1c or BMI. Hence, there may be a bias
towards cardiovascular events in the control group which may have obfuscated any
diﬀerences that may truly exist between them and individuals newly diagnosed with
diabetes.
Main Findings of Quality and Outcomes Framework 
Analyses
In the full models of patient-level emergency admission rates, where all
indicators of quality were adjusted for the eﬀects of attainment of other indicators
and additional patient characteristics, associations of a clinically significant
magnitude were observed for attainment of QOF indicators DM06 (HbA1c ≤ 7.4% /
57.4 mmol/mol) in 2005/06 for all lengths of follow-up and DM17 (TC ≤ 5.0 mmol/L)
in 2005/06 for lengths of follow-up between two and five years. The estimated
relative reductions in emergency admission rates for patients achieving DM06 are in
the order of 7.6% – 13.2%; patients achieving DM17 were subject to a 6.1% – 9.9%
relative reduction in emergency admission rates. The estimated eﬀects of receipt of
all three of the selected QOF indicators, whilst protective with regards to emergency
admission rates for follow-up periods of two to five years, did not exceed that of
any of the individual QOF indicators in any of the follow-up periods.
The pattern of associations between achievement of the selected QOF
indicators and readmission rates in the fully adjusted models indicated significant
associations between achieving DM06 in 2005/06 and reduced readmission rates,
with estimated relative rate reductions ranging between 12.8% – 19.7% across all
follow-up periods. Achieving DM12 (BP ≤ 145/85) in 2005/06 was associated with
significant increases in readmission rates for follow-up periods of one and two years
in all models, with an estimated relative rate increase of 10.3% – 19.4%; this
seemingly counterintuitive finding may result from the potentially harmful eﬀects of
overly aggressive treatment of hypertension100, 101, 203, 204, with side-eﬀects related to
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commencement of antihypertensive therapy being a driver of readmissions.
Associations between attainment of DM17 in 2005/06 and readmissions were only
observed in the fully-adjusted model utilising the number of NDA processes
achieved in 2005/06 for follow-up periods of four or five years, with estimated
relative rate reductions of 7.3% – 8.0%. The lack of association between DM17
attainment and readmission rates in the fully-adjusted model utilising the count of
NDA processes received may result from additional and explicit adjustment for
receipt of the NDA process describing checking of total cholesterol, which may
imply that engagement with care and the ancillary discussions pertaining to
secondary and tertiary prevention may have a greater impact on readmissions than
a specific treatment target.
Findings for the fully adjusted models for the odds of all-cause death were
somewhat unexpected, insofar as the majority statistically significant findings
indicated associations between attaining QOF targets and increased odds of death;
the sole exception was attainment of DM17 (TC ≤ 5.0 mmol/L) for follow-up periods
of four and five years in the fully-adjusted model utilising the count of NDA
processes received; DM17 was associated with increased odds of death for follow-
up lengths of one and two years (OR 1.099 – 1.224).
As these QOF targets are all based upon attaining a result that is below a certain
cut-oﬀ, the population of individuals who have achieved these targets may have a
range of values; as discussed before, overly aggressive control of blood pressure,
glycaemic load and total cholesterol have been associated with poorer outcomes in
other studies.100, 101, 203, 204
Another potential explanation is selection bias, whereby individuals who are
judged to be at greater risk may be more likely to have these variables tested and,
consequently, receive treatment to control their blood pressure, glycaemic load or
cholesterol levels; although these individuals may achieve these targets, the follow-
up period for this study may be insuﬃcient to detect any benefit resulting from
reductions in risk conferred by control of these physiological parameters.
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In the fully adjusted models of odds of death due to potentially diabetes-related
causes, attaining DM06 in 2005/06 was associated with reduced odds of potentially
diabetes-related death for follow-up periods of two to five years, with relative
reductions in the odds of death ranging between 13.0% – 16.2%. Whilst such a
finding supports the benefits of adequate glycaemic control in people with diabetes,
there is the potential for this observation to be compromised by the presence of
selection bias, whereby healthier individuals are more likely to have their HbA1c
regularly checked and their glycaemic control actively managed. 
Achievement of DM12 in 2005/06 was associated with reduced odds of death
due to a potentially diabetes-related cause for follow-up periods of four and five
years, with relative reductions in odds ranging between 9.5% – 10.9% over these
follow-up periods. Again, as with the findings for DM06, such associations may be
subject to a degree of selection bias; the lack of association between attaining a
blood pressure of ≤ 145/85 until four or more years of follow-up may also reflect a
degree of lag between reduction of mean vascular stress and subsequent reduction
of atherogenesis and risk of cardiovascular death.
Attaining all three of the selected QOF targets in 2005/06 only exerted an
additional benefit – that is, an estimated eﬀect that exceeded any of the individual
associations between individual QOF targets and outcomes – with respect to the
odds of potentially diabetes-related death. Such a finding indicates that attaining
multiple diabetes-related intermediate targets may indeed reduce the incidence of
life-threatening complications of diabetes, allowing patients to survive to the point
where they are more likely to die of a non-related cause. However, the lack of
additional benefit with respect to emergency admissions, readmissions and all-
cause mortality may indicate that other unmeasured factors obviate any synergy
between achievement of multiple treatment targets with respect to these outcomes.
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Main Findings of National Diabetes Audit Analyses
The care processes measured by the NDA do not specify clinical targets; they
simply measure whether a specified activity has taken place, which could be argued
to be a proxy measure of engagement with care.
Receipt of a number of the individual NDA care processes – BMI checks, total
cholesterol checks, foot review and retinal screening – in 2005/06 were associated
with reduced rates of emergency admissions across all time periods. Conversely,
three of the care processes – BP checks, creatinine checks and smoking status
checks – were actually associated with increased rates of emergency admissions
across all follow-up periods.
Receipt of HbA1c checks in 2005/06 only exhibited a significant association with
reduced emergency admission rates over three years of follow up, with no
significant associations with changes in emergency admission rates across other
follow-up periods. Receipt of urinary albumin testing in 2005/06 was associated
with a significant increase in emergency admission rates over the longest period of
follow-up, five years; associations with emergency admission rates across other,
shorter, follow-up periods were non-significant.
The pattern of associations between individual NDA care processes and
changes in readmission rates was similar to that observed for emergency
admissions in terms of NDA processes and follow-up periods. Receipt of BMI
checks, total cholesterol checks, foot review or retinal screening in 2005/06 were all
associated with decreased readmission rates. Receipt of BP checks, creatinine
checks and smoking status checks in 2005/06 were associated with increased
readmission rates. No consistent associations between receipt of HbA1c checks,
bar for readmissions over four years of follow up, were observed. No significant
associations between urinary albumin checks and changes in readmission rates
were observed for any length of follow-up.
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Once again, a potential explanation for the seemingly counterintuitive
observation that certain NDA care processes are associated with increased, rather
than decreased, emergency admission rates could be one of selection bias and
confounding by indication. Physicians may be more likely to perform certain checks
on individuals who they deem to be of higher risk, meaning that the sub-population
who received these checks represent a somewhat diﬀerent risk pool.
A slightly diﬀerent pattern of associations were observed between receipt of
individual NDA care processes and death due to any cause were observed. Receipt
of the NDA care processes pertaining to BMI checks, total cholesterol checks, foot
checks, HbA1c checks, retinal screening or urinary albumin checks in 2005/06 were
all associated with decreased odds of death across all follow-up periods. The
apparent protection with respect to odds of death may reflect that this particular
group of checks prompt delivery of secondary and tertiary prevention. Conversely,
the fact that receipt of creatinine checks in 2005/06 was associated with increased
odds of death across all time periods may reflect that individuals with established
chronic renal failure are more likely to have their renal function regularly checked. 
Checks of smoking status in 2005/06 exhibited a slightly more complex
association with odds of death, with receipt of this care process associated with a
significant reduction in odds of death over one year of follow-up, but a significant
increase in those odds over four and five years of follow-up. It should be noted that
the NDA smoking status check does not explicitly require referral to any smoking
cessation activities in order to be recorded as received. In the short-term, therefore,
receipt of this process may lead to a change in smoking behaviour that results in a
reduction in risk of respiratory disease; the increased in odds observed in the longer
term may result either from resumption of smoking or the onset of respiratory
disease resulting from long-term smoking. Some degree of selection bias is also
likely to exist, with individuals who have a history of smoking being more likely to
have their current smoking status checked.
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Receipt of the NDA total cholesterol check in 2005/06 was associated with
increased odds of death due to a potentially diabetes-related cause across all
lengths of follow-up. As the list of causes of death considered potentially diabetes-
related in these analyses comprised of a number of cardio- and cerebrovascular
diseases, such a finding may support the theory that individuals viewed to be at
increased risk of vascular disease are more likely to have this particular care
process carried out. Although there were significant associations with changes in
the odds of dying due a potentially diabetes-related cause for the longest follow-up
period in these analyses and receipt of the BMI or BP checks in 2005/06, the
associated significance levels (p = 0.049 and p = 0.025 respectively) are arguably of
borderline relevance in light of the number of variables included in the full model.
For the fully-adjusted models that utilised the number of NDA processes
received as opposed to receipt of individual processes, a common feature of the
pattern of associations with the various outcomes was that of a ‘cut-oﬀ’ in the
number of processes received below which associations with outcomes conferred
an increased admission rates or odds of death. As previously discussed, this
seemingly paradoxical finding may result from selection bias and confounding by
indication. Individuals with increased prior odds of unfavourable outcomes as a
result of the progression of their diabetes may be more likely to receive a greater
number of care processes. Conversely, those who receive relatively few (or no) care
processes may represent a subgroup of individuals who are very unlikely to
experience an unfavourable outcome. The net eﬀect of such a phenomenon, should
it hold true, would be the counterintuitive association between receipt of a low
number of care processes and improved outcomes, as observed in these analyses.
For the models examining emergency admission and readmission rates, receipt
of four to five or fewer NDA care processes was associated with increased
admission rates in comparison to individuals receiving no care process across the
majority of follow-up periods. Receipt of eight or nine care processes in 2005/06
was protective of readmissions across all lengths of follow-up, but significant
reductions in emergency admission rates were only observed at up to three years of
follow-up.
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There were significant associations with the number of NDA processes received
in 2005/06 and odds of death across all follow-up periods in the fully adjusted
models. As with the associations observed for emergency admissions and
readmissions, a ‘cut-oﬀ’ point with respect to favourable outcomes was evident.
Receipt of five or more NDA care processes was associated with reduced odds of
death in comparison to individuals receiving no care processes over all lengths of
follow-up; conversely, receipt of only one or two care processes was associated
with increased odds of death across all follow-up periods.
There appeared to be little in the way of consistent associations between the
number of NDA care processes received and the odds of death due to a potentially
diabetes-related cause; some associations did reach significance at the 95%
confidence level but, as stated previously, such associations should be interpreted
with caution in the context of the number of predictors included in the fully adjusted
models.
Taken as a whole, the findings of the associations (or, indeed, relevant lack of
certain associations) for NDA care processes suggest that engagement with care
processes reduce the risk of acute illness, as implied by the findings for emergency
admission rates, readmission rates and death due to any cause. It is important to
note that these outcomes are not limited to diabetes-specific events; on the other
hand, the general lack of association between NDA care processes in the fully
adjusted models, either individually or as a whole, with changes in the odds of
potentially diabetes-related death, in contrast to the reductions in odds of such
deaths with achievement of DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) and DM12 (BP
≤ 145/85) imply that actioning concerns raised during regular reviews, of which
compliance with process measures may be a proxy measure of, is vital to reducing
the risk posed by diabetes and that engagement with care in and of itself may not
be suﬃcient to reduce the likelihood of death resulting from diabetes.
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Patients who received no NDA processes may view themselves, and be viewed
by their primary care team, to be of acceptably low risk of unscheduled care and
mortality – meaning that regular review is subjectively viewed as a low priority. As
such, the case mix of individuals in the group who received no NDA care processes
is more likely to represent a lower collective risk.
Those who have received some NDA care processes may well have an
objectively and subjectively elevated risk but are, for whatever reason, poorly
engaged with their ongoing care. Those who received the highest numbers of NDA
care processes likely have a need for regular review, but are engaged with their
care, unlocking opportunities for early intervention and secondary and tertiary
prevention, thereby reducing the likelihood of emergency admissions and death.
Whilst the primary aim of these analyses have been to explore associations
between markers of high-quality diabetes management in primary care and
outcomes such as emergency admissions, readmissions and death, consistent and
strong associations were observed between increasing deprivation and poor
outcomes. The estimated benefits of living in the most aﬄuent areas of England
exceeded the magnitude of those associated with a number of quality indicators,
emphasising the importance of socio-economic factors in influencing the outcomes
that a patient may reasonably expect from high-quality primary care.
Strengths and Limitations
These analyses examining the relationships between the quality of diabetes
management in primary care and a range of ‘hard’ outcomes (emergency
admissions, readmissions and death) have a number of strengths. The highly
granular, patient-level data allows for explicit links between primary care activity
and outcomes to be made, eliminating any inference from metrics of practice-level
performance on the quality of care a specific patient has actually received. The
resolution to which primary care consultation data was provided also allowed for
accurate identification of eligible patients, further reducing bias.
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There were, however, a number of shortcomings of both the data provided and
the analytical methods necessitated by some of these shortcomings. CPRD is a
voluntary data collection system to which practices can opt to be a part of; as such,
it is likely that the included practices are not wholly representative of English
general practices and may be more likely to include well-organised, larger
practices.223 As such, the associations observed in these analyses may not be
wholly generalisable to patients registered to English general practices.
The attainment of certain NDA care processes in the sample of patients with
diabetes contained in the CPRD-HES dataset in 2005/06 diﬀered considerably from
that observed in England as a whole. This could reflect the possibility that the
sample of patients with diabetes contained within the CPRD-HES dataset is not
wholly representative of the whole of England, as the Read codes used for these
studies were based upon those utilised for the original NDA data extraction. That is
not to say that the CPRD dataset is not representative as a whole when considering
the entire registered population; the diﬀerences in the population with diabetes in
the dataset delivered by the MHRA could result from chance as a result of the
random sampling process or, potentially, the sub-population with diabetes in their
dataset not truly reflecting that of all individuals with diabetes in England.
From an analytical standpoint, the large sample sizes available lent considerable
statistical power to the analyses performed. The appropriateness of models was
also checked, and alternative methods employed where necessary to maximise the
quality of inferences gleaned from analyses.
Whilst CPRD data was reviewed and declared fit-for-purpose and compatible
with the CPRD ‘Gold’ standard by the MHRA prior to delivery of the dataset,
erroneous data was identified in a small proportion of patient records. These
analyses also had to assume that all entered data was, in fact, correct and that
there was no diﬀerential measurement biases across individuals, patient groups or
practices. However, such concerns would be pertinent to all studies utilising
observational primary care data sourced from a number of practices.
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The anonymisation of patient and practice data by the MHRA also introduced
certain limitations, in particular the lack of ability to link additional datasets
describing, for example, other environmental exposures, levels of practice staﬃng
and global practice performance. As such, it is likely that a certain degree of
residual confounding remains – but there was no practicable way to quantify the
degree or reduce the impact of this confounding.
The lack of explicit classification of patients with diabetes into T1DM and T2DM
necessitated estimation of each patient’s actual diabetes type; however, the
approach utilised for determination of diabetes was validated against the group of
patients of unequivocal diabetes type. 
Co-morbidity, an important potential confounder if left unaccounted for, was
quantified through an adaption of the Charlson co-morbidity index.205, 206 Whilst the
updated weights for various disease categories had been validated in a multi-
national study207, whether these weights are appropriate estimates of the burden of
co-morbidity in the CPRD practice population cannot be verified and, as highlighted
in the analysis of the impact of co-morbidity by diabetes status, may not be entirely
accurate. Furthermore, it could be argued that the impact of certain co-morbidities
are dependent on not only primary and secondary care quality, but other
socioeconomic and environmental factors, the measurement of which is beyond the
scope of these analyses.
The intention of these analyses was to explore the eﬀects of the quality of
treatment actually received by a patient and, to that end, they purposefully did not
exclude individuals flagged as QOF exceptions. This approach, whilst
advantageous for examining ‘real-world’ eﬀectiveness, may have included some
individuals who were atypical in some fashion; for example, one such reason that an
individual may have been declared as an exception is on the grounds of an
underlying diagnosis of metastatic cancer. 
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It is likely that, under the assumption that regular checks and reviews for
diabetes would have ceased on compassionate grounds, that these individuals
would be classified as having not attained QOF targets or not receiving NDA care
processes. Should this be the case, it is conceivable that the estimates of odds of
death for achievement of quality targets and processes may overestimate the
benefits of receipt of high-quality care.
Closing Summary
The findings from these patient-level analyses provide further insight into the
associations observed in the practice-level analyses presented earlier in this thesis.
The findings of these analyses not only indicate the importance of attaining
intermediate clinical targets can have on minimising unfavourable outcomes, but
also the central role that engagement with regular clinical reviews have on
improving outcomes in people with diabetes.
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Conclusions
Overview of Findings
The analyses presented in this thesis have consistently indicated that there are
some aspects of primary care quality that can have a statistically and clinically
significant impact on the outcomes of individuals with diabetes mellitus, lending
credence to the classification of diabetes mellitus a as primary care sensitive
condition.
Over the coming decades, the population of England will, on average, become
older224, a phenomenon that will likely increase pressure on health services and
increase the number of individuals with chronic diseases such as diabetes.
Furthermore, the English population is becoming increasingly sedentary and
obese225, risk factors for the development of and poorer outcomes from diabetes
and cardiovascular disease. Projections indicate that, by 2030, there will be an
additional 1.6 million individuals with diabetes compared to 2010; this increase not
only represents a absolute increase in the number of cases, but also increased
prevalence, with the English prevalence of diabetes rising from 7.4% in 2010 to
9.5% in 2030.26
The NHS will, without doubt, face increasing demand for the management of
diabetes, and it is essential that services are configured in a manner that maximises
the potential for good patient outcomes in coǌunction with cost-eﬀective care.
Some of the most consistent findings from the analyses contained in this thesis
indicate that some of the most significant gains in patient outcomes could be
realised through regular review of patients and improving accessibility of services.
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Practice-level analyses indicated that those practices in the highest fifth of
performance for the group of diabetes QOF indicators pertaining to processes of
care (indicators DM02 – DM04, DM08 – DM11, DM13 – DM16, DM18, DM21 and
DM22, depending on QOF year) experience age-sex adjusted admission rates that
are up to 9.1% lower than practices in the lowest fifth of performance.
The importance of regular reviews and checks – even without specification of a
particular treatment target – were further highlighted by the associations observed
between the receipt of NDA care processes and outcomes.
Delivery of certain NDA care processes were associated with improved
outcomes, with BMI checks, total cholesterol checks, foot checks and retinal
screening conferring protection against emergency admissions, readmissions and
death over all follow-up periods in fully adjusted patient-level models.
Furthermore, patients who received all nine care processes as described by the
National Diabetes audit in 2005/06 were subject to an emergency admission rate
that was 53.7% lower for the first year of follow-up and continued to provide
significant benefits with respect to emergency admissions up to three years of
follow-up, with a relative rate reduction of 16.4%.
Receipt of all 9 NDA care processes was also associated with marked
reductions in readmission rates, with relative rate reductions of 71.4% in the first
year of follow-up and 29.4% over five years of follow-up. Engagement with process
measures also conferred reduced odds of death due to any cause, with individuals
receiving all nine care processes in 2005/06 exhibiting reductions in the odds of
death of 96.5% during the first year of follow-up and 40.3% over five years of
follow-up.
It is conceivable that the total number of care processes received by a patient is
a proxy marker of engagement with regular, scheduled diabetes care; patients who
are able to attend frequent diabetes reviews – under the assumption that their
practice is able to oﬀer such reviews – are assumedly more likely to attain the
highest number of care processes. Conversely, the groups of patients who have
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received relatively few care processes are, for whatever reason, are less likely to be
engaged with care. It is also likely that regular reviews provide prompts and
opportunities for patient education and secondary and tertiary prevention, factors
that are likely to be linked with reduced risk of the development of complications of
diabetes and potentially avoidable unscheduled hospitalisations.
One of the key enablers of delivery of regular checks to patients is practice
accessibility, metrics of which – PE07 (the ability to book an appointment within 2
working days) and PE08 (the ability to book an appointment more than 2 days in
advance) – were indirectly measured through responses to the GP Patient Survey. 
In practice-level analyses, associations between achievement of indicator PE08,
the ability of patients to book appointments more than two days in advance, were
observed – practices in the best performing fifth for this indicator had significantly
reduced emergency admission rates in comparison to their peers in the worst
performing fifth, with relative rate reductions of between 6.0% – 8.8%.
The benefits associated with the ability for patients with a chronic disease such
as diabetes to book scheduled appointments to discuss and review their ongoing
care, as opposed to requests for urgent short-term care, doubtless support the
delivery of proactive, rather than reactive, care. The availability of such
appointments may well enable patient engagement and preparedness of their
primary care team, key components of eﬀective care for chronic disease.226
Unfortunately, both PE07 and PE08, as of 2011/12227, are no longer part of QOF,
divorcing a proportion of practice remuneration from the ability of patients to book
scheduled appointments. Although the GP Patient Survey continues to be
distributed to a sample of the registered population in England, the lack of financial
incentives to ensure availability of appointments to discuss non-urgent issues has
the potential to negatively impact the outcomes for people with diabetes, as there
may be an inferred prioritisation of urgent problems in the distribution of available
appointments. 
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Whilst the associations observed between processes measures and outcomes
are generally encouraging, the importance of attaining specific intermediate clinical
targets should not be ignored.
Although associations between thematic groupings of QOF indicators and
emergency admissions were largely non-significant in the fully adjusted models,
some associations between individual attainment of certain QOF indicators and
outcomes were observed. In patient-level analyses, achievement of DM06 (HbA1c ≤
7.4% / 57.4 mmol/mol) conferred protection against emergency admissions and
readmissions even after adjustment for other indicators of high-quality care; DM17
(TC ≤ 5.0 mmol/L) similarly conferred protection against readmissions.
The associations observed for increased odds of death due to any cause and
attainment of the intermediate clinical outcomes in QOF were unexpected, but may
arise from selection bias, where physicians may be more likely to check and
aggressively manage individuals they view to be at high risk. An alternative
explanation is that a number of individuals who have attained these targets have
been treated to the degree where limited further benefit can be realised and,
potentially, the risks of harm are greater.
The ability of practices to declare patients as exceptions to various QOF targets
may have diluted any relationships between target-driven indicators and outcomes;
although these patients will not have been counted insofar as QOF attainment is
concerned, they will still have been present in the practice-level tallies of emergency
admissions. Patients who have been declared as exceptions are likely to be those
who either cannot access services, are unwilling or unable to comply with treatment
recommendations, have already received maximal therapy or have been excepted
from QOF on compassionate grounds.
When examining relationships between the level of patients a practice has
declared as an exception and emergency admissions, practices who are in the
highest fifth of exception reporting for the process group of QOF indicators
experienced emergency admission rates that were 10% – 12% higher than those in
the lowest fifth of exception reporting for three of the four QOF years where
exception reporting data was available.
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Unexpectedly, the fifth of practices with the highest levels of exception reporting
for the intermediate cardiovascular outcomes QOF group were associated with
lower emergency admission rates for three of the four QOF years where exception
reporting data was available. Considering that the practice-level analyses only
examined admissions occurring within a given QOF year, such a finding may relate
to the short-term reduction in side-eﬀects associated with anti-hypertensive and
cholesterol-reducing therapy, whereas the deleterious eﬀects of elevated blood
pressure and hypercholesterolaemia may not be realised for a number of years.
Whilst it can be argued that practices should not be penalised for patients who
are unwilling to engage with treatment or for whom aggressive treatment would not
be appropriate, there is a danger of disenfranchising those who cannot engage with
treatment due to social, environmental or mobility barriers. Exception reporting
does not apply to NDA care processes and could, therefore, be argued to better
reflect ‘real world’ outcomes of the delivery of high-quality diabetes care. Indeed, it
was for this specific reason – ascertainment of the ‘real world’ impact of
interventions as opposed to the eﬀect on those who are able to engage and comply
with treatment – that the decision was made not to account for exception reporting
in the patient-level analyses reported in this thesis.
An interesting diﬀerentiation between the outcomes of receipt of care processes
and achievement of intermediate clinical outcomes was observed in the analyses
examining the odds of death due to a potentially diabetes-related cause. Attaining
DM06 (HbA1c ≤ 7.4% / 57.4 mmol/mol) or DM12 (BP ≤ 145/85) in 2005/06 was
associated with significantly reduced odds of death due to a diabetes-related
cause – in other words, the individuals who achieved either of these QOF indicators
were more likely to die of something unrelated to diabetes as opposed to a
condition related to it. Such a finding may indicate that the benefits of care
processes extend beyond the risks associated with diabetes, but that attainment of
certain clinical targets act more specifically on the risks to life posed by diabetes.
- 209 -
Whilst these analyses have demonstrated that delivery of high-quality care can
lead to improved outcomes, the wider socioeconomic environment may exert some
of the strongest and most consistent eﬀects with respect to changes in the rates
and odds of favourable outcomes.
In practice-level analyses, practices located in the least deprived tenth of
England were subject to emergency admission rates that were between 28% – 38%
lower than those located in the most deprived tenth of England. Similar associations
were also present in the patient-level analyses, with patients living in the most
aﬄuent fifth of England experiencing emergency admission and readmission rates
23% – 30% lower than those living in the most deprived fifth; for all-cause mortality,
those living in the most aﬄuent areas had odds of death that were approximately
22% – 34% lower than those living in the most deprived areas.
Deprivation is associated with a number of factors that can influence the quality
of management in primary care and the likelihood of satisfactory outcomes of
diabetes; high levels of deprivation are associated with poorer QOF achievement142,
147, patterns of health behaviours228, emergency hospitalisations13, 141, 200, prevalence
of chronic disease163 and multi-morbidity.229 However, the presence of
socioeconomic deprivation in and of itself is beyond the sphere of influence of
primary care – even though it can have profound eﬀects on the ability of patients to
access services, maintain healthy lifestyles and adversely aﬀect outcomes.
Such findings reinforce the notion that primary care – and, in a wider sense,
healthcare as a whole – cannot be viewed as a closed system. External factors are
important determinants of health outcomes that must be taken account of not only
in the measurement of healthcare performance but also in the allocation of
resources, thereby supporting equitable access to opportunities for individuals to
maximise their own health.
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Strengths and Limitations
The intention of this final chapter is to describe and discuss the general,
overarching themes identified through the various analyses. As such, the major
strengths and weaknesses of the analyses performed will be discussed here;
specific issues pertaining to practice- and patient-level analyses are discussed in
the relevant sections of preceding chapters (see pages 111-113 and 201-204).
One of the major strengths of all the analyses that have been undertaken for the
purposes of this thesis is one of sample size. For the practice-level models,
approximately 8,000 practices were included for all analyses; for patient-level
analyses, over 67,000 people with diabetes were included in the models exploring
relationships between quality of care received and outcomes. These sample sizes
allowed for identification of relationships that may have been obscured in smaller
analyses and granted suﬃcient power to allow adjustments such as clustering by
PCT in the practice-level models.
Another major strength of the analyses performed was that a number of health
and non-health predictors were included as predictors that were able to be included
in the models of health outcomes. This allowed for assessment of how various
factors may modulate health outcomes in a scenario that more closely resembles
‘real world’ clinical practice as opposed to the relatively rarefied environment of
clinical trials and carefully managed prospective cohort studies. The ‘full’ models
performed in both the practice- and patient-level analyses allowed for exploration of
the eﬀect of a particular quality marker when adjusted for the eﬀect of other quality
markers. As such, a more representative exploration of the benefits associated with
a given indicator of quality was possible.
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Despite the strengths of the approaches used in the various analyses contained
in this thesis, there are certain limitations that merit discussion. In previous sections
of this thesis, the representativeness of the population with diabetes provided for
analysis in the CPRD-HES dataset has been discussed; although the CPRD dataset
as a whole is considered to be representative of the registered population in
England, whether the same holds true for sub-populations identified by the
presence of a chronic disease is not known. Furthermore, the patient records
supplied amount to a random sample of 125,000 individuals with diabetes – only
4% of the total registered population with diabetes in 2013.230
The potential lack of representativeness of the research population may explain
the diﬀerences observed in the overall attainment of NDA care processes observed
in the dataset compared to that observed nationally for 2005/06. Furthermore, the
National Diabetes Audit for 2005/06 only sampled patients from 2,416 general
practices in England and Wales, amounting to 35% of the registered population
with diabetes for that year.231
It is, therefore, entirely possible that the groups of patients whose data was
utilised for the patient-level analyses presented in this thesis and the National
Diabetes Audit – both of which measure process attainment in 2005/06 – are
mutually exclusive. This raises the possibility that sampling error may contribute to
the marked discrepancies observed for process attainment between the individuals
included in this study and reported attainment levels in the National Diabetes Audit,
especially as identification of process attainment for these analyses was identified
using the same Read codes as those employed by the National Diabetes Audit.
Despite the fact that a relatively low proportion of the total number of people in
England with diabetes was used, the sample size remained large, lending
considerable power to the analyses performed. Furthermore, diﬀerences in
associations were modelled on the level of individual patients and were adjusted for
age, sex, ethnicity, deprivation and co-morbidity, which may well improve the
generalisability of these findings to the wider population with diabetes.
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One of the strengths of the CPRD-HES dataset was its longitudinal nature,
allowing for temporal delineation between healthcare events and outcomes.
However, the maximum length of follow-up in the patient-level analyses was five
years. The decision to commence observation at the start of the 2005/06 QOF year
was made to allow for QOF to become established in practice workflows, as it was
only introduced in 2004/05; data beyond the end of the 2009/10 QOF year (the fifth
year of observation) was incomplete for a number of practices, introducing an upper
limit on follow-up time. Whilst certain associations were observed over the available
follow-up period, it is unknown whether these hold true – or, indeed, whether
additional associations become apparent – over longer follow-up periods.
The receipt of aspects of care considered to be reflective of high quality were
only measured for 2005/06 in the patient-level analysis. Whilst it is likely that a
patient who achieved a certain quality indicator in one year is more likely to attain it
again in future years, changes in the quality of care received by patients in
subsequent years was not modelled. However, the consistent and biologically
plausible associations observed for many of the quality indicators in 2005/06 likely
indicate meaningful associations between markers of quality and outcomes.
Attention should also be drawn to the short follow-up period used for practice-
level analyses; each QOF year was modelled in isolation, meaning that models only
described events that occurred within that year. This approach makes the implicit
assumption that the maximal eﬀect of diﬀerences in quality on emergency
admissions would be realised within 12 months; this might be appropriate for some
acute illnesses, but is highly likely to be inadequate for changes in risk profiles for
other precipitants of emergency admissions, such as cardiovascular disease.
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The use of all-cause emergency admissions and readmissions, as opposed to
diabetes-specific admissions, in the patient-level analyses was chosen so as to
provide maximum comparability with the findings from the practice-level models. As
such, the associations observed between markers of high-quality diabetes care and
unscheduled hospital admissions may more closely reflect the overall impact that
primary care quality can have on total unscheduled care utilisation. That being said,
it is well-established that diabetes is an accepted risk factor for a wide range of
diseases that aﬀect a large number of organ systems; on these grounds, the lack of
exclusion of admissions for certain diseases could be argued to be sound.
One of the intentions of the methodology employed for these analyses was to
make them readily applicable to the activities of primary care in England; as such,
use of markers of quality such as QOF and NDA were utilised. Use of these markers
necessitated use of ‘cut-oﬀs’ for variables such as blood pressure, HbA1c and total
cholesterol. As alluded to in the discussion sections of previous chapters, it is likely
that there is variation in the actual levels of these measurements in the population
that has been identified as achieving a given ‘cut oﬀ’ value. Other studies have
indicated a U-shaped relationship between many of these indicators and the
occurrence of favourable outcomes.100, 101 It is therefore conceivable that a number
of individuals who have been deemed successful in achieving a given quality
indicator may have measurements that would indicate an excess risk, which may
introduce a bias favouring a null result for a given quality indicator.
Despite the considerable eﬀort undertaken to adjust for a number of health and
non-health predictors of outcomes, it is likely that a considerable degree of residual
confounding remains in the various models. The variation in outcomes attributable
to unclustered practice-level models was estimated to only amount to around 2% of
the total variation, likely reflecting unmeasured diﬀerences in patient populations,
local health interventions and socio-environmental factors. Patient-level models are
likely to also contain a degree of residual confounding, partially due to the lack of
practice identifiers that precluded linkage of additional datasets, but also through
the absence of controlling for variables such as family history, total pack-years
smoked, the burden of polypharmacy and housing circumstances amongst others.
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Comparison to Existing Literature
Glycaemic Control
A number of previous studies, which have used routine data, longitudinal data
and bespoke prospective cohorts, have examined the relationship between quality
of care and outcomes for diabetes and other chronic diseases.
In these analyses, there was little evidence to indicate an association between
glycaemic control and the occurrence of outcomes such as unplanned hospital
admissions and death due to any cause. Studies such as the United Kingdom
Prospective Diabetes Study (UKPDS), a prospective cohort study that followed over
5,000 individuals newly diagnosed with T2DM for a median follow-up period of 10
years, indicated that glycaemic control conferred protection against the
complications of diabetes, with a 1% reduction in HbA1c reducing the risk of any
diabetes end-point by 21%33 and that intensive glucose control reduced the risk of
any diabetes-related end-point by 9%.31
Conversely, the Action to Control Cardiovascular Risk in Diabetes (ACCORD)
trial, a prospective multi-centre trial including over 10,000 American and Canadian
individuals with established T2DM, observed that intensive management of HbA1c
(with a target of ≤ 6.0% / 42.1 mmol/mol) was associated with an increased risk of
cardiovascular death.232
More recently, a study based on a similar dataset CPRD-HES dataset to that
used for this analysis, observed that reduction of HbA1c to levels below 6.25%
(44.8 mmol/mol) was associated with an excess risk of death due to any cause,
compatible with the findings of the ACCORD trial.101 A similar finding was observed
in a recent meta-analysis describing outcomes of individuals with diabetes across
strata of glycaemic control.76
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For the practice-level analyses presented in this thesis, some sporadic and
statistically significant associations were observed between attainment of the strict
glycaemic control QOF indicator group, comprising of HbA1c targets ranging
between 7.0% (53.0 mmol/mol) and 7.4% (57.4 mmol/mol), and increased
emergency admission rates. The vast majority of the associations which did not
reach statistical significance also suggested an increase in emergency admission
rates from practices with the highest levels of attainment of strict glycaemic control.
Patient-level analyses, utilising QOF indicator DM06 (HbA1c ≤ 7.4% / 57.4
mmol/mol) as a therapeutic target, indicated that attainment of this indicator was
associated with decreased emergency admission rates (relative reductions of
~11%), readmission rates (relative reductions of ~16%) and reduced odds of dying
from a diabetes-related cause (relative reductions of ~14%).
The associations observed in the patient-level analyses seem broadly
compatible with previous findings, however the eﬀect of extreme reductions in
HbA1c were not modelled. The lack of associations in the practice-level models
between glycaemic control and emergency hospital admissions likely result from
diﬀerences in the classification of end-points and potential variations in the levels of
glycaemic control achieved in each practice’s population. It should also be noted
that the population included in these studies is comprised of individuals with T1DM
and T2DM with varying lengths of time with diabetes, meaning that the study
findings from UKPDS may not be wholly generalisable to the study population
described in this thesis.
Blood Pressure
The current body of evidence supports control, up to a certain limit, of blood
pressure in order to minimise risks to health posed by vascular disease in
individuals with diabetes.
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Evidence from the UKPDS cohort indicated that reduction of blood pressure was
associated with a reduced risk of the occurrence of any diabetes-related endpoint
(relative reduction ~24%) but bore no association with all-cause mortality.96, 97
However, the blood pressure target (150/85, mean actual achieved BP 144/82) for
this particular arm of UKPDS could be considered to be sub-therapeutic by
contemporary standards.
The ACCORD trial, which separated individuals with T2DM into intensive (SBP ≤
120 mmHg) and conventional (SBP ≤ 140 mmHg) blood pressure treatment arms,
did not observe any significant diﬀerences in the observed rates of fatal and non-
fatal cardiovascular endpoints over a mean follow-up of 4.7 years.233
Two recent studies100, 101 utilising a similar CPRD-HES dataset to that used for
the patient-level analyses presented in this thesis noted a U-shaped relationship
between the levels of blood pressure achieved and all-cause mortality, in a manner
analogous to that observed for glycaemic control. Reducing blood pressure to
below 130/80 mmHg was not associated with reductions in risk of all-cause
mortality in newly diagnosed diabetics100; however, attainment of very low blood
pressures (SBP < 110 – 115 and DBP < 72.5 – 75 mmHg) conferred an increased
risk of all-cause mortality in people with a recent diagnosis of T2DM.100, 101
The findings from the presented analyses pertaining to patient-level models of
the odds of death from a diabetes-related cause appear broadly compatible with
that of UKPDS, insofar as a modest BP target of ≤ 145/85 mmHg conferring
reduced odds of dying from a diabetes-related cause for follow-up periods lasting
four to five years (relative reductions of ~10%).
However, in these analyses, patients that attained DM06 (BP ≤ 145/85 mmHg)
exhibited an increased rate of emergency admissions and readmissions during the
first two years of follow-up (relative increases of ~5% – 11% and ~10% – 19%
respectively) and increased odds of all-cause mortality across all lengths of follow-
up (relative increases of ~21% – 84%, with reducing magnitude of eﬀect over longer
follow-up periods).
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These findings appear incompatible with associations described in the existing
literature. No detailed analysis was performed on the actual levels of blood pressure
attained by individuals; as such, it is unknown how aggressively blood pressure was
managed in the individuals who died and whether it was controlled to a degree that
introduced excess risk.
Another possibility is that the individuals identified as having a level of
cardiovascular risk commensurate with a need for blood pressure control were
identified as such, but failed to have their blood pressure controlled, on average, to
a level that conferred a meaningful level of benefit. Should this be the case, the
elevated odds of death observed may simply reflect the identification of a sub-
population that is at elevated risk. 
It should be noted that the patient-level analyses in this thesis do not account
for QOF exceptions, so it is conceivable that individuals who are terminally ill and
have concomitant low blood pressure resulting from cardiovascular dysfunction,
could introduce a degree of bias that favours a result suggesting increased odds of
death.
Furthermore, the associations described from the fully-adjusted models in these
analyses take into account attainment of a number of other quality targets, which
other studies may have not explicitly controlled for and may explain, to a degree,
seemingly incompatible findings.
Regardless of the source of the stark diﬀerences noted between these studies
and results published from previous studies, further exploration of this deviation
from the existing body of evidence is warranted.
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Cholesterol
In comparison to studies examining the eﬀects of blood pressure reduction and
normalisation of glycaemic load, relatively few studies exist that describe the
relationship between control of lipids and outcomes in individuals with diabetes.201
Recent interventional studies tend to focus on low-density lipoprotein (LDL) as
opposed to total cholesterol, the lipid measure utilised for the analyses included in
this thesis.
The Heart Protection Study (HPS)234 and Collaborative Atorvastatin Diabetes
Study (CARDS)235 both examined the eﬀects of statin therapy on cardiovascular
endpoints in individuals with T2DM; the study group for HPS was restricted to
individuals with high LDL cholesterol, whereas CARDS limited inclusion to
individuals with normal levels of LDL cholesterol. Both HPS and CARDS
demonstrated significant reductions in the occurrence of cardiovascular endpoints
(relative reductions of 0.78 and 0.63 respectively; LDL concentrations in treatment
vs. placebo groups were 2.3 mmol/L vs. 3.3 mmol/L and 1.8 mmol/L vs. 3.0 mmol/L
respectively). There is also some evidence that the protection against the
occurrence of cardiovascular endpoints associated with statin therapy is
independent of LDL cholesterol levels, as the beneficial eﬀects of statin therapy
were observed to persist even once controlled for LDL levels in CARDS. CARDS
also examined associations with all-cause mortality, but observed reductions were
non-significant.
In a retrospective cohort study utilising a similar dataset to the one used in these
analyses101, a U-shaped association between total cholesterol levels and hazard of
death due to any cause was observed. Total cholesterol levels in the range of ≥ 2.5
mmol/L to < 3.5 mmol/L and > 4.5 mmol/L and ≤ 5.5 mmol/L conferred protection
against all-cause mortality compared to individuals with a total cholesterol level
between 3.5 mmol/L and 4.5 mmol/L; total cholesterol levels below 2.5 mmol/L
were associated with increased hazards of mortality (a relative increase of 40%).
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In these analyses, achieving a total cholesterol of ≤ 5.0 mmol/L (DM17) was
associated with reduced emergency admission rates for lengths of follow-up
ranging between two and four years in fully-adjusted patient-level models (relative
rate decreases of ~9%). Attaining a total cholesterol level of ≤ 5.0 was, however,
associated with increased odds of death over one and two years of follow-up
(relative increases of ~22% and ~9.9% respectively). No consistent associations
were observed between attainment of a total cholesterol target of ≤ 5.0 mmol/L and
odds of death due to a diabetes-related cause or readmissions.
The protection with respect to emergency admission rates associated with total
cholesterol levels of ≤ 5.0 mmol/L seem appear broadly compatible with existing
evidence. However, the findings regarding an association between achieving a total
cholesterol of ≤ 5.0 mmol/L and increased odds of death could be argued to
deviate from accepted findings.
As noted for the comparison of the findings related to blood pressure for these
studies, the fully-adjusted patient-level models do not take account of QOF
exception reporting, meaning that the presence of individuals at high risk of
imminent death may have introduced an element of bias to the results reported in
this thesis. It should also be noted that HPS and CARDS did not consider the
diabetic population as a whole, excluding patients with or without pre-existing high
levels of LDL cholesterol; furthermore, these studies described associations
between LDL cholesterol as opposed to total cholesterol, which may limit the
generalisability of their findings to the methodology utilised for these analyses.
Additionally, the analyses performed for this thesis did not account for receipt of
specific cholesterol lowering therapies, further limiting direct comparison with HPS
and CARDS.
Another potential explanation for these findings is that the QOF total cholesterol
target of ≤ 5.0 mmol/L is simply not stringent enough to confer benefits with respect
to odds of death; the evidence-based recommendations from NICE currently
stipulate a total cholesterol target of ≤ 4.0 mmol/L for individuals with T2DM.70
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Conclusion
The analyses presented in this thesis lend considerable credence to the
classification of diabetes mellitus as a primary care sensitive condition. Improving
the quality of diabetes management in primary care stands to reduce unscheduled
demand on hospital services, improve outcomes for patients and allow for
rationalisation of expenditure across the health system in an era where demands
upon it stand to increase considerably.
A number of significant determinants of emergency admissions, readmissions
and mortality lie outside of the sphere of influence of primary care; inequities in
outcomes by deprivation, which continue to exist even when receipt of high-quality
care is taken into account, must be addressed and represent a major source of
avoidable unscheduled hospital care utilisation and, potentially, avoidable deaths.
It is also clear from these analyses that patient and practitioner engagement with
diabetes care is of central importance to maximising outcomes for patients and
reducing the demand for unscheduled hospital care. Such engagement extends
beyond mere achievement of targets; regular clinical review, measured in these
analyses by practice-level performance in the process group of QOF indicators and
receipt of NDA care processes by patients are strongly and consistently linked with
improved outcomes. That is not to say that attainment of intermediate targets is
unimportant – but explicit recognition that quality of diabetes care extends beyond
such targets is important. 
There is a clear opportunity for primary care to improve outcomes for individuals
with diabetes and provide that care in an approachable, appropriate and cost-
eﬀective manner. However, realising this opportunity will require investment in
improving accessibility of services and ensuring that general practices are
adequately resourced, both in terms of the current burden of diabetes and that
which is projected for the coming decades, to deliver comprehensive, high-quality
care.
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Appendix
Full Regression Tables for Partially 
Adjusted Practice-Level Models
Table A1. Full results from multiple-variable negative binomial regression model of fifths of
underlying achievement of QOF process indicators against emergency admissions.
2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
5 - 14 1.015 0.139 1.010 0.368 1.012 0.249 1.017 0.125 1.002 0.828 0.986 0.158
15 - 44 1.006 0.473 0.997 0.742 1.006 0.409 1.010 0.162 1.002 0.727 0.990 0.177
45 - 64 1.000 0.953 0.994 0.390 1.004 0.608 1.003 0.641 0.997 0.651 0.989 0.103
65 - 74 1.016 0.144 1.019 0.136 1.007 0.518 1.011 0.258 0.996 0.673 0.982 0.080
≥ 75 0.991 0.391 0.985 0.143 0.993 0.526 0.996 0.682 0.991 0.339 0.977 0.015
Sex % Male 1.003 0.496 1.009 0.045 1.005 0.432 1.003 0.632 1.006 0.187 1.004 0.470
Ethnicity White Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Non-White 0.997 0.006 0.999 0.360 0.997 0.060 0.998 0.081 0.996 0.001 0.997 0.010
Unknown 0.999 0.418 0.998 0.276 0.999 0.715 0.996 0.109 0.998 0.264 0.999 0.607
List Size Quartile < 4,000 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
4,000 – 7,999 0.991 0.517 0.990 0.477 0.983 0.280 0.972 0.077 0.984 0.265 0.985 0.369
≥ 8,000 0.966 0.056 0.955 0.018 0.959 0.046 0.952 0.010 0.959 0.017 0.968 0.092
GP FTEs per 1,000 patients 0.958 0.084 0.945 0.055 0.981 0.524 0.972 0.433 1.002 0.957 0.988 0.760
Diabetes Prevalence 0.957 0.001 0.917 < 0.001 0.960 0.003 0.974 0.036 0.976 0.013 0.971 0.015
IMD Decile
( 1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.832 < 0.001 0.834 < 0.001 0.850 < 0.001 0.860 < 0.001 0.864 < 0.001 0.887 < 0.001
3 0.797 < 0.001 0.817 < 0.001 0.819 < 0.001 0.844 < 0.001 0.835 < 0.001 0.850 < 0.001
4 0.743 < 0.001 0.757 < 0.001 0.781 < 0.001 0.809 < 0.001 0.800 < 0.001 0.821 < 0.001
5 0.732 < 0.001 0.720 < 0.001 0.764 < 0.001 0.778 < 0.001 0.778 < 0.001 0.791 < 0.001
6 0.717 < 0.001 0.714 < 0.001 0.726 < 0.001 0.772 < 0.001 0.767 < 0.001 0.762 < 0.001
7 0.700 < 0.001 0.691 < 0.001 0.723 < 0.001 0.759 < 0.001 0.756 < 0.001 0.773 < 0.001
8 0.679 < 0.001 0.673 < 0.001 0.707 < 0.001 0.739 < 0.001 0.734 < 0.001 0.731 < 0.001
9 0.656 < 0.001 0.641 < 0.001 0.692 < 0.001 0.741 < 0.001 0.744 < 0.001 0.719 < 0.001
10 0.660 < 0.001 0.618 < 0.001 0.657 < 0.001 0.704 < 0.001 0.729 < 0.001 0.704 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Urban 0.920 0.004 0.914 0.005 0.881 < 0.001 0.896 < 0.001 0.889 < 0.001 0.914 0.001
QOF Process UA 
Fifth
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.976 0.217 0.938 < 0.001 0.965 0.020 0.966 0.022 0.939 < 0.001 0.964 0.009
3 0.991 0.661 0.956 0.017 0.978 0.209 0.952 0.010 0.956 0.007 0.968 0.040
4 0.983 0.436 0.947 0.010 0.952 0.002 0.941 0.002 0.929 < 0.001 0.966 0.043
5 0.980 0.361 0.950 0.009 0.959 0.039 0.925 < 0.001 0.932 < 0.001 0.953 0.010
- 239 -
Table A2. Full results from multiple-variable negative binomial regression model of fifths of exception
reporting for QOF process indicators against emergency admissions.
2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group Reference Group
5 - 14 1.013 0.236 1.018 0.106 1.005 0.645 0.988 0.247
15 - 44 1.006 0.393 1.011 0.144 1.004 0.538 0.993 0.304
45 - 64 1.004 0.586 1.004 0.600 0.999 0.861 0.991 0.187
65 - 74 1.009 0.434 1.013 0.198 0.998 0.853 0.985 0.133
≥ 75 0.993 0.533 0.996 0.719 0.992 0.434 0.979 0.024
Sex % Male 1.005 0.382 1.003 0.579 1.007 0.178 1.004 0.475
Eth White Reference Group Reference Group Reference Group Reference Group
Non-White 0.997 0.069 0.998 0.118 0.997 0.002 0.997 0.017
Unknown 0.999 0.714 0.996 0.108 0.998 0.283 0.999 0.654
List Size Quartile < 4,000 Reference Group Reference Group Reference Group Reference Group
4,000 – 7,999 0.983 0.285 0.975 0.102 0.984 0.257 0.985 0.355
≥ 8,000 0.958 0.036 0.953 0.011 0.955 0.007 0.964 0.051
GP FTEs per 1,000 patients 0.978 0.473 0.967 0.369 0.996 0.907 0.983 0.645
Diabetes Prevalence 0.962 0.006 0.976 0.054 0.978 0.021 0.973 0.023
IMD Decile
( 1 = Most 
Deprived)
1 Reference Group Reference Group Reference Group Reference Group
2 0.851 < 0.001 0.861 < 0.001 0.864 < 0.001 0.891 < 0.001
3 0.819 < 0.001 0.847 < 0.001 0.839 < 0.001 0.853 < 0.001
4 0.781 < 0.001 0.811 < 0.001 0.802 < 0.001 0.825 < 0.001
5 0.765 < 0.001 0.780 < 0.001 0.780 < 0.001 0.793 < 0.001
6 0.726 < 0.001 0.772 < 0.001 0.767 < 0.001 0.764 < 0.001
7 0.723 < 0.001 0.760 < 0.001 0.757 < 0.001 0.775 < 0.001
8 0.708 < 0.001 0.739 < 0.001 0.735 < 0.001 0.734 < 0.001
9 0.693 < 0.001 0.743 < 0.001 0.746 < 0.001 0.722 < 0.001
10 0.656 < 0.001 0.703 < 0.001 0.727 < 0.001 0.706 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group Reference Group
Urban 0.882 < 0.001 0.896 < 0.001 0.888 < 0.001 0.913 0.001
QOF Process ER 
Fifth
1 Reference Group Reference Group Reference Group Reference Group
2 0.997 0.837 0.994 0.650 1.007 0.651 1.015 0.371
3 1.000 0.996 1.034 0.066 1.015 0.334 1.031 0.059
4 1.025 0.227 1.052 0.006 1.030 0.081 1.047 0.010
5 1.057 0.010 1.067 0.001 1.078 < 0.001 1.076 < 0.001
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Table A3. Full results from multiple-variable negative binomial regression model of fifths of
underlying achievement of QOF cardiovascular indicators against emergency admissions.
2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
5 - 14 1.016 0.132 1.009 0.405 1.012 0.267 1.016 0.138 1.003 0.809 0.986 0.162
15 - 44 1.006 0.460 0.997 0.690 1.005 0.438 1.010 0.191 1.003 0.715 0.991 0.182
45 - 64 1.000 0.968 0.993 0.350 1.003 0.663 1.003 0.717 0.997 0.653 0.989 0.104
65 - 74 1.016 0.141 1.019 0.150 1.007 0.549 1.010 0.288 0.995 0.659 0.982 0.076
≥ 75 0.991 0.407 0.984 0.143 0.993 0.523 0.996 0.678 0.991 0.374 0.977 0.016
Sex % Male 1.003 0.458 1.010 0.033 1.005 0.396 1.003 0.571 1.007 0.154 1.004 0.463
Eth White Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Non-White 0.997 0.007 0.999 0.391 0.997 0.060 0.998 0.091 0.996 0.001 0.997 0.013
Unknown 0.999 0.418 0.998 0.277 0.999 0.712 0.996 0.113 0.998 0.281 0.999 0.635
List Size Quartile < 4,000 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
4,000 – 7,999 0.990 0.486 0.989 0.441 0.983 0.279 0.975 0.111 0.985 0.310 0.987 0.437
≥ 8,000 0.965 0.045 0.953 0.013 0.960 0.048 0.957 0.023 0.961 0.021 0.970 0.111
GP FTEs per 1,000 patients 0.956 0.069 0.942 0.042 0.978 0.466 0.968 0.380 0.998 0.951 0.985 0.694
Diabetes Prevalence 0.957 0.001 0.917 < 0.001 0.960 0.003 0.974 0.035 0.976 0.013 0.971 0.014
IMD Decile
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group( 1 = Most 
Deprived) 2 0.833 < 0.001 0.834 < 0.001 0.850 < 0.001 0.860 < 0.001 0.864 < 0.001 0.888 < 0.001
3 0.797 < 0.001 0.818 < 0.001 0.819 < 0.001 0.845 < 0.001 0.837 < 0.001 0.852 < 0.001
4 0.743 < 0.001 0.757 < 0.001 0.780 < 0.001 0.809 < 0.001 0.801 < 0.001 0.822 < 0.001
5 0.731 < 0.001 0.719 < 0.001 0.763 < 0.001 0.778 < 0.001 0.778 < 0.001 0.791 < 0.001
6 0.717 < 0.001 0.713 < 0.001 0.724 < 0.001 0.768 < 0.001 0.765 < 0.001 0.761 < 0.001
7 0.699 < 0.001 0.689 < 0.001 0.721 < 0.001 0.757 < 0.001 0.755 < 0.001 0.772 < 0.001
8 0.679 < 0.001 0.672 < 0.001 0.706 < 0.001 0.736 < 0.001 0.732 < 0.001 0.731 < 0.001
9 0.656 < 0.001 0.640 < 0.001 0.690 < 0.001 0.740 < 0.001 0.744 < 0.001 0.719 < 0.001
10 0.659 < 0.001 0.617 < 0.001 0.655 < 0.001 0.702 < 0.001 0.728 < 0.001 0.703 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Urban 0.919 0.004 0.913 0.004 0.881 < 0.001 0.895 < 0.001 0.886 < 0.001 0.913 0.001
QOF CVS UA Fifth
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.003 0.873 0.986 0.451 0.984 0.339 0.991 0.515 1.005 0.716 1.003 0.824
3 1.017 0.401 0.993 0.693 0.997 0.866 1.008 0.632 0.993 0.643 0.993 0.614
4 1.004 0.820 0.995 0.781 0.989 0.528 0.992 0.634 0.996 0.823 1.004 0.815
5 1.008 0.727 0.986 0.515 0.989 0.605 1.002 0.906 1.017 0.396 1.009 0.651
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Table A4. Full results from multiple-variable negative binomial regression model of fifths of exception
reporting for QOF cardiovascular indicators against emergency admissions.
2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group Reference Group
5 - 14 1.011 0.299 1.017 0.130 1.004 0.720 0.987 0.217
15 - 44 1.005 0.488 1.010 0.178 1.004 0.621 0.992 0.253
45 - 64 1.003 0.711 1.003 0.697 0.998 0.756 0.990 0.152
65 - 74 1.006 0.581 1.011 0.259 0.997 0.745 0.984 0.106
≥ 75 0.993 0.498 0.995 0.668 0.992 0.399 0.978 0.019
Sex % Male 1.005 0.389 1.003 0.575 1.007 0.188 1.004 0.462
Eth White Reference Group Reference Group Reference Group Reference Group
Non-White 0.997 0.056 0.998 0.093 0.996 0.002 0.997 0.013
Unknown 0.999 0.722 0.996 0.112 0.998 0.277 0.999 0.621
List Size Quartile < 4,000 Reference Group Reference Group Reference Group Reference Group
4,000 – 7,999 0.985 0.349 0.975 0.105 0.985 0.295 0.985 0.329
≥ 8,000 0.963 0.068 0.956 0.018 0.958 0.012 0.965 0.050
GP FTEs per 1,000 patients 0.978 0.472 0.967 0.369 0.996 0.907 0.982 0.628
Diabetes Prevalence 0.961 0.004 0.975 0.045 0.977 0.018 0.974 0.024
IMD Decile
1 Reference Group Reference Group Reference Group Reference Group( 1 = Most 
Deprived) 2 0.850 < 0.001 0.860 < 0.001 0.863 < 0.001 0.890 < 0.001
3 0.818 < 0.001 0.845 < 0.001 0.837 < 0.001 0.852 < 0.001
4 0.779 < 0.001 0.809 < 0.001 0.799 < 0.001 0.823 < 0.001
5 0.762 < 0.001 0.778 < 0.001 0.778 < 0.001 0.792 < 0.001
6 0.724 < 0.001 0.770 < 0.001 0.764 < 0.001 0.763 < 0.001
7 0.721 < 0.001 0.757 < 0.001 0.755 < 0.001 0.773 < 0.001
8 0.706 < 0.001 0.736 < 0.001 0.731 < 0.001 0.732 < 0.001
9 0.691 < 0.001 0.740 < 0.001 0.743 < 0.001 0.720 < 0.001
10 0.655 < 0.001 0.701 < 0.001 0.726 < 0.001 0.704 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group Reference Group
Urban 0.881 < 0.001 0.894 < 0.001 0.887 < 0.001 0.913 0.001
QOF CVS ER Fifth
1 Reference Group Reference Group Reference Group Reference Group
2 0.969 0.045 1.009 0.543 0.986 0.359 1.018 0.238
3 0.978 0.217 1.008 0.627 1.014 0.314 1.015 0.355
4 0.968 0.079 1.003 0.861 0.989 0.532 1.040 0.022
5 0.996 0.870 1.023 0.269 1.028 0.173 1.056 0.010
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Table A5. Full results from multiple-variable negative binomial regression model of fifths of
underlying achievement of QOF strict glycaemic control indicators against emergency admissions.
2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
5 - 14 1.016 0.137 1.010 0.361 1.012 0.238 1.016 0.145 1.003 0.772 0.986 0.161
15 - 44 1.006 0.465 0.997 0.701 1.005 0.460 1.010 0.192 1.003 0.677 0.990 0.163
45 - 64 1.000 0.957 0.993 0.355 1.003 0.698 1.003 0.723 0.997 0.693 0.988 0.096
65 - 74 1.016 0.142 1.019 0.144 1.007 0.542 1.010 0.291 0.996 0.669 0.982 0.073
≥ 75 0.991 0.397 0.985 0.145 0.993 0.507 0.995 0.676 0.992 0.410 0.977 0.014
Sex % Male 1.003 0.475 1.011 0.023 1.006 0.317 1.003 0.566 1.007 0.148 1.005 0.410
Eth White Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Non-White 0.997 0.007 0.999 0.491 0.998 0.106 0.998 0.086 0.996 0.002 0.997 0.016
Unknown 0.999 0.409 0.998 0.290 0.999 0.773 0.996 0.114 0.998 0.290 0.999 0.651
List Size Quartile < 4,000 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
4,000 – 7,999 0.990 0.480 0.990 0.468 0.984 0.304 0.975 0.110 0.988 0.390 0.992 0.595
≥ 8,000 0.964 0.042 0.956 0.016 0.963 0.062 0.958 0.022 0.965 0.031 0.976 0.176
GP FTEs per 1,000 patients 0.957 0.073 0.940 0.037 0.976 0.430 0.968 0.384 0.998 0.965 0.988 0.745
Diabetes Prevalence 0.958 0.001 0.916 < 0.001 0.957 0.001 0.974 0.035 0.976 0.011 0.969 0.007
IMD Decile
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group( 1 = Most 
Deprived) 2 0.833 < 0.001 0.835 < 0.001 0.852 < 0.001 0.861 < 0.001 0.865 < 0.001 0.889 < 0.001
3 0.797 < 0.001 0.819 < 0.001 0.820 < 0.001 0.845 < 0.001 0.838 < 0.001 0.854 < 0.001
4 0.742 < 0.001 0.759 < 0.001 0.781 < 0.001 0.810 < 0.001 0.802 < 0.001 0.823 < 0.001
5 0.731 < 0.001 0.720 < 0.001 0.763 < 0.001 0.778 < 0.001 0.779 < 0.001 0.790 < 0.001
6 0.717 < 0.001 0.712 < 0.001 0.723 < 0.001 0.768 < 0.001 0.766 < 0.001 0.762 < 0.001
7 0.700 < 0.001 0.689 < 0.001 0.720 < 0.001 0.758 < 0.001 0.757 < 0.001 0.774 < 0.001
8 0.679 < 0.001 0.671 < 0.001 0.704 < 0.001 0.736 < 0.001 0.733 < 0.001 0.730 < 0.001
9 0.656 < 0.001 0.640 < 0.001 0.689 < 0.001 0.740 < 0.001 0.744 < 0.001 0.718 < 0.001
10 0.660 < 0.001 0.617 < 0.001 0.652 < 0.001 0.702 < 0.001 0.729 < 0.001 0.702 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Urban 0.919 0.003 0.914 0.004 0.884 < 0.001 0.894 < 0.001 0.888 < 0.001 0.914 0.001
QOF Strict 
Glycaemic Control 
UA Fifth
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.002 0.925 0.990 0.640 1.035 0.135 1.000 0.987 0.969 0.079 0.980 0.157
3 1.002 0.929 1.015 0.546 1.029 0.271 0.976 0.218 0.958 0.053 0.980 0.186
4 1.002 0.950 1.037 0.249 1.037 0.267 0.995 0.827 0.983 0.524 1.010 0.626
5 0.994 0.840 1.034 0.348 1.092 0.017 1.000 0.995 1.015 0.666 1.034 0.248
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Table A6. Full results from multiple-variable negative binomial regression model of fifths of exception
reporting for QOF strict glycaemic control indicators against emergency admissions.
2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group Reference Group
5 - 14 1.011 0.275 1.017 0.115 1.004 0.711 0.987 0.202
15 - 44 1.005 0.452 1.010 0.167 1.004 0.601 0.992 0.247
45 - 64 1.003 0.654 1.004 0.634 0.998 0.810 0.990 0.156
65 - 74 1.007 0.536 1.012 0.242 0.997 0.752 0.983 0.103
≥ 75 0.993 0.515 0.996 0.699 0.992 0.413 0.978 0.019
Sex % Male 1.005 0.381 1.003 0.574 1.007 0.180 1.004 0.513
Eth White Reference Group Reference Group Reference Group Reference Group
Non-White 0.997 0.055 0.998 0.081 0.996 0.001 0.997 0.008
Unknown 0.999 0.715 0.996 0.111 0.998 0.272 0.999 0.640
List Size Quartile < 4,000 Reference Group Reference Group Reference Group Reference Group
4,000 – 7,999 0.985 0.337 0.976 0.121 0.986 0.304 0.986 0.373
≥ 8,000 0.961 0.054 0.957 0.019 0.958 0.012 0.967 0.063
GP FTEs per 1,000 patients 0.977 0.464 0.967 0.363 0.993 0.842 0.980 0.597
Diabetes Prevalence 0.962 0.005 0.976 0.057 0.979 0.025 0.974 0.028
IMD Decile
1 Reference Group Reference Group Reference Group Reference Group( 1 = Most 
Deprived) 2 0.849 < 0.001 0.860 < 0.001 0.862 < 0.001 0.890 < 0.001
3 0.818 < 0.001 0.846 < 0.001 0.838 < 0.001 0.852 < 0.001
4 0.779 < 0.001 0.810 < 0.001 0.801 < 0.001 0.823 < 0.001
5 0.762 < 0.001 0.779 < 0.001 0.779 < 0.001 0.792 < 0.001
6 0.725 < 0.001 0.772 < 0.001 0.764 < 0.001 0.763 < 0.001
7 0.722 < 0.001 0.760 < 0.001 0.756 < 0.001 0.773 < 0.001
8 0.706 < 0.001 0.737 < 0.001 0.734 < 0.001 0.734 < 0.001
9 0.691 < 0.001 0.742 < 0.001 0.746 < 0.001 0.722 < 0.001
10 0.655 < 0.001 0.702 < 0.001 0.728 < 0.001 0.706 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group Reference Group
Urban 0.880 < 0.001 0.895 < 0.001 0.886 < 0.001 0.912 0.001
QOF Strict 
Glycaemic Control 
ER Fifth
1 Reference Group Reference Group Reference Group Reference Group
2 0.991 0.528 1.012 0.418 0.987 0.315 1.010 0.552
3 0.983 0.347 1.020 0.225 0.998 0.915 1.023 0.129
4 1.001 0.955 1.023 0.171 1.024 0.185 1.024 0.202
5 1.025 0.326 1.055 0.012 1.059 0.015 1.079 0.002
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Table A7. Full results from multiple-variable negative binomial regression model of fifths of
underlying achievement of QOF intermediate glycaemic control indicators against emergency
admissions.
2009/10 2010/11
IRR p IRR p
Age 0 - 4 Reference Group Reference Group
5 - 14 1.002 0.861 0.985 0.137
15 - 44 1.002 0.750 0.990 0.150
45 - 64 0.996 0.618 0.988 0.087
65 - 74 0.995 0.635 0.981 0.061
≥ 75 0.991 0.360 0.976 0.012
Sex % Male 1.007 0.169 1.004 0.471
Eth White Reference Group Reference Group
Non-White 0.996 0.001 0.997 0.010
Unknown 0.998 0.269 0.999 0.622
List Size Quartile < 4,000 Reference Group Reference Group
4,000 – 7,999 0.987 0.377 0.990 0.554
≥ 8,000 0.964 0.034 0.974 0.161
GP FTEs per 1,000 patients 0.999 0.976 0.987 0.735
Diabetes Prevalence 0.976 0.015 0.972 0.014
IMD Decile
1 Reference Group Reference Group( 1 = Most 
Deprived) 2 0.865 < 0.001 0.888 < 0.001
3 0.838 < 0.001 0.852 < 0.001
4 0.801 < 0.001 0.823 < 0.001
5 0.779 < 0.001 0.790 < 0.001
6 0.767 < 0.001 0.761 < 0.001
7 0.757 < 0.001 0.772 < 0.001
8 0.733 < 0.001 0.731 < 0.001
9 0.744 < 0.001 0.719 < 0.001
10 0.729 < 0.001 0.702 < 0.001
Area 
Classification
Rural Reference Group Reference Group
Urban 0.888 < 0.001 0.914 0.001
QOF Intermediate 
Glycaemic Control 
UA Fifth
1 Reference Group Reference Group
2 0.966 0.027 0.958 0.003
3 0.955 0.010 0.991 0.594
4 0.971 0.126 0.970 0.098
5 0.992 0.720 1.014 0.538
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Table A8. Full results from multiple-variable negative binomial regression model of fifths of exception
reporting for QOF intermediate glycaemic control indicators against emergency admissions.
2009/10 2010/11
IRR p IRR p
Age 0 - 4 Reference Group Reference Group
5 - 14 1.004 0.689 0.987 0.200
15 - 44 1.004 0.587 0.992 0.242
45 - 64 0.999 0.838 0.990 0.159
65 - 74 0.997 0.778 0.984 0.109
≥ 75 0.992 0.427 0.978 0.019
Sex % Male 1.007 0.173 1.004 0.512
Eth White Reference Group Reference Group
Non-White 0.996 0.001 0.997 0.009
Unknown 0.998 0.268 0.999 0.636
List Size Quartile < 4,000 Reference Group Reference Group
4,000 – 7,999 0.986 0.316 0.986 0.385
≥ 8,000 0.958 0.013 0.966 0.062
GP FTEs per 1,000 patients 0.994 0.865 0.981 0.617
Diabetes Prevalence 0.978 0.023 0.974 0.030
IMD Decile
1 Reference Group Reference Group( 1 = Most 
Deprived) 2 0.862 < 0.001 0.890 < 0.001
3 0.837 < 0.001 0.852 < 0.001
4 0.800 < 0.001 0.823 < 0.001
5 0.779 < 0.001 0.794 < 0.001
6 0.765 < 0.001 0.764 < 0.001
7 0.757 < 0.001 0.775 < 0.001
8 0.734 < 0.001 0.737 < 0.001
9 0.745 < 0.001 0.724 < 0.001
10 0.728 < 0.001 0.707 < 0.001
Area 
Classification
Rural Reference Group Reference Group
Urban 0.887 < 0.001 0.912 0.001
QOF Intermediate 
Glycaemic Control 
ER Fifth
1 Reference Group Reference Group
2 1.001 0.965 1.012 0.408
3 1.008 0.602 1.038 0.014
4 1.032 0.086 1.027 0.149
5 1.066 0.006 1.093 < 0.001
- 246 -
Table A9. Full results from multiple-variable negative binomial regression model of fifths of
underlying achievement of QOF moderate glycaemic control indicators against emergency
admissions.
2005/06 2006/07 2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
5 - 14 1.016 0.133 1.009 0.435 1.011 0.299 1.016 0.146 1.002 0.858 0.985 0.153
15 - 44 1.006 0.453 0.996 0.673 1.005 0.495 1.010 0.190 1.002 0.731 0.990 0.167
45 - 64 1.000 0.996 0.993 0.346 1.002 0.717 1.003 0.703 0.997 0.643 0.988 0.096
65 - 74 1.017 0.136 1.019 0.153 1.005 0.617 1.011 0.262 0.996 0.674 0.981 0.063
≥ 75 0.991 0.417 0.984 0.142 0.993 0.501 0.995 0.672 0.991 0.361 0.977 0.014
Sex % Male 1.003 0.526 1.010 0.039 1.005 0.382 1.003 0.621 1.007 0.186 1.004 0.450
Eth White Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Non-White 0.997 0.006 0.999 0.359 0.997 0.060 0.998 0.081 0.996 0.001 0.997 0.009
Unknown 0.999 0.394 0.998 0.266 0.999 0.722 0.996 0.108 0.998 0.261 0.999 0.620
List Size Quartile < 4,000 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
4,000 – 7,999 0.990 0.496 0.990 0.493 0.985 0.348 0.975 0.114 0.985 0.307 0.991 0.592
≥ 8,000 0.964 0.041 0.955 0.017 0.965 0.082 0.958 0.025 0.961 0.022 0.977 0.205
GP FTEs per 1,000 patients 0.959 0.091 0.942 0.044 0.977 0.452 0.971 0.427 1.000 0.992 0.986 0.713
Diabetes Prevalence 0.957 0.001 0.917 < 0.001 0.960 0.003 0.974 0.036 0.976 0.013 0.972 0.017
IMD Decile
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group( 1 = Most 
Deprived) 2 0.832 < 0.001 0.833 < 0.001 0.851 < 0.001 0.859 < 0.001 0.864 < 0.001 0.889 < 0.001
3 0.797 < 0.001 0.818 < 0.001 0.818 < 0.001 0.845 < 0.001 0.838 < 0.001 0.853 < 0.001
4 0.742 < 0.001 0.759 < 0.001 0.780 < 0.001 0.809 < 0.001 0.800 < 0.001 0.822 < 0.001
5 0.732 < 0.001 0.719 < 0.001 0.762 < 0.001 0.779 < 0.001 0.778 < 0.001 0.791 < 0.001
6 0.718 < 0.001 0.713 < 0.001 0.723 < 0.001 0.770 < 0.001 0.766 < 0.001 0.761 < 0.001
7 0.702 < 0.001 0.691 < 0.001 0.720 < 0.001 0.758 < 0.001 0.756 < 0.001 0.772 < 0.001
8 0.680 < 0.001 0.673 < 0.001 0.705 < 0.001 0.738 < 0.001 0.734 < 0.001 0.731 < 0.001
9 0.658 < 0.001 0.641 < 0.001 0.690 < 0.001 0.742 < 0.001 0.745 < 0.001 0.720 < 0.001
10 0.661 < 0.001 0.619 < 0.001 0.653 < 0.001 0.704 < 0.001 0.730 < 0.001 0.703 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
Urban 0.921 0.005 0.913 0.004 0.880 < 0.001 0.896 < 0.001 0.888 < 0.001 0.912 0.001
QOF Moderate 
Glycaemic Control  
UA Fifth
1 Reference Group Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.003 0.889 1.001 0.953 0.986 0.443 0.991 0.505 0.988 0.487 0.955 0.004
3 1.006 0.794 0.949 0.012 0.992 0.707 0.971 0.109 0.962 0.029 0.970 0.107
4 0.971 0.193 0.990 0.667 0.974 0.313 0.976 0.179 0.980 0.318 0.982 0.366
5 0.980 0.448 0.980 0.442 1.024 0.366 0.969 0.150 0.977 0.250 1.008 0.687
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Table A10. Full results from multiple-variable negative binomial regression model of fifths of
exception reporting for QOF moderate glycaemic control indicators against emergency admissions.
2007/08 2008/09 2009/10 2010/11
IRR p IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group Reference Group
5 - 14 1.011 0.285 1.017 0.115 1.005 0.658 0.987 0.210
15 - 44 1.005 0.475 1.010 0.167 1.004 0.549 0.992 0.258
45 - 64 1.003 0.677 1.004 0.630 0.999 0.876 0.990 0.172
65 - 74 1.007 0.543 1.012 0.223 0.998 0.833 0.984 0.119
≥ 75 0.993 0.503 0.996 0.686 0.993 0.453 0.978 0.021
Sex % Male 1.006 0.366 1.003 0.587 1.007 0.172 1.004 0.510
Eth White Reference Group Reference Group Reference Group Reference Group
Non-White 0.997 0.055 0.998 0.089 0.996 0.001 0.997 0.011
Unknown 0.999 0.718 0.996 0.108 0.998 0.268 0.999 0.632
List Size Quartile < 4,000 Reference Group Reference Group Reference Group Reference Group
4,000 – 7,999 0.987 0.400 0.977 0.137 0.986 0.326 0.984 0.327
≥ 8,000 0.964 0.077 0.957 0.021 0.958 0.013 0.965 0.050
GP FTEs per 1,000 patients 0.978 0.466 0.968 0.387 0.994 0.881 0.981 0.621
Diabetes Prevalence 0.962 0.005 0.976 0.052 0.978 0.021 0.973 0.024
IMD Decile
1 Reference Group Reference Group Reference Group Reference Group( 1 = Most 
Deprived) 2 0.849 < 0.001 0.859 < 0.001 0.863 < 0.001 0.890 < 0.001
3 0.818 < 0.001 0.846 < 0.001 0.838 < 0.001 0.852 < 0.001
4 0.780 < 0.001 0.809 < 0.001 0.800 < 0.001 0.823 < 0.001
5 0.763 < 0.001 0.780 < 0.001 0.780 < 0.001 0.793 < 0.001
6 0.726 < 0.001 0.771 < 0.001 0.766 < 0.001 0.764 < 0.001
7 0.722 < 0.001 0.760 < 0.001 0.757 < 0.001 0.774 < 0.001
8 0.707 < 0.001 0.738 < 0.001 0.734 < 0.001 0.735 < 0.001
9 0.692 < 0.001 0.741 < 0.001 0.746 < 0.001 0.723 < 0.001
10 0.656 < 0.001 0.702 < 0.001 0.728 < 0.001 0.706 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group Reference Group
Urban 0.880 < 0.001 0.895 < 0.001 0.887 < 0.001 0.913 0.001
QOF Moderate 
Glycaemic Control  
ER Fifth
1 Reference Group Reference Group Reference Group Reference Group
2 0.971 0.080 0.997 0.829 0.989 0.412 1.023 0.116
3 0.975 0.121 1.003 0.865 1.017 0.236 1.046 0.002
4 0.975 0.222 1.016 0.332 1.027 0.169 1.043 0.045
5 1.021 0.400 1.054 0.017 1.064 0.004 1.087 < 0.001
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Table A11. Full results from multiple-variable negative binomial regression model of fifths of
underlying achievement of QOF indicator PE07 against emergency admissions.
2008/09 2009/10 2010/11
IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group
5 - 14 1.019 0.081 1.005 0.610 0.989 0.302
15 - 44 1.011 0.127 1.004 0.532 0.993 0.319
45 - 64 1.005 0.539 0.999 0.864 0.991 0.208
65 - 74 1.012 0.241 0.997 0.784 0.984 0.114
≥ 75 0.998 0.862 0.994 0.524 0.981 0.045
Sex % Male 1.004 0.468 1.008 0.118 1.006 0.336
Eth White Reference Group Reference Group Reference Group
Non-White 0.997 0.064 0.996 0.001 0.997 0.007
Unknown 0.996 0.112 0.998 0.272 0.999 0.614
List Size Quartile < 4,000 Reference Group Reference Group Reference Group
4,000 – 7,999 0.969 0.054 0.978 0.120 0.977 0.164
≥ 8,000 0.950 0.009 0.948 0.003 0.952 0.014
GP FTEs per 1,000 patients 0.974 0.482 1.004 0.912 0.995 0.896
Diabetes Prevalence 0.973 0.026 0.974 0.007 0.969 0.007
IMD Decile
1 Reference Group Reference Group Reference Group( 1 = Most 
Deprived) 2 0.861 < 0.001 0.865 < 0.001 0.889 < 0.001
3 0.845 < 0.001 0.838 < 0.001 0.854 < 0.001
4 0.812 < 0.001 0.803 < 0.001 0.825 < 0.001
5 0.781 < 0.001 0.782 < 0.001 0.793 < 0.001
6 0.772 < 0.001 0.769 < 0.001 0.765 < 0.001
7 0.761 < 0.001 0.757 < 0.001 0.776 < 0.001
8 0.739 < 0.001 0.736 < 0.001 0.734 < 0.001
9 0.744 < 0.001 0.748 < 0.001 0.722 < 0.001
10 0.707 < 0.001 0.732 < 0.001 0.708 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group
Urban 0.898 < 0.001 0.890 < 0.001 0.918 0.001
QOF PE07 UA
1 Reference Group Reference Group Reference Group
2 0.981 0.244 0.958 0.008 0.962 0.060
3 0.957 0.019 0.963 0.079 0.964 0.084
4 0.941 0.002 0.946 0.007 0.937 0.006
5 0.945 0.008 0.928 0.001 0.903 < 0.001
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Table A12. Full results from multiple-variable negative binomial regression model of fifths of
underlying achievement of QOF indicator PE08 against emergency admissions.
2008/09 2009/10 2010/11
IRR p IRR p IRR p
Age 0 - 4 Reference Group Reference Group Reference Group
5 - 14 1.018 0.090 1.004 0.697 0.987 0.192
15 - 44 1.012 0.100 1.004 0.530 0.992 0.262
45 - 64 1.005 0.476 0.999 0.847 0.991 0.177
65 - 74 1.012 0.211 0.997 0.756 0.983 0.093
≥ 75 0.998 0.878 0.993 0.506 0.980 0.028
Sex % Male 1.004 0.462 1.008 0.115 1.005 0.363
Eth White Reference Group Reference Group Reference Group
Non-White 0.998 0.077 0.996 0.001 0.997 0.010
Unknown 0.996 0.099 0.998 0.253 0.999 0.593
List Size Quartile < 4,000 Reference Group Reference Group Reference Group
4,000 – 7,999 0.959 0.013 0.972 0.056 0.971 0.088
≥ 8,000 0.932 < 0.001 0.938 0.001 0.943 0.003
GP FTEs per 1,000 patients 0.974 0.465 1.004 0.921 0.993 0.843
Diabetes Prevalence 0.969 0.010 0.973 0.006 0.966 0.005
IMD Decile
1 Reference Group Reference Group Reference Group( 1 = Most 
Deprived) 2 0.864 < 0.001 0.866 < 0.001 0.889 < 0.001
3 0.848 < 0.001 0.839 < 0.001 0.854 < 0.001
4 0.813 < 0.001 0.803 < 0.001 0.825 < 0.001
5 0.781 < 0.001 0.781 < 0.001 0.794 < 0.001
6 0.774 < 0.001 0.769 < 0.001 0.765 < 0.001
7 0.762 < 0.001 0.759 < 0.001 0.777 < 0.001
8 0.742 < 0.001 0.738 < 0.001 0.735 < 0.001
9 0.748 < 0.001 0.750 < 0.001 0.723 < 0.001
10 0.712 < 0.001 0.737 < 0.001 0.710 < 0.001
Area 
Classification
Rural Reference Group Reference Group Reference Group
Urban 0.901 < 0.001 0.891 < 0.001 0.919 0.002
QOF PE08 UA
1 Reference Group Reference Group Reference Group
2 0.948 0.002 0.995 0.770 0.981 0.322
3 0.937 0.001 0.971 0.112 0.954 0.021
4 0.905 < 0.001 0.937 0.001 0.938 0.005
5 0.897 < 0.001 0.937 0.005 0.909 < 0.001
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List of Fields Provided in CPRD Tables
Field name Description Type Format 
patid Encrypted unique identifier given to a patient in GPRD INTEGER 20
vmid Old VM id for the patient when the practice was using the VAMP system INTEGER 20
gender Patient’s gender INTEGER 1
yob Patient’s year of birth INTEGER 4
mob Patient’s month of birth (for those aged under 16). 0 indicates no month set INTEGER 2
marital Patient’s current martial status INTEGER 3
famnum Family ID number INTEGER 20
chsreg Value to indicate whether the patient is registered with Child Health Surveillance INTEGER 1
chsdate Date of registration with Child Health Surveillance DATE dd/mm/yyyy 
prescr Type of prescribing exemption the patient has currently (e.g. medical or maternity) INTEGER 3
capsup Level of capitation supplement the patient has currently (e.g. low, medium, or high) INTEGER 3
ses Patient’s socio-economic status. Currently 0; to be populated in future builds INTEGER 1
frd 
Date the patient first registered with the practice. If patient 
only has ‘temporary’ records, the date is the first encounter
with the practice; if patient has ‘permanent’ records it is 
the date of the first ‘permanent’ record (excluding 
preceding temporary records) 
DATE dd/mm/yyyy 
crd 
Date the patient’s current period of registration with the 
practice began (date of the first ‘permanent’ record after 
the latest transferred out period). If there are no 
‘transferred out periods’, the date is equal to ‘frd’ 
DATE dd/mm/yyyy 
regstat Status of registration detailing gaps and temporary patients INTEGER 2
reggap Number of days missing in the patients registration details INTEGER 5
internal Number of internal transfer out periods, in the patient’s registration details INTEGER 2
tod Date the patient transferred out of the practice, if relevant. Empty for patients who have not transferred out DATE dd/mm/yyyy 
toreason Reason the patient transferred out of the practice. Includes'Death' as an option INTEGER 3
deathdate Date of death of patient – derived using a GPRD algorithm DATE dd/mm/yyyy 
accept Flag to indicate whether the patient has met certain quality standards: 1 = acceptable, 0 = unacceptable INTEGER 1
Table A13. Data fields in patient table of CPRD data.
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Field name Description Type Format 
pracid Encrypted unique identifier given to a specific practice in GPRD INTEGER 3
region 
Value to indicate where in the UK the practice is based. 
The region denotes the Strategic Health Authority for 
practices within England, and the country i.e. Wales, 
Scotland, or Northern Ireland for the rest 
INTEGER 3
lcd Date of the last collection for the practice DATE dd/mm/yyyy 
uts 
Date at which the practice data is deemed to be of 
research quality. Derived using a GPRD algorithm that 
primarily looks at practice death recording and gaps in the 
data 
DATE dd/mm/yyyy 
Table A14. Data fields in practice table of CPRD data.
Field name Description Type Format 
staﬃd Encrypted unique identifier given to the practice staﬀ member entering the data INTEGER 20
gender Staﬀ’s gender INTEGER 1
role Role of the member of staﬀ who created the event INTEGER 3
Table A15. Data fields in staﬀ table of CPRD data.
Field name Description Type Format 
patid Encrypted unique identifier given to a patient in GPRD INTEGER 20
eventdate Date associated with the event, as entered by the GP DATE dd/mm/yyyy 
sysdate Date the event was entered into Vision DATE dd/mm/yyyy 
constype Type of consultation (e.g. Surgery Consultation, Night Visit,Emergency etc) INTEGER 3
consid The consultation identifier linking events at the same consultation, when used in combination with pracid INTEGER 20
staﬃd The identifier of the practice staﬀ member entering the data. A value of 0 indicates that the staﬃd is unknown INTEGER 20
duration The length of time (minutes) between the opening, and closing of the consultation record INTEGER 10
Table A16. Data fields in consultation table of CPRD data.
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Field name Description Type Format 
patid Encrypted unique identifier given to a patient in GPRD INTEGER 20
eventdate Date associated with the event, as entered by the GP DATE dd/mm/yyyy 
sysdate Date the event was entered into Vision DATE dd/mm/yyyy 
constype Code for the category of event recorded within the GP system (e.g. diagnosis or symptom) INTEGER 3
consid Identifier that allows information about the consultation to be retrieved, when used in combination with pracid INTEGER 20
medcode GPRD unique code for the medical term selected by the GP INTEGER 20
staﬃd Identifier of the practice staﬀ member entering the data. A value of 0 indicates that the staﬃd is unknown INTEGER 20
textid 
Identifier that allows freetext information on the event to be
retrieved, when used in combination with pracid and event 
type ‘Clinical’. A value of 0 indicates that there is no 
freetext information for this event 
INTEGER 20
episode Episode type for a specific clinical event INTEGER 3
enttype Identifier that represents the structured data area in Vision where the data was entered INTEGER 5
adid 
Identifier that allows additional information to be retrieved 
for this event, when used in combination with pracid. A 
value of 0 signifies that there is no additional information 
associated with the event. 
INTEGER 20
Table A17. Data fields in clinical table of CPRD data.
Field name Description Type Format 
patid Encrypted unique identifier given to a patient in GPRD INTEGER 20
enttype Identifier that represents the structured data area in Vision where the data was entered INTEGER 5
adid 
Identifier that allows information about the original clinical 
event to be retrieved, when used in combination with 
pracid 
INTEGER 20
data1 Depends on Entity Type NUMERIC 15.3
data2 Depends on Entity Type NUMERIC 15.3
data3 Depends on Entity Type NUMERIC 15.3
data4 Depends on Entity Type INTEGER 12
data5 Depends on Entity Type INTEGER 12
data6 Depends on Entity Type INTEGER 12
data7 Depends on Entity Type INTEGER 4
Table A18. Data fields in additional clinical details table of CPRD data.
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Field name Description Type Format 
patid Encrypted unique identifier given to a patient in GPRD INTEGER 20
eventdate Date associated with the event, as entered by the GP DATE dd/mm/yyyy 
sysdate Date the event was entered into Vision DATE dd/mm/yyyy 
constype Code for the category of event recorded within the GP system (e.g. management or administration) INTEGER 3
consid Identifier that allows information about the consultation to be retrieved, when used in combination with pracid INTEGER 20
medcode GPRD unique code for the medical term selected by the GP INTEGER 20
staﬃd Identifier of the practice staﬀ member entering the data. A value of 0 indicates that the staﬃd is unknown INTEGER 20
textid 
Identifier that allows freetext information on the event to be
retrieved, when used in combination with pracid and event 
type ‘Referral’. A value of 0 indicates that there is no 
freetext information for this event 
INTEGER 20
source Classification of the source of the referral e.g. GP, Self INTEGER 2
nhsspec Referral speciality according to the National Health Service(NHS) classification INTEGER 3
fhsaspec Referral speciality according to the Family Health Services Authority (FHSA) classification INTEGER 3
inpatient Classification of the type of referral, e.g. Day case, In patient INTEGER 2
attendance Category describing whether the referral event is the first visit, a follow-up etc INTEGER 2
urgency Classification of the urgency of the referral e.g. Routine, Urgent INTEGER 2
Table A19. Data fields in referral table of CPRD data.
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Field name Description Type Format 
patid Encrypted unique identifier given to a patient in GPRD INTEGER 20
eventdate Date associated with the event, as entered by the GP DATE dd/mm/yyyy 
sysdate Date the event was entered into Vision DATE dd/mm/yyyy 
constype Code for the category of event recorded within the GP system (e.g. intervention) INTEGER 3
consid Identifier that allows information about the consultation to be retrieved, when used in combination with pracid INTEGER 20
medcode GPRD unique code for the medical term selected by the GP INTEGER 20
staﬃd Identifier of the practice staﬀ member entering the data. A value of 0 indicates that the staﬃd is unknown INTEGER 20
textid 
Identifier that allows freetext information on the event to be
retrieved, when used in combination with pracid and event 
type ‘Immunisation’. A value of 0 indicates that there is no 
freetext information for this event 
INTEGER 20
immstype Individual components of an immunisation, e.g. Mumps, Rubella, Measles INTEGER 4
stage Stage of the immunisation given, e.g. 1, 2, B2 INTEGER 2
status Status of the immunisation e.g. Advised, Given, Refusal INTEGER 3
compound Immunisation compound administered – may be a single ormulti-component preparation, e.g. MMR INTEGER 4
source Location where the immunisation was administered, e.g. Inthis practice INTEGER 3
reason Reason for administering the immunisation, e.g. Routine measure INTEGER 3
method Route of administration for the immunisation, e.g. Oral, Intramuscular INTEGER 3
Table A20. Data fields in immunisation table of CPRD data.
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Field name Description Type Format 
patid Encrypted unique identifier given to a patient in GPRD INTEGER 20
eventdate Date associated with the event, as entered by the GP DATE dd/mm/yyyy 
sysdate Date the event was entered into Vision DATE dd/mm/yyyy 
constype Code for the category of event recorded within the GP system (e.g. examination) INTEGER 3
consid Identifier that allows information about the consultation to be retrieved, when used in combination with pracid INTEGER 20
medcode GPRD unique code for the medical term selected by the GP INTEGER 20
staﬃd Identifier of the practice staﬀ member entering the data. A value of 0 indicates that the staﬃd is unknown INTEGER 20
textid 
Identifier that allows freetext information on the event to be
retrieved, when used in combination with pracid and event 
type ‘Test’. A value of 0 indicates that there is no freetext 
information for this event 
INTEGER 20
enttype Identifier that represents the structured data area in Vision where the data was entered INTEGER 5
For Entity Types with 4 Data Fields
data1 Qualifier INTEGER 3
data2 Normal range from NUMERIC 16.3
data3 Normal range to NUMERIC 16.3
data4 Normal range basis NUMERIC 16.3
For Entity Types with 7 Data Fields
data1 Operator INTEGER 3
data2 Value NUMERIC 16.3
data3 Unit of measure INTEGER 4
data4 Qualifier INTEGER 3
data5 Normal range from NUMERIC 16.3
data6 Normal range to NUMERIC 16.3
data7 Normal range basis (or peak flow device for entity type 311) INTEGER 2
For Entity Types with 8 Data Fields
data1 Operator INTEGER 3
data2 Value NUMERIC 16.3
data3 Unit of measure INTEGER 4
data4 Qualifier INTEGER 3
data5 Normal range from NUMERIC 16.3
data6 Normal range to NUMERIC 16.3
data7 Normal range basis INTEGER 2
data8 Expected delivery date INTEGER 10
Table A21. Data fields in test table of CPRD data.
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Field name Description Type Format 
patid Encrypted unique identifier given to a patient in GPRD INTEGER 20
eventdate Date associated with the event, as entered by the GP DATE dd/mm/yyyy 
sysdate Date the event was entered into Vision DATE dd/mm/yyyy 
consid Identifier that allows information about the consultation to be retrieved, when used in combination with pracid INTEGER 20
prodcode GPRD unique code for the treatment selected by the GP INTEGER 20
staﬃd Identifier of the practice staﬀ member entering the data. A value of 0 indicates that the staﬃd is unknown INTEGER 20
textid 
Identifier that allows freetext information (dosage) on the 
event to be retrieved, when used in combination with 
pracid and event type ‘Therapy’. A value of 0 indicates that
there is no freetext information for the event. Use the 
Common Dosages Lookup (constituting ~ 95% of dosage 
strings in data) to interpret values < 100,000 
INTEGER 20
bnfcode Code representing the chapter & section from the British National Formulary for the product selected by GP INTEGER 5
qty Total quantity entered by the GP for the prescribed product INTEGER 20
ndd 
Numeric daily dose prescribed for the event. Derived using
a GPRD algorithm on common dosage strings 
(represented by textid < 100,000). Value is set to 0 for all 
dosage strings represented by textid > 100,000 
NUMERIC 10.3
numdays Number of treatment days prescribed for a specific therapy event INTEGER 20
numpacks Number of individual product packs prescribed for a specific therapy event INTEGER 8
packtype Pack size or type of the prescribed product INTEGER 10
issueseq 
Number to indicate whether the event is associated with a 
repeat schedule. Value of 0 implies the event is not part of 
a repeat prescription. A value ≥ 1 denotes the issue 
number for the prescription within a repeat schedule 
INTEGER 20
Table A22. Data fields in therapy table of CPRD data.
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List of Fields Provided in HES Tables
Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRDGOLD INTEGER 20
HESid
A unique identifier given to a patient in the HES data. An 
individual that has contributed to more than one GPRD 
practice at diﬀerent times has the same HESid
INTEGER 10
HESstart
Start of valid HES data collection for patient: max 
(01/04/1997, patient’s current registration date (crd), 
practice UTS date)
DATE DD/MM/YYYY
HESend
End of valid HES data collection for patient: min 
(31/12/2010, patient’s transfer out date, practice last 
collection date (lcd), practice linkage date)
DATE DD/MM/YYYY
match
Flag indicating strength of matching:
0 = No match (never hospitalised)
1 = Hospitalised (Linked using NHS, DOB, & gender)
INTEGER 1
Table A23. Data fields in source table of HES data.
Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRDGOLD INTEGER 20
pracid The encrypted unique identifier given to a specific practice in GPRD GOLD INTEGER 3
birthyear Patient’s year of birth according to GPRD records INTEGER 4
gender Patient’s gender according to GPRD records INTEGER 1
ethnos Patient’s ethnicity derived from HES records in years 1997 – 2010 CHAR 10
HESstart
Start of valid HES data collection for patient: max 
(01/04/1997, patient’s current registration date (crd), 
practice UTS date)
DATE DD/MM/YYYY
HESend
End of valid HES data collection for patient: min 
(31/12/2010, patient’s transfer out date, practice last 
collection date (lcd), practice linkage date)
DATE DD/MM/YYYY
Table A24. Data fields in patient table of HES data.
Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRDGOLD INTEGER 20
spno Spell number uniquely identifying a hospitalisation INTEGER 20
admidate Date of admission DATE DD/MM/YYYY
discharged Date of discharge DATE DD/MM/YYYY
admimeth Method of admission INTEGER 2
admisorc Source of admission INTEGER 2
disdest Destination on discharge INTEGER 2
dismeth Method of discharge INTEGER 1
duration Duration of hospitalisation spell in days INTEGER 5
elecdate Date of decision to admit patient DATE DD/MM/YYYY
elecdur Waiting time (diﬀerence in days between elecdate and admidate) INTEGER 5
Table A25. Data fields in hospitalisation table of HES data.
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Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRD GOLD INTEGER 20
spno Spell number uniquely identifying a hospitalisation INTEGER 20
epikey Episode key uniquely identifying an episode of care INTEGER 20
admidate Date of admission DATE DD/MM/YYYY
epistart Date of start of episode DATE DD/MM/YYYY
epiend Date of end of episode DATE DD/MM/YYYY
discharged Date of discharge DATE DD/MM/YYYY
eorder Order of episode within spell INTEGER 3
epidur Duration of episode in days INTEGER 5
epitype Type of episode (general, delivery, birth, psychiatric etc.) INTEGER 1
admimeth Method of admission INTEGER 2
admisorc Source of admission INTEGER 2
disdest Destination on discharge INTEGER 2
dismeth Method of discharge INTEGER 1
mainspef Speciality under which consultant is contracted CHAR 3
tretspef Speciality under which consultant is working in period of care CHAR 3
pconsult Consultant code (pseudonymised) CHAR 16
intmanig Intended management INTEGER 1
classpat
Patient Classification: (Actual Management)
1=Ordinary admission; 2=Day case admission; 
3=Regular day attendee; 4=Regular night attendee; 
5=Mothers and babies using only delivery facilities; 
8=Not applicable (other maternity event)
INTEGER 1
firstreg First regular day or night admission? CHAR 2
Table A26. Data fields in episodes table of HES data.
Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRD GOLD INTEGER 20
spno Number uniquely identifying a hospitalisation INTEGER 20
epikey Episode key uniquely identifying an episode of care INTEGER 20
epistart Start date of episode of care DATE DD/MM/YYYY
epiend Date of end of episode DATE DD/MM/YYYY
ICD An ICD10 diagnosis code in XXX or XXX.X format CHAR 5
ICDx 5th/6th characters of the ICD code (if available) CHAR 2
primary 1 if code is primary diagnosis code in episode, 0 if not INTEGER 1
Table A27. Data fields in diagnoses by episode table of HES data.
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Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRD GOLD INTEGER 20
spno Spell number uniquely identifying a hospitalisation INTEGER 20
admidate Date of admission DATE DD/MM/YYYY
discharged Date of discharge DATE DD/MM/YYYY
ICD An ICD10 diagnosis code in XXX or XXX.X format CHAR 5
ICDx 5th/6th characters of the ICD code (if available) CHAR 2
Table A28. Data fields in diagnoses by hospitalisation table of HES data.
Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRD GOLD INTEGER 20
spno Spell number uniquely identifying a hospitalisation INTEGER 20
admidate Date of admission DATE DD/MM/YYYY
discharged Date of discharge DATE DD/MM/YYYY
ICD_PRIMARY Primary ICD10 diagnosis code in XXX or XXX.X format CHAR 5
ICDx 5th/6th characters of the ICD code (if available) CHAR 2
Table A29. Data fields in primary diagnoses across hospitalisation table of HES data.
Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRD GOLD INTEGER 20
spno Spell number uniquely identifying a hospitalisation INTEGER 20
admidate Date of admission DATE DD/MM/YYYY
discharged Date of discharge DATE DD/MM/YYYY
ICD_PRIMARY Primary ICD10 diagnosis code in XXX or XXX.X format CHAR 5
ICDx 5th/6th characters of the ICD code (if available) CHAR 2
Table A30. Data fields in procedures table of HES data.
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Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRD GOLD INTEGER 20
spno Spell number uniquely identifying a hospitalisation INTEGER 20
epikey Episode key uniquely identifying an episode of care INTEGER 20
epistart Date of start of episode DATE DD/MM/YYYY
epiend Date of end of episode DATE DD/MM/YYYY
eorder Order of episode within spell INTEGER 3
epidur Duration of episode in days INTEGER 5
numacp Number of augmented care periods within episode INTEGER 2
acpn Order of an augmented care episode within a sequence of episodes that make up a period of augmented care INTEGER 2
acpstar Start date of a period of augmented care DATE DD/MM/YYYY
acpend End date of a period of augmented care DATE DD/MM/YYYY
acpdur Duration of augmented care period in days INTEGER 8
intdays Number of days of intensive care in a period of augmented care INTEGER 5
depdays Number of days of high dependency care in a period of augmented care INTEGER 5
acploc Location of a patient during a period of augmented care INTEGER 2
acpsour Location of patient immediately before the period of augmented care INTEGER 2
acpdisp Destination of a discharged patient after a period of augmented care INTEGER 2
acpout Augmented care period outcome indicator INTEGER 2
acpplan Flag for whether ACP was planned in advance of admission to ACP location CHAR 1
acpspef Code for main specialty of consultant clinically managing the ACP CHAR 3
orgsup Number of organ support systems used (up to five) during an ACP INTEGER 2
acpdqind Currently no Information on variable CHAR 1
Table A31. Data fields in augmented care periods table of HES data.
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Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRD GOLD INTEGER 20
spno Spell number uniquely identifying a hospitalisation INTEGER 20
epikey Episode key uniquely identifying an episode of care INTEGER 20
admidate Date of admission DATE DD/MM/YYYY
discharged Date of discharge DATE DD/MM/YYYY
epistart Date of start of episode DATE DD/MM/YYYY
epiend Date of end of episode DATE DD/MM/YYYY
eorder Order of episode within spell INTEGER 3
ccstartdate Date on which the critical care period started DATE DD/MM/YYYY
ccstarttime Time at which the critical care period started CHAR 8
ccdisrdydate Critical care discharge ready date DATE DD/MM/YYYY
ccdisrdytime Critical care discharge ready time CHAR 8
ccdisdate Critical care discharge date DATE DD/MM/YYYY
ccdistime Critical care discharge time CHAR 8
ccadmitype Critical care admission type INTEGER 2
ccadmisorc Critical care admission source INTEGER 2
ccsorcloc Specific location in the admission source INTEGER 2
ccdisstat Patient’s status at time of discharge INTEGER 2
ccdisdest Critical care discharge destination INTEGER 2
ccdisloc Principle location the patient is being discharged to for further care INTEGER 2
cclev2days Total calendar days during which level 2 care alone was provided during the period INTEGER 5
cclev3days Total calendar days during which level 3 care was provided during the period INTEGER 5
bcardsupdays Number of days of basic cardiovascular support INTEGER 5
acardsupdays Number of days of advanced cardiovascular support INTEGER 5
bressupdays Number of days of basic respiratory support INTEGER 5
aressupdays Number of days of advanced respiratory support INTEGER 5
gisupdays Number of days of gastrointestinal support INTEGER 5
liversupdays Number of days of liver support INTEGER 5
neurosupdays Number of days of neurological support INTEGER 5
rensupdays Number of days of renal support INTEGER 5
dermsupdays Number of days of dermatological support INTEGER 5
orgsupmax Maximum number of organ systems supported at any one time, at any point in the critical care period INTEGER 2
ccunitfun Critical care unit function INTEGER 2
unitbedconfig Critical care unit bed configuration INTEGER 2
bestmatch
Flag stating whether the row represents the best match 
between the critical care & episode start & end dates for 
this critical care period
INTEGER 2
ccaprel
Comparision of dates of the critical care period and the 
associated inpatient episode. Used in derivation of the 
‘bestmatch’ field
INTEGER 2
Table A32. Data fields in critical care table of HES data.
- 262 -
Field name Description Type Format
patid The encrypted unique identifier given to patient in GPRD GOLD INTEGER 20
spno Spell number uniquely identifying a hospitalisation INTEGER 20
epikey Episode key uniquely identifying an episode of care INTEGER 20
epistart Date of start of episode DATE DD/MM/YYYY
epiend Date of end of episode DATE DD/MM/YYYY
eorder Order of episode within spell INTEGER 3
epidur Duration of episode in days INTEGER 5
numbaby Number of babies delivered at the end of a single pregnancy. Both live and stillborn babies are counted CHAR 1
numtailb Number of baby tails INTEGER 1
matordr Order of birth INTEGER 1
neocare Neonatal level of care INTEGER 1
wellbaby
Well baby check flag - indicates whether the episode 
relates to a well baby (a neonate receiving normal levels 
of care, usually given by a mother or mother substitute)
CHAR 1
anasdate First antenatal assessment date DATE DD/MM/YYYY
birordr The position in the sequence of births CHAR 1
birstat Indicates whether the baby was born alive or dead (still birth). INTEGER 1
biresus Identifies resuscitation method used to get the baby breathing INTEGER 1
sexbaby Sex of baby CHAR 1
birweit Weight of the baby in grams immediately after birth INTEGER 4
delmeth Method used to deliver a baby that is a registrable birth CHAR 1
delonset Method used to induce (initiate) labour, rather than to accelerate it INTEGER 1
delinten Intended type of delivery place INTEGER 1
delplac Actual type of delivery place INTEGER 1
delchang Reason for changing the delivery place type INTEGER 1
delprean Anaesthetic or analgesic administered before and during labour and delivery INTEGER 1
delposan Anaesthetic or analgesic administered after delivery INTEGER 1
delstat Status of the person conducting the delivery INTEGER 1
anagest
Gestation period in weeks at the date of the first 
antenatal assessment (calculated from anadate, gestat 
and the dobbaby)
INTEGER 2
gestat Length of gestation - number of completed weeks of gestation INTEGER 2
numpreg Number of previous pregnancies that resulted in a registrable birth (live or still born) INTEGER 2
matage Mother's age at delivery INTEGER 3
neodur Baby's age in days INTEGER 3
antedur Antenatal days of stay INTEGER 3
postdur Postnatal days of stay INTEGER 3
Table A33. Data fields in maternity table of HES data.
- 263 -
Log-Log Plots of Survival Function for 
QOF Indicators and NDA Processes
Figure A1. Log-log plot of survival function for strata of the number of NDA processes achieved in
2005/06.
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Figure A2. Log-log plot of survival functions for receipt of individual NDA processes achieved in
2005/06.
Figure A3. Log-log plot of survival functions for receipt of individual QOF indicators achieved in
2005/06.
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Full Regression Tables for Partially 
Adjusted Patient-Level Models
Emergency Admissions and QOF Attainment
Table A34. Full results from multiple-variable zero-inflated negative binomial regression model of
attainment of DM06 in 2005/06 against emergency admissions.
Table A35. Full results from multiple-variable zero-inflated negative binomial regression model of
attainment of DM12 in 2005/06 against emergency admissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.864 0.013 0.804 < 0.001 0.810 < 0.001 0.828 < 0.001 0.844 < 0.001
Years With DM 1.004 0.076 1.004 0.004 1.005 < 0.001 1.004 < 0.001 1.004 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.011 0.730 1.051 0.022 1.050 0.007 1.041 0.011 1.040 0.007
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.163 0.370 1.050 0.679 1.080 0.426 1.050 0.561 0.988 0.880
45 – 64y 1.048 0.776 0.987 0.908 0.989 0.906 0.973 0.746 0.945 0.457
65 – 74y 1.210 0.254 1.125 0.316 1.113 0.268 1.093 0.296 1.057 0.469
≥ 75y 1.371 0.058 1.307 0.022 1.347 0.002 1.368 < 0.001 1.344 < 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.825 < 0.001 0.810 < 0.001 0.814 < 0.001 0.834 < 0.001 0.834 < 0.001
3 0.797 < 0.001 0.751 < 0.001 0.753 < 0.001 0.764 < 0.001 0.783 < 0.001
4 0.792 < 0.001 0.737 < 0.001 0.735 < 0.001 0.749 < 0.001 0.757 < 0.001
5 0.753 < 0.001 0.703 < 0.001 0.693 < 0.001 0.697 < 0.001 0.702 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.226 < 0.001 1.310 < 0.001 1.331 < 0.001 1.317 < 0.001 1.316 < 0.001
CCI = 2 1.440 < 0.001 1.496 < 0.001 1.514 < 0.001 1.471 < 0.001 1.418 < 0.001
CCI = 3 1.706 < 0.001 1.869 < 0.001 1.804 < 0.001 1.731 < 0.001 1.666 < 0.001
CCI ≥ 4 2.070 < 0.001 2.128 < 0.001 2.066 < 0.001 1.935 < 0.001 1.793 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.042 0.257 1.107 < 0.001 1.120 < 0.001 1.119 < 0.001 1.100 < 0.001
Current Smoker 1.135 0.011 1.232 < 0.001 1.235 < 0.001 1.242 < 0.001 1.248 < 0.001
Unknown 1.187 0.003 1.335 < 0.001 1.403 < 0.001 1.437 < 0.001 1.417 < 0.001
DM06 0.826 < 0.001 0.830 < 0.001 0.845 < 0.001 0.847 < 0.001 0.849 < 0.001
Convergence not achieved
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.830 0.002 0.777 < 0.001 0.785 < 0.001 0.803 < 0.001 0.820 < 0.001
Years With DM 1.005 0.015 1.006 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.015 0.632 1.054 0.016 1.051 0.006 1.041 0.011 1.039 0.009
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.151 0.404 1.056 0.640 1.086 0.394 1.054 0.538 0.987 0.867
45 – 64y 1.034 0.842 0.984 0.890 0.988 0.896 0.969 0.709 0.937 0.393
65 – 74y 1.167 0.355 1.097 0.429 1.090 0.374 1.068 0.440 1.030 0.703
≥ 75y 1.322 0.094 1.269 0.041 1.310 0.005 1.326 0.001 1.297 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.823 < 0.001 0.809 < 0.001 0.814 < 0.001 0.836 < 0.001 0.836 < 0.001
3 0.797 < 0.001 0.752 < 0.001 0.754 < 0.001 0.765 < 0.001 0.784 < 0.001
4 0.789 < 0.001 0.735 < 0.001 0.734 < 0.001 0.749 < 0.001 0.757 < 0.001
5 0.750 < 0.001 0.704 < 0.001 0.693 < 0.001 0.697 < 0.001 0.702 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.238 < 0.001 1.318 < 0.001 1.341 < 0.001 1.329 < 0.001 1.327 < 0.001
CCI = 2 1.449 < 0.001 1.496 < 0.001 1.518 < 0.001 1.475 < 0.001 1.421 < 0.001
CCI = 3 1.733 < 0.001 1.888 < 0.001 1.827 < 0.001 1.758 < 0.001 1.691 < 0.001
CCI ≥ 4 2.089 < 0.001 2.137 < 0.001 2.083 < 0.001 1.956 < 0.001 1.810 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.037 0.323 1.103 < 0.001 1.116 < 0.001 1.115 < 0.001 1.096 < 0.001
Current Smoker 1.138 0.009 1.234 < 0.001 1.239 < 0.001 1.246 < 0.001 1.252 < 0.001
Unknown 1.238 < 0.001 1.394 < 0.001 1.460 < 0.001 1.478 < 0.001 1.454 < 0.001
DM12 0.981 0.430 0.976 0.185 0.968 0.044 0.942 < 0.001 0.939 < 0.001
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Table A36. Full results from multiple-variable zero-inflated negative binomial regression model of
attainment of DM17 in 2005/06 against emergency admissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.836 0.002 0.784 < 0.001 0.792 < 0.001 0.810 < 0.001 0.826 < 0.001
Years With DM 1.005 0.015 1.006 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.992 0.808 1.035 0.117 1.035 0.057 1.028 0.083 1.028 0.057
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.161 0.376 1.063 0.602 1.084 0.400 1.056 0.519 0.989 0.881
45 – 64y 1.084 0.628 1.019 0.874 1.011 0.905 0.993 0.933 0.956 0.555
65 – 74y 1.258 0.171 1.164 0.196 1.139 0.179 1.114 0.207 1.065 0.413
≥ 75y 1.396 0.046 1.329 0.015 1.357 0.002 1.372 < 0.001 1.333 < 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.825 < 0.001 0.809 < 0.001 0.813 < 0.001 0.834 < 0.001 0.834 < 0.001
3 0.799 < 0.001 0.753 < 0.001 0.754 < 0.001 0.766 < 0.001 0.785 < 0.001
4 0.787 < 0.001 0.734 < 0.001 0.734 < 0.001 0.749 < 0.001 0.757 < 0.001
5 0.753 < 0.001 0.706 < 0.001 0.695 < 0.001 0.698 < 0.001 0.703 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.247 < 0.001 1.325 < 0.001 1.343 < 0.001 1.330 < 0.001 1.327 < 0.001
CCI = 2 1.440 < 0.001 1.496 < 0.001 1.515 < 0.001 1.472 < 0.001 1.420 < 0.001
CCI = 3 1.741 < 0.001 1.898 < 0.001 1.828 < 0.001 1.757 < 0.001 1.690 < 0.001
CCI ≥ 4 2.110 < 0.001 2.149 < 0.001 2.084 < 0.001 1.953 < 0.001 1.807 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.050 0.175 1.112 < 0.001 1.122 < 0.001 1.120 < 0.001 1.101 < 0.001
Current Smoker 1.140 0.008 1.232 < 0.001 1.235 < 0.001 1.240 < 0.001 1.246 < 0.001
Unknown 1.129 0.038 1.294 < 0.001 1.367 < 0.001 1.404 < 0.001 1.395 < 0.001
DM17 0.761 < 0.001 0.817 < 0.001 0.840 < 0.001 0.850 < 0.001 0.869 < 0.001
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Readmissions and QOF Attainment
Table A37. Full results from multiple-variable zero-inflated negative binomial regression model of
attainment of DM06 in 2005/06 against readmissions.
Table A38. Full results from multiple-variable zero-inflated negative binomial regression model of
attainment of DM12 in 2005/06 against readmissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.863 0.296 0.786 0.017 0.733 < 0.001 0.754 < 0.001 0.807 0.002
Years With DM 1.000 0.995 1.002 0.469 1.003 0.261 1.002 0.443 1.002 0.269
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.936 0.388 1.026 0.630 1.050 0.260 0.998 0.952 1.004 0.900
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.955 0.922 1.042 0.898 1.179 0.532 1.185 0.452 1.103 0.628
45 – 64y 0.625 0.321 0.699 0.259 0.812 0.425 0.791 0.296 0.737 0.126
65 – 74y 0.553 0.212 0.654 0.185 0.725 0.221 0.700 0.113 0.666 0.043
≥ 75y 0.553 0.210 0.596 0.105 0.708 0.186 0.714 0.135 0.664 0.041
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.922 0.454 0.888 0.125 0.838 0.005 0.847 0.002 0.827 < 0.001
3 0.808 0.058 0.704 < 0.001 0.707 < 0.001 0.733 < 0.001 0.736 < 0.001
4 0.902 0.382 0.785 0.002 0.721 < 0.001 0.736 < 0.001 0.756 < 0.001
5 0.717 0.006 0.711 < 0.001 0.689 < 0.001 0.692 < 0.001 0.704 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.050 0.622 1.218 0.003 1.211 < 0.001 1.269 < 0.001 1.266 < 0.001
CCI = 2 1.078 0.495 1.233 0.008 1.247 0.001 1.316 < 0.001 1.309 < 0.001
CCI = 3 1.283 0.062 1.427 < 0.001 1.469 < 0.001 1.517 < 0.001 1.566 < 0.001
CCI ≥ 4 1.622 0.001 1.790 < 0.001 1.822 < 0.001 1.787 < 0.001 1.761 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.052 0.563 1.176 0.008 1.166 0.002 1.144 0.001 1.133 0.001
Current Smoker 0.891 0.326 1.058 0.491 1.034 0.620 1.018 0.752 1.103 0.053
Unknown 1.230 0.142 1.436 < 0.001 1.518 < 0.001 1.540 < 0.001 1.587 < 0.001
DM06 0.752 < 0.001 0.753 < 0.001 0.791 < 0.001 0.795 < 0.001 0.811 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.825 0.171 0.756 0.005 0.705 < 0.001 0.727 < 0.001 0.776 < 0.001
Years With DM 1.001 0.722 1.004 0.164 1.005 0.079 1.003 0.164 1.004 0.083
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.948 0.484 1.040 0.460 1.056 0.203 1.003 0.933 1.007 0.836
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.972 0.952 1.058 0.861 1.195 0.499 1.193 0.435 1.102 0.632
45 – 64y 0.650 0.360 0.706 0.274 0.823 0.455 0.794 0.302 0.732 0.118
65 – 74y 0.555 0.213 0.640 0.163 0.717 0.205 0.687 0.096 0.649 0.031
≥ 75y 0.551 0.205 0.576 0.083 0.693 0.160 0.693 0.103 0.640 0.026
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.902 0.345 0.884 0.110 0.839 0.005 0.851 0.003 0.832 < 0.001
3 0.808 0.061 0.709 < 0.001 0.709 < 0.001 0.737 < 0.001 0.739 < 0.001
4 0.895 0.351 0.776 0.002 0.717 < 0.001 0.735 < 0.001 0.757 < 0.001
5 0.705 0.004 0.709 < 0.001 0.686 < 0.001 0.694 < 0.001 0.705 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.084 0.412 1.253 0.001 1.237 < 0.001 1.294 < 0.001 1.287 < 0.001
CCI = 2 1.110 0.343 1.256 0.004 1.257 < 0.001 1.322 < 0.001 1.312 < 0.001
CCI = 3 1.312 0.042 1.461 < 0.001 1.496 < 0.001 1.557 < 0.001 1.603 < 0.001
CCI ≥ 4 1.663 0.001 1.826 < 0.001 1.856 < 0.001 1.818 < 0.001 1.787 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.039 0.666 1.167 0.011 1.159 0.003 1.134 0.003 1.125 0.001
Current Smoker 0.898 0.363 1.059 0.483 1.036 0.596 1.019 0.740 1.101 0.058
Unknown 1.299 0.063 1.535 < 0.001 1.595 < 0.001 1.590 < 0.001 1.635 < 0.001
DM12 0.976 0.640 0.981 0.631 0.950 0.125 0.916 0.003 0.922 0.003
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Table A39. Full results from multiple-variable zero-inflated negative binomial regression model of
attainment of DM17 in 2005/06 against readmissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.830 0.184 0.769 0.009 0.719 < 0.001 0.738 < 0.001 0.785 < 0.001
Years With DM 1.001 0.783 1.004 0.178 1.005 0.077 1.003 0.160 1.004 0.083
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.931 0.345 1.023 0.669 1.042 0.337 0.991 0.796 0.996 0.912
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.921 0.864 1.039 0.905 1.172 0.546 1.179 0.467 1.100 0.636
45 – 64y 0.637 0.342 0.711 0.284 0.826 0.464 0.802 0.326 0.746 0.142
65 – 74y 0.581 0.253 0.670 0.210 0.740 0.251 0.713 0.133 0.673 0.049
≥ 75y 0.554 0.211 0.596 0.105 0.708 0.187 0.712 0.131 0.658 0.037
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.931 0.511 0.890 0.130 0.838 0.005 0.848 0.002 0.828 < 0.001
3 0.825 0.087 0.712 < 0.001 0.711 < 0.001 0.738 < 0.001 0.742 < 0.001
4 0.904 0.391 0.776 0.002 0.718 < 0.001 0.735 < 0.001 0.757 < 0.001
5 0.720 0.007 0.716 < 0.001 0.692 < 0.001 0.694 < 0.001 0.706 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.114 0.274 1.266 < 0.001 1.245 < 0.001 1.302 < 0.001 1.292 < 0.001
CCI = 2 1.091 0.428 1.251 0.005 1.253 < 0.001 1.322 < 0.001 1.313 < 0.001
CCI = 3 1.340 0.028 1.479 < 0.001 1.509 < 0.001 1.564 < 0.001 1.607 < 0.001
CCI ≥ 4 1.708 < 0.001 1.838 < 0.001 1.869 < 0.001 1.823 < 0.001 1.791 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.065 0.473 1.179 0.007 1.162 0.002 1.137 0.002 1.129 0.001
Current Smoker 0.897 0.353 1.054 0.521 1.029 0.671 1.012 0.841 1.096 0.071
Unknown 1.170 0.267 1.410 0.001 1.482 < 0.001 1.499 < 0.001 1.558 < 0.001
DM17 0.703 < 0.001 0.804 < 0.001 0.826 < 0.001 0.826 < 0.001 0.851 < 0.001
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Odds of Death (all-cause) and QOF Attainment
Table A40. Full results from logistic regression model of attainment of DM06 in 2005/06 against
death (all cause).
Table A41. Full results from logistic regression model of attainment of DM12 in 2005/06 against
death (all cause).
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.642 < 0.001 0.681 < 0.001 0.782 < 0.001 0.863 0.019 0.855 0.007
Years With DM 1.003 0.393 1.002 0.443 1.006 0.004 1.008 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.826 < 0.001 0.856 < 0.001 0.859 < 0.001 0.845 < 0.001 0.840 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.111 0.210 1.295 0.516 1.528 0.251 1.683 0.115
45 – 64y 4.419 < 0.001 6.533 0.001 3.918 < 0.001 4.554 < 0.001 4.933 < 0.001
65 – 74y 14.278 < 0.001 18.979 < 0.001 11.703 < 0.001 13.007 < 0.001 14.390 < 0.001
≥ 75y 43.897 < 0.001 62.828 < 0.001 40.128 < 0.001 48.707 < 0.001 57.083 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.950 0.462 0.844 0.001 0.826 < 0.001 0.844 < 0.001 0.843 < 0.001
3 0.968 0.638 0.795 < 0.001 0.786 < 0.001 0.778 < 0.001 0.782 < 0.001
4 0.836 0.010 0.753 < 0.001 0.770 < 0.001 0.781 < 0.001 0.778 < 0.001
5 0.753 < 0.001 0.668 < 0.001 0.662 < 0.001 0.654 < 0.001 0.663 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.264 < 0.001 1.234 < 0.001 1.311 < 0.001 1.313 < 0.001 1.339 < 0.001
CCI = 2 2.585 < 0.001 2.376 < 0.001 2.495 < 0.001 2.528 < 0.001 2.521 < 0.001
CCI = 3 3.024 < 0.001 3.275 < 0.001 3.428 < 0.001 3.531 < 0.001 3.575 < 0.001
CCI ≥ 4 4.976 < 0.001 4.867 < 0.001 5.096 < 0.001 5.554 < 0.001 5.871 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.002 0.972 1.076 0.046 1.123 < 0.001 1.148 < 0.001 1.162 < 0.001
Current Smoker 1.403 < 0.001 1.590 < 0.001 1.738 < 0.001 1.757 < 0.001 1.877 < 0.001
Unknown 0.321 < 0.001 0.443 < 0.001 0.659 < 0.001 0.835 0.001 1.028 0.565
DM06 0.550 < 0.001 0.678 < 0.001 0.742 < 0.001 0.772 < 0.001 0.804 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.577 < 0.001 0.635 < 0.001 0.743 < 0.001 0.826 0.002 0.825 0.001
Years With DM 1.006 0.030 1.005 0.045 1.008 < 0.001 1.010 < 0.001 1.012 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.821 < 0.001 0.857 < 0.001 0.859 < 0.001 0.845 < 0.001 0.839 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.095 0.214 1.290 0.521 1.524 0.254 1.677 0.117
45 – 64y 4.288 < 0.001 6.334 0.002 3.833 0.001 4.470 < 0.001 4.853 < 0.001
65 – 74y 13.092 < 0.001 17.657 < 0.001 11.082 < 0.001 12.412 < 0.001 13.832 < 0.001
≥ 75y 38.844 < 0.001 57.215 < 0.001 37.395 < 0.001 45.828 < 0.001 54.224 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.955 0.508 0.849 0.001 0.830 < 0.001 0.847 < 0.001 0.846 < 0.001
3 0.969 0.652 0.797 < 0.001 0.788 < 0.001 0.780 < 0.001 0.783 < 0.001
4 0.834 0.009 0.753 < 0.001 0.770 < 0.001 0.781 < 0.001 0.778 < 0.001
5 0.757 < 0.001 0.670 < 0.001 0.663 < 0.001 0.656 < 0.001 0.663 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.299 < 0.001 1.253 < 0.001 1.326 < 0.001 1.326 < 0.001 1.350 < 0.001
CCI = 2 2.642 < 0.001 2.401 < 0.001 2.513 < 0.001 2.544 < 0.001 2.535 < 0.001
CCI = 3 3.162 < 0.001 3.353 < 0.001 3.488 < 0.001 3.586 < 0.001 3.624 < 0.001
CCI ≥ 4 5.219 < 0.001 4.995 < 0.001 5.196 < 0.001 5.649 < 0.001 5.961 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.998 0.961 1.069 0.067 1.117 < 0.001 1.143 < 0.001 1.158 < 0.001
Current Smoker 1.432 < 0.001 1.611 < 0.001 1.756 < 0.001 1.773 < 0.001 1.893 < 0.001
Unknown 0.357 < 0.001 0.500 < 0.001 0.727 < 0.001 0.907 0.068 1.093 0.064
DM12 0.777 < 0.001 0.961 0.228 0.984 0.569 0.977 0.362 0.963 0.113
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2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.604 < 0.001 0.654 < 0.001 0.760 < 0.001 0.843 0.007 0.840 0.003
Years With DM 1.006 0.032 1.004 0.056 1.008 < 0.001 1.010 < 0.001 1.012 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.729 < 0.001 0.800 < 0.001 0.815 < 0.001 0.808 < 0.001 0.808 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.140 0.202 1.307 0.501 1.538 0.244 1.691 0.112
45 – 64y 4.994 < 0.001 7.104 0.001 4.176 < 0.001 4.801 < 0.001 5.164 < 0.001
65 – 74y 16.926 < 0.001 21.062 < 0.001 12.671 < 0.001 13.893 < 0.001 15.255 < 0.001
≥ 75y 47.581 < 0.001 66.106 < 0.001 41.741 < 0.001 50.296 < 0.001 58.810 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.936 0.348 0.837 < 0.001 0.821 < 0.001 0.840 < 0.001 0.840 < 0.001
3 0.956 0.518 0.789 < 0.001 0.782 < 0.001 0.775 < 0.001 0.780 < 0.001
4 0.836 0.011 0.752 < 0.001 0.769 < 0.001 0.780 < 0.001 0.777 < 0.001
5 0.768 < 0.001 0.675 < 0.001 0.667 < 0.001 0.659 < 0.001 0.667 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.311 < 0.001 1.262 < 0.001 1.334 < 0.001 1.333 < 0.001 1.356 < 0.001
CCI = 2 2.611 < 0.001 2.391 < 0.001 2.510 < 0.001 2.543 < 0.001 2.534 < 0.001
CCI = 3 3.122 < 0.001 3.350 < 0.001 3.492 < 0.001 3.592 < 0.001 3.629 < 0.001
CCI ≥ 4 5.133 < 0.001 4.957 < 0.001 5.169 < 0.001 5.626 < 0.001 5.936 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.033 0.505 1.096 0.013 1.140 < 0.001 1.164 < 0.001 1.176 < 0.001
Current Smoker 1.391 < 0.001 1.585 < 0.001 1.734 < 0.001 1.752 < 0.001 1.872 < 0.001
Unknown 0.244 < 0.001 0.376 < 0.001 0.573 < 0.001 0.739 < 0.001 0.917 0.073
DM17 0.343 < 0.001 0.525 < 0.001 0.597 < 0.001 0.638 < 0.001 0.670 < 0.001
Table A42. Full results from logistic regression model of attainment of DM17 in 2005/06 against
death (all cause).
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Odds of Death Due to Diabetes-Related Causes and 
QOF Attainment
Table A43. Full results from logistic regression model of attainment of DM06 in 2005/06 against
death due to a potentially diabetes-related cause.
Table A44. Full results from logistic regression model of attainment of DM12 in 2005/06 against
death due to a potentially diabetes-related cause.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.729 0.085 0.742 0.028 0.689 0.001 0.753 0.006 0.740 0.001
Years With DM 1.019 0.001 1.013 0.002 1.013 < 0.001 1.013 < 0.001 1.013 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.040 0.655 1.019 0.758 1.029 0.570 1.029 0.515 1.014 0.713
Age Group < 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.426 0.779 0.990 0.990 1.237 0.780 0.941 0.927
45 – 64y 1.883 0.230 2.037 0.566 1.421 0.651 1.714 0.467 1.008 0.991
65 – 74y 2.047 0.169 2.070 0.557 1.364 0.689 1.615 0.518 0.968 0.960
≥ 75y 2.256 0.116 2.278 0.506 1.601 0.544 1.902 0.385 1.177 0.799
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.030 0.822 1.042 0.655 0.993 0.930 0.990 0.874 0.966 0.566
3 1.039 0.772 1.020 0.833 0.998 0.982 1.006 0.929 0.991 0.876
4 0.892 0.391 0.904 0.272 0.927 0.315 0.901 0.113 0.880 0.030
5 0.814 0.151 0.803 0.027 0.807 0.009 0.854 0.026 0.843 0.007
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.719 0.005 0.890 0.152 0.913 0.165 0.941 0.276 0.963 0.447
CCI = 2 0.692 0.001 0.782 0.002 0.844 0.010 0.890 0.041 0.916 0.088
CCI = 3 0.888 0.389 1.058 0.564 1.117 0.174 1.136 0.077 1.184 0.010
CCI ≥ 4 0.613 0.001 0.789 0.029 0.811 0.023 0.858 0.063 0.877 0.083
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.939 0.504 0.871 0.043 0.910 0.091 0.915 0.069 0.941 0.163
Current Smoker 0.803 0.117 0.753 0.004 0.746 < 0.001 0.766 < 0.001 0.785 < 0.001
Unknown 1.096 0.719 0.829 0.244 0.947 0.635 0.963 0.680 0.933 0.377
DM06 0.924 0.347 0.911 0.117 0.869 0.004 0.882 0.003 0.881 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.719 0.071 0.732 0.021 0.671 0.001 0.734 0.003 0.723 < 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.041 0.643 1.020 0.751 1.027 0.599 1.026 0.563 1.010 0.802
Age Group < 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.404 0.789 1.003 0.997 1.252 0.768 0.948 0.935
45 – 64y 1.883 0.230 1.996 0.577 1.431 0.645 1.724 0.463 1.009 0.989
65 – 74y 2.036 0.172 2.010 0.573 1.361 0.692 1.610 0.520 0.960 0.950
≥ 75y 2.242 0.118 2.202 0.524 1.583 0.554 1.883 0.393 1.159 0.818
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.032 0.811 1.042 0.659 0.994 0.937 0.990 0.878 0.966 0.567
3 1.038 0.776 1.020 0.830 1.002 0.983 1.009 0.895 0.993 0.904
4 0.890 0.384 0.901 0.260 0.927 0.310 0.902 0.116 0.881 0.031
5 0.815 0.153 0.803 0.027 0.807 0.009 0.854 0.026 0.843 0.007
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.719 0.005 0.891 0.157 0.917 0.183 0.946 0.322 0.968 0.520
CCI = 2 0.693 0.001 0.783 0.002 0.847 0.011 0.895 0.053 0.921 0.111
CCI = 3 0.890 0.400 1.063 0.531 1.124 0.149 1.147 0.057 1.198 0.006
CCI ≥ 4 0.615 0.001 0.795 0.034 0.821 0.033 0.870 0.090 0.888 0.120
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.936 0.485 0.869 0.039 0.910 0.090 0.917 0.076 0.942 0.172
Current Smoker 0.805 0.122 0.751 0.003 0.744 < 0.001 0.768 < 0.001 0.787 < 0.001
Unknown 1.101 0.703 0.836 0.268 0.961 0.727 0.969 0.731 0.938 0.417
DM12 1.014 0.865 0.978 0.710 0.935 0.172 0.911 0.032 0.904 0.009
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Table A45. Full results from logistic regression model of attainment of DM17 in 2005/06 against
death due to a potentially diabetes-related cause.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.720 0.073 0.730 0.020 0.669 0.001 0.734 0.003 0.723 < 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.049 0.583 1.030 0.638 1.033 0.523 1.030 0.503 1.012 0.753
Age Group < 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.395 0.792 0.983 0.983 1.237 0.780 0.945 0.931
45 – 64y 1.862 0.239 1.932 0.595 1.388 0.673 1.688 0.480 1.002 0.997
65 – 74y 2.024 0.176 1.944 0.591 1.318 0.722 1.576 0.539 0.953 0.941
≥ 75y 2.241 0.119 2.144 0.537 1.539 0.578 1.846 0.408 1.152 0.826
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.034 0.804 1.044 0.641 0.995 0.945 0.991 0.890 0.967 0.570
3 1.043 0.749 1.025 0.788 1.004 0.962 1.009 0.889 0.992 0.898
4 0.892 0.391 0.903 0.272 0.927 0.312 0.902 0.117 0.881 0.031
5 0.813 0.146 0.803 0.028 0.810 0.009 0.857 0.029 0.845 0.008
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.717 0.005 0.887 0.143 0.914 0.171 0.944 0.303 0.968 0.510
CCI = 2 0.694 0.001 0.784 0.002 0.846 0.011 0.891 0.044 0.917 0.095
CCI = 3 0.891 0.402 1.060 0.551 1.121 0.161 1.141 0.066 1.192 0.007
CCI ≥ 4 0.617 0.001 0.795 0.034 0.819 0.030 0.866 0.079 0.884 0.104
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.933 0.464 0.864 0.031 0.904 0.071 0.911 0.057 0.938 0.142
Current Smoker 0.806 0.123 0.749 0.003 0.743 < 0.001 0.766 < 0.001 0.785 < 0.001
Unknown 1.112 0.677 0.848 0.308 0.979 0.853 0.991 0.918 0.957 0.582
DM17 1.112 0.200 1.093 0.137 1.030 0.558 1.001 0.986 0.979 0.597
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Emergency Admissions and NDA Attainment
Table A46. Full results from multiple-variable zero-inflated negative binomial regression model of the
number of NDA care processes received in 2005/06 against emergency admissions.
Table A47. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA BMI care process in 2005/06 against emergency admissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.852 0.006 0.798 < 0.001 0.802 < 0.001 0.818 < 0.001 0.832 < 0.001
Years With DM 1.005 0.015 1.005 0.001 1.005 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.990 0.737 1.032 0.137 1.035 0.056 1.031 0.055 1.033 0.026
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.211 0.259 1.088 0.470 1.109 0.280 1.075 0.396 1.006 0.939
45 – 64y 1.154 0.395 1.054 0.649 1.039 0.687 1.015 0.861 0.973 0.722
65 – 74y 1.246 0.193 1.169 0.183 1.148 0.154 1.121 0.181 1.072 0.367
≥ 75y 1.282 0.140 1.289 0.030 1.350 0.002 1.375 < 0.001 1.339 < 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.830 < 0.001 0.813 < 0.001 0.818 < 0.001 0.837 < 0.001 0.836 < 0.001
3 0.809 < 0.001 0.759 < 0.001 0.760 < 0.001 0.770 < 0.001 0.787 < 0.001
4 0.790 < 0.001 0.740 < 0.001 0.742 < 0.001 0.754 < 0.001 0.760 < 0.001
5 0.755 < 0.001 0.708 < 0.001 0.700 < 0.001 0.700 < 0.001 0.704 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.250 < 0.001 1.334 < 0.001 1.345 < 0.001 1.335 < 0.001 1.332 < 0.001
CCI = 2 1.447 < 0.001 1.498 < 0.001 1.500 < 0.001 1.464 < 0.001 1.413 < 0.001
CCI = 3 1.753 < 0.001 1.907 < 0.001 1.807 < 0.001 1.744 < 0.001 1.682 < 0.001
CCI ≥ 4 2.009 < 0.001 2.098 < 0.001 2.013 < 0.001 1.908 < 0.001 1.777 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.158 < 0.001 1.196 < 0.001 1.179 < 0.001 1.163 < 0.001 1.130 < 0.001
Current Smoker 1.294 < 0.001 1.347 < 0.001 1.305 < 0.001 1.294 < 0.001 1.284 < 0.001
Unknown 1.121 0.047 1.324 < 0.001 1.399 < 0.001 1.434 < 0.001 1.423 < 0.001
NDA Processess 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.484 < 0.001 1.286 < 0.001 1.164 0.003 1.055 0.264 1.011 0.810
2 1.745 < 0.001 1.449 < 0.001 1.284 < 0.001 1.178 0.001 1.115 0.015
3 1.447 < 0.001 1.330 < 0.001 1.194 < 0.001 1.106 0.019 1.068 0.099
4 1.351 < 0.001 1.317 < 0.001 1.217 < 0.001 1.135 0.001 1.115 0.002
5 0.926 0.099 1.013 0.720 0.996 0.891 0.972 0.348 0.970 0.279
6 0.707 < 0.001 0.838 < 0.001 0.873 < 0.001 0.883 < 0.001 0.897 < 0.001
7 0.604 < 0.001 0.743 < 0.001 0.813 < 0.001 0.834 < 0.001 0.866 < 0.001
8 0.574 < 0.001 0.713 < 0.001 0.769 < 0.001 0.803 < 0.001 0.847 < 0.001
9 0.458 < 0.001 0.631 < 0.001 0.741 < 0.001 0.784 < 0.001 0.829 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.847 0.005 0.790 < 0.001 0.794 < 0.001 0.813 < 0.001 0.828 < 0.001
Years With DM 1.005 0.012 1.005 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.996 0.886 1.038 0.081 1.039 0.032 1.034 0.036 1.034 0.022
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.224 0.232 1.072 0.551 1.097 0.336 1.063 0.472 0.990 0.895
45 – 64y 1.119 0.501 1.010 0.931 1.015 0.878 0.992 0.925 0.952 0.524
65 – 74y 1.240 0.201 1.129 0.301 1.123 0.229 1.096 0.279 1.048 0.543
≥ 75y 1.300 0.119 1.246 0.060 1.317 0.004 1.338 0.001 1.304 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.822 < 0.001 0.812 < 0.001 0.815 < 0.001 0.835 < 0.001 0.835 < 0.001
3 0.800 < 0.001 0.755 < 0.001 0.756 < 0.001 0.766 < 0.001 0.784 < 0.001
4 0.793 < 0.001 0.739 < 0.001 0.739 < 0.001 0.752 < 0.001 0.759 < 0.001
5 0.751 < 0.001 0.707 < 0.001 0.697 < 0.001 0.699 < 0.001 0.704 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.230 < 0.001 1.325 < 0.001 1.343 < 0.001 1.334 < 0.001 1.332 < 0.001
CCI = 2 1.400 < 0.001 1.474 < 0.001 1.492 < 0.001 1.458 < 0.001 1.409 < 0.001
CCI = 3 1.740 < 0.001 1.905 < 0.001 1.819 < 0.001 1.751 < 0.001 1.686 < 0.001
CCI ≥ 4 1.978 < 0.001 2.094 < 0.001 2.024 < 0.001 1.913 < 0.001 1.778 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.069 0.056 1.124 < 0.001 1.129 < 0.001 1.125 < 0.001 1.104 < 0.001
Current Smoker 1.138 0.008 1.226 < 0.001 1.227 < 0.001 1.234 < 0.001 1.241 < 0.001
Unknown 1.018 0.759 1.192 < 0.001 1.286 < 0.001 1.343 < 0.001 1.348 < 0.001
NDA BMI Process 0.548 < 0.001 0.666 < 0.001 0.739 < 0.001 0.782 < 0.001 0.819 < 0.001
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Table A48. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA BP care process in 2005/06 against emergency admissions.
Table A49. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA cholesterol care process in 2005/06 against emergency admissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.838 0.003 0.782 < 0.001 0.788 < 0.001 0.807 < 0.001 0.823 < 0.001
Years With DM 1.005 0.013 1.006 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.015 0.628 1.054 0.016 1.052 0.005 1.043 0.008 1.041 0.006
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.191 0.299 1.073 0.547 1.095 0.346 1.063 0.473 0.995 0.951
45 – 64y 1.091 0.603 1.009 0.940 1.004 0.970 0.983 0.839 0.948 0.487
65 – 74y 1.241 0.198 1.132 0.291 1.111 0.277 1.084 0.342 1.042 0.594
≥ 75y 1.389 0.049 1.301 0.024 1.331 0.003 1.344 < 0.001 1.311 < 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.824 < 0.001 0.811 < 0.001 0.815 < 0.001 0.836 < 0.001 0.836 < 0.001
3 0.799 < 0.001 0.754 < 0.001 0.755 < 0.001 0.766 < 0.001 0.785 < 0.001
4 0.793 < 0.001 0.737 < 0.001 0.736 < 0.001 0.751 < 0.001 0.758 < 0.001
5 0.752 < 0.001 0.705 < 0.001 0.694 < 0.001 0.697 < 0.001 0.702 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.246 < 0.001 1.322 < 0.001 1.344 < 0.001 1.331 < 0.001 1.328 < 0.001
CCI = 2 1.436 < 0.001 1.492 < 0.001 1.515 < 0.001 1.472 < 0.001 1.419 < 0.001
CCI = 3 1.739 < 0.001 1.889 < 0.001 1.826 < 0.001 1.756 < 0.001 1.688 < 0.001
CCI ≥ 4 2.077 < 0.001 2.130 < 0.001 2.077 < 0.001 1.948 < 0.001 1.804 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.049 0.184 1.107 < 0.001 1.118 < 0.001 1.115 < 0.001 1.095 < 0.001
Current Smoker 1.143 0.007 1.232 < 0.001 1.237 < 0.001 1.243 < 0.001 1.249 < 0.001
Unknown 1.118 0.059 1.311 < 0.001 1.399 < 0.001 1.441 < 0.001 1.434 < 0.001
NDA BP Process 0.762 < 0.001 0.864 < 0.001 0.902 < 0.001 0.917 < 0.001 0.934 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.838 0.003 0.786 < 0.001 0.792 < 0.001 0.810 < 0.001 0.825 < 0.001
Years With DM 1.005 0.010 1.005 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.014 0.643 1.051 0.022 1.050 0.007 1.042 0.010 1.040 0.007
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.219 0.241 1.086 0.484 1.097 0.337 1.065 0.459 0.997 0.965
45 – 64y 1.172 0.344 1.049 0.679 1.026 0.786 1.002 0.982 0.962 0.617
65 – 74y 1.313 0.106 1.179 0.161 1.140 0.177 1.108 0.227 1.060 0.448
≥ 75y 1.412 0.040 1.330 0.015 1.354 0.002 1.366 < 0.001 1.329 < 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.825 < 0.001 0.810 < 0.001 0.814 < 0.001 0.834 < 0.001 0.834 < 0.001
3 0.805 < 0.001 0.756 < 0.001 0.757 < 0.001 0.767 < 0.001 0.785 < 0.001
4 0.786 < 0.001 0.736 < 0.001 0.737 < 0.001 0.751 < 0.001 0.758 < 0.001
5 0.758 < 0.001 0.706 < 0.001 0.695 < 0.001 0.698 < 0.001 0.703 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.253 < 0.001 1.332 < 0.001 1.348 < 0.001 1.334 < 0.001 1.331 < 0.001
CCI = 2 1.406 < 0.001 1.481 < 0.001 1.503 < 0.001 1.465 < 0.001 1.414 < 0.001
CCI = 3 1.761 < 0.001 1.906 < 0.001 1.825 < 0.001 1.754 < 0.001 1.688 < 0.001
CCI ≥ 4 2.079 < 0.001 2.134 < 0.001 2.063 < 0.001 1.938 < 0.001 1.796 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.063 0.085 1.116 < 0.001 1.123 < 0.001 1.120 < 0.001 1.099 < 0.001
Current Smoker 1.146 0.005 1.235 < 0.001 1.236 < 0.001 1.242 < 0.001 1.247 < 0.001
Unknown 1.021 0.719 1.219 < 0.001 1.322 < 0.001 1.380 < 0.001 1.385 < 0.001
NDA Cholesterol Process 0.592 < 0.001 0.734 < 0.001 0.805 < 0.001 0.843 < 0.001 0.875 < 0.001
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Table A50. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA creatinine care process in 2005/06 against emergency admissions.
Table A51. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA foot check care process in 2005/06 against emergency admissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.827 0.001 0.778 < 0.001 0.786 < 0.001 0.805 < 0.001 0.822 < 0.001
Years With DM 1.005 0.014 1.005 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.014 0.655 1.054 0.016 1.052 0.005 1.043 0.008 1.041 0.006
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.199 0.283 1.079 0.518 1.096 0.342 1.064 0.463 0.997 0.968
45 – 64y 1.109 0.535 1.018 0.876 1.006 0.947 0.986 0.867 0.951 0.508
65 – 74y 1.270 0.154 1.146 0.245 1.116 0.258 1.089 0.318 1.045 0.566
≥ 75y 1.408 0.041 1.315 0.019 1.337 0.003 1.350 < 0.001 1.316 < 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.826 < 0.001 0.811 < 0.001 0.815 < 0.001 0.836 < 0.001 0.836 < 0.001
3 0.807 < 0.001 0.757 < 0.001 0.757 < 0.001 0.767 < 0.001 0.786 < 0.001
4 0.792 < 0.001 0.738 < 0.001 0.736 < 0.001 0.751 < 0.001 0.758 < 0.001
5 0.760 < 0.001 0.708 < 0.001 0.695 < 0.001 0.698 < 0.001 0.703 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.249 < 0.001 1.325 < 0.001 1.345 < 0.001 1.332 < 0.001 1.329 < 0.001
CCI = 2 1.439 < 0.001 1.495 < 0.001 1.516 < 0.001 1.473 < 0.001 1.419 < 0.001
CCI = 3 1.767 < 0.001 1.905 < 0.001 1.832 < 0.001 1.759 < 0.001 1.691 < 0.001
CCI ≥ 4 2.110 < 0.001 2.146 < 0.001 2.082 < 0.001 1.952 < 0.001 1.806 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.050 0.172 1.108 < 0.001 1.118 < 0.001 1.115 < 0.001 1.096 < 0.001
Current Smoker 1.143 0.007 1.233 < 0.001 1.237 < 0.001 1.243 < 0.001 1.249 < 0.001
Unknown 1.101 0.102 1.302 < 0.001 1.400 < 0.001 1.445 < 0.001 1.439 < 0.001
NDA Creatinine Process 0.747 < 0.001 0.857 < 0.001 0.905 < 0.001 0.922 < 0.001 0.941 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.834 0.002 0.785 < 0.001 0.792 < 0.001 0.811 < 0.001 0.827 < 0.001
Years With DM 1.005 0.012 1.005 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.012 0.690 1.047 0.034 1.045 0.015 1.037 0.020 1.037 0.013
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.230 0.222 1.089 0.468 1.106 0.295 1.070 0.426 1.001 0.992
45 – 64y 1.148 0.409 1.036 0.759 1.031 0.750 1.003 0.968 0.965 0.640
65 – 74y 1.287 0.134 1.166 0.190 1.144 0.163 1.110 0.221 1.063 0.426
≥ 75y 1.359 0.068 1.304 0.023 1.356 0.002 1.366 < 0.001 1.332 < 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.827 < 0.001 0.813 < 0.001 0.816 < 0.001 0.836 < 0.001 0.836 < 0.001
3 0.800 < 0.001 0.755 < 0.001 0.756 < 0.001 0.767 < 0.001 0.785 < 0.001
4 0.802 < 0.001 0.743 < 0.001 0.741 < 0.001 0.754 < 0.001 0.760 < 0.001
5 0.761 < 0.001 0.712 < 0.001 0.700 < 0.001 0.702 < 0.001 0.705 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.246 < 0.001 1.330 < 0.001 1.344 < 0.001 1.333 < 0.001 1.332 < 0.001
CCI = 2 1.443 < 0.001 1.492 < 0.001 1.505 < 0.001 1.466 < 0.001 1.416 < 0.001
CCI = 3 1.744 < 0.001 1.893 < 0.001 1.814 < 0.001 1.746 < 0.001 1.682 < 0.001
CCI ≥ 4 2.048 < 0.001 2.097 < 0.001 2.035 < 0.001 1.919 < 0.001 1.784 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.063 0.083 1.119 < 0.001 1.124 < 0.001 1.121 < 0.001 1.100 < 0.001
Current Smoker 1.152 0.004 1.229 < 0.001 1.230 < 0.001 1.237 < 0.001 1.244 < 0.001
Unknown 1.009 0.875 1.195 < 0.001 1.299 < 0.001 1.360 < 0.001 1.366 < 0.001
NDA Foot Check Process 0.557 < 0.001 0.688 < 0.001 0.763 < 0.001 0.806 < 0.001 0.843 < 0.001
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Table A52. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA HbA1c care process in 2005/06 against emergency admissions.
Table A53. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA retinal screening care process in 2005/06 against emergency admissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.836 0.002 0.782 < 0.001 0.788 < 0.001 0.807 < 0.001 0.823 < 0.001
Years With DM 1.005 0.020 1.005 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.015 0.649 1.055 0.014 1.052 0.005 1.043 0.008 1.041 0.006
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.161 0.377 1.065 0.592 1.092 0.363 1.060 0.494 0.994 0.934
45 – 64y 1.064 0.710 1.005 0.968 1.003 0.978 0.982 0.831 0.948 0.485
65 – 74y 1.203 0.271 1.122 0.326 1.108 0.288 1.082 0.358 1.040 0.609
≥ 75y 1.347 0.075 1.291 0.029 1.329 0.003 1.343 0.001 1.311 < 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.825 < 0.001 0.810 < 0.001 0.815 < 0.001 0.836 < 0.001 0.835 < 0.001
3 0.801 < 0.001 0.755 < 0.001 0.757 < 0.001 0.768 < 0.001 0.786 < 0.001
4 0.782 < 0.001 0.732 < 0.001 0.733 < 0.001 0.748 < 0.001 0.756 < 0.001
5 0.745 < 0.001 0.698 < 0.001 0.689 < 0.001 0.692 < 0.001 0.698 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.249 < 0.001 1.325 < 0.001 1.345 < 0.001 1.332 < 0.001 1.328 < 0.001
CCI = 2 1.444 < 0.001 1.496 < 0.001 1.514 < 0.001 1.471 < 0.001 1.418 < 0.001
CCI = 3 1.729 < 0.001 1.891 < 0.001 1.822 < 0.001 1.752 < 0.001 1.686 < 0.001
CCI ≥ 4 2.070 < 0.001 2.135 < 0.001 2.073 < 0.001 1.946 < 0.001 1.803 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.046 0.216 1.108 < 0.001 1.119 < 0.001 1.116 < 0.001 1.097 < 0.001
Current Smoker 1.148 0.005 1.238 < 0.001 1.241 < 0.001 1.246 < 0.001 1.251 < 0.001
Unknown 1.159 0.011 1.335 < 0.001 1.414 < 0.001 1.456 < 0.001 1.447 < 0.001
NDA HbA1c Process 0.784 < 0.001 0.859 < 0.001 0.891 < 0.001 0.909 < 0.001 0.929 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.840 0.003 0.785 < 0.001 0.790 < 0.001 0.808 < 0.001 0.824 < 0.001
Years With DM 1.005 0.022 1.005 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.012 0.714 1.052 0.019 1.050 0.006 1.041 0.011 1.039 0.008
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.119 0.505 1.041 0.732 1.073 0.467 1.048 0.582 0.989 0.882
45 – 64y 1.021 0.903 0.972 0.805 0.977 0.805 0.964 0.664 0.938 0.401
65 – 74y 1.144 0.424 1.085 0.487 1.078 0.440 1.062 0.481 1.030 0.703
≥ 75y 1.285 0.133 1.242 0.064 1.290 0.008 1.315 0.001 1.295 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.840 < 0.001 0.825 < 0.001 0.826 < 0.001 0.845 < 0.001 0.843 < 0.001
3 0.807 < 0.001 0.762 < 0.001 0.761 < 0.001 0.771 < 0.001 0.790 < 0.001
4 0.801 < 0.001 0.746 < 0.001 0.743 < 0.001 0.756 < 0.001 0.763 < 0.001
5 0.778 < 0.001 0.726 < 0.001 0.709 < 0.001 0.709 < 0.001 0.712 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.244 < 0.001 1.322 < 0.001 1.341 < 0.001 1.330 < 0.001 1.328 < 0.001
CCI = 2 1.448 < 0.001 1.501 < 0.001 1.515 < 0.001 1.473 < 0.001 1.419 < 0.001
CCI = 3 1.711 < 0.001 1.883 < 0.001 1.812 < 0.001 1.746 < 0.001 1.681 < 0.001
CCI ≥ 4 2.054 < 0.001 2.121 < 0.001 2.063 < 0.001 1.937 < 0.001 1.795 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.047 0.203 1.112 < 0.001 1.122 < 0.001 1.119 < 0.001 1.099 < 0.001
Current Smoker 1.168 0.002 1.252 < 0.001 1.246 < 0.001 1.249 < 0.001 1.253 < 0.001
Unknown 1.195 0.002 1.359 < 0.001 1.437 < 0.001 1.478 < 0.001 1.462 < 0.001
NDA Retinal Screening Process 0.683 < 0.001 0.760 < 0.001 0.819 < 0.001 0.852 < 0.001 0.874 < 0.001
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Table A54. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA smoking status care process in 2005/06 against emergency admissions.
Table A55. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA urinary albumin care process in 2005/06 against emergency admissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.833 0.002 0.780 < 0.001 0.786 < 0.001 0.805 < 0.001 0.821 < 0.001
Years With DM 1.005 0.017 1.006 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.007 0.836 1.051 0.023 1.051 0.006 1.043 0.008 1.043 0.004
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.154 0.396 1.057 0.638 1.088 0.381 1.059 0.497 0.995 0.946
45 – 64y 1.050 0.772 0.988 0.916 0.990 0.914 0.972 0.733 0.940 0.417
65 – 74y 1.186 0.309 1.102 0.407 1.091 0.369 1.067 0.446 1.028 0.719
≥ 75y 1.325 0.092 1.270 0.041 1.310 0.005 1.326 0.001 1.298 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.824 < 0.001 0.810 < 0.001 0.815 < 0.001 0.836 < 0.001 0.836 < 0.001
3 0.800 < 0.001 0.753 < 0.001 0.755 < 0.001 0.766 < 0.001 0.785 < 0.001
4 0.787 < 0.001 0.735 < 0.001 0.735 < 0.001 0.750 < 0.001 0.758 < 0.001
5 0.750 < 0.001 0.704 < 0.001 0.693 < 0.001 0.697 < 0.001 0.702 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.245 < 0.001 1.320 < 0.001 1.342 < 0.001 1.329 < 0.001 1.326 < 0.001
CCI = 2 1.445 < 0.001 1.496 < 0.001 1.517 < 0.001 1.473 < 0.001 1.419 < 0.001
CCI = 3 1.730 < 0.001 1.887 < 0.001 1.825 < 0.001 1.754 < 0.001 1.687 < 0.001
CCI ≥ 4 2.075 < 0.001 2.132 < 0.001 2.079 < 0.001 1.951 < 0.001 1.807 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.140 0.001 1.142 < 0.001 1.129 < 0.001 1.113 < 0.001 1.078 < 0.001
Current Smoker 1.281 < 0.001 1.287 < 0.001 1.257 < 0.001 1.245 < 0.001 1.230 < 0.001
Unknown 1.266 < 0.001 1.414 < 0.001 1.481 < 0.001 1.513 < 0.001 1.490 < 0.001
NDA Smoking Status Process 0.824 < 0.001 0.936 0.003 0.977 0.236 1.000 0.989 1.024 0.142
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.839 0.003 0.781 < 0.001 0.788 < 0.001 0.806 < 0.001 0.821 < 0.001
Years With DM 1.005 0.014 1.005 < 0.001 1.006 < 0.001 1.005 < 0.001 1.005 < 0.001
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.011 0.724 1.052 0.020 1.051 0.006 1.043 0.008 1.041 0.005
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.139 0.439 1.051 0.673 1.086 0.391 1.059 0.501 0.994 0.939
45 – 64y 1.029 0.862 0.981 0.871 0.988 0.900 0.972 0.738 0.941 0.429
65 – 74y 1.159 0.378 1.095 0.437 1.089 0.376 1.069 0.436 1.031 0.692
≥ 75y 1.306 0.110 1.266 0.044 1.310 0.005 1.328 0.001 1.300 0.001
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.819 < 0.001 0.807 < 0.001 0.813 < 0.001 0.835 < 0.001 0.836 < 0.001
3 0.795 < 0.001 0.752 < 0.001 0.754 < 0.001 0.766 < 0.001 0.785 < 0.001
4 0.791 < 0.001 0.737 < 0.001 0.736 < 0.001 0.750 < 0.001 0.758 < 0.001
5 0.750 < 0.001 0.704 < 0.001 0.693 < 0.001 0.696 < 0.001 0.702 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.233 < 0.001 1.316 < 0.001 1.340 < 0.001 1.329 < 0.001 1.327 < 0.001
CCI = 2 1.439 < 0.001 1.490 < 0.001 1.514 < 0.001 1.472 < 0.001 1.419 < 0.001
CCI = 3 1.730 < 0.001 1.884 < 0.001 1.824 < 0.001 1.755 < 0.001 1.688 < 0.001
CCI ≥ 4 2.071 < 0.001 2.132 < 0.001 2.078 < 0.001 1.950 < 0.001 1.806 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.036 0.323 1.101 < 0.001 1.114 < 0.001 1.112 < 0.001 1.093 < 0.001
Current Smoker 1.140 0.008 1.234 < 0.001 1.238 < 0.001 1.245 < 0.001 1.250 < 0.001
Unknown 1.210 0.001 1.385 < 0.001 1.465 < 0.001 1.506 < 0.001 1.490 < 0.001
NDA Urinary Albumin Process 0.782 < 0.001 0.886 < 0.001 0.934 0.001 0.965 0.061 0.991 0.585
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Readmissions and NDA Attainment
Table A56. Full results from multiple-variable zero-inflated negative binomial regression model of the
number of NDA care processes received in 2005/06 against readmissions.
Table A57. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA BMI care process in 2005/06 against readmissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.835 0.199 0.772 0.010 0.726 < 0.001 0.747 < 0.001 0.795 0.001
Years With DM 1.000 0.945 1.003 0.294 1.003 0.198 1.002 0.308 1.003 0.152
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.896 0.140 0.989 0.835 1.020 0.652 0.980 0.585 0.993 0.838
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.898 0.824 1.061 0.855 1.202 0.484 1.183 0.457 1.112 0.600
45 – 64y 0.609 0.299 0.727 0.317 0.844 0.515 0.811 0.349 0.757 0.163
65 – 74y 0.533 0.190 0.684 0.237 0.756 0.287 0.715 0.137 0.681 0.056
≥ 75y 0.466 0.110 0.575 0.084 0.702 0.177 0.704 0.119 0.660 0.038
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.935 0.526 0.885 0.108 0.836 0.004 0.851 0.003 0.829 < 0.001
3 0.849 0.136 0.717 < 0.001 0.718 < 0.001 0.745 < 0.001 0.745 < 0.001
4 0.932 0.539 0.789 0.003 0.727 < 0.001 0.746 < 0.001 0.763 < 0.001
5 0.744 0.013 0.735 < 0.001 0.701 < 0.001 0.699 < 0.001 0.708 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.095 0.349 1.272 < 0.001 1.245 < 0.001 1.305 < 0.001 1.296 < 0.001
CCI = 2 1.126 0.272 1.270 0.002 1.252 < 0.001 1.316 < 0.001 1.304 < 0.001
CCI = 3 1.370 0.017 1.515 < 0.001 1.506 < 0.001 1.551 < 0.001 1.601 < 0.001
CCI ≥ 4 1.611 0.001 1.760 < 0.001 1.774 < 0.001 1.749 < 0.001 1.732 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.209 0.029 1.308 < 0.001 1.254 < 0.001 1.204 < 0.001 1.176 < 0.001
Current Smoker 1.079 0.514 1.229 0.012 1.136 0.060 1.080 0.184 1.146 0.009
Unknown 1.139 0.350 1.416 < 0.001 1.470 < 0.001 1.471 < 0.001 1.519 < 0.001
NDA Processess 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.374 0.036 1.156 0.237 1.054 0.620 0.915 0.349 0.879 0.146
2 1.501 0.007 1.262 0.055 1.055 0.620 0.926 0.422 0.896 0.221
3 1.420 0.011 1.358 0.005 1.202 0.054 1.106 0.238 1.095 0.248
4 1.496 0.001 1.427 < 0.001 1.272 0.004 1.138 0.080 1.086 0.231
5 0.782 0.016 0.930 0.357 0.920 0.222 0.900 0.079 0.886 0.031
6 0.590 < 0.001 0.767 < 0.001 0.785 < 0.001 0.780 < 0.001 0.797 < 0.001
7 0.464 < 0.001 0.638 < 0.001 0.721 < 0.001 0.746 < 0.001 0.796 < 0.001
8 0.354 < 0.001 0.506 < 0.001 0.594 < 0.001 0.635 < 0.001 0.688 < 0.001
9 0.291 < 0.001 0.446 < 0.001 0.526 < 0.001 0.551 < 0.001 0.603 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.809 0.132 0.762 0.007 0.713 < 0.001 0.738 < 0.001 0.788 < 0.001
Years With DM 1.002 0.656 1.005 0.144 1.004 0.126 1.003 0.207 1.003 0.102
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.936 0.379 1.015 0.771 1.035 0.414 0.990 0.777 0.996 0.897
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.171 0.739 1.150 0.663 1.254 0.389 1.205 0.409 1.091 0.667
45 – 64y 0.786 0.608 0.766 0.399 0.874 0.605 0.815 0.362 0.741 0.134
65 – 74y 0.703 0.455 0.717 0.297 0.776 0.332 0.714 0.135 0.661 0.039
≥ 75y 0.616 0.301 0.600 0.108 0.722 0.212 0.704 0.119 0.642 0.027
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.933 0.512 0.887 0.116 0.836 0.004 0.846 0.002 0.826 < 0.001
3 0.840 0.115 0.713 < 0.001 0.713 < 0.001 0.740 < 0.001 0.741 < 0.001
4 0.963 0.749 0.796 0.004 0.731 < 0.001 0.744 < 0.001 0.762 < 0.001
5 0.744 0.014 0.722 < 0.001 0.694 < 0.001 0.694 < 0.001 0.704 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.034 0.730 1.242 0.001 1.231 < 0.001 1.301 < 0.001 1.293 < 0.001
CCI = 2 1.035 0.752 1.234 0.008 1.232 0.001 1.305 < 0.001 1.299 < 0.001
CCI = 3 1.385 0.014 1.522 < 0.001 1.532 < 0.001 1.578 < 0.001 1.614 < 0.001
CCI ≥ 4 1.579 0.002 1.788 < 0.001 1.801 < 0.001 1.775 < 0.001 1.751 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.084 0.345 1.202 0.002 1.175 0.001 1.142 0.001 1.134 0.001
Current Smoker 0.908 0.403 1.062 0.456 1.028 0.679 1.004 0.941 1.089 0.094
Unknown 1.093 0.535 1.277 0.013 1.359 < 0.001 1.395 < 0.001 1.469 < 0.001
NDA BMI Process 0.429 < 0.001 0.571 < 0.001 0.652 < 0.001 0.705 < 0.001 0.753 < 0.001
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Table A58. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA BP care process in 2005/06 against readmissions.
Table A59. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA cholesterol care process in 2005/06 against readmissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.834 0.195 0.770 0.009 0.716 < 0.001 0.736 < 0.001 0.785 < 0.001
Years With DM 1.001 0.736 1.004 0.162 1.005 0.079 1.003 0.149 1.004 0.072
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.953 0.523 1.038 0.484 1.057 0.198 1.006 0.869 1.009 0.771
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.108 0.828 1.118 0.729 1.220 0.448 1.205 0.409 1.107 0.613
45 – 64y 0.753 0.545 0.753 0.370 0.852 0.539 0.813 0.356 0.745 0.140
65 – 74y 0.674 0.402 0.697 0.258 0.751 0.273 0.708 0.125 0.664 0.041
≥ 75y 0.642 0.344 0.617 0.129 0.719 0.206 0.710 0.128 0.651 0.032
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.914 0.409 0.889 0.126 0.839 0.005 0.850 0.002 0.829 < 0.001
3 0.827 0.093 0.715 < 0.001 0.715 < 0.001 0.741 < 0.001 0.742 < 0.001
4 0.926 0.516 0.785 0.002 0.724 < 0.001 0.742 < 0.001 0.761 < 0.001
5 0.722 0.008 0.714 < 0.001 0.690 < 0.001 0.694 < 0.001 0.705 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.083 0.417 1.252 0.001 1.240 < 0.001 1.300 < 0.001 1.292 < 0.001
CCI = 2 1.063 0.581 1.245 0.006 1.250 0.001 1.318 < 0.001 1.309 < 0.001
CCI = 3 1.322 0.036 1.469 < 0.001 1.501 < 0.001 1.560 < 0.001 1.602 < 0.001
CCI ≥ 4 1.590 0.002 1.798 < 0.001 1.842 < 0.001 1.805 < 0.001 1.775 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.069 0.441 1.176 0.008 1.161 0.003 1.133 0.003 1.125 0.001
Current Smoker 0.901 0.372 1.057 0.500 1.032 0.638 1.015 0.797 1.099 0.064
Unknown 1.166 0.282 1.394 0.001 1.462 < 0.001 1.488 < 0.001 1.540 < 0.001
NDA BP Process 0.639 < 0.001 0.781 < 0.001 0.816 < 0.001 0.836 < 0.001 0.854 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.823 0.163 0.765 0.008 0.715 < 0.001 0.734 < 0.001 0.783 < 0.001
Years With DM 1.001 0.801 1.004 0.187 1.004 0.109 1.003 0.198 1.004 0.096
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.953 0.522 1.037 0.487 1.055 0.214 1.004 0.923 1.008 0.806
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.967 0.945 1.094 0.781 1.189 0.512 1.188 0.446 1.101 0.633
45 – 64y 0.699 0.451 0.768 0.406 0.854 0.546 0.823 0.385 0.758 0.165
65 – 74y 0.617 0.311 0.711 0.287 0.754 0.281 0.716 0.140 0.675 0.050
≥ 75y 0.579 0.250 0.623 0.138 0.717 0.203 0.716 0.137 0.660 0.039
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.963 0.726 0.894 0.144 0.839 0.005 0.848 0.002 0.828 < 0.001
3 0.869 0.208 0.722 < 0.001 0.721 < 0.001 0.745 < 0.001 0.745 < 0.001
4 0.912 0.427 0.782 0.002 0.724 < 0.001 0.741 < 0.001 0.761 < 0.001
5 0.767 0.028 0.726 < 0.001 0.695 < 0.001 0.697 < 0.001 0.706 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.122 0.242 1.270 < 0.001 1.252 < 0.001 1.307 < 0.001 1.296 < 0.001
CCI = 2 1.005 0.964 1.228 0.010 1.238 0.001 1.311 < 0.001 1.304 < 0.001
CCI = 3 1.333 0.030 1.487 < 0.001 1.506 < 0.001 1.561 < 0.001 1.605 < 0.001
CCI ≥ 4 1.612 0.001 1.793 < 0.001 1.830 < 0.001 1.793 < 0.001 1.766 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.102 0.257 1.192 0.004 1.171 0.001 1.141 0.002 1.131 0.001
Current Smoker 0.914 0.434 1.064 0.449 1.037 0.591 1.016 0.783 1.101 0.059
Unknown 1.104 0.487 1.321 0.005 1.406 < 0.001 1.443 < 0.001 1.514 < 0.001
NDA Cholesterol Process 0.500 < 0.001 0.682 < 0.001 0.750 < 0.001 0.784 < 0.001 0.823 < 0.001
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Table A60. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA creatinine care process in 2005/06 against readmissions.
Table A61. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA foot check care process in 2005/06 against readmissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.819 0.155 0.760 0.006 0.710 < 0.001 0.731 < 0.001 0.780 < 0.001
Years With DM 1.001 0.741 1.004 0.175 1.005 0.089 1.003 0.167 1.004 0.079
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.946 0.465 1.041 0.444 1.060 0.176 1.007 0.838 1.011 0.738
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.003 0.994 1.090 0.790 1.200 0.488 1.198 0.424 1.114 0.594
45 – 64y 0.693 0.439 0.741 0.345 0.840 0.503 0.810 0.347 0.749 0.148
65 – 74y 0.623 0.319 0.686 0.238 0.739 0.250 0.704 0.120 0.666 0.043
≥ 75y 0.596 0.272 0.609 0.120 0.709 0.189 0.707 0.124 0.654 0.034
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.945 0.603 0.898 0.162 0.843 0.007 0.853 0.003 0.831 < 0.001
3 0.855 0.165 0.725 < 0.001 0.719 < 0.001 0.744 < 0.001 0.744 < 0.001
4 0.917 0.457 0.787 0.003 0.724 < 0.001 0.741 < 0.001 0.760 < 0.001
5 0.749 0.018 0.727 < 0.001 0.696 < 0.001 0.698 < 0.001 0.707 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.099 0.339 1.257 0.001 1.243 < 0.001 1.301 < 0.001 1.293 < 0.001
CCI = 2 1.079 0.486 1.254 0.004 1.255 < 0.001 1.321 < 0.001 1.312 < 0.001
CCI = 3 1.358 0.021 1.489 < 0.001 1.513 < 0.001 1.569 < 0.001 1.610 < 0.001
CCI ≥ 4 1.683 < 0.001 1.828 < 0.001 1.857 < 0.001 1.815 < 0.001 1.785 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.077 0.395 1.184 0.006 1.165 0.002 1.137 0.002 1.127 0.001
Current Smoker 0.905 0.394 1.062 0.463 1.034 0.623 1.015 0.791 1.100 0.062
Unknown 1.160 0.296 1.397 0.001 1.487 < 0.001 1.512 < 0.001 1.578 < 0.001
NDA Creatinine Process 0.658 < 0.001 0.798 < 0.001 0.845 < 0.001 0.860 < 0.001 0.890 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.797 0.106 0.745 0.003 0.703 < 0.001 0.727 < 0.001 0.781 < 0.001
Years With DM 1.001 0.771 1.004 0.157 1.004 0.102 1.003 0.182 1.004 0.092
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.953 0.522 1.032 0.549 1.048 0.276 0.998 0.964 1.003 0.916
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.084 0.866 1.181 0.605 1.274 0.358 1.237 0.347 1.130 0.546
45 – 64y 0.739 0.523 0.783 0.439 0.886 0.642 0.836 0.424 0.763 0.175
65 – 74y 0.651 0.367 0.732 0.329 0.785 0.357 0.729 0.161 0.681 0.056
≥ 75y 0.587 0.261 0.631 0.148 0.745 0.260 0.728 0.158 0.666 0.043
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.925 0.461 0.875 0.081 0.830 0.003 0.846 0.002 0.825 < 0.001
3 0.824 0.080 0.707 < 0.001 0.710 < 0.001 0.739 < 0.001 0.741 < 0.001
4 0.951 0.663 0.793 0.003 0.729 < 0.001 0.745 < 0.001 0.762 < 0.001
5 0.732 0.009 0.722 < 0.001 0.695 < 0.001 0.697 < 0.001 0.706 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.055 0.578 1.243 0.001 1.228 < 0.001 1.293 < 0.001 1.291 < 0.001
CCI = 2 1.104 0.362 1.252 0.004 1.246 0.001 1.312 < 0.001 1.307 < 0.001
CCI = 3 1.375 0.016 1.490 < 0.001 1.514 < 0.001 1.558 < 0.001 1.605 < 0.001
CCI ≥ 4 1.609 0.001 1.744 < 0.001 1.798 < 0.001 1.767 < 0.001 1.750 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.089 0.321 1.191 0.004 1.159 0.003 1.131 0.003 1.124 0.002
Current Smoker 0.938 0.583 1.063 0.449 1.027 0.687 1.008 0.889 1.092 0.083
Unknown 1.058 0.688 1.270 0.015 1.363 < 0.001 1.411 < 0.001 1.478 < 0.001
NDA Foot Check Process 0.453 < 0.001 0.607 < 0.001 0.692 < 0.001 0.742 < 0.001 0.778 < 0.001
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Table A62. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA HbA1c care process in 2005/06 against readmissions.
Table A63. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA retinal screening care process in 2005/06 against readmissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.838 0.207 0.771 0.009 0.719 < 0.001 0.737 < 0.001 0.784 < 0.001
Years With DM 1.001 0.890 1.004 0.203 1.005 0.089 1.003 0.171 1.004 0.088
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.932 0.355 1.035 0.510 1.053 0.228 1.002 0.953 1.008 0.793
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.082 0.867 1.108 0.750 1.227 0.435 1.209 0.400 1.120 0.575
45 – 64y 0.725 0.492 0.746 0.356 0.849 0.528 0.811 0.349 0.749 0.147
65 – 74y 0.632 0.329 0.687 0.238 0.746 0.262 0.703 0.118 0.664 0.041
≥ 75y 0.608 0.285 0.607 0.116 0.713 0.195 0.706 0.120 0.652 0.033
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.908 0.373 0.888 0.123 0.840 0.006 0.851 0.003 0.829 < 0.001
3 0.822 0.082 0.717 < 0.001 0.716 < 0.001 0.743 < 0.001 0.743 < 0.001
4 0.890 0.322 0.771 0.001 0.715 < 0.001 0.733 < 0.001 0.754 < 0.001
5 0.699 0.003 0.704 < 0.001 0.681 < 0.001 0.685 < 0.001 0.697 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.085 0.410 1.255 0.001 1.239 < 0.001 1.300 < 0.001 1.292 < 0.001
CCI = 2 1.095 0.408 1.256 0.004 1.256 < 0.001 1.325 < 0.001 1.314 < 0.001
CCI = 3 1.304 0.046 1.473 < 0.001 1.493 < 0.001 1.553 < 0.001 1.595 < 0.001
CCI ≥ 4 1.583 0.002 1.806 < 0.001 1.835 < 0.001 1.799 < 0.001 1.772 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.054 0.548 1.176 0.008 1.162 0.002 1.137 0.002 1.127 0.001
Current Smoker 0.893 0.334 1.062 0.460 1.038 0.577 1.017 0.764 1.101 0.058
Unknown 1.214 0.170 1.438 < 0.001 1.521 < 0.001 1.543 < 0.001 1.608 < 0.001
NDA HbA1c Process 0.697 < 0.001 0.792 < 0.001 0.838 < 0.001 0.847 < 0.001 0.884 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.827 0.177 0.761 0.007 0.714 < 0.001 0.735 < 0.001 0.783 < 0.001
Years With DM 1.002 0.709 1.004 0.176 1.004 0.096 1.003 0.194 1.003 0.106
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.944 0.448 1.037 0.494 1.057 0.196 1.004 0.909 1.008 0.794
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.852 0.741 0.994 0.984 1.156 0.581 1.172 0.482 1.100 0.636
45 – 64y 0.583 0.260 0.667 0.205 0.799 0.389 0.779 0.264 0.729 0.114
65 – 74y 0.499 0.147 0.618 0.134 0.701 0.176 0.675 0.081 0.646 0.030
≥ 75y 0.494 0.140 0.548 0.061 0.670 0.127 0.674 0.079 0.632 0.022
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.931 0.513 0.908 0.212 0.853 0.012 0.863 0.006 0.842 < 0.001
3 0.824 0.086 0.727 < 0.001 0.720 < 0.001 0.746 < 0.001 0.747 < 0.001
4 0.905 0.397 0.784 0.002 0.725 < 0.001 0.743 < 0.001 0.764 < 0.001
5 0.753 0.021 0.756 0.001 0.713 < 0.001 0.712 < 0.001 0.719 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.094 0.361 1.266 < 0.001 1.244 < 0.001 1.300 < 0.001 1.293 < 0.001
CCI = 2 1.129 0.270 1.280 0.002 1.268 < 0.001 1.332 < 0.001 1.321 < 0.001
CCI = 3 1.293 0.053 1.453 < 0.001 1.479 < 0.001 1.546 < 0.001 1.595 < 0.001
CCI ≥ 4 1.670 0.001 1.825 < 0.001 1.856 < 0.001 1.813 < 0.001 1.783 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.044 0.620 1.176 0.008 1.167 0.002 1.137 0.002 1.128 0.001
Current Smoker 0.941 0.605 1.101 0.242 1.057 0.407 1.029 0.615 1.108 0.043
Unknown 1.247 0.114 1.490 < 0.001 1.577 < 0.001 1.604 < 0.001 1.652 < 0.001
NDA Retinal Screening Process 0.590 < 0.001 0.684 < 0.001 0.778 < 0.001 0.815 < 0.001 0.840 < 0.001
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Table A64. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA smoking status care process in 2005/06 against readmissions.
Table A65. Full results from multiple-variable zero-inflated negative binomial regression model of
receipt of the NDA urinary albumin care process in 2005/06 against readmissions.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.830 0.183 0.761 0.007 0.709 < 0.001 0.729 < 0.001 0.778 < 0.001
Years With DM 1.001 0.776 1.004 0.179 1.005 0.080 1.003 0.149 1.004 0.072
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.932 0.357 1.031 0.569 1.053 0.229 1.004 0.912 1.012 0.712
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 1.009 0.986 1.056 0.865 1.200 0.488 1.204 0.410 1.120 0.574
45 – 64y 0.672 0.399 0.710 0.282 0.829 0.471 0.802 0.323 0.741 0.134
65 – 74y 0.581 0.250 0.647 0.173 0.720 0.211 0.688 0.097 0.652 0.033
≥ 75y 0.564 0.223 0.578 0.086 0.694 0.162 0.693 0.103 0.641 0.027
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.912 0.398 0.887 0.121 0.840 0.006 0.851 0.003 0.832 < 0.001
3 0.819 0.077 0.712 < 0.001 0.712 < 0.001 0.739 < 0.001 0.741 < 0.001
4 0.898 0.361 0.776 0.002 0.718 < 0.001 0.737 < 0.001 0.759 < 0.001
5 0.708 0.005 0.710 < 0.001 0.687 < 0.001 0.693 < 0.001 0.705 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.083 0.418 1.253 0.001 1.238 < 0.001 1.297 < 0.001 1.289 < 0.001
CCI = 2 1.084 0.463 1.248 0.005 1.255 < 0.001 1.321 < 0.001 1.312 < 0.001
CCI = 3 1.304 0.046 1.460 < 0.001 1.494 < 0.001 1.555 < 0.001 1.600 < 0.001
CCI ≥ 4 1.647 0.001 1.814 < 0.001 1.847 < 0.001 1.812 < 0.001 1.788 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.170 0.089 1.240 0.001 1.204 0.001 1.157 0.001 1.123 0.005
Current Smoker 1.034 0.781 1.143 0.123 1.087 0.244 1.047 0.449 1.103 0.074
Unknown 1.351 0.033 1.565 < 0.001 1.638 < 0.001 1.653 < 0.001 1.694 < 0.001
NDA Smoking Status Process 0.763 < 0.001 0.882 0.007 0.926 0.055 0.956 0.205 0.998 0.946
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
IRR p IRR p IRR p IRR p IRR p
DM Type T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.852 0.254 0.761 0.006 0.708 < 0.001 0.729 < 0.001 0.779 < 0.001
Years With DM 1.002 0.678 1.004 0.201 1.004 0.093 1.003 0.165 1.004 0.080
Gender Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.926 0.316 1.031 0.564 1.055 0.211 1.006 0.879 1.011 0.742
Age Group < 25y Reference Group Reference Group Reference Group Reference Group Reference Group
25 – 44y 0.934 0.887 1.020 0.951 1.184 0.521 1.201 0.417 1.115 0.588
45 – 64y 0.612 0.301 0.681 0.230 0.816 0.435 0.799 0.315 0.740 0.132
65 – 74y 0.527 0.179 0.624 0.142 0.710 0.192 0.686 0.095 0.652 0.033
≥ 75y 0.518 0.164 0.559 0.069 0.686 0.151 0.693 0.103 0.642 0.027
IMD 1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.894 0.304 0.877 0.089 0.832 0.004 0.847 0.002 0.829 < 0.001
3 0.784 0.031 0.704 < 0.001 0.706 < 0.001 0.735 < 0.001 0.739 < 0.001
4 0.887 0.307 0.775 0.002 0.718 < 0.001 0.737 < 0.001 0.759 < 0.001
5 0.699 0.003 0.707 < 0.001 0.685 < 0.001 0.691 < 0.001 0.704 < 0.001
CCI Group CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.074 0.468 1.248 0.001 1.236 < 0.001 1.295 < 0.001 1.288 < 0.001
CCI = 2 1.107 0.352 1.247 0.005 1.253 < 0.001 1.317 < 0.001 1.309 < 0.001
CCI = 3 1.346 0.026 1.476 < 0.001 1.503 < 0.001 1.559 < 0.001 1.603 < 0.001
CCI ≥ 4 1.661 0.001 1.819 < 0.001 1.849 < 0.001 1.811 < 0.001 1.784 < 0.001
Smoking Status Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.034 0.703 1.162 0.014 1.154 0.004 1.128 0.004 1.121 0.002
Current Smoker 0.885 0.298 1.054 0.521 1.031 0.647 1.016 0.781 1.100 0.062
Unknown 1.250 0.111 1.504 < 0.001 1.597 < 0.001 1.629 < 0.001 1.679 < 0.001
NDA Urinary Albumin Process 0.673 < 0.001 0.815 < 0.001 0.873 0.002 0.921 0.031 0.946 0.111
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Odds of Death (all-cause) and NDA Attainment
Table A66. Full results from multiple-variable logistic regression model of the number of NDA care
processes received in 2005/06 against odds of death (all cause).
Table A67. Full results from multiple-variable logistic regression model of receipt of the NDA BMI
care process received in 2005/06 against odds of death (all cause).
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.713 0.001 0.740 < 0.001 0.841 0.014 0.921 0.199 0.909 0.105
Years With DM 1.002 0.547 1.001 0.576 1.006 0.005 1.009 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.752 < 0.001 0.807 < 0.001 0.821 < 0.001 0.815 < 0.001 0.814 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.397 0.143 1.433 0.366 1.672 0.165 1.824 0.069
45 – 64y 5.963 < 0.001 9.093 < 0.001 5.086 < 0.001 5.708 < 0.001 6.034 < 0.001
65 – 74y 22.052 < 0.001 28.624 < 0.001 16.161 < 0.001 17.152 < 0.001 18.445 < 0.001
≥ 75y 56.396 < 0.001 85.034 < 0.001 51.150 < 0.001 60.233 < 0.001 69.308 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.942 0.423 0.841 0.001 0.825 < 0.001 0.845 < 0.001 0.846 < 0.001
3 1.001 0.993 0.803 < 0.001 0.793 < 0.001 0.784 < 0.001 0.789 < 0.001
4 0.873 0.066 0.764 < 0.001 0.778 < 0.001 0.787 < 0.001 0.782 < 0.001
5 0.777 0.001 0.671 < 0.001 0.664 < 0.001 0.655 < 0.001 0.663 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.425 < 0.001 1.314 < 0.001 1.372 < 0.001 1.363 < 0.001 1.380 < 0.001
CCI = 2 2.555 < 0.001 2.345 < 0.001 2.479 < 0.001 2.517 < 0.001 2.509 < 0.001
CCI = 3 3.013 < 0.001 3.265 < 0.001 3.416 < 0.001 3.524 < 0.001 3.560 < 0.001
CCI ≥ 4 4.408 < 0.001 4.458 < 0.001 4.739 < 0.001 5.219 < 0.001 5.536 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.380 < 0.001 1.376 < 0.001 1.363 < 0.001 1.347 < 0.001 1.337 < 0.001
Current Smoker 1.723 < 0.001 1.931 < 0.001 2.039 < 0.001 1.999 < 0.001 2.107 < 0.001
Unknown 0.148 < 0.001 0.272 < 0.001 0.461 < 0.001 0.615 < 0.001 0.801 < 0.001
NDA Processess 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 1.853 < 0.001 1.938 < 0.001 2.025 < 0.001 1.936 < 0.001 1.984 < 0.001
2 1.747 < 0.001 1.916 < 0.001 2.117 < 0.001 2.043 < 0.001 2.117 < 0.001
3 0.905 0.269 1.230 0.009 1.400 < 0.001 1.507 < 0.001 1.585 < 0.001
4 0.596 < 0.001 0.905 0.163 1.078 0.252 1.104 0.108 1.228 0.001
5 0.254 < 0.001 0.518 < 0.001 0.643 < 0.001 0.687 < 0.001 0.752 < 0.001
6 0.114 < 0.001 0.286 < 0.001 0.411 < 0.001 0.466 < 0.001 0.536 < 0.001
7 0.069 < 0.001 0.211 < 0.001 0.332 < 0.001 0.404 < 0.001 0.474 < 0.001
8 0.044 < 0.001 0.173 < 0.001 0.287 < 0.001 0.354 < 0.001 0.419 < 0.001
9 0.055 < 0.001 0.148 < 0.001 0.242 < 0.001 0.322 < 0.001 0.404 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.662 < 0.001 0.699 < 0.001 0.802 0.002 0.883 0.052 0.874 0.022
Years With DM 1.004 0.238 1.002 0.301 1.006 0.001 1.009 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.762 < 0.001 0.819 < 0.001 0.832 < 0.001 0.824 < 0.001 0.823 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.237 0.177 1.351 0.450 1.583 0.214 1.733 0.096
45 – 64y 5.232 < 0.001 7.736 < 0.001 4.448 < 0.001 5.069 < 0.001 5.411 < 0.001
65 – 74y 17.205 < 0.001 22.698 < 0.001 13.409 < 0.001 14.600 < 0.001 15.926 < 0.001
≥ 75y 43.868 < 0.001 67.408 < 0.001 42.463 < 0.001 51.261 < 0.001 59.857 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.943 0.417 0.835 0.001 0.819 < 0.001 0.838 < 0.001 0.839 < 0.001
3 0.983 0.818 0.793 < 0.001 0.785 < 0.001 0.777 < 0.001 0.781 < 0.001
4 0.877 0.069 0.768 < 0.001 0.781 < 0.001 0.790 < 0.001 0.785 < 0.001
5 0.792 0.002 0.681 < 0.001 0.670 < 0.001 0.660 < 0.001 0.668 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.376 < 0.001 1.302 < 0.001 1.369 < 0.001 1.363 < 0.001 1.383 < 0.001
CCI = 2 2.475 < 0.001 2.314 < 0.001 2.460 < 0.001 2.504 < 0.001 2.502 < 0.001
CCI = 3 3.010 < 0.001 3.298 < 0.001 3.449 < 0.001 3.551 < 0.001 3.585 < 0.001
CCI ≥ 4 4.449 < 0.001 4.552 < 0.001 4.846 < 0.001 5.331 < 0.001 5.656 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.106 0.047 1.149 < 0.001 1.180 < 0.001 1.197 < 0.001 1.203 < 0.001
Current Smoker 1.359 < 0.001 1.564 < 0.001 1.717 < 0.001 1.736 < 0.001 1.856 < 0.001
Unknown 0.159 < 0.001 0.254 < 0.001 0.411 < 0.001 0.546 < 0.001 0.699 < 0.001
NDA BMI Process 0.136 < 0.001 0.253 < 0.001 0.329 < 0.001 0.374 < 0.001 0.417 < 0.001
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Table A68. Full results from multiple-variable logistic regression model of receipt of the NDA BP care
process in 2005/06 against odds of death (all cause).
Table A69. Full results from multiple-variable logistic regression model of receipt of the NDA
cholesterol care process in 2005/06 against odds of death (all cause).
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.633 < 0.001 0.670 < 0.001 0.771 < 0.001 0.851 0.011 0.844 0.004
Years With DM 1.005 0.098 1.003 0.128 1.007 < 0.001 1.010 < 0.001 1.012 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group
Female 0.819 < 0.001 0.856 < 0.001 0.860 < 0.001 0.846 < 0.001 0.841 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.246 0.175 1.352 0.448 1.584 0.214 1.730 0.097
45 – 64y 5.296 < 0.001 7.676 < 0.001 4.373 < 0.001 4.972 < 0.001 5.279 < 0.001
65 – 74y 17.667 < 0.001 22.489 < 0.001 13.092 < 0.001 14.202 < 0.001 15.381 < 0.001
≥ 75y 50.582 < 0.001 71.429 < 0.001 43.563 < 0.001 51.905 < 0.001 59.815 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.931 0.315 0.834 < 0.001 0.820 < 0.001 0.840 < 0.001 0.840 < 0.001
3 0.959 0.554 0.788 < 0.001 0.783 < 0.001 0.776 < 0.001 0.781 < 0.001
4 0.861 0.035 0.762 < 0.001 0.777 < 0.001 0.786 < 0.001 0.782 < 0.001
5 0.764 < 0.001 0.671 < 0.001 0.664 < 0.001 0.656 < 0.001 0.665 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.384 < 0.001 1.297 < 0.001 1.359 < 0.001 1.353 < 0.001 1.371 < 0.001
CCI = 2 2.685 < 0.001 2.420 < 0.001 2.533 < 0.001 2.563 < 0.001 2.549 < 0.001
CCI = 3 3.164 < 0.001 3.368 < 0.001 3.499 < 0.001 3.595 < 0.001 3.626 < 0.001
CCI ≥ 4 5.006 < 0.001 4.870 < 0.001 5.098 < 0.001 5.563 < 0.001 5.877 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.062 0.232 1.109 0.005 1.146 < 0.001 1.166 < 0.001 1.175 < 0.001
Current Smoker 1.358 < 0.001 1.570 < 0.001 1.726 < 0.001 1.748 < 0.001 1.871 < 0.001
Unknown 0.138 < 0.001 0.257 < 0.001 0.440 < 0.001 0.598 < 0.001 0.784 < 0.001
NDA BP Process 0.168 < 0.001 0.318 < 0.001 0.421 < 0.001 0.481 < 0.001 0.548 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.683 < 0.001 0.705 < 0.001 0.802 0.002 0.880 0.045 0.870 0.017
Years With DM 1.003 0.320 1.002 0.306 1.006 0.001 1.009 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.803 < 0.001 0.847 < 0.001 0.854 < 0.001 0.841 < 0.001 0.837 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.425 0.137 1.437 0.362 1.668 0.167 1.812 0.072
45 – 64y 5.718 < 0.001 8.846 < 0.001 4.899 < 0.001 5.488 < 0.001 5.778 < 0.001
65 – 74y 19.725 < 0.001 26.517 < 0.001 14.936 < 0.001 15.922 < 0.001 17.088 < 0.001
≥ 75y 52.862 < 0.001 81.412 < 0.001 48.515 < 0.001 57.094 < 0.001 65.403 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.934 0.350 0.834 < 0.001 0.820 < 0.001 0.840 < 0.001 0.841 < 0.001
3 0.974 0.717 0.791 < 0.001 0.785 < 0.001 0.778 < 0.001 0.782 < 0.001
4 0.873 0.062 0.766 < 0.001 0.780 < 0.001 0.790 < 0.001 0.785 < 0.001
5 0.798 0.004 0.686 < 0.001 0.675 < 0.001 0.665 < 0.001 0.672 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.382 < 0.001 1.297 < 0.001 1.361 < 0.001 1.356 < 0.001 1.375 < 0.001
CCI = 2 2.583 < 0.001 2.368 < 0.001 2.496 < 0.001 2.533 < 0.001 2.526 < 0.001
CCI = 3 3.126 < 0.001 3.360 < 0.001 3.492 < 0.001 3.589 < 0.001 3.619 < 0.001
CCI ≥ 4 4.836 < 0.001 4.759 < 0.001 4.999 < 0.001 5.466 < 0.001 5.780 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.091 0.090 1.129 0.001 1.161 < 0.001 1.179 < 0.001 1.188 < 0.001
Current Smoker 1.365 < 0.001 1.572 < 0.001 1.725 < 0.001 1.744 < 0.001 1.864 < 0.001
Unknown 0.138 < 0.001 0.243 < 0.001 0.411 < 0.001 0.556 < 0.001 0.719 < 0.001
NDA Cholesterol Process 0.123 < 0.001 0.260 < 0.001 0.354 < 0.001 0.408 < 0.001 0.458 < 0.001
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Table A70. Full results from multiple-variable logistic regression model of receipt of the NDA
creatinine care process in 2005/06 against odds of death (all cause).
Table A71. Full results from multiple-variable logistic regression model of receipt of the NDA foot
check care process in 2005/06 against odds of death (all cause).
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.623 < 0.001 0.666 < 0.001 0.768 < 0.001 0.849 0.010 0.844 0.004
Years With DM 1.004 0.174 1.003 0.172 1.007 < 0.001 1.010 < 0.001 1.012 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.815 < 0.001 0.854 < 0.001 0.858 < 0.001 0.845 < 0.001 0.840 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.339 0.154 1.389 0.408 1.616 0.194 1.760 0.087
45 – 64y 5.371 < 0.001 8.057 < 0.001 4.512 < 0.001 5.096 < 0.001 5.400 < 0.001
65 – 74y 18.365 < 0.001 23.867 < 0.001 13.597 < 0.001 14.633 < 0.001 15.812 < 0.001
≥ 75y 52.904 < 0.001 76.025 < 0.001 45.329 < 0.001 53.545 < 0.001 61.556 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.944 0.420 0.841 0.001 0.825 < 0.001 0.844 < 0.001 0.844 < 0.001
3 0.988 0.866 0.800 < 0.001 0.790 < 0.001 0.781 < 0.001 0.785 < 0.001
4 0.873 0.055 0.767 < 0.001 0.780 < 0.001 0.789 < 0.001 0.784 < 0.001
5 0.795 0.003 0.685 < 0.001 0.673 < 0.001 0.663 < 0.001 0.670 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.379 < 0.001 1.293 < 0.001 1.354 < 0.001 1.349 < 0.001 1.369 < 0.001
CCI = 2 2.679 < 0.001 2.417 < 0.001 2.529 < 0.001 2.559 < 0.001 2.548 < 0.001
CCI = 3 3.285 < 0.001 3.428 < 0.001 3.540 < 0.001 3.629 < 0.001 3.655 < 0.001
CCI ≥ 4 5.267 < 0.001 4.997 < 0.001 5.188 < 0.001 5.641 < 0.001 5.946 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.060 0.244 1.106 0.006 1.143 < 0.001 1.163 < 0.001 1.174 < 0.001
Current Smoker 1.403 < 0.001 1.593 < 0.001 1.741 < 0.001 1.759 < 0.001 1.878 < 0.001
Unknown 0.162 < 0.001 0.290 < 0.001 0.485 < 0.001 0.647 < 0.001 0.828 < 0.001
NDA Creatinine Process 0.202 < 0.001 0.375 < 0.001 0.487 < 0.001 0.544 < 0.001 0.597 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.651 < 0.001 0.694 < 0.001 0.799 0.001 0.881 0.047 0.873 0.021
Years With DM 1.004 0.173 1.003 0.232 1.007 0.001 1.009 < 0.001 1.011 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.786 < 0.001 0.833 < 0.001 0.842 < 0.001 0.831 < 0.001 0.828 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.258 0.172 1.360 0.440 1.590 0.210 1.740 0.094
45 – 64y 5.281 < 0.001 7.874 < 0.001 4.505 < 0.001 5.120 < 0.001 5.461 < 0.001
65 – 74y 18.190 < 0.001 23.803 < 0.001 13.880 < 0.001 15.020 < 0.001 16.341 < 0.001
≥ 75y 49.827 < 0.001 73.827 < 0.001 45.375 < 0.001 54.141 < 0.001 62.790 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.962 0.596 0.844 0.001 0.825 < 0.001 0.843 < 0.001 0.843 < 0.001
3 0.981 0.789 0.793 < 0.001 0.786 < 0.001 0.778 < 0.001 0.782 < 0.001
4 0.880 0.077 0.770 < 0.001 0.782 < 0.001 0.791 < 0.001 0.786 < 0.001
5 0.785 0.002 0.679 < 0.001 0.670 < 0.001 0.661 < 0.001 0.668 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.368 < 0.001 1.298 < 0.001 1.365 < 0.001 1.360 < 0.001 1.380 < 0.001
CCI = 2 2.582 < 0.001 2.377 < 0.001 2.505 < 0.001 2.542 < 0.001 2.533 < 0.001
CCI = 3 2.901 < 0.001 3.236 < 0.001 3.407 < 0.001 3.521 < 0.001 3.563 < 0.001
CCI ≥ 4 4.570 < 0.001 4.614 < 0.001 4.878 < 0.001 5.346 < 0.001 5.659 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.099 0.064 1.141 < 0.001 1.173 < 0.001 1.190 < 0.001 1.198 < 0.001
Current Smoker 1.368 < 0.001 1.571 < 0.001 1.722 < 0.001 1.740 < 0.001 1.860 < 0.001
Unknown 0.167 < 0.001 0.269 < 0.001 0.436 < 0.001 0.577 < 0.001 0.735 < 0.001
NDA Foot Check Process 0.124 < 0.001 0.262 < 0.001 0.352 < 0.001 0.402 < 0.001 0.445 < 0.001
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Table A72. Full results from multiple-variable logistic regression model of receipt of the NDA HbA1c
care process in 2005/06 against odds of death (all cause).
Table A73. Full results from multiple-variable logistic regression model of receipt of the NDA retinal
screening care process in 2005/06 against odds of death (all cause).
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.597 < 0.001 0.652 < 0.001 0.758 < 0.001 0.841 0.006 0.839 0.003
Years With DM 1.005 0.116 1.003 0.150 1.007 < 0.001 1.010 < 0.001 1.012 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.823 < 0.001 0.856 < 0.001 0.859 < 0.001 0.845 < 0.001 0.840 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.200 0.186 1.331 0.472 1.561 0.228 1.713 0.103
45 – 64y 4.842 < 0.001 7.145 0.001 4.156 < 0.001 4.768 < 0.001 5.138 < 0.001
65 – 74y 15.319 < 0.001 20.400 < 0.001 12.229 < 0.001 13.433 < 0.001 14.838 < 0.001
≥ 75y 45.702 < 0.001 66.224 < 0.001 41.294 < 0.001 49.648 < 0.001 58.264 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.933 0.329 0.838 0.001 0.823 < 0.001 0.843 < 0.001 0.843 < 0.001
3 0.979 0.763 0.801 < 0.001 0.792 < 0.001 0.783 < 0.001 0.787 < 0.001
4 0.783 0.001 0.726 < 0.001 0.752 < 0.001 0.766 < 0.001 0.765 < 0.001
5 0.673 < 0.001 0.625 < 0.001 0.632 < 0.001 0.630 < 0.001 0.640 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.330 < 0.001 1.272 < 0.001 1.341 < 0.001 1.338 < 0.001 1.361 < 0.001
CCI = 2 2.604 < 0.001 2.388 < 0.001 2.506 < 0.001 2.538 < 0.001 2.530 < 0.001
CCI = 3 3.075 < 0.001 3.321 < 0.001 3.465 < 0.001 3.565 < 0.001 3.604 < 0.001
CCI ≥ 4 5.020 < 0.001 4.881 < 0.001 5.097 < 0.001 5.549 < 0.001 5.857 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.027 0.596 1.091 0.018 1.133 < 0.001 1.156 < 0.001 1.169 < 0.001
Current Smoker 1.432 < 0.001 1.610 < 0.001 1.754 < 0.001 1.769 < 0.001 1.888 < 0.001
Unknown 0.260 < 0.001 0.389 < 0.001 0.601 < 0.001 0.774 < 0.001 0.951 0.295
NDA HbA1c Process 0.312 < 0.001 0.501 < 0.001 0.608 < 0.001 0.658 < 0.001 0.682 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.577 < 0.001 0.636 < 0.001 0.744 < 0.001 0.827 0.003 0.827 0.001
Years With DM 1.005 0.094 1.003 0.147 1.007 < 0.001 1.010 < 0.001 1.012 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.817 < 0.001 0.849 < 0.001 0.853 < 0.001 0.840 < 0.001 0.835 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.117 0.208 1.298 0.511 1.532 0.248 1.686 0.114
45 – 64y 4.399 < 0.001 6.525 0.001 3.914 < 0.001 4.549 < 0.001 4.932 < 0.001
65 – 74y 13.585 < 0.001 18.405 < 0.001 11.430 < 0.001 12.739 < 0.001 14.160 < 0.001
≥ 75y 39.516 < 0.001 58.750 < 0.001 38.115 < 0.001 46.585 < 0.001 55.056 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.010 0.883 0.883 0.015 0.856 < 0.001 0.870 < 0.001 0.866 < 0.001
3 1.015 0.832 0.822 < 0.001 0.808 < 0.001 0.796 < 0.001 0.798 < 0.001
4 0.883 0.076 0.783 < 0.001 0.795 < 0.001 0.802 < 0.001 0.797 < 0.001
5 0.832 0.014 0.716 < 0.001 0.699 < 0.001 0.685 < 0.001 0.690 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.290 < 0.001 1.250 < 0.001 1.324 < 0.001 1.324 < 0.001 1.348 < 0.001
CCI = 2 2.602 < 0.001 2.387 < 0.001 2.506 < 0.001 2.538 < 0.001 2.529 < 0.001
CCI = 3 3.034 < 0.001 3.285 < 0.001 3.436 < 0.001 3.540 < 0.001 3.579 < 0.001
CCI ≥ 4 5.037 < 0.001 4.900 < 0.001 5.115 < 0.001 5.569 < 0.001 5.878 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.020 0.685 1.091 0.018 1.135 < 0.001 1.158 < 0.001 1.171 < 0.001
Current Smoker 1.445 < 0.001 1.619 < 0.001 1.760 < 0.001 1.775 < 0.001 1.893 < 0.001
Unknown 0.347 < 0.001 0.462 < 0.001 0.678 < 0.001 0.857 0.004 1.045 0.351
NDA Retinal Screening Process 0.290 < 0.001 0.464 < 0.001 0.563 < 0.001 0.623 < 0.001 0.658 < 0.001
- 287 -
Table A74. Full results from multiple-variable logistic regression model of receipt of the NDA
smoking status care process in 2005/06 against odds of death (all cause).
Table A75. Full results from multiple-variable logistic regression model of receipt of the NDA urinary
albumin care process in 2005/06 against odds of death (all cause).
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.602 < 0.001 0.651 < 0.001 0.756 < 0.001 0.836 0.005 0.833 0.002
Years With DM 1.005 0.097 1.004 0.105 1.007 < 0.001 1.010 < 0.001 1.012 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.774 < 0.001 0.828 < 0.001 0.839 < 0.001 0.831 < 0.001 0.830 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.128 0.205 1.302 0.506 1.535 0.246 1.689 0.113
45 – 64y 4.661 < 0.001 6.717 0.001 3.978 < 0.001 4.589 < 0.001 4.951 < 0.001
65 – 74y 14.890 < 0.001 19.185 < 0.001 11.688 < 0.001 12.880 < 0.001 14.210 < 0.001
≥ 75y 42.610 < 0.001 60.969 < 0.001 38.935 < 0.001 47.136 < 0.001 55.364 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.950 0.463 0.843 0.001 0.825 < 0.001 0.844 < 0.001 0.844 < 0.001
3 0.974 0.712 0.796 < 0.001 0.787 < 0.001 0.779 < 0.001 0.783 < 0.001
4 0.839 0.013 0.752 < 0.001 0.769 < 0.001 0.780 < 0.001 0.777 < 0.001
5 0.751 < 0.001 0.667 < 0.001 0.661 < 0.001 0.654 < 0.001 0.663 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.327 < 0.001 1.268 < 0.001 1.337 < 0.001 1.334 < 0.001 1.355 < 0.001
CCI = 2 2.639 < 0.001 2.401 < 0.001 2.515 < 0.001 2.544 < 0.001 2.534 < 0.001
CCI = 3 3.160 < 0.001 3.357 < 0.001 3.486 < 0.001 3.580 < 0.001 3.615 < 0.001
CCI ≥ 4 5.066 < 0.001 4.923 < 0.001 5.143 < 0.001 5.604 < 0.001 5.920 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 1.903 < 0.001 1.575 < 0.001 1.468 < 0.001 1.395 < 0.001 1.341 < 0.001
Current Smoker 3.272 < 0.001 2.586 < 0.001 2.440 < 0.001 2.252 < 0.001 2.256 < 0.001
Unknown 0.409 < 0.001 0.522 < 0.001 0.747 < 0.001 0.930 0.170 1.123 0.013
NDA Smoking Status Process 0.236 < 0.001 0.477 < 0.001 0.608 < 0.001 0.700 < 0.001 0.772 < 0.001
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.595 < 0.001 0.649 < 0.001 0.756 < 0.001 0.838 0.005 0.835 0.002
Years With DM 1.006 0.029 1.004 0.055 1.008 < 0.001 1.010 < 0.001 1.012 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 0.819 < 0.001 0.851 < 0.001 0.854 < 0.001 0.841 < 0.001 0.837 < 0.001
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 2.118 0.208 1.298 0.511 1.532 0.248 1.686 0.114
45 – 64y 4.408 < 0.001 6.520 0.001 3.911 < 0.001 4.544 < 0.001 4.921 < 0.001
65 – 74y 13.650 < 0.001 18.406 < 0.001 11.427 < 0.001 12.727 < 0.001 14.116 < 0.001
≥ 75y 40.258 < 0.001 59.351 < 0.001 38.428 < 0.001 46.882 < 0.001 55.246 < 0.001
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 0.949 0.457 0.843 0.001 0.825 < 0.001 0.843 < 0.001 0.843 < 0.001
3 0.972 0.682 0.796 < 0.001 0.787 < 0.001 0.778 < 0.001 0.782 < 0.001
4 0.866 0.039 0.770 < 0.001 0.783 < 0.001 0.792 < 0.001 0.786 < 0.001
5 0.762 < 0.001 0.671 < 0.001 0.664 < 0.001 0.656 < 0.001 0.664 < 0.001
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 1.295 < 0.001 1.253 < 0.001 1.327 < 0.001 1.327 < 0.001 1.351 < 0.001
CCI = 2 2.613 < 0.001 2.392 < 0.001 2.509 < 0.001 2.540 < 0.001 2.531 < 0.001
CCI = 3 3.110 < 0.001 3.337 < 0.001 3.479 < 0.001 3.577 < 0.001 3.613 < 0.001
CCI ≥ 4 5.079 < 0.001 4.939 < 0.001 5.157 < 0.001 5.615 < 0.001 5.927 < 0.001
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.992 0.876 1.069 0.071 1.117 < 0.001 1.142 < 0.001 1.157 < 0.001
Current Smoker 1.431 < 0.001 1.611 < 0.001 1.756 < 0.001 1.772 < 0.001 1.891 < 0.001
Unknown 0.353 < 0.001 0.472 < 0.001 0.690 < 0.001 0.871 0.009 1.066 0.176
NDA Urinary Albumin Process 0.268 < 0.001 0.497 < 0.001 0.597 < 0.001 0.658 < 0.001 0.717 < 0.001
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Odds of Death Due to Diabetes-Related Causes and 
NDA Attainment
Table A76. Full results from multiple-variable logistic regression model of the number of NDA care
processes received in 2005/06 against odds of death due to a potentially diabetes-related cause.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.724 0.078 0.733 0.022 0.672 0.001 0.739 0.003 0.726 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender
Male
Female 1.056 0.530 1.024 0.702 1.026 0.615 1.024 0.591 1.012 0.769
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.336 0.820 0.952 0.951 1.200 0.812 0.917 0.895
45 – 64y 1.892 0.229 1.877 0.614 1.347 0.703 1.630 0.511 0.965 0.956
65 – 74y 2.038 0.173 1.900 0.607 1.283 0.749 1.525 0.570 0.920 0.897
≥ 75y 2.260 0.116 2.091 0.554 1.494 0.607 1.783 0.436 1.111 0.870
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.038 0.778 1.051 0.591 1.003 0.974 1.000 0.997 0.971 0.620
3 1.043 0.752 1.029 0.760 1.008 0.921 1.018 0.792 0.997 0.964
4 0.898 0.420 0.907 0.290 0.933 0.354 0.911 0.153 0.885 0.039
5 0.809 0.139 0.808 0.033 0.815 0.012 0.864 0.039 0.847 0.009
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.716 0.005 0.886 0.139 0.911 0.156 0.942 0.285 0.967 0.501
CCI = 2 0.697 0.001 0.787 0.003 0.847 0.011 0.891 0.044 0.918 0.097
CCI = 3 0.888 0.391 1.055 0.587 1.117 0.174 1.136 0.076 1.188 0.009
CCI ≥ 4 0.626 0.001 0.803 0.043 0.819 0.031 0.863 0.073 0.883 0.102
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.929 0.440 0.886 0.083 0.932 0.219 0.939 0.212 0.955 0.307
Current Smoker 0.792 0.098 0.768 0.008 0.769 0.001 0.793 0.001 0.801 0.001
Unknown 1.090 0.733 0.849 0.313 0.990 0.929 1.002 0.986 0.964 0.646
NDA Processess 
Met
0 Reference Group Reference Group Reference Group Reference Group Reference Group
1 0.782 0.099 0.814 0.118 0.887 0.310 0.885 0.263 0.874 0.189
2 0.898 0.462 0.893 0.383 0.966 0.763 0.963 0.724 0.913 0.368
3 1.054 0.738 1.007 0.955 0.984 0.890 0.920 0.419 0.948 0.580
4 1.089 0.578 1.126 0.325 1.141 0.205 1.124 0.218 1.058 0.514
5 1.010 0.948 1.102 0.366 1.058 0.542 1.064 0.448 1.011 0.885
6 1.120 0.434 1.141 0.176 1.104 0.222 1.041 0.575 1.003 0.966
7 1.126 0.473 0.971 0.773 0.958 0.606 0.949 0.472 0.956 0.498
8 1.400 0.260 0.903 0.490 0.877 0.246 0.843 0.074 0.872 0.110
9 0.961 0.945 0.990 0.973 0.896 0.631 0.918 0.639 0.889 0.454
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Table A77. Full results from multiple-variable logistic regression model of receipt of the NDA BMI
care process in 2005/06 against odds of death due to a potentially diabetes-related cause.
Table A78. Full results from multiple-variable logistic regression model of receipt of the NDA BP care
process in 2005/06 against odds of death due to a potentially diabetes-related cause.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.718 0.069 0.731 0.021 0.672 0.001 0.737 0.003 0.725 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.047 0.597 1.022 0.730 1.027 0.597 1.026 0.550 1.012 0.766
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.406 0.788 0.981 0.981 1.227 0.788 0.937 0.921
45 – 64y 1.891 0.228 1.996 0.577 1.403 0.663 1.688 0.480 0.994 0.993
65 – 74y 2.045 0.170 2.011 0.573 1.333 0.712 1.575 0.540 0.945 0.929
≥ 75y 2.271 0.113 2.207 0.522 1.544 0.576 1.833 0.413 1.136 0.842
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.038 0.781 1.043 0.652 0.993 0.921 0.990 0.874 0.966 0.561
3 1.042 0.755 1.021 0.823 1.000 0.996 1.008 0.909 0.992 0.895
4 0.893 0.397 0.902 0.262 0.927 0.311 0.903 0.120 0.882 0.033
5 0.817 0.157 0.804 0.029 0.809 0.009 0.857 0.029 0.845 0.008
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.716 0.005 0.890 0.154 0.915 0.174 0.944 0.308 0.968 0.518
CCI = 2 0.696 0.001 0.783 0.002 0.843 0.009 0.889 0.039 0.915 0.087
CCI = 3 0.895 0.421 1.062 0.538 1.120 0.163 1.140 0.068 1.191 0.008
CCI ≥ 4 0.623 0.001 0.795 0.035 0.814 0.026 0.860 0.066 0.879 0.089
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.935 0.477 0.867 0.036 0.908 0.086 0.915 0.069 0.940 0.160
Current Smoker 0.808 0.127 0.750 0.003 0.744 < 0.001 0.767 < 0.001 0.785 < 0.001
Unknown 1.107 0.688 0.838 0.275 0.961 0.730 0.972 0.759 0.945 0.475
NDA BMI Process 1.102 0.256 1.016 0.784 0.949 0.291 0.939 0.148 0.942 0.135
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.718 0.070 0.731 0.020 0.669 0.001 0.734 0.003 0.722 < 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.040 0.648 1.021 0.740 1.030 0.562 1.030 0.501 1.015 0.702
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.394 0.793 0.978 0.978 1.234 0.782 0.943 0.929
45 – 64y 1.896 0.226 1.976 0.583 1.387 0.674 1.681 0.484 0.992 0.990
65 – 74y 2.053 0.168 1.990 0.579 1.318 0.723 1.569 0.543 0.942 0.926
≥ 75y 2.263 0.115 2.185 0.528 1.537 0.579 1.839 0.411 1.141 0.837
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.034 0.803 1.044 0.644 0.995 0.945 0.991 0.894 0.968 0.580
3 1.041 0.760 1.023 0.806 1.003 0.965 1.010 0.885 0.993 0.912
4 0.892 0.391 0.902 0.265 0.927 0.310 0.902 0.116 0.881 0.031
5 0.814 0.151 0.804 0.029 0.810 0.010 0.857 0.029 0.845 0.008
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.716 0.005 0.888 0.145 0.914 0.169 0.943 0.297 0.967 0.495
CCI = 2 0.693 0.001 0.783 0.002 0.845 0.010 0.891 0.045 0.918 0.096
CCI = 3 0.893 0.411 1.062 0.537 1.122 0.158 1.141 0.066 1.192 0.008
CCI ≥ 4 0.619 0.001 0.798 0.037 0.820 0.031 0.866 0.080 0.885 0.106
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.934 0.468 0.864 0.032 0.904 0.072 0.911 0.055 0.935 0.128
Current Smoker 0.804 0.120 0.749 0.003 0.743 < 0.001 0.766 < 0.001 0.785 < 0.001
Unknown 1.100 0.708 0.839 0.275 0.978 0.845 0.996 0.963 0.972 0.724
NDA BP Process 1.069 0.433 1.067 0.334 1.030 0.606 1.018 0.731 1.021 0.664
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Table A79. Full results from multiple-variable logistic regression model of receipt of the NDA
cholesterol care process in 2005/06 against odds of death due to a potentially diabetes-related
cause.
Table A80. Full results from multiple-variable logistic regression model of receipt of the NDA
creatinine care process in 2005/06 against odds of death due to a potentially diabetes-related cause.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.719 0.071 0.730 0.020 0.666 < 0.001 0.730 0.002 0.720 < 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.015 < 0.001 1.014 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.047 0.595 1.022 0.722 1.031 0.545 1.031 0.482 1.016 0.684
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.353 0.811 0.943 0.942 1.197 0.814 0.926 0.907
45 – 64y 1.866 0.238 1.891 0.607 1.318 0.722 1.614 0.519 0.969 0.961
65 – 74y 2.025 0.177 1.910 0.601 1.251 0.773 1.506 0.581 0.920 0.897
≥ 75y 2.246 0.119 2.109 0.546 1.472 0.619 1.773 0.439 1.117 0.863
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.044 0.748 1.048 0.613 0.997 0.974 0.992 0.908 0.968 0.582
3 1.046 0.737 1.029 0.758 1.007 0.925 1.011 0.871 0.994 0.916
4 0.898 0.419 0.905 0.282 0.927 0.313 0.902 0.113 0.880 0.030
5 0.811 0.142 0.804 0.029 0.808 0.009 0.855 0.027 0.844 0.007
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.710 0.004 0.885 0.134 0.912 0.157 0.941 0.280 0.965 0.481
CCI = 2 0.701 0.001 0.789 0.003 0.850 0.013 0.894 0.051 0.919 0.103
CCI = 3 0.897 0.430 1.063 0.532 1.125 0.149 1.143 0.064 1.193 0.007
CCI ≥ 4 0.622 0.001 0.802 0.042 0.825 0.037 0.870 0.089 0.886 0.113
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.929 0.439 0.859 0.026 0.900 0.058 0.907 0.045 0.933 0.116
Current Smoker 0.805 0.121 0.747 0.003 0.741 < 0.001 0.765 < 0.001 0.784 < 0.001
Unknown 1.098 0.713 0.851 0.318 1.000 0.999 1.018 0.851 0.984 0.837
NDA Cholesterol Process 1.247 0.009 1.174 0.007 1.132 0.015 1.091 0.054 1.056 0.189
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.718 0.070 0.732 0.021 0.670 0.001 0.734 0.003 0.723 < 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender
Male
Female 1.039 0.656 1.021 0.734 1.030 0.560 1.030 0.502 1.015 0.708
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.383 0.798 0.976 0.976 1.236 0.781 0.947 0.934
45 – 64y 1.890 0.228 1.961 0.587 1.384 0.676 1.686 0.481 1.001 0.999
65 – 74y 2.047 0.169 1.973 0.583 1.313 0.726 1.574 0.540 0.951 0.938
≥ 75y 2.251 0.117 2.165 0.533 1.533 0.582 1.844 0.409 1.150 0.827
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.032 0.813 1.042 0.658 0.994 0.939 0.991 0.890 0.967 0.575
3 1.039 0.772 1.020 0.831 1.002 0.974 1.009 0.889 0.993 0.908
4 0.891 0.385 0.901 0.259 0.926 0.307 0.902 0.117 0.881 0.032
5 0.817 0.156 0.802 0.027 0.809 0.009 0.857 0.029 0.845 0.008
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.721 0.005 0.889 0.150 0.914 0.170 0.944 0.303 0.968 0.510
CCI = 2 0.693 0.001 0.783 0.002 0.845 0.010 0.891 0.044 0.917 0.096
CCI = 3 0.891 0.402 1.061 0.544 1.121 0.160 1.141 0.066 1.192 0.008
CCI ≥ 4 0.616 0.001 0.794 0.034 0.819 0.030 0.866 0.079 0.884 0.103
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.939 0.503 0.866 0.035 0.904 0.072 0.911 0.057 0.937 0.137
Current Smoker 0.806 0.122 0.750 0.003 0.743 < 0.001 0.766 < 0.001 0.785 < 0.001
Unknown 1.102 0.702 0.840 0.280 0.979 0.854 0.991 0.924 0.960 0.611
NDA Creatinine Process 0.968 0.694 1.030 0.648 1.029 0.611 1.003 0.958 0.989 0.805
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Table A81. Full results from multiple-variable logistic regression model of receipt of the NDA foot
check care process in 2005/06 against odds of death due to a potentially diabetes-related cause.
Table A82. Full results from multiple-variable logistic regression model of receipt of the NDA HbA1c
care process in 2005/06 against odds of death due to a potentially diabetes-related cause.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.714 0.065 0.730 0.020 0.670 0.001 0.735 0.003 0.724 < 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.046 0.606 1.023 0.717 1.029 0.566 1.028 0.524 1.014 0.729
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.421 0.782 0.985 0.985 1.241 0.776 0.945 0.931
45 – 64y 1.845 0.246 2.005 0.575 1.404 0.663 1.706 0.471 1.002 0.998
65 – 74y 2.006 0.182 2.022 0.570 1.334 0.711 1.592 0.530 0.952 0.939
≥ 75y 2.222 0.123 2.221 0.519 1.553 0.570 1.861 0.401 1.149 0.828
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.030 0.825 1.044 0.645 0.994 0.937 0.991 0.889 0.967 0.574
3 1.043 0.750 1.024 0.802 1.002 0.982 1.009 0.899 0.993 0.904
4 0.893 0.393 0.903 0.267 0.927 0.311 0.903 0.120 0.882 0.032
5 0.811 0.143 0.804 0.029 0.810 0.009 0.857 0.030 0.846 0.008
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.718 0.005 0.890 0.154 0.915 0.176 0.945 0.311 0.968 0.518
CCI = 2 0.692 0.001 0.784 0.002 0.845 0.010 0.891 0.043 0.917 0.094
CCI = 3 0.889 0.396 1.062 0.539 1.121 0.159 1.141 0.067 1.191 0.008
CCI ≥ 4 0.619 0.001 0.797 0.036 0.818 0.029 0.863 0.073 0.881 0.097
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.930 0.441 0.865 0.033 0.907 0.079 0.914 0.065 0.938 0.148
Current Smoker 0.803 0.118 0.750 0.003 0.744 < 0.001 0.766 < 0.001 0.785 < 0.001
Unknown 1.120 0.655 0.845 0.296 0.970 0.788 0.979 0.819 0.953 0.544
NDA Foot Check Process 1.176 0.077 1.055 0.367 0.989 0.821 0.963 0.377 0.968 0.395
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.720 0.072 0.731 0.021 0.668 0.001 0.733 0.003 0.722 < 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.042 0.637 1.021 0.741 1.029 0.563 1.030 0.502 1.015 0.704
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.458 0.766 0.987 0.987 1.236 0.781 0.943 0.928
45 – 64y 1.890 0.228 2.056 0.561 1.398 0.666 1.683 0.482 0.991 0.989
65 – 74y 2.035 0.173 2.065 0.558 1.326 0.717 1.569 0.543 0.941 0.924
≥ 75y 2.239 0.119 2.264 0.509 1.546 0.574 1.839 0.410 1.139 0.839
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.043 0.751 1.044 0.639 0.995 0.945 0.991 0.891 0.967 0.578
3 1.042 0.758 1.021 0.826 1.002 0.980 1.009 0.895 0.993 0.903
4 0.899 0.425 0.905 0.281 0.929 0.323 0.903 0.120 0.882 0.033
5 0.823 0.173 0.807 0.032 0.812 0.010 0.858 0.031 0.847 0.009
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.712 0.004 0.887 0.142 0.913 0.165 0.942 0.292 0.966 0.486
CCI = 2 0.692 0.001 0.783 0.002 0.846 0.011 0.892 0.045 0.918 0.098
CCI = 3 0.894 0.419 1.063 0.534 1.123 0.155 1.142 0.064 1.193 0.007
CCI ≥ 4 0.623 0.001 0.797 0.036 0.821 0.032 0.867 0.083 0.885 0.109
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.929 0.438 0.865 0.032 0.904 0.070 0.910 0.053 0.934 0.122
Current Smoker 0.798 0.107 0.747 0.003 0.741 < 0.001 0.765 < 0.001 0.783 < 0.001
Unknown 1.096 0.717 0.839 0.277 0.978 0.847 0.997 0.970 0.973 0.731
NDA HbA1c Process 1.157 0.087 1.068 0.265 1.045 0.359 1.029 0.495 1.035 0.367
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Table A83. Full results from multiple-variable logistic regression model of receipt of the NDA retinal
screening care process in 2005/06 against odds of death due to a potentially diabetes-related cause.
Table A84. Full results from multiple-variable logistic regression model of receipt of the NDA
smoking status care process in 2005/06 against odds of death due to a potentially diabetes-related
cause.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.719 0.071 0.732 0.021 0.671 0.001 0.736 0.003 0.724 < 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.041 0.647 1.019 0.760 1.028 0.586 1.027 0.537 1.014 0.728
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.388 0.796 0.985 0.985 1.224 0.791 0.941 0.927
45 – 64y 1.883 0.230 1.966 0.586 1.401 0.665 1.674 0.487 0.993 0.992
65 – 74y 2.037 0.172 1.979 0.582 1.330 0.713 1.563 0.547 0.944 0.928
≥ 75y 2.242 0.119 2.169 0.532 1.549 0.573 1.826 0.416 1.141 0.837
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.032 0.813 1.044 0.640 0.998 0.975 0.996 0.950 0.969 0.601
3 1.038 0.776 1.022 0.819 1.003 0.966 1.012 0.860 0.994 0.925
4 0.890 0.384 0.904 0.272 0.929 0.329 0.906 0.132 0.883 0.035
5 0.815 0.152 0.806 0.031 0.814 0.012 0.863 0.039 0.848 0.010
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.720 0.005 0.890 0.153 0.914 0.170 0.943 0.299 0.967 0.504
CCI = 2 0.693 0.001 0.782 0.002 0.844 0.010 0.890 0.043 0.917 0.094
CCI = 3 0.891 0.403 1.061 0.545 1.119 0.166 1.138 0.072 1.190 0.008
CCI ≥ 4 0.616 0.001 0.793 0.033 0.818 0.029 0.863 0.074 0.882 0.099
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.937 0.489 0.869 0.039 0.907 0.081 0.914 0.064 0.937 0.140
Current Smoker 0.805 0.121 0.752 0.004 0.744 < 0.001 0.767 < 0.001 0.785 < 0.001
Unknown 1.102 0.702 0.836 0.268 0.968 0.779 0.984 0.860 0.960 0.604
NDA Retinal Screening Process 1.006 0.970 0.958 0.620 0.938 0.332 0.919 0.131 0.959 0.391
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.718 0.070 0.732 0.021 0.673 0.001 0.736 0.003 0.725 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.045 0.608 1.020 0.746 1.025 0.619 1.026 0.556 1.011 0.780
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.395 0.793 1.001 0.999 1.251 0.769 0.955 0.944
45 – 64y 1.917 0.218 1.981 0.581 1.427 0.648 1.712 0.468 1.010 0.988
65 – 74y 2.072 0.163 1.995 0.577 1.357 0.694 1.598 0.527 0.960 0.949
≥ 75y 2.289 0.110 2.186 0.527 1.574 0.559 1.866 0.399 1.157 0.820
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.039 0.776 1.042 0.660 0.994 0.938 0.991 0.890 0.967 0.571
3 1.048 0.724 1.020 0.836 0.999 0.995 1.008 0.900 0.993 0.901
4 0.896 0.412 0.901 0.259 0.925 0.301 0.902 0.115 0.881 0.031
5 0.816 0.154 0.803 0.028 0.807 0.009 0.856 0.028 0.845 0.008
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.719 0.005 0.890 0.154 0.917 0.183 0.945 0.316 0.969 0.526
CCI = 2 0.695 0.001 0.782 0.002 0.843 0.009 0.891 0.043 0.917 0.093
CCI = 3 0.898 0.438 1.062 0.541 1.119 0.166 1.140 0.068 1.191 0.008
CCI ≥ 4 0.622 0.001 0.794 0.033 0.814 0.026 0.863 0.072 0.881 0.096
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.895 0.263 0.872 0.063 0.943 0.340 0.942 0.274 0.970 0.537
Current Smoker 0.760 0.058 0.755 0.007 0.781 0.004 0.797 0.003 0.819 0.004
Unknown 1.078 0.767 0.839 0.277 0.985 0.897 0.998 0.985 0.970 0.700
NDA Smoking Status Process 1.176 0.126 0.990 0.885 0.916 0.124 0.934 0.175 0.932 0.120
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Table A85. Full results from multiple-variable logistic regression model of receipt of the NDA urinary
albumin care process in 2005/06 against odds of death due to a potentially diabetes-related cause.
2005/06 2005/06 - 2006/07 2005/06 - 2007/08 2005/06 - 2008/09 2005/06 - 2009/10
OR p OR p OR p OR p OR p
DM Type
T1DM Reference Group Reference Group Reference Group Reference Group Reference Group
T2DM 0.719 0.071 0.732 0.021 0.670 0.001 0.735 0.003 0.723 < 0.001
Years With DM 1.019 0.001 1.014 0.001 1.014 < 0.001 1.014 < 0.001 1.014 < 0.001
Gender
Male Reference Group Reference Group Reference Group Reference Group Reference Group
Female 1.041 0.639 1.021 0.740 1.029 0.570 1.029 0.516 1.014 0.717
Age Group
< 25y No Events Reference Group Reference Group Reference Group Reference Group
25 – 44y Reference Group 1.395 0.792 0.987 0.987 1.241 0.777 0.946 0.932
45 – 64y 1.886 0.229 1.982 0.581 1.404 0.662 1.696 0.476 0.998 0.998
65 – 74y 2.036 0.172 1.996 0.577 1.334 0.710 1.584 0.535 0.949 0.936
≥ 75y 2.242 0.119 2.188 0.527 1.554 0.570 1.854 0.404 1.148 0.829
IMD
1 Reference Group Reference Group Reference Group Reference Group Reference Group
2 1.032 0.812 1.042 0.659 0.994 0.935 0.990 0.880 0.966 0.565
3 1.041 0.762 1.020 0.831 1.002 0.980 1.009 0.892 0.993 0.902
4 0.892 0.390 0.901 0.260 0.927 0.314 0.903 0.121 0.881 0.032
5 0.815 0.152 0.803 0.028 0.810 0.009 0.857 0.029 0.845 0.008
CCI Group
CCI = 0 Reference Group Reference Group Reference Group Reference Group Reference Group
CCI = 1 0.717 0.005 0.890 0.154 0.915 0.175 0.944 0.304 0.967 0.504
CCI = 2 0.693 0.001 0.783 0.002 0.845 0.010 0.891 0.044 0.917 0.095
CCI = 3 0.892 0.409 1.062 0.540 1.121 0.160 1.141 0.067 1.191 0.008
CCI ≥ 4 0.616 0.001 0.794 0.033 0.819 0.030 0.865 0.078 0.883 0.102
Smoking Status
Non-Smoker Reference Group Reference Group Reference Group Reference Group Reference Group
Ex-Smoker 0.939 0.503 0.868 0.037 0.906 0.076 0.911 0.056 0.936 0.132
Current Smoker 0.807 0.125 0.751 0.003 0.743 < 0.001 0.765 < 0.001 0.784 < 0.001
Unknown 1.109 0.684 0.837 0.270 0.971 0.795 0.987 0.889 0.962 0.617
NDA Urinary Albumin Process 1.189 0.326 1.002 0.981 0.977 0.746 0.956 0.468 0.969 0.553
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